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Abstract
Introduction: Measurement of antibodies at a single time point in malaria-endemic populations
and associating them with protection and susceptibility has given insight into the development and
maintenance of the immune response to malaria. Immunity to malaria is a dynamic process that
takes place over a number of years in different stages, which implies that antibody measurement at
a single time point may not adequately encompass acquisition of immunity.
Methods: Antibody responses to merozoite antigens (AMA 1 and MSP2) were measured in 300
children aged 0-10 years twice a year for three years. Each child was followed up on a weekly basis
for episodes of malaria. Factors affecting antibody responses at each time point and antibody
contributions to protection from malaria were investigated, and the association between functional
activity of anti-AMA 1 antibodies and protection was assessed.
Results: Anti-AMA 1 and anti-MSP2 antibody responses were dependent on the amount of prior
and ongoing exposure and paralleled the decline in malaria transmission that occurred during the
study period. High antibody responses were generated after 2-3 episodes of parasitemia and were
likely to drop on further exposure. There was no evidence for polarisation of )gG responses to
AMA I. The association between antibody responses and protection/risk of malaria was dependent
on both the sample time and analysis method used. Antibody responses to AMA 1(W2mef) were
associated with an increased risk of malaria over the study period. Antibodies to MSP2(3D7) may
be associated with protection from malaria. Antibodies to a functional invasion inhibitory epitope
of AMA 1(3D7) were rare but associated with protection from malaria.
Conclusion: Longitudinal assessment of antibody levels gives a more complete picture of
acquisition and maintenance of malaria immunity. Antibodies can be both a measure of protection
or susceptibility. These findings enrich knowledge on acquisition of immunity and will impact
vaccination development and immunisation strategies.
Acknowledgements
I would like to thank my supervisors; James Beeson for his insights and critique, and Kevin Marsh for
all his support. Thank you for allowing me to take this project in the direction it went and encouraging
me to believe in myself. I have grown tremendously in the process and I am grateful.
This project benefited from the contributions of the following individuals; Kurt Lackovic and Jack
Richards with the high throughput ELISA technique, Robin Anders for the antigens, Fiona McCallum
for her growth inhibition assay data, Tom Williams and Edna Ogada for the haemoglobinopathy and
cohort data, and Greg Fegan for his statistics expertise.
Many thanks to the study participants, the KEMRI-Wellcome Trust Research programme, the Malaria
Immunology team, and the unit librarian. I thank Moses, Bames, Oscar, and Elizabeth for their
camaraderie, Nimmo and Alex Maina for their assistance, and the rest of the group for making this
project possible. The amount of field data involved would not exist without the efforts of the malaria
surveillance team.
My experience at WEHI could not have been better. I would like to thank the Beeson group - in
particular Joanne, Jack, Linda, Fiona, Danny, and Kristina - for their friendship and support during the
long hours spent on invasion inhibitory assays.
Edna, Zena, Sophie, Betty, Janine, Jane, Ben, Greg, Alex, and Steve - thank you for encouraging me
when the going got tough and celebrating the good times. My office mates and fellow students - your
support has been irreplaceable.
To my family - thank you for being both an inspiration and a challenge. Even though you sometimes
didn't understand exactly what AMA 1 and MSP2 were you were my biggest fans. Thank you.
And finally for the children experiencing malaria today - I hope that this work will contribute to
reducing your burden.
Table of Contents
List of Figures viii
List of Tables xi
Chapter 1 - Introduction 1
1.1 The burden of malaria I
1.2 The lifecycle of Plasmodium falciparum 2
1.3 P.jalciparum merozoite invasion of erythrocytes 5
1.4 Immunity to blood-stages of P. falciparum 10
1.4.1 Innate immune responses to infection 11
1.4.2 Adaptive immune responses to infection 13
1.4.2.1 Cell-Mediated immunity to malaria 14
1.4.2.2 The role of antibodies in protection against malaria 15
1.4.2.2.1 Invasion inhibition 16
1.4.2.2.2 Adhesion inhibition 17
1.4.2.2.3 Antibody-dependent cellular inhibition 18
1.4.3 Antibody maintenance in malaria 19
1.4.4 Haemoglobinopathies and resistance to malaria 21
1.4.5 The effect of exposure on immunity to malaria 23
1.4.6 The effect of age on immunity to malaria 25
1.5 Two vaccine candidates in review: apical membrane antigen I (AMAI) and membrane surface
antigen (MSP2) 28
1.5.1.2 Polymorph isms of AMA 1 29
1.5.1.3 Function of AMA I 31
1.5.1 Apical membrane antigen I (AMA I) 28
1.5.1.1 Location and structure of AMA I 28
1.5.1.4 AMA I-specific invasion inhibition 32
1.5.1.5 Vaccine potential of AMA I in animal models 34
1.5.1.6 Naturally acquired antibodies to AMAI 36
1.5.1.7 The role of anti-AM A I antibodies in protection from clinical disease 37
1.5.2 Merozoite surface protein 2 (MSP2) 38
1.5.2.1 Location and structure of MSP2 38
1.5.2.2 Polymorphisms of MSP2 39
1.5.2.3 Function ofMSP2 ··.. ·..··· ··.. ·· ·· ···· .. · ·.. ··.. · 40
1.5.2.4 Vaccine potential of MSP2 in animal models .41
1.5.2.5 Naturally acquired antibodies to MSP2 42
1.5.2.6 The role of anti-MSP2 antibodies in protection from clinical disease .43
1.6 Development of vaccines against malaria 44
1.6.1 Pre-erythrocytic stage vaccines 44
1.6.2 Erythrocytic stage vaccines 45
1.6 3 Transmission-blocking vaccines '" .. '" 46
1.6.4 AMAI vaccines 47
1.6.5 MSP2 vaccines 49
1.7 Longitudinal studies of antibodies to asexual antigens of P. Jalciparum ·················· 50
1.8 Rationale of this study 51
1.9 Aims of this study 54
1.9.1 Hypothesis 1 54
1.9.2 Hypothesis 2 55
1.9.3 Hypothesis 3 55
1.9.4 Hypothesis 4 56
1.9.5 Hypothesis 5 56
1.9.6 Hypothesis 6 57
1.9.7 Hypothesis 7 57
Chapter 2 - Materials and Metbods 59
2.1 Study area and population 59
2.2 Study design 59
2.3 Sample collection 60
2.4 Weekly surveillance 61
2.5 Case definition 62
2.6 Cohort study - study populations, sample collection, and surveillance " 62
ii
2.7 Recombinant P. falciparum antigens 62
2.7.1 AMAI 62
2.7.2 MSP2 63
2.8 Other antigens 63
2.8.1 Schizont extract 63
2.8.2 Tetanus toxoid 63
2.9 Monoclonal antibodies 63
2.10 Enzyme linked immunosorbent assay (ELISA) 64
2.10.1 Standard ELISA 64
2.10.2 High throughput ELISA 65
2.10.3 Competition ELISA 68
2.11 Growth inhibition assay '" 69
2.12 Statistical analysis 70
2.12.1 Acquisition of antibodies to AMA I and MSP2 71
2.12.2 Antibody response ranking 71
2.12.3 Factors affecting antibody titres at sample time 72
2.12.4 Locally weighted scatter-plot smoothing (LOWESS) 72
2.12.5 Probability of a high antibody response after recorded exposure 72
2.12.6 Multivariate analysis of variance (MANOY A) for repeated measures 73
2.12.7 Generalised estimating equations (GEE) 73
2.12.8 Protection against clinical malaria (Cross sectional risk analysis) 75
2.12.9 Protection against clinical malaria (Longitudinal risk analysis) 76
2.12.10 Acquisition of antibody responses to specific epitopes of AMAI(3D7) 76
2.12.1 I Epitope-specific antibody responses and rate of clinical malaria 76
2.12.12 Epitope-specific antibody responses and protection against clinical malaria 77
2.13 Cohort descriptions 77
2.13.1 Longitudinal Ngerenya cohort 77
2.13.2 Ngerenya September 1998 cohort 80
2.13.3 Chonyi October 2000 cohort 80
iii
Chapter 3 - Identif'Jeation of facton determining the acquisition and levels of antibodies to
AMAI and MSPl, and the influence of changing malaria transmission intensity
••••••••••••••••••••••••••••••••••••.••••••••••.••.••••••••.•.•••.•••••••••..••••.••••...•••••••••..••.•.••••.••..••.81
3.1 Introduction 81
3.2 Methods 84
3.2.1 Study population, sample collection, and surveillance 84
3.2.2 Enzyme-linked immunosorbent assay (ELISA) 84
3.2.3 Statistical analysis 85
3.3 Results 86
3.3.1 The prevalence and magnitude of IgG responses increases with age 86
3.3.2 Acquisition ofIgO responses increase with measures of exposure 91
3.3.3 Declining malaria transmission affects acquisition of IgG responses 95
3.3.4 Concurrent parasitemia boosts IgG responses 96
3.3.5 Diminished 19O responses are observed in the presence ofhaemoglobinopathies 96
3.3.6 Age, concurrent parasitemia, haemoglobinopathies, and prior exposure have variable effects
on IgO responses that are dependent on malaria transmission levels 104
3.3.6.1 Univariate analysis of factors associated with IgG responses i. l07
3.3.6.2 Multivariable analysis off actors associated with IgG responses 114
3.3.7 Increased prior P. falciparum exposure does not always result in a high titre response to
AMAI and MSP2 117
3.3.8 The probability of antibody positivity is dependent on antigen characteristics 121
3.3.9 Antibody responses to AMA 1correlate with those to MSP2 124
3.4 Discussion 126
Chapter 4 - Longitudinal patterns ofIgG responses to AMAI and MSP2 133
4.1 Introduction 133
4.2 Methods 135
4.2.1 Statistical analysis 135
4.3 Results 137
4.3.1 Fluctuating IgG responses to AMA 1 and MSP2 parallel the decline in malaria transmission
......................................................................................................... 137
4.3.2 Longitudinal patterns of IgG responses do not increase in magnitude with increasing age
......................................................................................................... 147
iv
4.3.3 Concurrent parasitemia at sampling positively influences the longitudinal IgO response
patterns to merozoite antigens 152
4.3.4 The sickle trait and alpha-thalassemia result in lower longitudinal antibody responses to
AMA 1 and MSP2 158
4.3.5 Age and recurrent parasitemia exert the greatest effect on longitudinal patterns of IgO
responses to merozoite antigens 162
4.3.6 Antibody responses to merozoite antigens are better maintained by older children in the
face of declining malaria transmission 164
4.4 Discussion 167
Chapter 5 - The association of anti-merozoite antibody responses with protection from clinical
malaria 175
5.1 Introduction 175
5.2 Methods 178
5.2.1 Statistical analysis 178
5.2.1.1 Risk analysis with cross sectional data format 178
5.2.1.2 Risk analysis with longitudinal data format 179
5.3 Results 179
5.3.1 Factors affecting the risk of malaria six months post-sampling 179
5.3.2 The association of antibody responses with protection from malaria six months post-
sampling is dependent on malaria transmission at sampling 182
5.3.3 Longitudinal analysis of factors affecting the risk of malaria 185
5.3.4 Contrasting associations between anti-merozoite antibody responses and protection against
malaria ]86
5.4 Discussion ]88
Chapter 6 - Acquisition and maintenance of isotype and subclass antibody responses to
AMA1(3D7) and their association with protection against malaria 195
6.] Introduction 195
6.2 Methods ]97
6.2.1 Enzyme-linked immunosorbent assay (ELISA) 197
6.2.2 Statistical analysis 198
6.3 Results 198
6.3.] The predominant IgO response to AMA I is of the IgO I subclass ]98
6.3.2 Diminished IgG subclass responses are seen in the presence of alpha-thalassemia 206
6.3.3 The IgO] response to AMA] is predominant over the study period 208
v
6.3.4 Increasing episodes of clinical malaria do not affect the balance of IgO 1 and Ig03
responses to AMAI 214
6.3.5 Increased prior P. falciparum exposure does not always result in high subclass and isotype
responses to AMAI 216
6.3.6 The association between isotype and subclass responses to AMAI and protection from
clinical malaria 224
6.4 Discussion 226
Chapter 7 - Acquisition and prevalence of antibodies to specific epitopes of AMAI and their
assoeiation with invasion inhibition and protection from clinical malaria 231
7. t Introduction 231
7.2 Methods 234
7.2.1 Study populations, sample collection, and surveillance 234
7.2.2 Monoclonal antibodies 235
7.2.3 Enzyme-linked immunosorbent assay (ELISA) 235
. 7.2.3.1 Standard ELISA 235
7.2.3.2 Competition ELISA ·.. ··.. ··.. ···.. ·.. ·· ·.. · 236
7.2.4 Growth inhibition assay (OIA) 236
7.2.S Statistical analysis 236
7.3 Results 237
7.3.1 Serological prevalence and reactivity to specific epitopes of AMAI in malaria endemic
settings
...................................................... ······· 237
7.3.2 Age- and exposure-related acquisition ofepitope-specific antibodies 239
7.3.3 Relationship between epitope-specific IgO, anti-AMAI IgO, and IgO responses to schizont
protein extract 243
7.3.4 Association of antibodies to AMAI with protection from clinical malaria 247
7.3.S Association of combined epitope responses with protection from clinical malaria 258
7.3.6 Association between epitope-specific antibodies and inhibition of P. jalciparum growth
......................................................................................................... 260
7.3.7 Association between anti-AMAI IgM interactions and specific mAb epitopes 262
7.4 Discussion 264
Chapter 8 - COD(:luding remarks 269
Refereaees 275
Appendix 1 - Supplementary data (chapter 3) 309
vi
Appendix 2 - Supplementary data (chapter 4) 367
Appendix 3 - Supplementary data (chapter 6) 377
vii
List of Figures
Figure 1.1 The life cycle of Plasmodium falciparum .4
Figure 1.2 Plasmodium jalciparum merozoite structure and antigens 5
Figure 1.3 Merozoite invasion of erythrocytes 6
Figure 1.4 Population indices of immunity to malaria in Kilifi district 14
Figure I.S Structure of the P. falciparum AMA 1 ectodomain 29
Figure 1.6 Gene layouts of MSP2 allelic families .40
Figure 1.1 High throughput duplicates assay correlation 66
Figure 1.2 Correlation between standard ELISA and high throughput ELISA techniques 68
Fllure 3.1 Prevalence of detectable IgG to various merozoite antigens by age 90
Filure 3.2 IgG responses to AMAI and MSP2 by age 92
Fllure 3.3 JgG responses to AMA 1 and MSP2 by schizont protein reactivity 94
Figure 3.4 IgG responses in the presence or absence ofhaemoglobinopathies 98
Fipre 3.S JgG responses to schizont protein and tetanus toxoid in the presence or absence of
haemoglobinopathies 100
Figure 3.6JgG responses by age in the presence or absence of the sickle trait 101
Filure 3.7JgG responses by age in the presence or absence of alpha-thalassemia 105
Figure 3.8 Predicted probability of high IgG titres after recorded exposure 119
Figure 3.9 Predicted probability of a sero-positive IgG response after recorded exposure 123
Figure 4.1 Longitudinal IgG responses to AMA 1 and MSP2 138
Figure 4.1 Tracking of antibody IgG responses to AMA 1 and MSP2 140
Filure 4.3 Longitudinal JgG responses for selected individuals aged of 0-2 years at the start of the
study 142
Figure 4.4 Longitudinal IgG responses for selected individuals aged of 2-5.5 years at the start of the
study 143
Figure 4.S Longitudinal IgG responses for selected individuals aged of 6-7 years at the start of the
study 144
Filure 4.6 Mean longitudinal IgG titres 145
Figure 4.7 LongitudinallgG responses to AMA I(W2met) by age 148
Figure4. 8 LongitudinallgG responses to MSP2(3D7) by age 149
Figure 4.9 Mean longitudinal IgG titres by age 151
Figure 4.10 Mean longitudinal IgG titres by concurrent parasitemia 153
viii
Figure 4.11 Mean longitudinal JgG titres by different levels of malaria exposure 157
Figure 4.12 Mean longitudinal JgG titres in the presence and absence of the sickle trait .160
Figure 4.13 Mean longitudinal JgG titres in the presence and absence of alpha-thalassemia 161
Figure 6.1 Prevalence of total JgG, subclass and JgM responses AMAl(3D7) by age 199
Figure 6.2 Antibody responses to AMA1(3D7) by schizont protein reactivity 206
Figure 6.3 Antibody responses to AMAl(3D7) in the presence and absence of hemoglobinopathies
.......................................................................................................... 208
Figure 6.4 Longitudinal antibody responses to AMA1(3D7) 209
Figure 6.5 Longitudinal antibody responses to AMA 1(3D7) for selected individuals 211
Figure 6.6 Mean longitudinal antibody responses to AMA 1(3D7) 212
Figure 6.7 Mean longitudinal antibody responses to AMAl(3D7) by age 214
Figure 6.8 Mean longitudinal antibody responses to AMA 1(3D7) in children with different numbers of
clinical episodes 21 5
Figure 6.9 Predicted probability of high antibody responses to AMAI(3D7) after recorded exposure
.......................................................................................................... 217
Figure 6.10 Predicted probability of detectable antibody responses to AMAI(3D7) after recorded
exposure 22 I
Figure 6.11 Predicted probability of detectable antibody responses to AMA 1(3D7) after recorded
exposure at different ages 223
Figure 7.1 X-ray structure of P. Jalciparum AMA 1 domains I and II 233
Figure 7.2 Proportion of individuals with positive reactivity to AMAI(3D7) epitopes by age 240
Figure 7.3 Antibody responses to AMA 1(3D7) epitopes by age 242
Figure 7.4 Correlation between antibody reactivity to AMAI(3D7) epitopes and schizont extract
........................................................................................................ 244
Figure 7.5 Correlation between antibody reactivity to recombinant AMAI(3D7) and specific epitopes
......................................................................................................... 245
Figure 7.6 Correlation between antibody reactivity to specific AMAI(3D7) epitopes 246
Figure 7.7 Kaplan-Meier survival curves for the response to recombinant AMAI (3D7) 248
Figure 7.8 Kaplan-Meier survival curves for the response to the IF9 epitope 249
Figure 7.9 Kaplan-Meier survival curves for the response to the 2C5 epitope 250
F' 7 10 K I M' . I f h h 5G .tgure. ap an- eier surviva curves or t e response to t e 8 epitope 251
Figure 7.11 Kaplan-Meier survival curves for different categories of response to the IF9 epitope
........................................................................................................................................ 255
Figure 7.12 Kaplein-Meier survival curves for combined antibody responses to AMAI(3D7) ........ 259
ix
Figure 7.13 Correlation between anti-AMA1(3D7) IgG and growth inhibition 261
Figure 7.14 Correlation between anti-AMA1(3D7) IgG and IF9 epitope reactivity with growth
inhibition 262
Figure 7.1S Correlation between anti-AMA 1(307) IgG and IF9 epitope reactivity with anti-
AMAI(3D7) IgM 263
Figure 8.1 Factores affecting antibody reponses to AMA 1 and MSP2 at different malaria transmission
intensities 270
x
List of Tables
Table 2.1 Ngerenya, longitudinal study gender and parasite distribution 78
Table 2.2 Ngerenya, longitudinal study participants mean and median ages 78
Table 2.3 Ngerenya, longitudinal study prevalence of parasitemic and mild malaria episodes 79
Table 2.4 Ngerenya, September 1998 cohort age and parasite distribution 80
Table 2.5 Chonyi, October 2000 cohort age and parasite distribution 80
Table 3.1 Prevalence of IgG to AMA 1 (W2mef) by age and sample time 87
Table 3.2 Prevalence of IgG to AMA I (HB3) by age and sample time 87
Table 3.3 Prevalence of IgO to AMA I (307) by age and sample time 88
Table 3.4 Prevalence of IgG to MSP2 (307) by age and sample time 88
Table 3.5 Prevalence of IgO to MSP2 (Fe27) by age and sample time 89
Table 3.6 IgG responses to AMAI and MSP2 by age and parasite status in May 2002 93
Table 3.7 Median IgG levels to AMAI and MSP2 at each sample time 95
Table 3.8 IgG responses in the presence or absence ofhaemoglobinopathies in May 2002 99
Table 3.9 IgG responses by age in the presence or absence of the sickle trait in May 2002 102
Table 3.10 IgG responses by age in the presence or absence of alpha-thalassemia in May 2002 106
Table 3.11A Factors affecting IgG titres to AMA I(W2mef) in May 2002 108
Table 3.11 B Factors affecting IgG titres to AMA I(W2mef) in October 2002 109
Table 3.11 C Factors affecting IgG titres to AMA I(W2mef) in May 2003 110
Table 3.11D Factors affecting IgG titres to AMA I(W2mef) in October 2003 111
Table 3.11 E Factors affecting IgG titres to AMA 1(W2mef) in May 2004 112
Table 3.11F Factors affecting IgG titres to AMAl(W2mef) in October 2004 113
Table 3.12 Effect of various factors on IgG responses at different malaria transmission intensities
........................................................................................................ 116
Table 3.13 Correlation between anti-AMA 1 and anti-MSP2 IgO responses 125
Table 3.14 Correlation between anti-AMA I(W2mef) responses at each sampling time 125
Table 3.15 Correlation between anti-MSP2(3D7) responses at each sampling time 125
Table 4.1 Changes in z-scores over the study period 141
Table 4.2 Changes in IgG titres, univariate GEE 146
xi
Table 4.3 Changes in IgG titres compared to baseline 147
Table 4.4 The effect of age on IgG titres, univariate GEE 150
Table 4.S The effect of concurrent parasitemia on IgG titres, univariate GEE 154
Table 4.6 Distribution of parasitemic episodes in the intervals 155
Table 4.7 The effect of malaria exposure on IgG titres, univariate GEE 158
Table 4.8 The effect of sickle trait on IgG titres, univariate GEE 159
Table 4.9 The effect of alpha-thalassemia on IgG titres, univariate GEE 159
Table 4.10 Factors affecting anti-AMAI IgG titres, multivariable GEE 163
Table 4.11 Factors affecting anti-MSP2 IgG titres, multivariable GEE 164
Table 4.1l Anti-AMA 1(W2met) IgG decay rates between May and October 2004 165
Table 4.13 Anti-MSP2(3D7) IgG decay rates between May and October 2004 166
Table S.l Factors affecting the risk of clinical malaria, univariate poisson regression 181
Table S.l Association between IgG responses and the risk of clinical malaria, univariate poisson
regression 183
Table S.3 Adjusted association between IgG responses and the risk of clinical malaria, multi variable
poisson regression 184
Table S.4 Factors affecting the risk of clinical malaria, univariate GEE 186
Table S.S Association between JgG responses and the risk of clinical malaria, univariate GEE 186
Table S.6 Adjusted association between IgG responses and the risk of clinical malaria, multi variable
GEE 189
Table 6.1 Prevalence of anti-AMA I(3D7) IgG by age and sample time 200
Table 6.1 Prevalence of anti-AMA I(3D7) IgG I by age and sample time 200
Table 6.3 Prevalence of anti-AMA I(3D7) IgG3 by age and sample time 201
Table 6.4 Prevalence of anti-AM A] (3D7) IgM by age and sample time 20]
Table 6.S Correlation between antibody responses to AMA 1(3D7) 203
Table 6.6 Antibody responses to AMA 1(3D7) by age and parasitemia in May 2002 205
Table 6.7 Changes in anti-AMAl(3D7) antibody responses, univariate GEE 212
Table 6.8 The effect of age on anti-AMA2(307) antibody responses, univariate GEE 213
Table 6.9 Association between antibody responses to AMA I(307) and the risk of clinical malaria,
poisson regression 225
Table 6.10 Association between antibody responses to AMAI(307) and the risk of clinical malaria,
GEE 226
xii
Table 7.1 Association between antibody responses above and below the median and the risk of clinical
malaria, Cox proportional hazards 253
Table 7.2 Association between antibody responses to the 1F9 epitope and the risk of clinical malaria,
Cox proportional hazards 256
Table 7.3 Association between antibody responses above and below the median and the risk of clinical
malaria, logistic regression 257
Table 7.4 Association between combined antibody responses to AMAl(3D7) and the risk of clinical
malaria, Cox proportional hazards 259
xiii
xiv
1 Introduction
1.1 The Burden of Malaria
More than 3 billion people live in areas where malaria transmission occurs and over I billion of
them reside in areas that are at the highest risk of malaria (> 1 reported case /1OOO/year). In Africa,
where 12% of all those at risk of malaria reside, there were an estimated 212 million cases of
malaria (90% of all cases worldwide) in 2006 which resulted in over 800,000 deaths, with most of
the burden occurring in children younger than 5 years of age (WHO 2008). Over 75% of the cases
of malaria in Africa were caused by Plasmodium [alciparum. With only an estimated 1 in 5
malaria deaths reported worldwide, malaria plays a significant role in world health (WHO 2008).
Though most of the burden of disease due to P. [alciparum is in Africa, malaria endemicity ranges
from hypoendemic to holoendemic as a result of the vector distribution and climate. Up to 12% of
surveys taken in a malaria transmission mapping study (Malaria Atlas Project, MAP) reported zero
parasite prevalence and only 29% reported parasite prevalence above 50% (Guerra et al. 2008).
Even with this great variation in malaria transmission across the continent, the disease has great
economic and social consequences and is believed to contribute to the poorer development indices
observed for endemic countries (Gallup and Sachs 2001; Sachs and Malaney 2002).
Transmission of P. [alciparum malaria varies greatly across Africa, and impacts on the risk of
infection and possible death early in life. Analysis from several sources indicates a wide range,
from as low as a single infectious bite in a decade to several bites daily (Hay et al. 2000).
Increasing malaria transmission intensity leads to increased clinical disease which is highest in
areas of moderate malaria transmission intensity. Clinical disease manifests in younger children as
malaria transmission rises and is seen in increasingly older individuals as malaria transmission
decreases or becomes unstable (Snow et al. 1997; Modiano et al. 1998; Reyburn et al. 2005; Idro et
al. 2006; O'Meara et al. 2008b; Okiro et al. 2009). This is due to the development of clinical
immunity early on in life in areas of stable malaria transmission. The majority of infections of P.
[alciparum in malaria endemic areas are sub-patent, do not result in any clinical symptoms, and are
indicative ofa degree of host immunity. Most of the clinical malaria that is seen is non-severe and
manifests as non-specific febrile illness which is either cleared by the immune system or with the
aid of anti-malarial therapy. Severe malarial syndromes (severe anaemia, impaired consciousness,
metabolic acidosis, malaria in pregnancy) are the cause of a million deaths annually in Africa.
Africa appears to be undergoing a reduction in malaria transmission (observed by falling parasite
prevalence rates and malaria hospital admissions) which has been attributed to large scale malaria
control programmes. Interventions such as the use of effective anti-malarial therapeutics and
insecticide treated bed nets (ITNs) have resulted in reducing both the burden of malaria and its
associated mortality in Africa. Widespread use of ITNs in Kenya resulted in a 44% reduction in
mortality children below 5 years over a two year period (Fegan et al. 2007). The combined use of
ITNs and artemisinin-based combination therapy in Zanzibar reduced mortality by 52% in under-
fives over a two year period (Bhattarai et al. 2007). The use of ITNs also affected malaria
transmission dynamics and reduced parasite prevalence 10-fold in the same study. The continued
use of these interventions has significantly reduced paediatric malaria admissions by up to 62% in
parts of Kenya associated with intensive malaria control programmes (Okiro et al. 2007). Some of
the reduction may be due to other factors such environmental and demographic changes.
1.2 The life cycle of Plasmodium Jalciparum
Malaria is caused by protozoan parasites of the genus Plasmoduim most of which are transmitted
by mosquito vectors. All of the five main species of Plasmodium that naturally infect humans (P.
falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi) are transmitted by the female
anopheline mosquito. All Plasmodium species causing human malaria have a complex life cycle
that involves two stages of replication occurring in the vertebrate host and insect vector (Figure
1.1). Sexual replication occurs in the mid-gut of the insect vector and asexual reproduction in the
human host. The vertebrate stage of the Iifecycle is made up of exo-erythrocytic and erythroytic
parts. Sporozoites injected by the biting mosquito enter the blood within an hour (Vanderberg and
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Frevert 2004; Amino et a1. 2006; Yamauchi et a1. 2007) and infect hepatocytes (Mota et al. 2002;
Pradel et a1. 2002; Frevert et a1. 2005; Baer et a1. 2007). The sporozoites develop in the hepatocyte
and generate numerous daughter merozoites per parent sporozoite within 14 days that are released
at once into the circulation; destroying the host hepatocyte.
Invasion of erythrocytes is thought to occur soon after merozoite release from hepatocytes. The
actual process of invasion is very quick (approximately 60 seconds) and will be discussed in detail
in following sections. Within the erythrocyte, the merozoite differentiates into a flat ring form of
the trophozoite stage and starts feeding on erythrocyte cytosol and haemoglobin (Aikawa et al.
1967; Langreth et at. 1978). During the mature trophozoite stage P. falciparum exports proteins to
the surface of the erythrocyte that are ligands for receptors on host cells and leads to sequestration
in various organs which protects the parasite from elimination by the spleen (Luse and Miller 1971;
Langreth and Peterson 1985). By 38-40 hours post invasion the trophozoite has further
differentiated into a schizont which divides to give 16-20 daughter merozoites (White and Kilbey
1996). At approximately 48 post invasion the distorted erythrocyte bursts and releases the
merozoites into the circulation to continue the erythrocytic cycle. It is during the asexual part of
the life cycle that the symptoms of malaria manifest.
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Figure I.1 Life cycle of Plasmodium parasites showing the various stages that can be targeted by host
immune responses. Human antibodies can act on newly injected sporozoites (i and ii), on merozoites (iv),
and on parasite derived proteins on the surface of infected erythrocytes (v and vi). Immune cells and their
related cytokines can act on infected hepatocytes and the infected erythrocytes (iii and v). In the mosquito
vector antibodies and complement can act on the invasive ookinetes (vii), and innate immunity on newly
released sporozoites (viii) (Greenwood et al. 2008).
Development of the initial sexual forms of the Plasmodium parasites also occurs during the
erythrocytic stage. The decision for development into gametocytes occurs during formation of
pigmented trophozoites (Bruce et al. 1990). The mechanisms involved in this differentiation are
both genetic, with different Plasmodium isolates differing in their propensity to form gametocytes
(Smalley et al. 1981; A lana and Carter 1990), as well as environmental (Price et al. 1996; Buckling
et al. 1999; Talman et al. 2004). Mature gametocytes have reduced adhesive properties and are
released into the circulation where uptake into the mosquito occurs during a blood meal.
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1.3 P.falciparum merozoite invasion of erythrocytes
The merozoite form of P. falciparum is ovoid in shape with an apical prominence at one end
(Langreth et al. 1978). The entire surface of the merozoite is covered in a 'fuzzy' coat of
glycoslphosphatidylinositol (GPf) anchored proteins and peripheral proteins bound to other
membrane-bound proteins (Sanders et al. 2005). Merozoites have a centrally placed nucleus,
ribosomes, a mitochondrion, and a plastid. The apical end of the parasite contains organelles
(micronemes, rhoptries, and dense granules) which secrete proteins that are involved 111 the
mvasion process. Several proteins located on the surface and in the apical organelles of the
merozoite have potential roles in invasion (Figure 1.2). A number of these proteins have been
characterised and will be discussed below.
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Figure 1.2 Structure and major antigens of the P.jalciparum merozoite. The apical end of the merozoite
has specific organelles involved in erythrocyte invasion. Surface proteins may be GPI anchored or associated
with GPI-anchored proteins by molecular interactions. Listed are known proteins of the merozoite surface
and organelles (Richards and Beeson 2009).
Prior to erythrocyte invasion, merozoites are released from the parent schizont in an explosive
event that serves to disperse the merozoites (Glushakova et al. 2005). Several proteases are
involved in the breakdown of the erythrocyte cytoskeleton and membrane, as well as the
parasitophorous vacuole (Salmon et al. 2001; Miller et al. 2002; Hodder et al. 2003). The first
contact that merozoites have with the erythrocyte appears to be a reversible, low affinity interaction
followed by reorientation of the merozoite to ensure interaction between the apical end and the
erythrocyte (Bannister and Dluzewski 1990). A non-reversible tight junction is then formed
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between the erythrocyte membrane and the merozoite. This junction moves along the surface of
the merozoite towards its posterior and permits entry of the merozoite into the erythrocyte. The
movement of the tight junction is powered by an actin and myosin mechanism common to all
apicomplexa (Soldati et al. 2004). Active entry into the erythrocyte results in shedding of the
'fuzzy' coat into the milieu by a serine protease (Harris et al. 2005b). The entire invasion process
takes around a minute from initial attachment to full entry (Figure 1.3) (Gilson and Crabb 2009).
Figure 1.3 Stages of merozoite invasion of erythrocytes. (A) Attachment; (8) apical reorientation; (C)
junction formation and the beginning of rhoptry discharge; (D and E) penetration of the merozoite past the
tight junction into a forming parasitophorous vacuole; (F and G) pinching of the junction, and resealing of the
red blood cell membrane. The surface coat of the merozoite is progressively stripped as it moves through the
tight junction (D to F). The membrane surrounding the fully invaded merozoite is termed the parasitophorous
vacuole membrane (Cowman et al. 2000).
Several merozoite proteins interact with receptors on the erythrocyte surface in each step of the
invasion process. A full discussion on each of these proteins is beyond the scope of this review but
a number of merozoite antigens will be described. The initial reversible attachment of the
merozoite to the erythrocytes is thought to be facilitated by several interactions, but knowledge of
these interactions is very limited. The best defined is the interaction between the most abundant
surface antigen, merozoite surface protein I (MSPl), and receptors on the erythrocyte surface
(Goel et al. 2003). MSPI is one of a family of membrane associated proteins that are present on
the merozoite surface. Following a proteolytic processing event at schizont rupture, MSPI appears
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on the surface of the merozoite as a GP} anchored complex made up of four fragments (Holder et
at. 1992). On invasion of the erythrocyte another proteolytic event (during shedding of the fuzzy
coat) results in cleavage of MSP142 into MSP119 which remains attached to the merozoite
(Blackman et at. 1990; Blackman and Holder 1992). MSP119 contains two epidermal growth factor
(EGF) -like domains that may have essential binding functions (Chitarra et at. 1999). Antibodies
specific to MSPI19 and MSP142 inhibit in vitro merozoite invasion (Blackman et al. 1990; Egan et
at. 1999; Morgan et at. 1999; Darko et at. 2005). In spite of its abundance, MSP1 is not essential
for parasite growth, as was seen by the successful replacement of P. falciparum MSPI EOF-like
domains with those from P. berghei MSP8 (Drew et at. 2004). MSP119 has been reported to bind to
band 3, and recent studies have found that MSP142 binds to heparin-like molecules (Boyle et at. in
press).
MSP2 will be discussed in detail later and will therefore be mentioned briefly here. MSP2 is
abundantly expressed on the surface of mature schizonts and merozoites, is 44-55 kDa in size, and
is also anchored to the merozoite surface via a OPl anchor (Ramasamy 1987; Epping et al. 1988;
Smythe 1988). This unstructured protein may have a role in erythrocyte invasion as was shown by
the formation of immune clusters of merozoites and inhibition of invasion by MSP2-specific
antibodies (Epping et at. 1988; M iettinen-Baumann et at. 1988; Clark et at. 1989; Lyon et at. 1989).
It appears to be essential as attempts to knock-out the gene have been unsuccessful (Cowman and
Crabb 2006).
MSP3 is a 48 kDa protein that is the product of a proteolytic processing of a precursor protein and
associates with other proteins on the merozoite surface (Oeuvray et at. 1994; LaCount et at. 2005).
MSP3 may have a role in erythrocyte invasion as parasites with a truncated form of the protein
invade erythrocytes less efficiently (Mills et al. 2002).
MSP4 is a 40 kDa polymorphic membrane anchored protein (Marshall et at. 1997). MSP4 has 53%
homology with sporozoite and liver stage antigen (SALSA) which is involved in the invasion of
hepatic cells. Antibodies to peptide sequences of SALSA have also recognised MSP4 on the
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merozoite surface (Puentes et al. 2004). A single high activity binding peptide (HABP) of MSP4
that binds to erythrocytes has low invasion inhibition activity and indicates that this protein may be
involved in the initial steps of erythrocyte recognition (Garcia et al. 2007).
MSP6 is a 48 kDa dimorphic protein that forms a complex with MSPI and MSP7 on the merozoite
surface (Trucco et al. 2001; Pearce et al. 2004). Antibodies induced in rabbits by immunisation
with recombinant MSP6 and MSP6-derived HABP inhibit merozoite invasion in vitro suggesting
that this protein has a role in invasion (Pearce et al. 2004; Lopez et al. 2006). MSP7 is a highly
conserved 41 kDa protein and is part of the above mentioned complex on the merozoite surface
(pachebat et al. 2001). Disruption of the msp 7 gene was reported to slow parasite growth and lead
to preferential invasion of reticulocytes (Tewari et al. 2005).
Serine repeat antigen (SERA) is a highly conserved protein that undergoes proteolytic processing
to shorter fragments that are associated with the merozoite surface (Li et al. 2oo2b; Sato et al.
2005). Early studies showed that monoclonal antibodies specific to SERA inhibited merozoite
invasion in vitro (Barr et al. 1991; Bathurst et al. 1993). SERA-specific antibodies have also been
shown to act with monocytes via antibody dependant cellular inhibition (ADCI) mechanisms to
inhibit parasite growth (Pang and Horii 1998; Soe et al. 2002).
Another group of antigens with possible roles in parasite invasion are found in the apical organelles
(micronemes and rhoptries) of the merozoite. Apical membrane antigen I (AMAl) is the most
studied of these and will be discussed in detail later in this chapter. Briefly, AMAI is an integral
membrane protein that is initially localised to the micronemes of the merozoite but spreads to the
merozoite surface after schizont rupture. AMA1 is thought to be involved in the apical re-
orientation of the merozoite, and possibly tight junction formation just before invasion occurs
(Alexander et al. 2006; Baum et al. 2008).
After re-orientation the invasion process begins and involves interactions between proteins secreted
from the apical organelles and receptors on the erythrocyte membrane. The erythrocyte binding
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antigens (EBA) have a Duffy binding-like (DBL) domain and are contained in the micronemes and
include EBA140, EBA175, EBA181, and EBLl (Camus and Hadley 1985; Gilberger et al. 2003b;
Mayer et al. 2004; Mayer et al. 2009). EBAs bind to sialic acid on the erythrocyte surface but can
utilise alternative receptors for erythrocyte invasion (Duraisingh et al. 2003b; Stubbs et al. 2005).
EBA175 is a 175KDa soluble protein that is found in the supernatant after schizont rupture (Sim et
al. 1992). Although EBA175 is involved in parasite invasion, gene disruption does not inhibit this
process thus showing that it is not essential for parasite invasion (Kaneko et al. 2000; Reed et al.
2000; Duraisingh et al. 2003a) because of a degree of redundancy between the different EBAhd
PtRh proteins. Interestingly, antibodies specific to EBAl75 are able to inhibit merozoite invasion
in vitro (Orlandi et al. 1992). EBAl81 is likely to playa similar role to that of EBA175.
Disruption of the gene has no detectable effect on parasite invasion (Gilberger et al. 2003a).
EBAl40 is not expressed by all P. falciparum strains and although it plays a role in invasion, it is
not required for invasion and growth of parasites (Thompson et al. 2001). EBA140 binds to
glycophorin C receptor on erythrocytes (Lobo et al. 2003).
Rhoptry proteins are thought to be released onto the merozoite membrane where they play
important roles during invasion. The reticulocyte binding protein homologue family (PtRh)
includes PtRh1, PtRh2a, PtRh2b, PtRh4, and PtRh5 which are variably expressed by the merozoite
(Rayner JC 2001; Duraisingh et at. 2003b; Stubbs et al. 2005; Triglia et al. 2005; Baum et al.
2009). The Rh proteins bind to various receptors on the erythrocyte surface so their variable
expression may be a way for the merozoite to utilise different invasion pathways (Duraisingh et at.
2003b; Stubbs et at. 2005) and evade immune responses (Persson et at. 2008). This family of
proteins are related to reticulocyte binding proteins in P. vivax which allow the merozoites to
preferentially invade reticulocytes rather than mature erythrocytes (Galinski et al. 1992; Galinski
and Barnwell 1996; Galinski et at. 2000). They are also related to the p235 rhoptry proteins in P.
yoelii. Interestingly, merozoites from the same schizont can express different members of these
proteins which may be a mechanism for immune evasion (Preiser et al. 1999).
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Rhl binds to a sialic acid-dependent trypsin-resistant receptor on the erythrocyte membrane
referred to as receptor Y (Rayner et a1. 2001). Anti-PtRHl antibodies inhibited merozoite invasion
of trypsin treated erythrocytes which helped defme a trypsin independent pathway of merozoite
invasion (Rayner et al. 2001). Two erythrocyte HABPs of PtRHl also had invasion inhibitory
activity in vitro (Valbuena et al. 2003). Though important in invasion, Rhl is not essential for
parasite survival as the gene has been successfully knocked out in P. falciparum parasites (Triglia
et al. 2005). Rh2a and Rh2b are proteins more than 350 kDa in size with identical amino acid
sequences apart from the C-terminal region (Rayner et a1. 2000; Triglia et a1. 2001). Both Rh2a
and Rh2b genes can be knocked out and have no effect on parasite survival although Rh2b is
required for interaction with receptor Z which is sialic-acid independent (Triglia et al. 200 I;
Duraisingh et al. 2003b). Although non-essential, these proteins are involved in invasion as
antibodies specific to both have inhibited invasion of3D7 parasites (Triglia et al. 2001). Rh4 has
been shown to be essential for invasion pathway switching via differential expression and is
responsible for sialic acid-independent invasion (Stubbs et al. 2005). Antibodies to Rh4 can also
inhibit invasion (Tham et a1. 2009).
Rhoptry associated protein I (RAPl) is found in a non-covalently bound complex (called QF3)
with RAP2 and RAP3 on the merozoite surface (Clark et a1. 1987; Ridley et al. 1990). Although
monoclonal antibodies to RAPI and RAP2 inhibit invasion, merzozoites with truncated RAPt
proteins can successfully invade erythrocytes (Schofield et al. 1986; Hamyuttanakom et al. 1992;
Baldi et al. 2000). All the proteins mentioned above and numerous others that are likely to have
roles in merozoite invasion of erythrocytes indicate the complexity of this process.
1.4 Immunity to blood-stages of P.falciparum infection
Due to the focus of this thesis, this review of immunity to malaria will focus only on P. falciparum
rather than other human malarias, and primarily focus on human studies rather than animal models.
Infection with P. falciparum in natve individuals may be clinically significant the first time. Only a
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few individuals develop significant clinical symptoms even with continuous exposure to the
parasite. Natural non-sterile immunity is acquired in these individuals as evidenced by the
presence of measurable parasites in their blood and a lack of clinical symptoms. This non-sterile
immunity is a combination of various immunological responses to infection. Clinical immunity is
defined as the acquired response that protects against disease in spite of the presence of
parasitaemia and protects against mild or 'severe disease. Anti-parasite immunity is the acquired
response that severely inhibits growth and replication of parasites or completely eliminates them
from the individual, or prevents the infection of hepatocytes. Clinical immunity develops earlier
than anti-parasite immunity. Reduction in severe disease incidence precedes the reduction of
parasitaemia by several years (Marsh and Snow 1997). In areas of moderate to high transmission,
after the initial susceptibility to severe malaria, children often develop clinical immunity by the age
of five. At this point they still have high parasite burdens. At the population level, this immunity
to severe non-cerebral malaria is generated after 2-3 episodes of disease (Gupta et al. 1999). Anti-
parasite immunity appears to be more difficult to generate and less efficacious in its nature.
Therefore immunity to malaria develops in three stages, with protection from severe disease
generated much earlier than that to mild disease, and finally, only partial immunity to parasitisation
per se.
Innate and adaptive immune responses are required for the establishment of both clinical and anti-
parasite immunity to P. falciparum malaria. Repeated infection of non-immune individuals shows
that the peak parasitaemia reached in an individual is independent of parasite strain or species
(Molineaux et al. 2002). This could be due to the induction of the innate immune system and is
supported by further studies showing that the mechanisms of innate immunity are triggered when
parasite density reaches a particular threshold (Kwiatkowski and Nowak 1991; Bruce and Day
2003). These mechanisms limit the maximum parasite density in a stage and strain independent
manner until the adaptive immune mechanisms can then eliminate the parasites (Richie 1988).
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1.4.1 IB_te lm.uBe responses to infection
The innate immune response is the first line of protection against all invasive organisms and is
carried out by the coordinated efforts of several cell types that are triggered by molecules
characteristic of microbial pathogens. Monocytes are found in the peripheral circulation before
migration into tissues and differentiation into macrophages. In these localities macrophages are
involved in the general clean up of end products resulting from normal cellular activity as well as
the destruction of extracellular and intracellular pathogens. Most macrophages are found in the
spleen where they play a role in the removal of altered or aged erythrocytes. Macrophages are
activated by pro-inflammatory cytokines and in this state can activate memory T cells as well as
promote 8 cell differentiation. Natural Killer (NK) cells are lymphocytes with natural cytotoxic
activity that do not require activation by any other cell type in order to act. Their activity is
regulated by a balance in the expression of inhibitory and activating receptors through which
inducible molecules, pathogen markers, or stress signals may be relayed. Natural Killer T (NKT)
cells are a line of cells that have the characteristics of both NK and T cells. They are found in the
periphery as well as the spleen and thymus and are particularly abundant in the liver. NKT cells
are directly cytotoxic to virus infected cells (Skold and Behar 2003) and could act in an
immunoregulatory manner in the activation of T cells (Hansen et al. 2003). roT cells are found in
the gut and mucosal tissues of adults. They are a small percentage of circulating T calls but may
play a part in immunity to intracellular pathogens such as Plasmodium (Die Ii et al. 200 I).
Dendritic cells are classic antigen presenting cells that reside in all tissues of the body. They
continuously screen their environment and are activated on interaction with foreign antigen or
cytokine release from infected cells. On activation they migrate to the lymph nodes and spleen
where they trigger a cascade of activation and maturation steps in cells of the adaptive immune
system. All these cell types respond to Plasmodium infection in model systems as well as natural
infection in humans.
Plasmodium infected erythrocytes bind to CD36 that is expressed on macrophages leading to their
phagocytosis in vitro (Serghides et al. 2003). Other in vitro studies show that macrophages release
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TNF-a when exposed to infected erythrocytes (Scragg et al. 1999; Hensmann and Kwiatkowski
2001). Even at sub-patent levels of infection, in vivo studies show elevated levels of NK cell
activation markers (Hermsen et al. 2003). These cells produce IFN-y soon after encountering
infected erythrocytes in vitro (Artavanis-Tsakonas and Riley 2002). NKT cells also produce IFN-
y, but later than NK cells (Artavanis-Tsakonas et al. 2003). y8T cells are activated by infected
erythrocytes and their numbers in the peripheral blood increase during acute disease (Hviid et al.
2001) and the frequency of these cells is twice as high in healthy Ghanaian adults compared to their
European counterparts (Hviid et al. 2000). yoT cells also inhibit growth of blood-stage P.
falciparum parasites when in contact with the infected erythrocyte (Troye-Blomberg et al. I999).
Infected erythrocytes have been shown to modulate the function as well as maturation of dendritic
cells (Urban et al. 1999). These cells have a reduced ability to produce 11-12and cannot activate
T cells. Dendritic cells that have derived from monocytes that have phagocytosed haemozoin are
unable to properly respond to maturation signals which will also have an effect on downstream
activation of effector cells (Skorokhod et al. 2004). The innate immune response is therefore
essential for limitation of the initial round of parasite replication and giving the host time to mount
an adaptive immune response.
1.4.2 Adaptive immune responses to infection
Naturally acquired immunity to malaria is dynamic and appears in those individuals with exposure
to the infective Plasmodium parasite. The earliest known evidence for acquired immunity to
malaria came about by examination of blood smears by Robert Koch from individuals living in
high and low malaria endemicity settings in Java in the late 1800s when he observed that control of
parasite density came sometime after immunity from clinical disease. This was confirmed some
decades later (McGregor et al. 1956). Later studies showed that acquired immunity to malaria
occurs in two main phases. Anti-disease immunity protects against morbidity and appears to be
acquired relatively quickly early on in life followed by anti-parasite immunity which protects
against high parasite densities but not total parasite clearance (Marsh and Snow 1997; Gupta et al.
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1999). Sterilising immunity to malaria is probably rarely achieved or sustained, and adults in
endemic areas are often asymptomatic carriers of Plasmodium. Population indices of immunity to
malaria in an area of meso endemic transmission in Kenya shows that immunity to severe disease is
achieved by the age of five followed by immunity to mild disease in children younger than 12 years
and eventual, though non-sterile parasite immunity in adults (Marsh 1992; Marsh and Kinyanjui
2006) (Figure 1.4).
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Figure 1.4 Population indices of immunity to malaria - Kilifi. The figure shows representative data from
a number of studies in Kilifi District on the coast of Kenya. The age pattern of asymptomatic parasite
prevalence and the period prevalence of both mild and severe clinical malaria are shown in relation to
maximum prevalence recorded (Marsh and Kinyanjui 2006).
1.4.2.1 Cell-mediated immunity to malaria
Cell-mediated responses play an important role in protective immunity to malaria but due to the
focus of this thesis will only be discussed briefly. Early evidence for cell-mediated immunity came
from murine malaria models that demonstrated the development of malaria immunity in the
absence of antibodies. Mice which had their B cell development inhibited or were genetically
deficient in B cells and had previously experienced parasite challenge managed to mount a
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secondary immune response but were unable to completely clear their infections (Grun and
Weidanz 1983; van der Heyde et at. 1994; von der Weid et at. 1996). Further evidence came from
the adoptive transfer of both splenic cells and T cells in the absence of antibodies to naive mice
which led to their protection from parasite challenge (Spitalny et at. 1977; Egan et al. 1987). A
possible mechanism for the action of cell-mediated immunity in the absence of antibodies would
involve an interaction between antigen presenting cells and CD4+ T cells leading to CD4+ T cell
activation and the resulting activation of macro phages and production of effector molecules (Good
2001). Implication of CD8+ T cells in murine immunity came from studies where CD8+ T cells
were depleted from immune mice and resulted in loss of immunity (Schofield et al. 1987; Weiss et
at. 1988).
In humans, a role for both CD4+ and CD8+ T cells in immunity to malaria has been suggested in a
number of studies. Malaria exposed human CD4+ T cells can proliferate and release IFN-y on
exposure to a range of pre-erythrocytic and erythrocytic antigens (Zevering et at. 1992; Ndungu et
al. 2006). The presence of CD4+ T cells that are specific to a conserved sequence in
circumsporozoite protein (CSP) were predictive of protection from both malaria infection and
disease in The Gambia over 4 months (Reece et at. 2004). CD8+ T cells, which are found in
naturally exposed populations as well as vaccinated individuals, have also been associated with
protection from severe malaria in children (Hill et at. 1991). Immune cells secrete both anti-
inflammatory and pro-inflammatory cytokines and the balance of these cytokines can contribute to
the various malaria syndromes as well as their possible outcomes, as has been seen in studies
carried out in Vietnam and Gabon on adults and children (Day et al. 1999; Perkins et al. 2000).
Down-regulation of IFN-y has been observed in individuals living in an area of high malaria-
transmission of Ghana compared to those living in an area of low-malaria transmission in the same
country (Rhee et at. 2001). The authors suggest that clinical immunity (as would be achieved by
individuals in high malaria-transmission settings) may be associated with the down-regulation of
pro-inflammatory cytokines and thus a reduction in the symptoms of malaria.
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1.4.2.2 The role of antibodies in protection against malaria
Antibodies have been shown to playa significant role in protection against malaria in both animal
models and human studies. The earliest evidence for the protective effect of antibodies was
produced by experiments carried out in the Gambia where purified immunoglobulin from immune
adults was transferred to children suffering from clinical malaria (Cohen et al. 1961). Eight out of
12 children (aged 4 - 30 months) managed to clear their parasitaemia. A later study endorsed the
earlier findings by showing the protective effect of purified African IgG on clinical symptoms as
well as parasitaemia in eight Thai patients (Sabchareon et al. 1991). Naturally occurring transfer of
antibodies from pregnant mothers to the foetus via the placenta also suggested a protective effect of
maternal antibodies from clinical disease and parasite density in infants below 6 months (Hogh et
al. 1995; Branch et al. 1998).
The three main mechanisms by which antibodies may carry out their protective role are; (a)
inhibition of invasion of merozoites into erythrocytes, (b) inhibition of adhesion of parasitised
erythrocytes to endothelial walls, and (c) antibody-immune cell interactions such as antibody-
dependent cellular inhibition (ADCI), neutrophil-mediated killing, and opsonic phagocytosis.
1.4.2.2.1 Invasion Inhibition
Inhibition of invasion was put forward as a possible mechanism of antibody action in 1970 when
the addition of immune serum to P. knowlesi cultures did not affect parasite growth but reduced
reinvasion of parasites (Cohen and Butcher 1970). In vitro inhibition activity was further
demonstrated by immune serum from convalescent Gambian children and healthy Papua New
Guinean adults (Wilson and Phillips 1976; Brown et al. 1982). Agglutination of merozoites by
monoclonal antibodies specific to merozoite antigens also led to a marked reduction in invasion
(Epstein et al. 1981). Possible mechanisms of invasion inhibition suggested are inhibition of
binding of merozoite proteins to erythrocyte receptors, agglutination of merozoites or inhibition of
processing of those antigens essential for invasion (Cohen and Butcher 1970; Blackman et al. 1994;
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Dutta et al. 2003). The effectiveness of invasion inhibitory antibodies was also reduced by the
action of naturally occurring antibodies that block the action of invasion inhibitory antibodies to
MSPI (Guevara Patino et al. 1997; Nwuba et al. 2002).
Though inhibition of invasion was shown to be dose dependent in early studies, higher antibody
titres were not always predictive of invasion inhibition by sera from different malaria endemic
regions of the Philippines (Cohen and Butcher 1970; Sy et al. 1990). Inhibition of invasion by
monoclonal and polyclonal antibodies specific to antigens involved in invasion such as MSPI
(Chappel and Holder 1993; Rotman et al. 1998), AMAI (Hodder et al. 2001), EBA175 (Narum et
al. 2000a; Rayner JC 2001), and Rh2b (Duraisingh et al. 2003b) showed the effective specific
action of antibodies though results were variable.
The observation that actual values of invasion inhibition (reported as the percentage growth
compared to a control culture) could vary widely even when using the same sera led to growth
inhibition assay (GIA) technique standardization (Persson et al. 2006). This high throughput
method produced results that were more consistent from smaller sample volumes. The high
throughput method allowed for population studies to be carried out where the relationship between
invasion inhibition and protection from clinical malaria could be investigated. It was hypothesised
that the amount of functional antibodies would increase with age and exposure. High levels would
likely be associated with protection from clinical malaria. Two studies carried out on samples from
Kenya show that invasion inhibition activity appears highest in children and decreases as children
get older (Dent et al. 2008; McCallum et al. 2008). Although high inhibitory activity was related to
a modest delay in time to infection in one study, there was no reduced risk of symptomatic malaria
in the other study (Dent et al. 2008; McCallum et al. 2008). These studies indicate that invasion
inhibition may playa more significant role when the parasite burden is relatively high (childhood)
but may not contribute much to protection against subsequent clinical malaria episodes.
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1.4.2.2.2 Adhesion Inhibition
Cytoadherence of parasitised erythrocytes to endothelial cells of capillaries and the downstream
associated effects are the cause of severe malaria syndromes. P. falciparum sequesters in organs in
order to evade clearance from the host via the spleen. During the mid-late trophozoite stage, the
parasite inserts proteins into the erythrocyte cell membrane that facilitate adhesion to endothelial
cells. These variant surface antigens (VSAs) - of which P. falciparum erythrocyte membrane
protein 1 (PtEMP-l) is the best known - bind to numerous receptors on host cell surfaces including
CD36 and inter-cellular adhesion membrane protein 1 (ICAM-I).
VSAs undergo clonal antigenic variation and utilize this antigenic switching to evade the host
immune response and maintain chronic infections (Brown et al. 1968; Butcher and Cohen 1972).
Up-regulation and expression of certain var genes is associated malaria pathogenesis including
severe childhood malaria and pregnancy associated malaria (Salanti et al. 2003; Deitsch and Hviid
2004; Jensen et al. 2004; Warimwe et al. 2009). VSAs are thought to be major targets of protective
immune responses as blocking their action is thought to have a direct effect on the pathogenesis of
malaria. Several studies have shown that individuals rarely have antibodies to the VSAs expressed
by the infecting isolates but these are quickly acquired after infection, and subsequent disease
episodes will be caused by parasites with VSA types that are not already recognized by the
individual (Marsh and Howard 1986; Bull et al. 1998; Giha et al. 1999; Ofori et al. 2002). Anti-
VSA antibodies that inhibit the adhesion of parasitised erythrocytes to chrondoitin sulphate A
(CSA) on placental cells have been detected in multigravidae women who appear more able to
induce this response faster than primigravidae women (Fried et al. 1998; Ricke et al. 2000; O'Neil-
Dunne et al. 2001; Costa et al. 2006). This action is thought to be one of the mechanisms that
protect against placental malaria. Anti-VSA antibodies also promote clearance of parasitised
erythrocytes by opsonic phagocytosis (Tebo et al. 2002; Keen et al. 2007; Feng et al. 2009).
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1.4.2.2.3 Antibody-dependent cellular inhibition
Antibody-dependent cellular inhibition (ADCI) involves an interaction of the Fe region of
antibodies with receptors on monocytes that induces destruction of the opsonised foreign. It has
also been suggested that monocytes release soluble factors that also inhibit parasite growth. Several
in vitro studies carried out in the 1980s showed that ADCI is a significant part of the antibody
dependent response to P. falciparum. Phagocytosis of merozoites and parasitised erythrocytes by
moncytes from malaria patients was seen only in the presence of hyper-immune sera from malaria
patients, whereas non-immune sera could not induce the phagocytosis of parasitised or non-
parasitised erythrocytes (Khusmith et al. 1982). The ability of monocytes from non-sensitised
individuals to phagocytose merozoites and parasitised erythrocytes with increasing efficiency as
sera from increasingly immune individuals was added cemented the role of antibodies in ADCI
(Khusmith and Druilhe 1983). A co-operative effect between non-sensitised monocytes and
immune sera on reduction of P. Jalciparum growth was also noted (Khusmith et al. 1982).
Antigen targets of antibodies involved in ADCI include MSP3 and GLURP (Oeuvray et al. 1994;
Theisen et al. 1998). These studies show a clear role for anti-malaria antibodies in ADCI.
1.4.3 Antibody maintenance in malaria
Antibody levels to merozoite antigens are short-lived and appear dependent on the level of malaria
transmission in the area. This has been shown in several studies including one in which antibody
levels to RAPI were measured in individuals living in areas with differing malaria endemicity
(Gambia, Indonesia, Kenya, and Sudan). Antibody levels increased with increasing malaria
endemicity (Jakobsen et al. 1997). More recently, a study carried out in Kenya measuring IgGI
and IgG3 levels to MSP1, MSP2, AMA I, and EBA 175 in convalescent children showed that
antibody levels dropped significantly 12 weeks after an episode of moderate to severe malaria
requiring hospital admission (Kinyanjui et al. 2007). In areas of seasonal malaria transmission,
antibody levels appear to be maintained as long as parasite exposure continues. Several studies
comparing the antibody response in adults and children during wet (high transmission) and dry
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(Iow transmission) seasons consistently support this observation (Fruh et al. 1991; Ramasamy et al.
1994; Cavanagh et al. 1998; Soares et al. 1999b; John et al. 2002). The drop in antibody
prevalence to several antigens including MSPl, MSP2, CSP, and liver stage antigen I (LSAI)
ranged nom 11% over five months in Kenya up to 50% over three months in Sri Lanka
(Ramasamy et al. 1994; John et al. 2002).
As antibody prevalence is positively associated with higher malaria transmission, the findings that
antibody levels are higher in parasitised individuals does not come as a surprise. Empirical
evidence for this was shown when the antibody levels to P. vivax MSPI in individuals whose
patent parasitaemia was treated by use of anti-malarial drugs dropped when the infection was
cleared (Soares et al. 1997). A further study showed an average 13-fold drop in antibody levels to
MSPI following treatment (Soares et al. 1999a). Other studies on MSP2 also showed that antibody
prevalence was associated with presence of parasites though there was only a significant increase in
the levels ofparasitised compared to non-parasitised children rather than in adults (AI-Yaman et al.
1994).
Not all antibody responses are short-lived; there appears to be a long-lived antibody response that
can be maintained in adults. Two studies in the Gambia showed no significant change in adult
antibody levels to MSPI and MSP2 over a period of up to two years although children exhibited
fluctuating levels of antibodies during the dry and rainy seasons over a period of three years (Riley
et al. 1993; Taylor et al. 1996). Antibodies to schizont and crude sporozoite extract were shown to
persist in adults from Senegal and Burkina Faso up to II years after they had settled in Paris
(Druilhe et al. 1986). Initial exposure to Plasmodium does not need to occur over a long period of
time. A single P. vivax outbreak that occurred in 1988 in a non-endemic region in Brazil was
followed by intensive anti-malaria therapy that cleared all parasitaemia in the population. Without
any subsequent exposure to malaria, antibodies to MSPI could still be detected in 47% of
individuals after 7 years (Braga et al. 1998).
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When taken into account, most evidence points to a relatively short-lived antibody response that is
rapidly initiated on subsequent exposure to antigen. But the fact that some antibodies can be
detected in some individuals long after exposure to malaria is indicative of sustained antibody
secretion by plasma cells. Antibodies may be released by long-lived plasma cells which occupy a
niche in the spleen and bone marrow (Slifka and Ahmed 1998; Manz et al. 2002) or sub-patent
persistent infection could also re-stimulate memory B cells (Ochsenbein et at. 2000; Bernasconi et
at. 2002). The evidence for immune memory against malaria is limited. But interestingly, small
numbers of memory B cells to MSPl, AMAl, and CIDRla have been detected in individuals
living in a malaria-endemic area (Dorfman et al. 2005).
Contrary to the response to malaria infection, natural or vaccine-induced antibody responses to
some other infections appear to be long-lived. Antibody titres to measles have a half life of 12
years and antibodies can still be detected using a plaque reduction neutralisation antibody assay up
to 33 years after vaccination (Dine et at. 2004). The long-lived antibody response to tetanus toxoid
also appears to be maintained by the effective establishment of a pool of long-lived plasma cells as
well as memory B cells. In the United Kingdom the triple vaccine for diphtheria, tetanus, and
pertussis (DTP) is given at 2-4 months and at 4-5 years; and the tetanus and low dose diptheira
vaccine (Td) given at 15-19 years as a booster. Even without the booster dose at 15-19 years,
protective levels of antibodies to tetanus toxoid could be detected in 53% of individuals over 60
years of age (Maple et al. 2000). In Kenya tetanus immunisation occurs as a single dose in infancy
with few opportunities for boosting either by immunisation. Antibodies to tetanus toxoid could
still be detected in 71% of Kenyan individuals tested (Dorfinan et at. 2005). Memory B cells
specific to tetanus toxoid are present in vaccinated individuals (Lanzavecchia et at. 1983;
Leyendeckers et at. 1999; Nanan et at. 2001).
1.4.4 Haemoglobinopathies and resistance to malaria
Sickle cell and a+ thalassemia are two main haemoglobinopathies affecting the incidence of
malarial disease in Africa. Sickle cell is caused by a structural variant S of haemoglobin which
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results in the adoption of a characteristic sickle shape by erythrocytes. Alpha (a+) thalassemia is
characterised by low production of normal a-globin chains during haemoglobin production. Early
observations that the prevalence of the sickle cell trait (HbAS) overlapped with areas of high
malaria transmission led to the hypothesis that HbAS individuals had a selective advantage against
their normal (HbAA) counterparts with regards to malaria outcome. Case control studies in West
and East Africa established that indeed, HbAS does confer a considerable resistance to severe and
complicated malaria (Willcox et a1. 1983; Aidoo et a1. 2002). More recently, it was shown that
although HbAS had no effect on asymptomatic malaria, it was almost 90% protective against
severe or complicated malaria in children below the age of five and resulted in parasite loads more
than 4-fold less than in HbAA children (Williams et al. 2005b).
The immunity conferred by HbAS is in part due to the physical nature of the erythrocytes although
immune regulation has also been implicated. Up-regulation of cell-mediated responses to malaria
antigens in individuals from Sudan along with increased recognition of parasite infected
erythrocytes in Gambian children was the initial evidence for immune regulation in HbAS
individuals (Marsh et a1. 1989; Bayoumi et a1. 1990; Abu-Zeid et a1. 1992). HbAS may regulate
both the innate and adaptive arms of immunity. This was investigated in a study in Kenya which
showed that protection from clinical malaria increased with age at a more rapid pace in HbAS
children than in HbAA children, thus implying a role for HbAS is regulation of the adaptive
immune response (Williams et al. 2005a).
Epidemiological studies in Melanesia suggested that a+ thalassemia is selected for by malaria
based on the altitude- and latitude-dependent correlation between P. falciparum prevalence and the
frequency of a+ thalassemia in the region (Flint et al. 1986; Yenchitsomanus et al. 1986). Studies
in Papua New Guinea and Kenya showed that homozygotes for a+ thalassemia were 60% more
protected than normal individuals from severe malaria (Alien et a1. 1997; Williams et al. 2005d).
Both these studies also showed that heterozygotes were also 40% more protected than normal
individuals. A smaller study in Ghana showed the same protective effect in heterozygotes but not
in homozygotes (Mockenhaupt et a1. 2004). Although inhibition of parasite growth and invasion
have been suggested as mechanisms for the protective action of a+ thalassemia, this seems unlikely
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as the parasite densities measured in the Kenyan study were no different in homozygotes and
normal individuals (Williams et at. 2005d; Wambua et at. 2006). Another study in Papua New
Guinea also suggested that mechanisms other than inhibition of parasite growth or invasion confer
this protection as they observed the same parasite densities as seen by Williams et al and Wambua
et al (Fowkes et at. 2008). Interestingly, when both haemoglobinopathies are inherited together,
their individual protection from severe malaria is lost. Children with HbAS and homozygous for
a+ thalassemia were at the same risk of severe malaria as baseline in a study carried out in Kenya
which may be explained by negative epistasis (Williams et at. 2005c).
A number of other haemoglobinlopathies have been associated with protection from malaria, but
will not be summarised here in the interests of space.
1.4.5 The effect of exposure on immunity to malaria
The distribution of malaria morbidity and mortality is dependent on malaria transmission intensity.
When hospital admissions due to malaria are analysed a pattern of rapidly increasing admission
rates with increasing transmission that saturates as transmission intensity rises is observed, and may
even decline in areas of hyperendemicity (Snow 1987; Trape et al. 1987; Marsh and Snow 1999).
Numerous studies, including some carried out in Burkina Faso, Uganda, and Tanzania indicate that
the mean age that children present with symptomatic malaria is consistently lower in areas of high
transmission (Modiano et al. 1998; Reyburn et at. 2005; Idro et al. 2006). The median age of
children presenting at hospital was 1 year in a high transmission setting compared to 3 years and 5
years in medium and low transmission settings (Reyburn et al. 2005).
In a recent longitudinal study that analysed malaria rates over 16 years in an area with changing
malaria transmission intensity the mean age of children experiencing clinical malaria increased as
malaria transmission decreased (O'Meara et al. 2008b). Although the incidence of cerebral malaria
initially increased over the study period, the overall rates of malaria mortality declined due to a
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decrease in the rates of severe malarial anaemia (O'Meara et al. 2008a). These results agree with
earlier fmdings that the prevalence of severe malaria syndromes is partly dependent on
transmission intensity. Presentation of cerebral malaria is higher in areas of low transmission
intensity whereas severe malarial anaemia is more prevalent in high transmission settings and is
exhibited by younger children than those presenting with cerebral malaria (Marsh and Snow 1999).
In areas of differing malaria endemicity there is a significant linear relationship between the
intensity of exposure as measured by the entomological inoculation rate (EIR) and both prevalence
and density of P. falciparum infection (McElroy et al. 1994; McElroy et al. 1997; Beier et al.
1999). Higher density parasitaemia was observed during high transmission seasons compared to
low transmission seasons although no overall change in parasite prevalence was seen from season
to season (Trape et al. 1993; McElroy et al. 1994). In a low transmission setting in Senegal,
incidence of primary episodes of clinical malaria peaked during the high-transmission season in
children between 7 and 11 years of age (Trape et al. 1993). Severe malaria is observed even in
areas of very low transmission intensity though the risk in childhood remains lowest in higher
transmission settings (Mbogo et a1. 1993; Mbogo et al. 1995).
A large study in Congo that involved 500,000 study participants residing in areas of different
transmission intensity indicated that large differences in malaria exposure may affect severe
malaria rates slightly (Trape et al. 1987). This was confirmed in later studies that investigated
malaria morbidity and mortality in infants and children living in areas of differing malaria
transmission. By examination of hospital admission records in Kenya and Tanzania it was
established that although the prevalence of severe disease was similar in both settings, the risk was
higher in children below the age of one when in high transmission settings but this fell dramatically
over the ensuing 10 years of life (Snow et al. 1994). In the comparable low transmission setting,
risk of severe disease became higher in the second year of life and remained so over the next ten
years.
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Further observations in five settings of variable transmission intensity confirmed that the mean age
of malaria disease decreased with increasing transmission intensity (Snow et al. 1997). In high
transmission settings the risk of severe malaria declined significantly after 6 months of age
compared to those in low transmission settings where the risk rose after five months and remained
high throughout infancy (Snow et al. 1998). In both Congo and Kenya, the incidence of severe
malaria was the lowest in children with the highest malaria exposure (Trape et al. 1987; Snow et al.
1997). These studies suggest that clinical immunity develops at different rates dependent on
transmission intensity. Children living in a high transmission setting are exposed to malaria earlier
and more frequently which leads to development of clinical immunity at a younger age.
1.4.6 The effect of age on immunity to malaria
The resistance to clinical malaria and infection that is exhibited by adults living in hyper- and holo-
endemic areas of malaria transmission is thought to be due to the cumulative exposure over many
years to malaria resulting in strong strain-specific and a degree of strain-transcending immunity.
Another hypothesis is that the immunity exhibited by adults over children may be contributed by
intrinsic host factors that are attributable to normal development of the host and immune system.
Observations in areas of differing malaria transmission intensity also point to an age-dependent
factor in immunity to severe disease. Over various transmission settings in Africa there is a trend
of reducing incidence of severe anaemia as children approach their fifth birthday whilst incidence
of cerebral malaria increases with age (Snow et al. 1994; Imbert et al. 1997; Snow et al. 1997;
Modiano et al. 1998). Two studies in children below 6 showed that as children got older parasite
prevalence dropped, and although they were at less risk of high density parasitaemia increasing age
was not predictive of reduced incidence of parasitaemia (Beadle et at. 1995; McElroy et at. 1997).
Peak parasitaemia in high transmission settings occurs in children at about five years of age and
declines in an age-dependent manner (Marsh et at. 1995). The same pattern is seen in low
transmission settings but with the peak occurring at an older age.
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The most convincing evidence for the age-dependent hypothesis comes from studies on
transmigrant populations in Irian Java. A re-settlement scheme of the Indonesian government from
densely populated non-malaria endemic islands to less populated malaria-endemic islands was the
setting for a natural experiment for the effect of age on malaria immunity (Baird et al. 1991; Baird
et al. 1993; Hudson Keenihan et al. 2003; Keenihan et al. 2003). Here, it was possible to separate
the effect of age and exposure as the transmigrants were a relatively naive population with 20
months exposure that could be age-matched and directly compared to that of the native population
that had experienced life-long exposure.
Comparison of parasite prevalence revealed that although overall parasite prevalence was higher in
the transmigrant population, both populations exhibited a decrease in prevalence as age increased
(Baird et al. 1991). Also, although overall time to first infection was shorter in the transmigrant
population than the native one, the time to first infection increased with age in both populations in
all age groups thus implying that the benefit of life-long exposure was no different in children and
adult natives. In malaria endemic populations there is a drop in parasite prevalence as age
increases which is attributed to immunity due to cumulative exposure to malaria. In the first year,
parasite prevalence in the transmigrant population of did not decrease with age although 16 to 24
months later a pattern of decreasing parasite prevalence with increasing age became apparent
(Baird et at. 1993).
On initially moving to malaria-endemic Irian Java, 95% of 240 transmigrants tested did not have
measurable antibodies to ring-infected erythrocyte antigen (RESA). 20 months later, not only
could antibodies to RESA be detected in the transmigrant population, sero-positivity significantly
increased with age (Baird et al. 1991). This pattern was similar to that in the native population
which, in that population would have been indicative of long term cumulative exposure to malaria.
Glycosyphosaphatidylinositol (GPI) anchors are the major carbohydrate modification in
erythrocytic P. falciparum, and are thought to be released into the circulation during schizont
rupture, and elicit an immune response in malaria exposed individuals. Anti-GPI antibodies in the
transmigrant population were measured at enrolment and after every malaria episode for up to 8
episodes over 3 years. Adults had significantly raised anti-GPI antibodies after a single infection of
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malaria that remained consistently high and did not rise after further infections (Hudson Keenihan
et al. 2003). In children anti-GPI antibodies rose significantly after each infection though their
responses remained significantly lower than those of adults after the first three infections. Over
the course of all infections, adults were 4 times more likely to have a high antibody response to
GPI (Hudson Keenihan et al. 2003).
In an extension of this study, antibody responses to pre-erythrocytic (CSP and TRAP) and
erythrocytic (EBA 175, MSPI-19, MSP4, RESA, and schizont extract) P. falcipaprum antigens
were measured after each infection. Across all the infections observed, adults were significantly
more likely to mount an antibody response to CSP (OR=I.8), TRAP (OR=4.2), RESA (OR=3.0),
schizont extract (OR=2.5%), MSPI-19 (OR=1.8), MSP4 (OR=2.7), and EBAI75 (OR=20.1),
although prevalence of the response to EBAI75 was lower than for the other erythrocytic antigens
in both adults and children, and may be explained by the limited time that EBA175 is exposed to
the immune system due to its apical organelle localisation in the merozoite (Keenihan et al. 2003).
A separate study carried out in Kenya has also produced evidence for the age-dependent immunity
hypothesis. The relationship between pubertal development and resistance to P. falciparum over
two transmission seasons was investigated in males between the ages of 12 and 34 years (Kurtis et
al. 200 I). All study participants were tested for parasites before being cleared of parasitaemia at
the beginning of each transmission season and then monitored for frequency and density of new
infections over the transmission season. Individuals with negative blood slides at the beginning of
the seasons before treatment were on average 3 years older than those with positive blood slides.
The development of resistance was investigated before, during, and after puberty. Resistance to P.
falciparum infection increased with age during puberty but not before puberty, and the frequency
of parasitaemia decreased with age after puberty. Increased levels of pubertal hormones DHEAS
(a measure of adrenarch) and testosterone (a measure of gonadarche) also predicted resistance to
infection independent of age (Kurtis et al. 200 I).
Adults and children also appear to be at different risks of severe disease during their primary
exposure to P. falciparum, During the first six months of a transmigrant community's exposure to
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malaria the adult transmigrants had a 4.S-fold higher risk of clinically diagnosed severe malaria
than their children (Baird et al. 1998). In low transmission settings malaria pathology appears at
lower parasite densities and the risk of disease at any parasite density is higher in older individuals
(petersen et al. 1991; Smith et a1. 1994). Studies on naive returned travellers have also mentioned
the higher severity of disease in older individuals; two will be mentioned here. Out of 135 returned
travellers in Israel with P. falciparum infection, those ~ 40 years were at higher risk of developing
severe malaria (OR=4.29) compared to those < 40 years old (Schwartz et a1. 2001). Another study
looking at malaria in returned travellers in Italy, there was a significant increase in the prevalence
of severe malaria (3% to 24%) with increasing age « 30 years to ~ SOyears) (Calleri et al. 1998).
1.5 Two vaccine candidates in review: Apical membrane antigen 1
(AMAl) and merozoite surface protein 2 (MSP2)
AMAI and MSP2 are merozoite proteins that are leading malaria vaccine candidates and will be
discussed in detail below. Their progress as vaccines will be discussed later in this chapter.
1.5.1 Apical Membrane Antigen 1 (AMA-l)
1.5.1.1 Location and structure of AMAI
AMAI was first identified in P. knowles; as an invariant merozoite antigen to which monoclonal
antibodies inhibited the in vitro invasion and growth of homologous parasites (Deans et al. 1982;
Deans et a1. 1984; Thomas et al. 1984). AMA-l is present in all Plasmodium species (Marshall et
al. 1989; Waters et at. 1990; Kappe and Adams 1996; Kocken et at. 2000) and is synthesised during
the late schizont stage as an 83kDA precursor protein that is localised to the micronemes of the
merozoite (Deans et at. 1984; Bannister et al. 2003). The N-terminal prosequence of the 83kDa
protein is cleaved in the micronemes and the mature 66kDa form of AMA 1 is then translocated on
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to the merozoite surface (Howell et al. 2001; Healer et al. 2002; Howell et al. 2003; Howell et al.
2005). Further processing of the 66kDa form occurs on the surface of the merozoite prior to
erythrocyte invasion. The protein is cleaved into 44-48kDa soluble forms by the membrane-bound
subtilisin-like PfSUB2 sheddase which leaves a small remnant of AMA 1 on the merozoite surface
(Howell et al. 2003; Harris et al. 2005b; Howell et al. 2005).
AMA I is a type 1 integral membrane protein that varies between 556 and 622 amino acids in
length, with P. falciparium AMA-l being 622 amino acids in length and only 50 of these making
up the cytoplasmic domain (Chesne-Seck et al. 2005). The ectodomain is made up of three
domains (DJ, DII, and DIll) (Figure 1.5) and an N-terminal prosequence that are held in a tertiary
structure by 8 conserved disulphide bonds (Hodder et al. 1996). Numerous interactions between
domains occurs resulting in the 'folding over' of the N-terminal end of DJ towards the merozoite
surface by interaction with the other two domains (Pizarro et al. 2005). DI and DII are more
structured than DIIJ and contain folding motifs of the plasminogen-apple-nematode (PAN) domain
family. That the PAN domain is associated with receptor binding function implicates AMA 1 in the
initial steps of erythrocyte invasion. Both DJ and DII contain loop sections with a 40 amino acid
conserved loop in both domains and unstructured loops in DI (Pizarro et al. 2005).
Figure 1.5 Schematic of the P. falciparum AMAI ectodomain, showing the three separate domains, I,
II and III. The locations of eight disulphide bridges are shown in blue. Residues shaded in red and magenta
represent mutations in different naturally occurring P. falciparum sequences (Nair et al. 2002).
29
1.5.1.2 Polymorpbisms of AMAI
AMAI is encoded on a single gene and is highly polymorphic (Thomas et al. 1990b; Chesne-Seck
et al. 2005). AMAI appears to be essential for parasite survival as attempts to knock out its gene
have not been successful (Triglia et al. 2000). It has 64 polymorphic positions that are spread
throughout its sequence with 32 in DI, 11 in 011, and 9 in DIll. The pro-sequence contains 9
polymorphisms and the cystolic region 3 (Chesne-Seck et al. 2005). Only one position (Glu197) is
heptamorphic, positions 200 and 201 are tetramorphic, and the rest either di- or trimorphic (Bai et
al.2005).
The crystal structure of AMAI reveals a long hydrophobic region in DI that is hypothesised to be a
ligand-binding site. It is surrounded by a region consisting of the highest number of polymorphic
residues in the protein (Bai et al. 2005). These polymorphisms appear to have arisen due to
diversifying selection in order to avoid invasion-inhibitory antibodies or other protective immune
responses (Cortes et al. 2003; Polley et al. 2003). Invasion inhibitory epitopes in domains II and III
have also been described (Nair et al. 2002; Mueller et al. 2003; Collins et al. 2007).
Polymorphisms in AMA1are thought to be a result of parasite evasion from host immune pressure.
Early studies showed that AMA was under positive selection as shown by the
synonymouslnonsynoymous rates at the AMAI loci (Escalante et al. 1998). A later study
confirmed that both T-cell epitopes and probable antibody binding sites on AMAI were under
positive balancing selection (Verra and Hughes 1999). Large scale genetic analyses in malaria
endemic populations in Papua New Guinea and India also revealed that DI was under positive
balancing selection (Cortes et al. 2003; Garg et al. 2007). Other analyses on populations in Nigeria
and Thailand also gave evidence for the same with regards to domains II and III (Polley and
Conway 2001; Polley et al. 2003). A role for the different polymorphisms in AMAI has been
suggested by experiments using transgenic parasites. Functional allelic replacement of domain I of
AMAI resulted in differing susceptibilities of P. falciparum strains to growth-inhibitory antibodies
thus suggesting a functional role for the polymorphisms in AMAI (Healer et al. 2004).
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A recent study showed that AMA I variants worldwide could be grouped into six distinct genetic
clusters (Duan et a1. 2008). A later study that contained a greater number of amal sequences from
different locations confirmed the six subgroups and their worldwide distribution as defined in the
smaller Duan et al study (Barry et a1. 2009), although another study has found a much large
number of clusters using this approach (Takala and Plowe 2009).
1.5.1.3 Function of AMAI
The successful invasion of murine erythrocytes by transgenic P. falciparum parasites containing
the complete P. chabaudi ectodomain was strong evidence for the role of AMA I in invasion of
erythrocytes (Triglia et a1. 2000). A study that measured the levels of invasion of parasites with
chimeric (P. falciparum and P. chabaudi) AMA I proteins in the presence of anti-PfAMA I
immunoglobulins showed that all three extracellular domains are involved in interactions with
erythrocyte surface molecules (Healer et a1. 2005). Merozoites can only initiate invasion of an
erythrocyte via their apical end. Clear evidence for the exact role of AMA I in invasion was
provided by ultrastructural analysis. Whilst anti-AMA I monoclonal antibodies allowed the initial
attachment of P. knowlesi merozoites to the erythrocyte membrane, they inhibited full invasion by
impeding reorientation of the merozoites (Mitchell et a1. 2004).
Host cell invasion by another apicomplexan parasite Toxoplasma gondii involves a complex that
includes T. gondii AMA I and three other rhoptry neck proteins (RON2, RON4, and RON5). An
ortholog of RON4 has been described in P. falciparum which associates with AMA I and is
localised to the moving junction (Alexander et al. 2006; Baum et al. 2008). RON2 was recently
described in P. falciparum with the AMA IIRON complex being detected in mature schizonts thus
indicating that complex formation in P. falciparum occurred well before invasion (Cao et a1. 2009).
To date, only one possible receptor for AMA 1 on the erythrocyte surface has been suggested. DIll
of recombinant PfAMA 1 binds to the receptor Kx on trypsin-treated erythrocytes, but cannot bind
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trypsin-treated Kxm.J. erythrocytes (Kato et al. 2005). Although parasites can still invade KxnuU
erythrocytes, it is at a significantly reduced rate, which further implicates Kx as a receptor for
AMAI. Domains I and Il of AMAI also have a role in the interaction between merozoite and
erythrocyte as shown by the successful adhesion of COS7 cells expressing P. yoelii DI and DII to
mouse and rat erythrocytes (Fraser et al. 2001). Interestingly, a role for AMAI in the invasion of
hepatocytes by sporozoites has also been suggested. PfAMAl is expressed in sporozoites where it
undergoes proteolytic processing similar to that in the merozoite. PfAMAI is no longer expressed
after the sporozoite has invaded the hepatocyte and anti-AMA1 immunoglobulins as well as serine
protease inhibitors that inhibit shedding of AMAI both inhibit sporozoite infectivity (Silvie et al.
2004).
Recent generation of P. falciparum GFP-tagged AMAI parasites indicate that AMAI could have
two distinct roles in the invasion process that are dependent on the short cytoplasmic domain of the
protein (Treeck et al. 2009). This study showed that even though parasites expressing AMA1with
heterologous EBA175 or Rh2b cytoplasmic domains had correctly trafficked AMA1, they were
unable to invade erythrocytes whereas those with homologous cytoplasmic domains from P. vivax
and P. berghei could functionally invade. Complete invasion also required the correctly
phosphorylated cytoplasmic domain. Non-phosphorylated mutant parasites were able to correctly
reorient themselves but could not invade thus implicating AMAI's two-step involvement in
merozoite invasion of erythrocytes (Treeck et al. 2009).
1.5.1.4 AMAl-specific invasion inhibition
Antibodies to AMA1 are able to inhibit invasion of erythrocytes by merozoites in vitro (Hodder et
al. 2001; Healer et al. 2004), and although most of these inhibitory antibodies are targeted to
polymorphic epitopes, and inhibitory antibodies are generally strain-specific, there is some
evidence that invasion-inhibitory antibodies could also recognize conserved or less polymorphic
epitopes (Kennedy et al. 2002; Collins et al. 2007). Inhibition of erythrocyte invasion by parasites
appears to be variant specific as well as cross reactive. Antibodies produced by the immunisation
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of rabbits with recombinant 3D7 PfAMA I significantly inhibited invasion of P. falciparum field
isolates and lab strains that share sequence similarity (eg. D 10) whereas those antibodies generated
by immunization with recombinant FVO PfAMA I were able to inhibit erythrocyte invasion by
field isolates as well as lab strains with divergent AMA I sequences (Duan et al. 2008). Though
both animal and human antibodies to AMA I can inhibit invasion of erythrocytes, most of the
antibodies tested interact with strain-specific epitopes in order to exert this functionality (Hodder et
al. 200 I). Interestingly, AMA I specific antibodies appear to have higher invasion inhibitory
activity than MSPI42 specific antibodies which could be indicative of this antigen's important role
in invasion (Miura et al. 2009). Antibodies to AMAI appear to exert their invasion inhibitory
effects via two main actions. The first is by cross-linking and trapping the final soluble 44-48kDa
AMA I fragments on the surface of the merozoite (Dutta et al. 2003). The other mechanism
involves inhibition of secondary processing of 66kDa AMA I and its subsequent redistribution on
the merozoite surface (Dutta et al. 2005). Recent evaluation of antibody responses in children
living in a malaria endemic are identified that Senegalese children with high antibody responses to
AMAI(FVO) also had higher growth inhibitory activity than those with lower antibody responses
although there was a age related decline in this activity (Courtin et al. 2009).
Several monoclonal antibodies to AMA 1 can also inhibit invasion in vitro. Monoclonal antibody
(mAb) IF9 is strain specific and inhibits invasion of3D7 and DIO P.falciparum parasites but not
HB3 or W2mef, and recognises a polymorphic epitope in domain I (Coley et al. 200 I; Coley et al.
2006). The D 10 and 3D7 strains of AMA I are identical in domain I but differ in domains II and
III. The actual binding site of mAb IF9 appears to be part of the hydrophobic trough and the
surrounding loops on the AMA I surface. This interaction between AMA I and mAb IF9 is quite
large, conformationally dependent, and substitution of residue 197 completely inhibits the AMA 1-
IF9 interaction (Coley et al. 2006). The interface between AMAI and IF9 is made up ofa large
buried area that the antibody protrudes into. Though this interface is unusual, binding of mAb IF9
does not significantly affect the structure of AMA 1 (Coley et al. 2007). Antibodies from exposed
individuals from Papua New Guinea compete with mAb IF9 for binding to AMA I, whereas
antibodies from non-malaria exposed individuals do not.
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Another invasion inhibitory monoclonal antibody that has been studied in detail is 4G2. Initial
studies showed that 4G2 exerted its inhibitory effects not by simple sterlc effects but by binding to
a functionally important part of AMAI. This same study revealed that the mAb 4G2 epitope was
conserved across all P. Jalciparum variants and was situated in the domain II loop of AMAI
(Collins et al. 2007). AMAI forms a complex with the essential rhoptry neck protein RON4 which
then associates with the moving junction during invasion. MAb 4G2 appears to exert its inhibitory
effects by binding to the domain II loop before the AMAIIRON4 complex forms and therefore
inhibits downstream invasion actions (Collins et al. 2009).
Monoclonal antibody 5G8 is not strain specific in its interactions with P. falciparum (Coley et al.
2006). It recognizes a 19 residue linear epitope in the N-terminal pro-sequence/pro-domain of
AMAI (Coley et al. 2001).
Inan attempt to investigate binding of AMAI to its receptor, phage display technology was used to
identify novel peptides that bound to AMAI. A IS-mer peptide (FI) that bound to PJAMAI alone
and inhibited invasion of human erythrocytes was identified. Further investigation identified its
epitope as the same one as that of mAb 4G2 (Li et al. 2002a). Following the success of this
method, another phage library containing peptides that bound to mAb 4G2dc I was investigated and
three reactive peptides (JI, J3, and J7) were identified. All the peptides elicited an immune
response from rabbits that recognized AMA 1, and both J I and J7 were recognized by human
plasma from Papua New Guinea (Casey et al. 2004). In vitro invasion inhibition by antibodies
specific to JI and J7 from human and rabbit palsma was also observed. A fourth 20-mer peptide
(RI) has also been identified that binds to the same epitope as FI and elicits a stronger invasion
inhibitory effect (Harris et al. 2005a). It appears that all the mentioned peptides and epitope-
specific antibodies bind to a 'hot spot' on AMAI and exert their invasion inhibitory effects in the
same manner.
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1.5.1.5 Vaccine potential of AMAI in animal models
Most of the evidence for AMA 1 as a potential target for protective immune responses has come
from vaccination/challenge animal studies. In all the studies, the use of correctly folded AMA 1 for
vaccination, followed by challenge with a homologous parasite strain, resulted in varying levels of
protection in all the animal models used (Deans et al. 1988; Collins et al. 1994; Anders et al. 1998;
Narum et al. 2000b; Salvatore et al. 2002; Stowers et al. 2002; Bums et al. 2003; Bums et al.
2004). Passive transfer of anti-AM A I specific mAb into BALB/c mice followed by challenge with
P. yoelii led to controlled sub-patent parasitaemia and survival of all the mice (Narum et al. 2000b).
In a study where five rhesus monkeys were vaccinated with P. vivax and challenged with P.
cynomolgi, antibody titres to PvAMAI were boosted and there was a slight reduction in
parasitaemia, but the animals were not protected from subsequent infection from P. cynomolgi
(Kocken et al. 1999). Another study where BALB/c mice were vaccinated with P. chabaudi DS
AMA I and challenged with P. chabaudi 556KA AMA 1 - which differs from the DS variant at 79
sites - resulted in no reduction in parasitaemia (Crewther et al. 1996). These two vaccination
studies showed that protection was as a result of a response to homologous rather than heterologous
parasites. More recently, immunisation of rabbits with a mixture of PfAMAl alleles (3D7, HB3,
and FVO) led to proportionally more antibody responses to conserved epitopes but also had the
same functional capacity to inhibit homologous parasite invasion as antibodies generated by single
allele immunisation (Kusi et al. 2009). Though earlier studies indicated that most antibodies to
AMA I were to strain specific epitopes, this one suggested that there is a large portion of functional
antibody responses to conserved epitopes that may be optimally induced by exposure to multiple
AMA I alleles. This finding was interpreted by the authors as good evidence for a multi-allele
single antigen vaccine approach.
Though some of the overall antibody response to AMA I is to conserved regions of the molecule, as
seen by the high concordance between antibody levels to various AMA I alleles and demonstrated
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using competition ELISA with different AMA 1 alleles, there is also a significant portion of the
antibody response that is strain-specific (Hodder et al. 2001; Polley et al. 2004; Cortes et al. 2005).
Currently the extent to which antibodies target conserved versus strain-specific epitopes and their
relevance to immunity is not clear. Passively transferred rabbit antibodies induced by vaccination
with PcAMAl DS did not reduce parasitaemia in mice challenged with P. chabaudi 566KA
whereas they significantly reduced parasitaemia in mice challenged with the homologous parasite
strains (Crewther et al. 1996). Also, the antibodies elicited by rabbit vaccination with AMAI 3D7
and antibodies induced by natural infection from Papua New Guinea which have been purified on
recombinant AMAI 3D7 selectively inhibit invasion of P. falciparum 3D7 compared to P.
falciparum HB3 (Hodder et al. 2001).
Up to half of the overall antibody response can be strain-specific. This was seen in one animal
study where vaccination with AMAI 3D7 or AMAI FVO induced two-fold higher antibody titres
to the homologous strain (Kennedy et al. 2002). Sera from immunised animals in the same study
also showed higher inhibitory activity towards parasites of the homologous strain. This strain-
specific invasion inhibition has also been observed in another study which measured invasion of P.
falciparum FCR3 and NF54 parasites (Kooken et al. 2002).
1.5.1.6 Naturally aequired antibodies to AMAI
AMAI is highly immunogenic and this is seen by its high recognition by sera from malaria
endemic populations. Several studies have reported above 65% antibody prevalence to various
alleles (307, HB3, 010, FVO, 7G8) of AMAI in populations from Africa and Australasia (Thomas
et al. 1994; Johnson et at. 2004; Polley et at. 2004; Cortes et al. 2005). Antibodies to DJ were more
prevalent than those to DII and DIll (Polley et at. 2004; Cortes et.al, 2005); however, it is unclear
whether domains expressed separately are correctly folded.
Antibody titres to AMA 1 increased with age in all the studies mentioned earlier except for one
where although there was an increase in antibody titres with age in one population, it was not the
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case for the other population studied (Thomas et al. 1994). These differences could be down to
differences in methodology or antigen (the AMA1 protein used in the Thomas et al study was
highly glycosylated, which is not the case for native AMA1). Antibodies also appear to be
acquired faster and earlier in areas of high transmission compared to low transmission, and
antibody titres are generally higher in parasitemic individuals (Polley et al. 2004). There is also
some evidence for the transfer of maternal antibodies to AMA1 across the uterus with more than
50% of newborns tested being positive for anti-AMAI antibodies (Riley et al. 2000; Metenou et al.
2007).
Strain-specific and cross-reactive antibodies to AMAI are detected in malaria endemic populations.
There are detectable responses to polymorphic epitopes measured by ELISA and invasion
inhibition assays (Hodder et al. 2001; Polley et al. 2004; Cortes et al. 2005). Antibodies to
polymorphic epitopes appear to dominate in childhood with the frequency of allele-specific
responses decreasing significantly with age (Cortes et at. 2005). Anti-AMAI antibodies in malaria
endemic populations are predominantly IgOI and Ig03 with very little Ig02 or Ig04 detected
(Riley et al. 2000; Polley et al. 2004; Metenou et al. 2007; Nebie et at. 2008; Stanisic et al. 2009).
Although titres of both IgO1 and Ig03 increased with age and exposure to malaria, IgO1 responses
predominated over Ig03 responses both in prevalence and intensity (Riley et al. 2000; Nebie et al.
2008; Stanisic et al. 2009).
1.5.1.7 The role of anti-AMAI antibodies in protection from clinical disease
Several immuno-epidemiological studies have been carried out in order to establish whether
antibodies to defined malaria antigens are associated with protection from malaria. They usually
involve measurement of antibodies at baseline with extended passive or active follow-up. The
results from these studies are not always clear and may conflict with each other. The role of
antibodies to AMA1 in protection from malaria is no different. To date, there are published studies
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that both support an association with protection as well as other studies that give evidence for the
opposite.
Three studies, two of them carried out in the same part of Kenya; provide evidence that antibodies
to AMAI are associated with protection. Anti-AMAI antibodies to the 3D7 and FVO variants
were associated with protection from clinical malaria in children and adults over a period of 6
months. This protection was seen only for those individuals who were parasite positive at the time
of sampling (Polley et al. 2004). A later study on samples from the same area on children showed
that high levels of antibody reactivity was associated with a reduced risk of hospital admittance
over 8 months (Osier et al. 2008). Although antibodies to AMAI were predictive of protection in
this study; it was only when anti-AMA1 antibodies were analysed in combination with those to
MSP2 or MSP3 that the protection was significant. A similar result had also been obtained from a
study carried out in The Gambia. Here, using a microarray immunoassay, antibody reactivity to
both AMA1 and MSP2 in combination was more predictive of protection with the individuals in
this group only experiencing asymptomatic malaria (Gray et al. 2007).
A slight trend towards protection was associated with high anti-AMA1 antibodies but was not
significant in another study carried out in a high transmission setting in Kenya. 10this study, any
parasitaemia was cleared by treatment at baseline and then individuals were followed up for 12
weeks and the point ofre-infection monitored. High antibody levels to AMAI were not associated
with a longer time to re-infection (John et al. 2005). Though high antibody titres to MSP3 were
associated with protection over a 6 year period in Dielmo Senegal, this protection did not appear to
be as a result of high anti-AMAI antibody titres, though they were prevalent in the population
(Roussilhon et al. 2007). 10 yet another study carried out in Burkina Faso, total anti-AMAI
antibodies were not associated with protection from clinical disease yet anti-AMA1 IgGI was
associated with protection (RR 0.87, p=0.013) (Nebie et al. 2008). A recent systematic review
supports the association between antibodies to AMAI and protection from malaria (Fowkes et al.
2010).
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1.5.2 Merozoite Surface Protein 2 (MSP2)
I.S.2.1 Location and structure of MSP2
MSP2 was discovered when a 45-55kDa protein was immune-precipitated by various monoclonal
antibodies that had been shown to inhibit invasion of P. Jalciparum parasites (Stanley et al. 1985;
Ramasamy 1987; Epping et al. 1988; Miettinen-Baumann et al. 1988; Smythe 1988). Using
immune-fluorescent staining techniques and immuno-electronmicrosopy, MSP2 was shown to be
one of the most abundant proteins on the surface of P. falciparum merozoites. It was also
identified in low abundance in the ring stage (Smythe 1988) and in greater abundance on the
surface of mature schizonts (Ramasamy 1987; Epping et al. 1988).
MSP2 is an integral-membrane protein that is anchored to the merozoite surface via a C-terminal
GPr anchor (Smythe 1988; Gerold et al. 1996). It is an intrinsically unstructured protein in solution
that forms amyloid-like fibrils under physiological pH (Low et al. 2007; Yang et al. 2007; Adda et
al. 2009). The N-terminal end of the protein may also interact with the merozoite surface
membrane leaving the central portion of the protein accessible to the external environment (Zhang
et al. 2008).
I.S.2.2 Polymorphisms of MSP2
MSP2 contains numerous point mutations throughout its gene. The gene sequence is made up of
conserved C- and N-terminal domains followed by flanking non-repeat variable sequences. The
central domain contains the most variability and is made up of several repeat sequences. It is these
repeat sequences that have been used to group the numerous MSP2 alleles into two main families
(Thomas et al. 1990a; Fenton et al. 1991; Smythe et al. 1991). An analysis of seven different
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MSP2 alleles split them into two families; one made up of 307, IC-I, IMRI43, MAD7l, NIG32;
and the second made up of FC27 and Kl (Smythe et al. 1991). These two groupings are generally
known as the '3D7-like' and 'FC27-1ike' MSP2 families. The 3D7-like family contains 4-8 amino
acid repeats with five different amino acids being used whereas the FC27-like family has 12 and 32
amino acids repeated up to 4 times (Figure 1.6).
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Figure 1.6 Schematic diagram of the structure of the two allelic families of MSP2 (Felger et al. 2003).
MSP2 appears to be under natural positive selection as shown by high
synonymous/nonsynonymous rates at the MSP2 locus (Hughes and Hughes 1995). A larger sample
of 100 MSP2 alleles from The Gambia, Tanzania, and Papua New Guinea were tested for
balancing selection using the Ewens- Watterson test for neutrality and gave significant results for
positive selection (Conway 1997). In yet another study, the evidence for positive selection at the
MSP2 locus was not as convincing as in the above studies because the excess of non-synonymous
substitutions was not very high (Escalante et al. 1998).
1.5.2.3 Function of MSP2
The precise function of MSP2 has not been identified but one was suggested from its initial
identification using invasion inhibitory antibodies (Stanley et al. 1985; Ramasamy 1987; Epping et
al. 1988; Miettinen-Baumann et al. 1988; Smythe 1988). Invasion inhibitory assays carried out
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during initial MSP2 identification showed some inhibition which lends credence to a possible role
for the protein in erythrocyte invasion (Epping et al. 1988; Miettinen-Baumann et al. 1988; Clark et
al. 1989). This is supported by its increased expression during late schizogony and maximal
expression in merozoites. However, a recent study found no invasion-inhibitory activity of MSP2
antibodies (Flueck et at. 2009). Amyloid-fibrils are present on the surface of bacteria and fungi and
may have a role in the invasion of substrates. Their formation of a coat on the surface of these
organisms has also been suggested as an immune evasion strategy (Gebbink et al. 2005). As MSP2
forms amyloid-like fibrils; this along with the invasion inhibition data may point towards a role in
erythrocyte invasion.
That MSP2 was initially identified using previously defined invasion inhibitory monoclonal
antibodies (13.4, 8GI0/48, and 9E3/48) supports a role for it in invasion (Ramasamy 1987; Epping
et al. 1988; Miettinen-Baumann et al. 1988; Clark et al. 1989). One study measured the effect of
monoclonal antibodies 8G 10/48 and 9E3/48 on actual parasite invasion of erythrocytes. 20%
inhibition was observed at low mAb concentrations and increased in a dose-dependent manner to as
high as 98%, thus proving that MSP2-specific invasion inhibition was possible (Epping et al.
1988). Recent observations have also shown that purified IgG from children with high antibody
responses to MSP2 was more efficient at inhibiting parasite growth than that from children with
low MSP2 responses (Courtin et al. 2009).
1.5.2.4 Vaccine potential of MSP2 in animal models
Though protection from parasite challenge was not seen in early animal vaccination studies, the
immunization of Saimiri monkeys with an MSP2 allele from the 3D7-like family elicited antibody
responses to both the 3D7-like and FC27-like families (Pye et al. 1991). MSP2 is not present in
rodent malarias which has limited the ability to evaluate MSP2 as a vaccine. A later study where
mice were immunised with octapeptides from the conserved N- and C-terminals from P.
Jalciparum showed that the dominant antibody response was directed to variable regions of MSP2
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and that the animals were protected against challenge with P. chabaudi (Saul et al. 1992);
presumably the antibodies cross-reacted with related epitopes. Following on from the study by
Saul et al; a chimeric protein made up of the N- and C- terminals of MSP2 was used to immunise
mice. This immunization elicited an antibody response that was comparable in titres to that elicited
by immunization with full-length recombinant MSP2 although the antibodies raised to the chimera
did not recognize the same parasites as the those elicited by full-length MSP2 (Lawrence et at.
2000).
1.5.2.5 Naturally acquired antibodies to MSPl
Naturally-acquired antibodies to MSP2 can be detected in malaria-endemic populations. Total
anti-MSP2 antibody prevalence is close to 100% by the age often in African populations (Taylor et
al. 1998; Polley et al. 2006). Malaria transmission intensity affects the acquisition of these
antibodies. In Kenya, antibody prevalence increased with age at a higher rate in a population
where malaria transmission was higher (Polley et al. 2006). In an area with very low to negligible
malaria transmission in Brazil, antibody prevalence to MSP2 did not rise higher than 30% (Scopel
et al. 2007).
Antibody prevalence and titres increase with age, and titres tend to be higher when parasites are
present in the host (Taylor et al. 1998; Metzger et at. 2003; Polley et al. 2006). Most of the
antibody response to MSP2 appears to be to the polymorphic central part of the antigen. In two
studies less than 5% of individuals recognized the conserved N- and C-terminal regions yet
responses to the polymorphic regions could be detected in up to 95% of sera (Taylor et al. 1995;
Metzger et at. 2003).
Naturally acquired allele specific antibodies to MSP2 have been detected. Both in malaria-endemic
populations and in naive returned travellers suffering a primary infection, a higher proportion of
antibodies to the circulating allelic family or infecting allelic family was detected (Tami et al. 2002;
Felger et al. 2003). In Kenya, it was shown that higher antibody titres to one MSP2 allelic family
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correlated with a higher parasite burden of the same allelic family whereas the antibody response to
the other allelic family were significantly lower (Polley et al. 2006). These allele-specific
antibodies are cross-reactive within the same family, with higher levels of cross-reactivity
occurring in the more polymorphic 3D7-like family (Tonhosolo et al. 2001; Franks et al. 2003).
Two studies have shown a lack of cross-reactivity between the two allelic MSP2 families,
indicating that the acquired antibody response is towards the variable regions (Taylor et al. 1995;
Franks et al. 2003). This is in agreement with the data obtained in animal models that was
mentioned earlier.
The response to MSP2 consists predominantly of the cytophilic subclasses; IgG I and IgG3. In
several studies, IgG3 responses were of a higher prevalence and intensity in all age groups (Taylor
et al. 1995; Taylor et al. 1998; Polley et al. 2006; Sarr et al. 2006; Tongren et al. 2006). Though
IgG 1 antibodies dominate in young children, the IgG3 response appears to begin overtake that of
IgG I by the age of two and continues to rise with increasing age until it is the dominant response
(Taylor et al. 1998; Tongren et al. 2006). In a single study IgG 1 antibody levels actually dropped
with age (Taylor et al. 1998). In another study the antibody response of adult non-immune returned
travellers experiencing a primary malaria episode displayed a predominantly IgG 1 response (Eisen
et al. 2007). These two results and those obtained by Tongren et al could indicate that IgG3
polarisation is due to cumulative malaria exposure, although a more recent study did not find any
evidence of polarisation (Stanisic et al. 2009).
1.5.2.6 The role of anti-MSP2 antibodies in protection from clinical disease
The earliest immuno-epidemiological data that indicated a role for anti-MSP2 antibodies in
protection from clinical malaria came from a study carried out in Papua New Guinea in preparation
for a vaccine trial. High antibody levels to MSP2 were retrospectively associated with fewer
episodes of fever and less anaemia (AI-Yaman et al. 1994). A year later, using a longitudinal study
design it was shown that anti-MSP2 (307) antibodies were associated with a reduced risk of
clinical malaria in the subsequent year (AI-Yaman et al. 1995). In Kenya, high antibody levels to
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MSP2 were associated with protection from malaria over 28 weeks although low antibody levels
were associated with an increased risk of malaria in the same period (Polley et at. 2006).
An interesting result regarding protection from clinical malaria was obtained in a study carried out
in The Gambia on 3-8 year oids. Though the dominant IgG3 response to 3D7-like MSP2 alleles
was associated with protection from clinical malaria over 6 months of follow-up, an IgGI response
to FC27-like MSP2 alleles was associated with an increased risk of malaria (Taylor et at. 1998).
The authors suggest that the age-related switch from IgGI to protective IgG3 anti-MSP2 antibodies
may be an explanation. A later study in The Gambia confirmed that anti-MSP2 IgG3 antibodies to
both the 3D7-like and FC27-like families were associated with a lower risk of clinical malaria
(Metzger et al. 2003). A recent retrospective study in Senegal that followed-up individuals
between the ages of 7 and 19 years for a year and associated antibody responses at the end of
follow-up with protection from malaria found that IgG3 antibodies to MSP2(3D7) were associated
with protection against malaria and high density parasitaemia whereas those to MSP2(FC27) were
of borderline significance (Courtin et at. 2009). This is contrast to a recent meta-analysis that did
not show a significant association between antibodies to MSP2 and protection from malaria
(Fowkes et at. 2010).
1.6 Development of vaccines against malaria
An effective vaccine is likely to playa large role in the multi-faceted global fight against malaria
and its debilitating mortality. Due to the complex life cycle of P.falciparum, the vaccine could act
at various points with a number of possible outcomes. Key stages that the vaccine may target
include the pre-erythrocytic, the asexual erythrocytic, or the sexual stages of P. falciparum. At
these various stages the vaccine could prevent infection, reduce disease and/or parasite burden, or
prevent transmission of the parasite.
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1.6.1 Pre-erythrocytic stage vaccines
Pre-erythrocytic stage vaccines primarily target the sporozoite or infected hepatocyte and by
preventing establishment of any infection will ideally result in sterile immunity. These vaccines
will have no effect on any existing blood-stage infections. The best evidence of their potential
came from the observations that irradiated sporozoites conferred complete protection from further
challenge in animal models and humans (Nussenzweig et at. 1967; Hoffman et at. 2002). The
logistics of providing sufficient numbers of irradiated sporozoites for use in the field are
challenging so potential subunit vaccines based on key sporozoite antigens have been developed.
The most promising of these subunit vaccines is based on circumsporozoite protein (CSP) which is
one of the most abundant proteins on the sporozoite surface. RTS,S/ AS02 is made up of the
tandem repeat tetra-peptide and C-terminal T-cell epitopes regions of CSP fused to hepatitis B
surface antigen S along with un-fused S antigen. The adjuvant AS02 is an oil-in-water emulsion
that contains immune-stimulants. Initial challenge trials in The Gambia gave up to 70% protection
against parasitaemia over 9 weeks although this protection waned quite quickly (Bojang et at.
2001). In an extensive phase lIb trial carried out in Mozambique on 1142 children ages 1-4 years
with 18 months follow-up, vaccination with RTS,S/AS02A was able to elicit almost 50%
protection from severe malaria and 30% protection from clinical malaria (Alonso et at. 2005).
Another phase I/Ilb trial ofRTS,S/AS02D in 214 infants in Mozambique with 6 months follow-up
resulted in close to 70% efficacy against new infections (Aponte et al. 2007). A later clinical trial
of RTS,S/AS02 on children below 5 years of age showed that this vaccine had an efficacy rate of
53% over 10 months of follow-up (Bejon et at. 2008). Although the efficacy of RTS,S/AS02 is
well below that of vaccines used against other infections, these results make it the most promising
malaria vaccine so far and phase lIb/III trials are underway in multiple African sites.
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1.6.2 Erytbroeytic stage vaccines
Erythrocytic stage vaccines target the antigens on the asexual parasite along with parasite-derived
proteins inserted into the infected erythrocyte membrane. As the asexual stage is when the clinical
symptoms of malaria occur, these vaccines aim to reduce the severity and possibly prevent disease
by reducing or eliminating parasite loads. These vaccines are primarily targeted to children and
pregnant mothers who bear the brunt of malaria morbidity and mortality. The major challenge that
erythrocytic stage vaccines need to overcome is the substantial antigen polymorphism that exists in
target antigens. Any potential vaccine will need to target those alleles that are most prevalent in the
population and if possible, investigations should be carried out before any trial commences. The
issue of antigen polymorphisms was highlighted in a study that was carried out to investigate
prevalence of MSP119 haplotypes in a malaria-endemic population in Mali where a vaccine trial
was about to start. The investigators found that out of 1363 malaria infections over 3 years, only
16%were of the vaccine haplotype (307) (Takala et al. 2007).
There are several malaria vaccines are based on a range of merozoite proteins, particularly MSP1,
MSP2, MSP3, and AMAI (Richards and Beeson 2009). Following disappointing results on an
earlier MSPI vaccine, two alternative vaccines MSPI-42(FVO)/Alhydrogel and MSPI-
42(3D7)1Alhydrogeltested in natve volunteers elicited a cross-reactive antibody response with very
low levels of invasion inhibition (Malkin et al. 2007). For the first time, antibody-dependent
cellular clearance of parasitaemia has be shown to be elicited by a vaccine based on conserved
MSP3 regions and B cell epitopes (Druilhe et al. 2005). AMAI and MSP2 vaccines will be
discussed in detail below.
1.6.3 Transmission-blocking vaccines
Transmission blocking vaccines aim to reduce the rate of new infections in the vaccinated
population which eventually leads to a reduction in overall disease. These vaccines will elicit herd
immunity by interrupting the sexual cycle in mosquito vectors and prevent individuals from
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passing on infections to others in the population. The first evidence of the possibility of blocking
malaria transmission by vaccination came by the passive transfer of antibodies from chickens
infected with P. gallinaceum that failed to kill parasites in their hosts yet killed parasites in
mosquitos that were fed infected blood meals (Carter and Chen 1976; Gwadz 1976). The proteins
involved in this immunity were localized to the gametocyte surface. P25 and P28 are ookinate
antigens that are expressed by P. Jalciparum and P. vivax and were discovered by the use of
transmission blocking monoclonal antibodies (Rener et al. 1983; Carter et al. 1984; Grotendorst et
al. 1984). A single phase I trial in naive volunteers vaccinated with a recombinant protein derived
from the Pvs25 surface antigen of P. vivax ookinates has been reported (Malkin et al. 2005b).
Vaccination with this antigen resulted in an antibody response that inhibited growth of ookinates in
mosquitoes thus demonstrating effective transmission blocking activity.
1.6.4 AMAl vaccines
There are currently a number of malaria vaccines based on AMA 1 that are undergoing clinical
trials. These are based on either the full length-AM A 1 ectodomain sequence (AMA l-C 1 and
FMP2.1/ AS02) or contain a peptide representative of the conserved region in the domain III loop
(PEV301 and PEV3A). The vaccines PEV301 and PEV3A both contain a CSP repeat region
peptide and utilize a virosome delivery system (Genton et al. 2007; Okitsu et al. 2007; Thompson
et al. 2008). Both have tested safely during phase I1I1atrials in malaria-naive volunteers and elicit
a significant antigen-specific antibody response (Genton et al. 2007; Thompson et al. 2008). The
potential for eliciting a long-lived affinity matured response over the course of immunisation was
suggested by the two-fold increase in avidity of the detected antibodies (Okitsu et al. 2007).
Though these results are encouraging, there remains a while until these formulations will be tested
in malaria-endemic populations.
FMP2.1/AS02 is based on the AMAI 307 sequence formulated with the AS02 adjuvant. A phase I
trial in malaria-naive volunteers showed that this vaccine could elicit cellular and functional
antibody responses as shown by inhibition of homologous parasite growth and inhibition of AMAI
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processing (polhemus et al. 2007). Due to the success of these results, a phase I trial was carried
out in Mali on malaria-exposed adults (Thera et al. 2008). Anti-AMA 1 antibodies increased over
the course of immunisation and reached a 6-fold peak from baseline levels two weeks after the
third vaccination. Significantly elevated levels of antibodies to AMA 1 were measured at the end of
the study (365 days post the first vaccination) and these antibodies were able to inhibit growth of
both the homologous parasite (3D7) along with a heterologous strain (FVO) (Thera et at. 2008).
Vaccination of malaria naive adults with AMAI/AS02A followed by sporozoite challenge resulted
in a significant reduction in parasite growth rates as detected by Q-PCR, but not light microscopy
(Spring et at. 2009). Phase I and II trials in children are currently underway. At the time of writing,
results of a recent phase 2 trial in Mali were presented at the MIM Pan-African malaria conference,
2009. The AMAlIAS02A containing AMAl-3D7 gave significant protection against malaria
episodes caused by 3D7-like alleles.
Of the malaria vaccines based on AMAl; AMAI-CI has progressed furthest in clinical trials.
AMA-CI contains two AMAI variants that are based on the full ectodomain sequence of 3D7 and
PVO that are adsorbed on Alhydroget. These variants differ at 25 amino acid position and were
picked in order to best represent the wide repertoire of AMA I variants that are present in malaria
endemic regions (Malkin et at. 2005a). Phase I trials in naive volunteers gave promising antibody
responses to both the variants after the second and third immunization, and purified IgG from the
vaccines was able to inhibit growth of 3D7 and PVO parasites (Malkin et al. 2005a). AMAI-CI
was the first AMA 1 vaccine to be tested in a malaria-endemic population. Antibody levels in
Malian adults increased rapidly after the first two vaccinations in a dose-dependent manner but
began to drop two weeks after the second vaccination, and did not rise after a third vaccination
(Dicko et al. 2007). There was also no increase in the growth inhibitory activity of the vaccine
induced antibodies. In order to reconcile this non-inhibitory response with the inhibitory one seen
in malaria-naive vaccinees, a study comparing vaccine-induced and naturally acquired anti-AMA 1
antibodies was carried out (Miura et al. 2008). This study revealed that the antibodies elicited by
vaccination were as effective as naturally acquired ones at inhibiting parasite growth when they
were affinity purified from serum, but part of the natural antibody response to AMA 1 or other
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antigens included a fraction of antibodies that blocked the action of AMA I-specific invasion
inhibitory antibodies. In a phase I trial in children from the same area, AMA l-C 1 elicited an
antibody response two weeks after the first vaccination that peaked at day 42 and fell by day 100
(Dicko et al. 2008). Only two doses of AMA I-C I were administered in this trial which may
explain the short-lived response. The authors suggested that as children have had less cumulative
exposure to malaria, they may require three doses of the vaccine to elicit longer-lived antibody
responses. In a Phase I trial in children there was no protection against high density parasitaemia
or clinical malaria conferred by this vaccine (Sagara et al. 2009). Recent evaluation of the immune
response of non-exposed AMA I-C I vacinees indicated that this vaccine may also be able to induce
the development of memory T-cells (Huaman et al. 2009).
1.6.5 MSP2Vaccines
Initial studies in development of a malaria vaccine based on MSP2 were not encouraging. The first
test of a combination vaccine containing MSP2 and CSP constructs in naive volunteers failed to
protect against parasite challenge although antibodies to both MSP2 and CSP had been elicited by
vaccination (Sturchler et al. 1995). Another phase I trial on naive volunteers using peptide
fragments of MSPI, MSP2, RESA, and a CSP T-cell epitope with Montanide ISAnO adjuvant
elicited weak antibody responses to all three antigens along with a strong T-cell response (Saul et
al. 1999). The authors suggest that this result could have been due to an ineffective adjuvant
reaction or the immunogenicity of the peptide constructs used.
To date, Combination B which contains fragments of MSPI (KI), MSP2 (307), and RESA with
Montanide ISAno adjuvant is the only MSP2-containing vaccine to go through clinical trials in a
malaria-endemic area. After successful tests for safety and immunogenicity in Papua New Guinean
adults, a phase l/Ilb trial in 120 5-9 year olds in the same area was carried out (Genton et al. 2000;
Genton et al. 2002; Genton et al. 2003). Combination B was safe in children and managed to elicit
measurable humoral and cellular immune responses (Genton et al. 2003). Combination B proved
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efficacious with a 62% reduction in parasite load but did not protect against clinical disease in one
year of follow-up (Genton et al. 2002). Half the children in the trial were pre-treated with SP to
clear parasitaemia before administration of the vaccine. This treatment may have interfered in the
action of the vaccine as those children who underwent treatment did not clear their parasitaemia
and had significantly lower cellular responses to MSPI (Genton et al. 2003). 10 fact, there was an
increase in the incidence of disease in vaccinated children in the subsequent year, most of which
was caused by non-vaccine MSP2 FC27 parasites (Genton et al. 2002). Combination B appeared
to elicit a strain-specific response to MSP2 that was confirmed by the low antibody titres to MSP2
FC27 in vaccinated children (Fluck et al. 2004). A new formulation of Combination B that
contains MSP2 antigens from the 3D7-like and FC27-like family is currently undergoing clinical
trials.
1.7 Longitudinal studies of antibodies to asexual antigens of P.
falciparum
There are only a few longitudinal studies with repeated antibody measurements to investigate the
acquisition of various antibodies to malarial antigens in endemic populations that have been carried
out in children (Branch et al. 1998; Giha et al. 1999; Udhayakumar et al. 2001; Biswas et al. 2008).
To date only two studies have shown a stable persistence of antibody levels to MSPI and AMAI in
adults (Riley et al. 1993; Udhayakumar et al. 2001). Most of the studies showed that antibodies to
PjMSPl, PvMSPI, PfAMAI, PvAMAl and PjEMPl are short-lived and decline significantly over
the study period though antibodies to PvAMA 1 could be detected in a few individuals up to 7 years
after an outbreak of P. vivax malaria in Brazil (Branch et al. 1998; Cavanagh et al. 1998; Giha et al.
1999; Soares et al. 1999a; Morais et al. 2006; Biswas et al. 2008). Antibody responses were
associated with parasitaemia at the time of sampling or an episode prior to sampling time. All the
mentioned studies have been limited in sample size and length of follow-up and have not examined
the relationship between antibody responses and malaria episodes in detail. A single study in
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infants followed up from birth to the age of one year found that anti-MSPI antibodies were
protective against subsequent parasitaemia and febrile illness (Branch et al. 1998).
Longitudinal studies allow the individual development of dynamic outcome variables to be studied
over time. The power of longitudinal studies lies in the ability to distinguish changes over time
within individuals from the differences in a cohort of individuals at baseline. The variability that is
inherent across individuals due to possible unmeasured variables that persist in time will be
minimized as each individual serves as their own control (Diggle et at. 2002).
As antibodies to merozoite antigens are generally short-lived, the calculation of a protective
response from a single time-point may not give a true picture of the contribution of antibodies to
long-term immunity or an individual's immune status. Longitudinal analysis of antibody levels
during the most intensive period of acquisition of immunity in malaria endemic areas (childhood)
may give a more detailed picture of antibody-associated immunity. Measurement of antibody
levels at several time points is required to properly assess their protective abilities. The data that is
collected in longitudinal studies is likely to give the best picture of acquisition of immunity to
malaria and the dynamic role that different factors play in protection against disease.
1.8 Rationale of this study
This project aims to investigate the acquisition and maintenance of antibodies to P. falciparum
AMA 1 and MSP2 in childhood and examine their role in protective immunity to malaria using
samples from well defined cohort and longitudinal studies in a malaria-endemic part of Kenya. As
stated earlier' natural immunity to malaria is non-sterile, protects against clinical disease, and
appears to be complete in adults living in malaria-endemic areas. An extension of this is that patent
parasitaemia along with clinical disease (mild or severe) could be markers of susceptibility to
malaria in individuals living in malaria-endemic areas. Those individuals without measureable
parasitaemia or symptoms in spite of continued exposure may be considered as having attained
effective anti-parasite and clinical immunity to malaria. To date there are no definitive empirical
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markers of this immune state. There is no measurement that can be taken in an individual and used
to consistently predict the likelihood of disease in a subsequent time period. To this end various
markers of an active immune response (antibodies, cytokines, and activated cells) have been used
to attempt to define the immune status of individuals exposed to malaria.
The most common of these immune markers is the presence or absence and levels of antibodies to
P. falciparum in sera. The earliest empirical evidence of a natural antibody response playing a role
in immunity to malaria came from experiments where the transfer of purified immunoglobulin
from immune adults to children suffering from clinical malaria led to the successful clearance of
parasitaemia in 8 out of 12 children (Cohen et al. 1961). This result was confirmed in other studies
and has led to the prolific measurement of antibodies in animal and human studies as markers of
immunity and/or exposure to malaria (Sabchareon et al. 1991; Hogh et al. 1995; Branch et al.
1998). As already discussed, antibodies exert their effects by inhibition of invasion of merozoites
into erythrocytes, inhibition of adhesion of parasitised erythrocytes to endothelial walls, opsonic
phagocytosis of infected erythrocytes, and antibody-dependent immune cell mediated inhibition or
killing of infected cells.
Immuno-epidemiological studies where antibodies to various antigens have been measured in
malaria-endemic populations have so far given us great insight into development and maintenance
of the immune response to malaria. The majority of these studies have measured antibodies at one
time point and associated them with protection or susceptibility to malaria in the future. Implicit in
this method is the assumption that the ability of an individual to mount an immune response can be
assessed at a single time point. Simple observations of individuals living in malaria endemic areas
show that this is not the case. Immunity to malaria is a dynamic process that takes place over a
number of years in different stages, is dependent on the age of the individual, the level of malaria
transmission in the area, and is both strain specific and cross-reactive (Bray et al. 1962; Collins et
al. 1966; Jeffery 1966; Marsh and Howard 1986; Trape et al. 1987; Forsyth et al. 1989; Baird et al.
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1991; Baird et al. 1993; Snow et al. 1997; Marsh and Snow 1999; Hudson Keenihan et al. 2003;
Keenihan et al. 2003; Marsh and Kinyanjui 2006).
Numerous immuno-epidemiological studies measuring the antibody response to these two
merozoite proteins and investigating their role in protection have been carried out. The results
from these studies are not as clear as those from animal models and conflict with each other. So far
three studies provide evidence that antibodies to AMA 1 are associated with protection from
malaria for up to 8 months after sample time (Polley et al. 2004; Gray et al. 2007; Osier et al.
2008), although in one study this was only in combination with an antibody response to MSP3
(Osier et al. 2008). Three studies have given the opposite result, with antibodies to AMAI not
being associated with protection from clinical malaria (John et at. 2005; Roussilhon et al. 2007;
Nebie et al. 2008) Four studies link antibodies to MSP2 with protection from future parasitaemia
and clinical malaria (Al- Yaman et al. 1994; Al-Yaman et al. 1995; Metzger et al. 2003; Polley et at.
2006), and another implies that the protective effect is dependent on an antibody response to both
MSP2 and MSP3 (Osier et al. 2008). One study showed that antibodies to FC27-like MSP2 alleles
were associated with increased risk of malaria in The Gambia (Taylor et at. 1998). Overall, data
from malaria-endemic areas show that antibodies to MSP2 were not significantly associated with
protection from clinical malaria whereas there was better evidence for those to AMAI (Fowkes et
al. 2010). The relative paucity of immune-epidemiological data from malaria-endemic areas when
these antigens are already in Phase 1111trials as potential malaria vaccines is not ideal. The fact that
malaria appears to be undergoing an epidemiological transition in those areas that the vaccines are
being targeted underscores the lack of substantial immuno-epidemiological data that may guide
future immunisation strategies.
There have been few longitudinal studies using repeated antibody measurements over time
investigating the acquisition of antibodies to malarial antigens during childhood (Branch et al.
1998; Cavanagh et al. 1998; Giha et at. 1999; Udhayakumar et al. 200 I; Morais et al. 2006;
Kinyanjui et al. 2007). Most studies have been limited in sample size and length of follow-up and
have not examined the relationship between malaria episodes in detail. Some studies suggest that
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antibodies elicited by exposure to P. falciparum and P. vivax may have a very short half-life
(Branch et al. 1998; Cavanagh et al. 1998; Soares et al. 1999a; Kinyanjui et al. 2007).
Measurement of antibody levels at several time points is required to properly assess their protective
abilities. The data that is collected in longitudinal studies gives the best picture of acquisition of
immunity and the dynamic role that different factors play in protection against disease.
The studies presented in this thesis will add to the current body of longitudinal immunological data
on the acquisition of malaria during the period (childhood) when immunity is being acquired in
malaria endemic populations. As this study is being carried out in a mid-low malaria transmission
area with a general reduction in malaria due to various human activity and climatic factors, this
study will sketch part of the currently emerging picture regarding acquisition of long-term
immunity against malaria at a time when severe malaria incidence is falling and could have a great
impact on vaccination development and immunisation strategy.
1.9 Aims of this study
There are four main objectives of this study:
1. Examine the dynamics of antibody acquisition and maintenance of antibodies to merozoite
antigens over time in relation to age, exposure, active parasitaemia, and erythrocyte
polymorphisms.
2. Determine whether antibodies to AMA1 and MSP2 are indicators of protection from clinical
malaria or markers of exposure.
3. Examine the acquisition of antibodies to a functional epitope of AMAI and the relationship
with protection from clinical malaria.
4. Examine the effect of repeated exposure on antibody repertoire and IgO isotypes specific to
AMAt.
The above objectives of this study will be fulfilled by investigating the following hypotheses:
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1.9.1 Hypothesis 1: Antibody levels fluctuate over time and become more stable with
increasing age and exposure
Longitudinal studies show that the antibody response to various malaria antigens is short lived and
fluctuant in young children (Branch et al. 1998; Kinyanjui et al. 2007) but remains stable in adults
(Riley et al. 1993; Taylor et al. 1996; Udhayakumar et al. 200 I). These studies were carried out in
areas of high transmission or in the case of Kinyanjui et al, investigated antibody levels in children
convalescing from malaria that required hospitalisation. Several studies also show that antibody
levels increase with increasing malaria transmission (Trape 1987; Snow et al. 1997; Marsh and
Snow 1999). Most of the data available has been collected in areas of saturating exposure so the
separate effects of age and exposure have been difficult to tease apart. What is still unknown is the
direct effect of measured episodes of exposure on antibody levels during childhood. I intend to
investigate this by examining the relationship between antibody levels, age, and parasitemic
episodes using both cross-sectional and longitudinal data.
1.9.2 Hypothesis 2: Maintenance of antibodies requires ongoing exposure to P. falclparum
Antibody levels are seen to increase with increasing malaria endemicity and tend to mirror malaria
transmission rates in areas of seasonal transmission (Ramasamy et al. 1994; Jakobsen et al. 1997;
John et al. 2002). In longitudinal studies antibody levels to different antigens have been associated
with parasitaemia at the time of sampling or an episode prior to sampling time (Branch et al. 1998;
Cavanagh et al. 1998; Giha et al. 1999; Soares et al. 1999a; Morais et al. 2006; Biswas et al. 2008).
It is not well understood whether individuals are able to maintain their high antibody response or to
acquire a significant antibody response in the face of reductions in malaria transmission. I intend
to look at this by investigating the association between different levels of exposure and
maintenance of antibody responses over the study period.
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1.9.3 Hypothesis 3: Acquisition of antibodies varies between different merozoite antigens
and different polymorphic variants of the same antigen
Antibody responses to different antigens can be both strain specific and cross-reactive. Field
studies have shown that antibodies to different variants of the same antigen tend to be correlated
but antibodies to different antigens may not be correlated (Bray et al. 1962; Collins et al. 1966;
Jeffery 1966; Forsyth et al. 1989; Marsh et al. 1989). Though many studies have studied the
acquisition of antibodies in childhood by looking at the antibody prevalence and levels in cross-
sections of malaria-endemic populations, substantial antibody data from the same children over a
number of years is not available for the comparison of differential acquisition. I intend to compare
the acquisition of antibodies to different recombinant AMAI (3D7, HB3, and W2met) and MSP2
(307 and FC27) variants.
1.9.4 Hypothesis 4: Maintenance of high levels of antibodies to AMAI and MSP2 are
associated with protection from clinical malaria
In prospective studies with follow-up for the incidence of clinical malaria, antibodies to both
AMAI and MSP2 have been associated with protection from malaria in some instances (AI-Yaman
et al. 1994; AI-Yaman et al. 1995; Polley et al. 2004; Polley et at. 2006; Gray et at. 2007; Osier et
at. 2008). Yet some longitudinal studies show that antibody responses are associated with
parasitaemia at the time of sampling or an episode prior to sampling time. What is unknown is
whether maintenance of higher antibody levels will protect against malaria or whether the high
levels are indicative of prolonged or repeated exposure. I intend to investigate this by analyzing
the risk of clinical malaria in individuals with different antibody responses to AMA 1 and MSP2 ,
and taking account of the factors influencing the induction and boosting of antibodies.
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1.9.5 Hypothesis 5: Antibodies to a defined invasion-inhibitory epitope on AMAI are
naturally acquired in malaria endemic populations and contribute to protection from
clinical disease
Naturally acquired antibodies to AMA 1 are able to inhibit invasion of erythrocytes by merozoites
in vitro, but little is known about the prevalence and extent of these responses (Hodder et a1. 2001;
Healer et al. 2004). Several monoclonal antibodies to AMA I can also inhibit invasion in vitro
(Coley et al. 200 I; Coley et a1. 2006; Collins et al. 2007; Collins et a1. 2009). Antibodies which
bind to the same epitope as one of these inhibitory mAb have also been detected in malaria
exposed individuals (Coley et al. 2007). As this is a functional inhibitory epitope on AMA I, it is
likely that presence of these epitope-specific antibodies is associated with protection from clinical
malaria. I intend to investigate the acquisition of mAb 1F9 epitope-specific antibodies and
determine their potential contribution to protection against clinical malaria
1.9.6 Hypothesis 6: Erythrocyte polymorphisms affect the acquisition and maintenance of
antibodies
Both the sickle cell trait (HbAS) and a+ thalassemia confer considerable resistance to severe and
complicated malaria (Williams et a1. 2005b; Williams et al. 2005d). The immunity conferred by
HbAS is in part due to the physical nature of the erythrocytes as well as immune regulation (Marsh
et al. 1989; Bayoumi et a1. 1990; Abu-Zeid et a1. 1992). The protective action of a+ thalassemia
could be via inhibition of parasite growth/invasion or other immunological mechanisms (Williams
et al. 2005d; Wambua et al. 2006; Fowkes et al. 2008). Although associations between
haemoglobinopathies and antibodies have been reported in cross-sectional studies, to date there are
no studies on the acquisition and maintenance of antibodies to malaria antigens in HbAS or a+
thalassemic individuals. I intend to investigate the acquisition and maintenance of antibodies in
these individuals and compare them with normal individuals.
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1.9.7 Hypothesis 7: The induction, maintenance, and protective effects of isotype and
subclass antibody responses to AMAI is dependent on amount of Plasmodium exposure
and age
Studies in Africa and Asia have shown that the cytophilic IgG 1 and IgG3 subclasses are the
predominant protective antibody responses to merozoite antigens whereas IgM predominates in
younger children who are susceptible to disease (Bouharoun- Tayoun and Druilhe 1992; Taylor et
al. 1995; Shi et al. 1996; Rzepczyk et al. 1997; Polley et al. 2006; Nebie et al. 2008; Stanisic et al.
2009). A number of factors including host genetics, antigen type, cumulative exposure, and age
have been implicated in determining the predominant subclass response to merozoite antigens
(Nguer et al. 1997; Taylor et al. 1998; Aucan et al. 2000; Aucan et al. 2001; Garraud et al. 2002;
Ntoumi et al. 2002; Ntoumi et al. 2005; Scopel et al. 2005). Increasing age has also been suggested
to polarize the antibody response to IgG 1 for AMA 1 though this was not seen in a more recent
study (Scopel et al. 2006; Tongren et al. 2006; Stanisic et al. 2009). Anti-AMA I antibodies in
malaria endemic populations are predominantly IgG 1 and IgG3 with very little IgG2 or IgG4
detected (Riley et al. 2000; Polley et al. 2004; Metenou et al. 2007; Nebie et al. 2008; Stanisic et al.
2009). I will investigate the patterns of subclass (IgGI, IgG3) and isotype (lgG, IgM) antibody
responses to AMA1(3D7) and compare the effects of various factors - in particular repeated
exposure and increasing age - on the magnitude of the antibody response and assess whether
specific isotype or subclass responses are associated with protection against clinical malaria in this
cohort of children.
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2 Materials and Methods
2.1 Study Area and Population
Kilifi District covers an area of 4,779 km', borders the Indian Ocean, and is located in the Coast
Province of the Republic of Kenya. It is one of the poorest districts in the country and has a
population of 650, 000. This study was carried out using samples from two locations 20km apart
within Kilifi district with similar demographic and socioeconomic characteristics (Mwangi et at.
2005). Kilifi district is predominantly settled by people of the Mijikenda tribe with farming as its
main income generation activity.
Most of the malaria in the study area results from P. falciparum infection which is predominatly
transmitted by An. gambiae s.l (Mbogo et at. 1993; Mbogo et al. 2003; Mwangi et at. 2003).
Transmission occurs biannually, during the rainy seasons of May-July and November-December.
Ngerenya is located north of Kilifi creek and is within an area that has been under demographic
surveillance since 1991 (Snow et al. 1993; Nevill et al. 1996). Chonyi is south of Kilifi creek and
is characterised by more fertile soils and a hillier landscape. Negrenya is a low transmission area
with an entomologic inoculation rate (EIR) of 10 infective bites per year whereas Chonyi is
considered a mid-high transmission setting with an EIR of 22-53 infective bites per year (Mbogo et
al. 1995; Mbogo et al. 2003).
2.2 Study Design
This study comprises of two components nested within an ongoing longitudinal study that was
established in 1998 to investigate the epidemiology of non-severe malaria in Kilifi district.
1. The major part of this study is an observational longitudinal cohort study with 6 sampling
points approximately six months apart. The cross sectional bleeds were carried out in May
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2002, October 2002, May 2003, October 2003, May 2004, and October 2004 with continuous
active weekly case detection.
2. A smaller cross sectional cohort study made up of two cohorts within the larger non-severe
malaria study.
The non-severe malaria study was established in 1998 in Ngerenya included both adults and
children and continued for a few months before recruitment in Chonyi began. 819 participants
were enrolled in Ngerenya and 783 participants in Chonyi (Mwangi et al. 2005). Verbal consent
in the local language was sought from all adults and from parents or primary care givers of all
children less than 14 years of age. Consent was also sought from the heads of households and
village elders. Written consent (thumb-print or signature) was then obtained for participation in the
study with the understanding that they could withdraw from the study at any point. Active weekly
surveillance of non-severe malaria was undertaken from enrolment. The study was modified in
August 2001 to include 300 children under the age of 8 years in Ngerenya alone. Active weekly
surveillance continued in the original manner. Children born into study households in Ngerenya
were recruited into the study at birth. Participants exited the study if consent was withdrawn, if
they moved out of the area for more than 2 months, or if they died. All participants exited the
study by the age of 10years.
2.3 Sample eolleetion
Cross sectional sampling was carried out in Ngerenya only in September 1998. Further cross
sectional bleeds occurred in both Chonyi and Ngerenya in July 1999, March 2000, July 2000,
October 2000, March 2001, and June 2001 (children and adults) (Mwangi 2003; Mwangi et al.
2005). The surveys were taken during 'high' (June, July) and 'low' (March, October) malaria
transmission seasons which correspond to the rainy and dry seasons. Axillary temperatures were
measured and blood smears taken for all participants and serum collected for further studies.
On modification of the study in August 200 I, cross sectional sampling was initiated just before the
malaria seasons in May and October (designated 'May' and 'October' bleeds). 5ml of venous
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blood was collected from each participant along with a blood smear and anthropometric data. The
cross sectional bleeds took place over a few weeks due to the distances between participating
households and other logistical issues. Sampling periods are as follows:
• May 2002 bleed; 13 May to 28 May 2002
• October 2002 bleed; 11 October to 27 November 2002
• May 2003 bleed; 12 May to 23 May 2003
• October 2003 bleed; 21 October to 9 February 2004
• May 2004 bleed; 26 April to 16 June 2004
• October 2004 bleed; 18 October to 9 December 2004
Parasitaemia was measured by light microscopy and one hundred high power fields were
examined before a slide was considered negative. Parasites were counted per 200 white blood cells
(WBCs) and density was calculated using an average count of 8000 WBC/~l of blood. Samples
were taken to the KEMRI CGMR-C laboratories where they were processed and the separated
serum stored at -20°C for use in antibody studies. Enrolled individuals were assigned ID numbers
that included the prefix 'N' (Ngerenya) or 'C' (Chonyi) to identify their area of residence. Serum
used for the study was obtained from labelled serum separator tubes and was diluted to 1:25 in
phosphate buffered saline (PBS) with 0.001 % sodium azide for preservation. Samples could then
be stored at 4°C but were kept at -20°C or -80°C for long term storage.
2.4 Weekly Surveillance
All households with individuals recruited into the study were visited by a fieldworker once a week.
Each participant had their axillary temperature measured by a digital thermometer (Becton
Dickinson). A temperature greater than 36°C was confirmed by three measurements. Participants
with a fever (temperature ~ 37.5°C) or a history of fever had a blood smear performed and if
unable to make it to the study clinic, the field workers dispensed malaria treatment. Sulfadioxine-
pryimethamine (SP) was the first line treatment, in accordance with national guidelines.
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2.S Case Definition
As the clinical signs of malaria are nonspecific, the presence of parasites accompanied by fever
may not be enough to define a clinical episode of malaria in an endemic area. Clinical mild
malaria is defined as any parasitaemia accompanied by a measurable fever in children <I year and
a parasitaemia ~2500/J1l of blood accompanied by fever in children ~1 year (Mwangi et at. 2005).
Any incidence of a parasite positive slide in the intervals between sampling is referred to as a
parasitemic episode (whether the child was symptomatic or asymptomatic). Any mild malaria
episodes as defined above are therefore a subgroup of parasitemic episodes.
2.6 Cohort study - Study populations, sample collection, and surveillance
Samples were obtained from cohort studies based in Kilifi District. The study samples comprised
of 130 serum samples from Ngrerenya collected in September 1998 (ages 0-85 years). 276
samples from Chonyi were collected in October 2000 from individuals 0-55 years of age. All
individuals were monitored weekly by active and passive surveillance for symptomatic illness and
malaria; any febrile episodes were investigated for malaria. Serum from 20 non-exposed British
and Australian donors were used as reference controls.
2.7 Recombinant P./alciparum antigens
2.7.1 AMAI
Recombinant, refolded AMAI (307, HB3, W2mef) ectodomain was received from Anders RF.
Full details of preparation can be found elsewhere (Hodder et at. 2001). Briefly, the P. falciparum
ectodomain was expressed in E. coli with an N-terminal hexa-His tag. Nucleotide sequences were
amplified from genomic DNA using PIu DNA polymerase and oligonucleotide primers. The
amplified products were digested with BamHI and Pstl, and ligated into pDs%6IRBsII/6xHis, and
transformed into E. coli strain JPA101. The protein was refolded using previously established
methods by diluting in a buffer containing reduced and oxidised glutathione (Anders et at. 1998).
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2.7.2 MSP2
Recombinant MSP2 (307 and FC27) was also received from Anders RF. Full length MSP2 was
expressed in E. coli with C-terminal His, tags and then purified using nickel chelate anion-
exchange and reversed-phase chromatography.
2.8 Other Antigens
2.8.1 Schizont Extract
Crude schizont antigen was obtained from Mosobo M. and Lowe B. at the KEMRI-Wellcome Trust
Research Programme, Kilifi. The antigen was prepared from the P. Jalciparum A4 clonal line,
derived from the ITO parent strain, by sonicating highly synchronised schizont stage parasites on
ice. Uninfected erythrocytes sonicated at the same frequency were used as a control antigen. The
antigens were stored at -80°C and thawed on ice just before use.
2.8.2 Tetanus Toxoid
Vaccine grade tetanus toxoid was obtained from Commonwealth Serum Laboratories (CSL),
Australia.
2.9 Monoclonal Antibodies
Monoclonal antibodies (mAb) were obtained from Coley AM and Anders RF. They were
generated using standard methods (Harlow and Lane 1988). MAb 1F9, 2C5, and 5G8 were
generated by immunization of mice with recombinant refolded 307 AMAI. MAbs were produced
in hybridoma cell cultures and purified by protein G chromatography (Coley et al. 2007). The
reactivity of the MAb to AMAI was assayed by ELISA, and immunofluorescence of307 schizonts
and merozoites (Coley et at. 2001).
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2.10' Enzyme Linked immunosorbent Assay
Enzyme linked immunosorbent assay (ELISA) is the standard in vitro method for measuring
antibody titres in plasma. Three different methods were used all based on standard ELISA
techniques and are described below.
2.10.1 StaDdard ELISA
Meausrement of the total anti-AMAI IgG titres was carried out using standard ELISA techniques.
Dynex Immunolon 4HBX ELISA plates (Dynex Technologies Inc) were coated with IOO~1of
IJ.1g1mlin PBS of antigen (307 AMA-I) per well and left overnight at 4°C. Wells were washed
three times using a wash buffer (PBS-Tween 20, 0.05%). 100J.1l1wellof blocking buffer (PBS-
Tween 20, 10% skimmed milk powder) was added to each well and the plates incubated at 37°C
for two hours. After a single wash with wash buffer, 100J.1l1wellof a 1:2000 dilution of sera i;-
sample buffer (PBS-Tween 20, 5% skimmed milk powder) was added to each well in duplicate and
incubated at room temperature for one hour. The plates were washed three times and incubated
with 1OO~lIwell of secondary antibody (HRP conjugated polyclonal rabbit anti-human IgG, Dako)
diluted at 1:2500 in sample buffer for one hour at room temperature. After three washes with wash
buffer, IOOJ.1l1wellof substrate solution (per 96 well plate: 2.45ml 0.1M Citric Acid, 5.2ml 0.1M
Na2HP04, 2.35ml H20, 4mg o-Phenylenediamine dihydrochloride [OPD], activated with 4J.11H202
just before use). The plates were then covered and incubated at room temperature for 10-15
minutes. The reaction was stopped by addition of 20J.11/well2M sulphuric acid and absorbance
measured at 492nm.
Standard ELISA was also used for measurement of the total antibody response to blood-stage
antigens, as a marker of exposure. A4 schizont extract produced using established methods was
used as the antigen at a dilution of 1:1000 (Ndungu et al. 2002). Uninfected sonicated erythrocytes
were used as control antigen. The standard ELISA protocol above was used with slight changes in
sera dilution (1: 1000) and secondary antibody dilution (1 :2000). Measurement of anti-lgM
antibodies to recombinant AMA 1 was carried out using the standard ELISA technique at a I: I00
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serum dilution. IgM antibodies were detected using HRP conjugated goat anti-human IgM
(Chemicon, API14P) at a 1:2500dilution.
Any ELISA sample with a difference greater than 25% between duplicates was repeated. Any
plate with more than a quarter of the samples having a discrepancy of greater than 25% between
duplicates was also repeated. A mean value for each sample was calculated and then all results
were standardized using the positive controls on each plate. The background absorbance from
negative control wells (using sera from a panel of non-exposed individuals) was then subtracted
from each value.
2.10.2 High Throughput ELISA
High throughput screening of potential drugs using robotics is an expanding practice in the
pharmaceutical and biotech industries and facilitates the testing of very large compound libraries.
Various methods are employed with certain factors in common. The standard ELISA technique
described above was adapted for use with these high throughput systems in order to reduce the
volume of sera used and increase the number of samples assayed in a single experiment and
thereby facilitate testing for multiple antibodies using all samples from the main Ngerenya cohort
described below.
To measure antibodies to multiple antigens a high throughput ELISA system was developed. This
system uses the Multi-Track (Perkin Elmer) and Multi-Position Dispenser (Perkin Elmer) and
allows antibody measurement of up to 10,000 samples in a single assay run. IgG to AMAI (307,
HB3, and W2mefvariants), MSP2 (307 and FC27 variants), and Tetanus Toxoid were measured in
all samples from the Ngerenya study. Specific isotypes (IgGl, IgG3, and IgM) were also measured
in all samples for AMAI (307).
Nunc Maxisorp 384 well plates (Nunc) were coated with the antigen of interest by addition of 50J.lI
per well of antigen diluted in PBS using a Multidrop 384 (Thermo Labsystems). AMAI (307,
HB3, W2mef) and MSP2 (3D7, FC27) were coated at a concentration of O.5J.lg/ml,and Tetanus
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Toxoid at a concentration of O.4LFU/ml. The plates were sealed and incubated overnight at 4°C.
Plates were then washed twice using PBS with 0.25% Tween 20 (wash buffer). Non-specific
binding was blocked by addition of 100fli per well of PBS with 0.1% Casein (Pierce) and 0.05%
Tween 20. The plates were then sealed and incubated overnight at 4°C. The plates were washed
once before addition of sera. 50fll of sera diluted in PBS with 0.1% Casein and 0.05% Tween 20
was added to each well and incubated for 2 hours at room temperature. Total IgG was measured at
a sera concentration of 1:4000 (AMAI), 1:I000 (MSP2), and 1:500 (Tetanus Toxoid). IgG I, IgG3,
and IgM to AMA I were measured at a sera concentration of 1: I 00.
Inter-well variability was examined by comparing results from duplicate wells in the same assay.
384 samples from the Ngerenya cohort were tested in a single assay in duplicate. The correlation
between duplicates was extremely high (correlation coefficient = 0.96) with no outliers (Figure
2.1). This strong association assured us that it would be feasible to carry out further testing of
samples in single wells.
3
2
r ~ = 0.96 P <0.001
2.5
N
~
.2 1.5
~
0.5
0.5 1.5
Replicate 1
2 2.5
Figure 2.1 Correlation between duplicate samples in the same assay, high throughput ELISA.
Spearman rank correlation, r, = 0.96: p <0.00 I; n = 384.
After the sera incubation, the plates were washed five times using wash buffer. 50fll of HRP
conjugated anti-human antibody diluted at 1:2500 in PBS with 0.1% Casein and 0.05% Tween 20
was added to each well and the plates were incubated for I hour at room temperature. HRP
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conjugated rabbit anti-human IgG (AP316P, Millipore Australia) was used in the assays measuring
total IgG.
The plates were then washed five times in wash buffer and 50J,l1 of 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) (A3219, Sigma) was added to each well. The plates
were incubated for 30 minutes in the dark to allow for sufficient colour change. Addition of 50J,l1
of 1% SDS per well stopped the reaction and absorbance was read at 405nm using an Envision
plate reader (Perkin Elmer). Antibody levels were expressed as an absorbance value (OD).
A pool of sera from Papua New Guinean adults and sera from individual adults were used as
positive controls and included on each 384 well plate. These were used to standardize the
absorbance readings across all the plates for each antigen. Sera from non-exposed Australian
individuals were used as negative controls. The reproducibility of the assay was evaluated by
comparing absorbance values obtained from two independent experiments carried out on different
days and using the same batch of samples. A coefficient of variation (CV) of 1.2% was observed
for this comparison which indicated good reproducibility. The results obtained from the optimized
high-throughput ELiSAs were compared to those obtained using a standard ELISA method. The
same reagents and samples were used in both assays. Samples were tested in duplicate in the
standard ELISA and a mean value obtained, compared with a single well in the high-throughput
ELISA. 272 samples from the May 2003 cross-sectional bleed were tested. There was a strong
correlation between both methods (r = 0.90) although there were a few non-concordant pairs
(Figure 2.2). Plate-to-plate reproducibility was good with positive controls that were tested on each
plate strongly correlating (r > 0.90, p < 0.001).
Detection of IgM was done using 50J,l1of a I :2500 dilution of HRP-conjugated polyclonal goat
anti-human IgM (Chemicon, Melbourne Australia) in PBS with 0.1% Casein and 0.05% Tween 20
as the secondary antibody. HRP-conjugated monoclonal mouse anti-human IgGl (IgGl clone
HP6069A, Calbiochem-Novabiochem Corp, CA USA) and HRP-conjugated monoclonal mouse
anti-human IgG3 (IgG3 clone HP6047, Calbiochem-Novabiochem Corp, CA USA) were also used
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at I :2500 dilutions to detect IgOl and Ig03 responses to AMA1(3D7). The specificity and
sensitivity of the IgO I and Ig03antihodies has been previously established (Stanisic et at. 2009).
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Figure 2.2 Correlation between standard ELISA (ST ELISA) and high throughput ELISA (HT
ELISA). Spearman rank correlation, rs = 0.90; p < 0.00 I; n = 272.
2.10.3 Competition ELISA
Antibodies to specific epitopes on AMA 1 (3D7) were measured by a competitive ELISA method.
Three monoclonal antibodies (lF9, 2C5, 508) with defined epitopes were used to compete with
naturally acquired antibodies. Monoclonal antibody 1F9 inhibits invasion of 3D7 and D lOP.
Jalciparum parasites, and recognises a polymorphic epitope in domain I (Coley et at. 200 I; Coley
et at. 2006). Monoclonal antibody 2C5 also reacts with 3D7 and DIO P. falciparum AMA I. Its
epitope is conformational and requires the entire, correctly folded AMA 1 ectodomain for reactivity
(Coley et at. 2006). MAb 508 recognizes a non-strain specific 19 residue linear epitope in the N-
terminal pro-sequence/pro-domain of AMA 1. The assay method was optimised with mAb IF9 first
then followed with the other two mAb. Optimisation for the concentration of monoclonal antibody
(mAb) to use was carried out by using the serial dilution method.
ELISAs were carried out using Dynex lmrnunolon 4HBX 96 well plates (Dynex Technologies Inc)
or Nunc Maxisorp 96 well plates (Nunc). Wells were coated with IOO~Iof O.51lg/ml in PBS of
antigen (3D7 AMA-I) and left overnight at 4°C. Wells were washed three times using a wash
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buffer (PBS-Tween 20, 0.05%). IOOIlI/well of blocking buffer (PBS-Tween 20, 10% skimmed
milk powder) was added to each well and the plates incubated at 37°C for two hours. Serial
concentrations mAbs IF9, 2C5, and 5GS were made up in sample buffer (PBS-Tween 20, 5%
skimmed milk powder). After washing the plates once with wash buffer, IOOIlI/well of each
concentration was added to duplicate wells and incubated at 37°C for one hour. The plates were
washed three times and incubated with IOOIlI/well of secondary antibody (HRP conjugated rabbit
anti-mouse IgG) diluted at 1:2500 in sample buffer for one hour at room temperature. After three
washes with wash buffer, IOOIlI/well of ABTS or OPO substrate solution was added. After 10 - 15
minutes incubation in the dark, the development reaction was stopped using 100JJ,I/well 1% SOS
(for use with ABTS) or 20IlI/well 2M sulphuric acid (for use with the OPO substrate solution). The
amount of antibody in each sample was then measured at 405nm (ABTS) or 492nm (OPO).
Standard curves for each mAb were then plotted and the optimum amount of mAb to compete with
the serum samples was decided upon. A value close to saturation but still on the linear part of the
curve was chosen so that there is enough mAb to occupy most specific sites in the absence of
competing antibody. The amount of mAb chosen to add into subsequent assays was 0.21lg/ml of
mAb 1F9 and mAb 2C5 and 0.121lg/ml of mAb 5GS. Serum samples were then tested for activity
to the specific epitopes as stated above. Sample dilutions were I :250 for 1F9 competition and
1:500 for 2C5 and 5GS competition in sample buffer with mAb at the stated concentrations added.
Reactivity was expressed as the percentage competition of the monoclonal antibody, with high
values indicating high levels of epitope-specific antibodies in the serum sample.
2.11 Growth Inhibition Assay
Assays were performed by Fiona McCallum using established methods (Persson et al. 2006;
McCallum et al. 200S). Heat inactivated dialysed sera was tested for inhibitory activity in 3077
sterile 96 well V-bottomed plates (Falcon) on highly synchronous P. falciparum 3D7 parasites.
The majority of the parasites were at the late pigmented trophozoite stage. The cultures were
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diluted with fresh erythrocytes to a starting parasitaemia 0.4% (for two cycle assays) and 0.7-0.8%
(for one cycle assays). The erythrocytes were resuspended in culture medium to I% hematocrit.
2SJIi of the parasite suspension was added to each well leaving the wells on the outside of the plate
blank. Sterile PBS was added to the blank. wells to keep the plate humid. 2.5,,1 of the serum
sample was added in duplicate. Positive controls of l00"g/ml and 10 ug/ml pharmaceutical grade
heparin and IF9 monoclonal antibody (against 3D7 AMA-I) were added to each plate. PBS was
added to act as a negative control. A reference smear from the remaining parasite sample used for
the assay was later used to determine the parasitaemia and stage of culture. The plate was then put
in a humidified chamber, gassed and incubated at 37OC. For a two cycle assay, the cultures were
fed after 48 hours by adding SJ11of media into each well. Duplicate plates each containing the
same serum samples but different transfected parasite clones were set up at the same time. After
36-48 hours (one cycle assay) or 78-84 hours (two cycle assay) when the parasites were at the late
ring or early trophozoite stage, the parasites were stained in the following manner. 100,,1 of
lOJ1g/ml ethidium bromide (molecular biology grade) in PBS was added to each well with gentle
mixing and incubated in the dark for 1 hour. The plates were spun at 1500rpm for 1 min to pellet
the erythrocytes. Supernatant was removed and the erythrocytes were resuspended in 200,,1 PBS
and the parasitaemia measured by flow cytometry.
2.12 Statistical Analysis
Data was cleaned and all analyses performed with STATA version 9.2 (StataCorp, College Station,
TX USA). Statistical significance was set at the conventional level (p ~ 0.05) for all tests. All OD
readings were standardised using the positive controls on each plate. Standardisation was carried
after the mean OD value of the blank wells was subtracted to remove the background. Using the
same positive control samples that were present on each plate, a calculation of the conversion
factor that would standardise the OD readings across all the plates was carried out as follows:
Conversion Factor = Positive control OD
Mean of all positive control OD"
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Standardised OD values were then calculated by dividing the OD value of the test samples by the
conversion factor. The cut-off value for antibody positivity to a particular antigen was calculated
as any value above the mean+ 3SD above the value of all the negative controls on each plate. The
cut-off value for a positive anti-AMA I IgG response was the same for all three variants (0.10 OD
units), and that for a positive anti-MSP2 response was 0.50 OD units for both variants tested. The
cut-off values for anti-AMA I (307) IgG I, IgG3, and IgM responses were 0.34 OD units, 0.07 OD
units, and 0.14 OD units respectively.
2.12.1 Acquisition of antibodies to AMA1 and MSP2
The chi' test for trend was used to assess the acquisition of antibodies to AMA I and MSP2 in
different age groups and at different sample times, comparing the proportion of individuals who
were antibody positive. As the antibody data was non-normally distributed, non-parametric
methods (Kruskal-Wallis and Mann-Whitney tests) were used to compare antibody levels.
Spearman rank correlation coefficients were used to examine the association between antibody
levels to different antigens.
2.12.2 Antibody response ranking
Tracking is a method used to investigate the stability of outcome variables over time. Rather than
calculating a tracking coefficient for each individual, a simpler method of visualizing relative
change over time was used. Each individual's antibody response was assigned as a rank within the
study population and its stability was investigated over the study period using adjusted z-scores
(standard normal deviates). The z-score was calculated using the following equation:
z x- J.l
u
Where X is the antibody measure, J1 is the mean, and a is the standard deviation. The z-score was
adjusted for age and sample time to take into account the increasing age of the children over the
study period and the reduction in malaria transmission.
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l.12.3 Factors affeeting aDtibody titres at sample time
To investigate the factors affecting antibody titres; univariate and multivariable linear regression
was carried out with age (one year intervals), parasite status (binary), sickle trait (categorical),
alpha-thalassemia (categorical), and prior parasitaemia/iliness (categorical) as covariates. All the
data was fitted into the multivariable model and then repeated after stratifying by parasite status at
sampling time as this modifies the effects of antibodies to P. falciparum blood-stage antigens (Bull
et al. 2002; Polley et al. 2004; Polley et al. 2006; Osier et al. 2008).
l.ll.4 LoeaUy Weighted Seatter-plot SmoothiDg
In order to reduce the large number of data points at each time point to a longitudinal pattern, mean
antibody levels were calculated and graphed using locally weighted scatter-plot smoothing
(LOWESS). LOWESS fits a low-degree polynomial to a determined subset of the data at each
point with explanatory variable values near the point where the response is being estimated
(Cleveland 1979; Cleveland and Devlin 1988). 80% of the data at each point was used to fit each
local polynomial using weighted least squares which gives less weight to points further away from
the point whose response is being estimated. LOWESS does not require the specification of a
function to fit a model to all of the data in the sample and requires large densely sampled data sets
to produce good models. With over 250 data points at each sample point, this model gave a
reasonable population mean.
l.12.5 Probability of a high antibody response after recorded P. fa/ciparum exposure
The probability of a high antibody response (above the 75th centile) to each antigen after recorded
exposure to P. falciparum was estimated by logistic regression, fitting the number of recorded
parasitemic episodes in the 6 months prior to sample time as a factor and adjusting for age. The
logits from these models were converted into probabilities to give estimates of risk (Mitchell and
Chen 2005). The probabilities were then plotted using the lowess smoothing technique to filter
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fluctuations and highlight the overall trend. This same analysis was employed to estimate and plot
the probability of being sero-positive to the various antigens.
2.12.6 Multivariate Analysis of Variance (MANOVA) for Repeated Measures
To test for differences in antibody levels over the study period MANOY A for repeated measures
was carried out. This statistical test is carried out for the T - 1 absolute differences between
subsequent measurements.
The F statistic for this test is calculated using the following equations:
(
N-T+l )
F = (N - 1) (I_1) JP
Where N is the number of subjects, T is the number of repeated measurements, v'; is the row vector
of differences between subsequent measurements, Yd is the column vector of differences between
subsequent measurements, and S d is the variance/covariance matrix of the differences between
subsequent measurements. MANOY A for repeated measures assumes that observations on
different subjects at each of the time points are independent and are multivariate normally
distributed (multivariate normal distribution is an extension of normal one dimensional distribution
- the assumption is that each linear combination of a random vector's components has a univariate
normal distribution).
2.12.7 Generalised Estimating Equations (GEE)
To investigate the effect of different predictor variables (X) on antibody levels (continuous
outcome variable, Y) generalised estimating equations (GEE) were used. GEE allow for the
analysis of longitudinal relationships using all available longitudinal data without summarizing the
longitudinal outcome into a single value (Twisk 2003). The model for GEE is an extension of
cross-sectional linear regression and uses the formula below as described by Twisk:
73
J C M
1'.=~ +I:~~..+ /Jzl +I:~.z..+ I: ~_G..+ B.
1-1 . i-I .. 1
Where fi, are the observations for subject i at time t, Po is the intercept, X;1j is the independent
variablej for subject i at time t,Pll is the regression coefficient for independent variablej, J is the
number of independent variables, t is time, P2 is the regression coefficient for time, Z;tl is the time-
dependent covariate k for subject i at time t, P3k is the regression coefficient for time-dependent
covariate k, K is the number of time-dependent covariates, G;m is the time-independent covariate m
for subject i,P4m is the regression coefficient for time-independent covariate m, M is the number of
time-independent covariates, and Bit is the 'error' for subject i at time t. The estimated PIj
represents the relationship between the longitudinal development of the outcome variable (fit) and
the development of different predictor variables (X;t). This model allows for simultaneous analysis
between variables at different time points. Repeated observations on the same subject are not
independent so a correction needs to be made for this within-subject correlation. An exchangeable
correlation structure is the simplest correlation structure. Here, correlations between subsequent
measurements are assumed to be the same irrespective of the length of the time interval. With
correlation values ranging from 0.6 to 0.75, it was decided that the exchangeable correlation
structure would work best with this dataset. This within-subject correlation structure is treated as a
covariate.
The above equation then becomes:
J
Y. = fJ,+ ~ fJ~. + ~ + ... + CORR.+ e.
1=1
Where CORR" is the working correlation structure.
The risk of experiencing a recorded episode of parasitaemia in the intervals was investigated using
GEE for 'count' outcome variables. This model uses the same equations as above and is
comparable to a poisson regression analysis except that within-subject correlation is taken into
account. An exchangeable correlation structure was also used in this model. Antibody measures
were entered into the model as continuous variables, age was a categorical variable defined by age
at the start of the study, parasitaemia was also a categorical variable defined by the number of times
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an individual had concurrent parasitaemia at sample time. Prior exposure was a count variable
defined by the number of times each individual had an episode of recorded parasitaemia in six
months prior to sample time. Sickle trait was entered as a binary variable (normal and
heterozygous) and a-thalassemia as a categorical variable (normal, heterozygous, homozygous).
2.12.8 Antibody responses and protection against clinical malaria (Cross sectional risk
analysis)
In order to investigate whether the risk of disease was dependent on the time that sampling
occurred, univariate and multivariate generalised linear models (GLM) were used on samples taken
during the May and October 2002 bleeds as well as those taken during the May 2003 bleeds. From
October 2003 to October 2004 there were no recorded episodes of clinical malaria in this cohort so
antibody measures for samples collected after the May 2003 bleed were not included in the
analysis. Univariate analysis was first carried out to assess the non-antibody factors that affected
the risk of clinical disease. These factors were age, concurrent parasitaemia, and
haemoglobinopathies. Each was included in the model in different ways. Age was a continuous
variable, concurrent parasitaemia was coded as both a binary variable (at sample time) and also as a
categorical variable when it described an individual's ongoing parasitemic status over the study
period (never parasitemic, parasitemic once, and recurrent parasitaemia). Sickle trait was a binary
variable and alpha-thalassemia a categorical variable (normal, heterozygous, homozygous).
Univariate analysis was carried out on the May and October 2002 samples as well as the May 2003
samples as described above. It was then carried out on all the samples in the study using the same
model but including a clustering indicator that identified repeated sampling on the same individuals
but ignored the longitudinal nature of the sampling. Each antibody response was also tested as a
continuous variable in the univariate models described above. Multivariable GLM analysis for the
risk of a clinical episode was carried out on the antibody responses for the May 2002 to May 2003
bleeds as well as for all samples and was adjusted for age, concurrent parasitaemia, and
haemoglobinopathies.
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2.12.9 Antibody responses and protection against clinical malaria (Longitudinal risk
analysis)
The overall risk of a clinical episode of malaria in this study was assessed using Generalised
Estimating Equations (GEE) for 'count' outcome variables. Univariate GEE analysis on antibody
responses and the non-antibody factors that may affect the risk of clinical malaria was carried out
followed by multivariable analysis on the adjusted effect of antibody responses to AMA1 and
MSP2. Recently published results from a separate study carried out in Kilifi has shown that
removal of those individuals without any exposure strengthened the protective association of some
malarial antigens against clinical disease (Polley et al. 2004; Bejon et al. 2009). With this in mind,
I carried out the multivariable analysis on only those children who had recorded exposure to
Plasmodium over the study period (as indicated by a positive blood smear during the weekly
surveillance or at sample time).
2.12.10 Acquisition of antibody responses to specific epitopes of AMA1(3D7)
Differences in median antibody levels were analysed using the Kruskal-Wallis test. Tests for trend
were used to check for patterns in the proportion of the population acquiring a particular response.
Antibody levels to recombinant AMAI (307), the 1F9, 2C5, 5G8 epitopes, and parasite growth in
vitro were compared using Spearmans rank correlation.
2.12.11 Association between epitope-specific antibody responses and rate of clinical malaria
In the Chonyi cohort (chapter 7), Kaplan-Meier survival functions were used to investigate the
failure rates and characteristics of the groups described above. Differences in survival functions
were tested using the Log-rank test. Differences in the likelihood of failure at any point during
follow up between high and low responders was analysed using Cox Proportional Hazards. Both
the unadjusted and age adjusted proportional hazards were investigated.
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2.12.12 Epitope-specific antibody responses and protection against clinical malaria
The relationship between antibody levels and the risk of experiencing a clinical malaria episode in
the 6 months post-sampling for the Chonyi cohort (chapter 7) was analysed using univariate and
then multivariable generalised linear models (GLM) that were adjusted for age (in 1 year
categories). Risk was expressed as a risk ratio as the outcome incidence was above 10%; and was
compared between those with high and low antibody responses (assigned using the median value)
in the entire cohort as well as in groups stratified by parasite status.
2.13 Cohort descriptions
Following are details of the characteristics of each of the cohorts used in this study.
2.13.1 Longitudinal Ngerenya Cohort
As described earlier, this study covers the period from May 2002 to October 2004. In total 1804
samples were analysed, 750 (44.6%) from females and 933 (55.4%) from males. There was an
average of 300 children per sampling point with 186 of them present at all six sampling points.
The gender distribution remained constant throughout the study (Table 2.1). This was an aging
cohort with the median age being 3.7 years in May2003 and 5.3 years in October 2004 (Table 2.2).
At each sampling point the age ranged from 0 to 9 years. Of the 1728 total samples where blood
smear data was available, 1550 (89.7%) were aparasitemic and 178 (10.3%) parasitemic at
sampling. Malaria transmission was on the decline over the latter part of the study as evidenced by
the number of children with parasites at each cross-sectional bleed. Parasite prevalence fell from
17.1% in May 2002 to 3.7% in October 2004 (Table 2.1 ).
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Table 2.1 Gender and parasite distribution at each cross sectional bleed (longitudinal study)
Gender %(n) Parasite status % (n)
Bleed
n Female Male n Negative Positive
May 2002 309 44.5 (133) 55.5 (166) 299 82.9 (248) 17.1 (51)
October 2002 295 44.4 (128) 55.6 (160) 292 92.8 (271) 7.2 (21)
May 2003 296 44.5 (130) 55.5 (162) 288 86.8 (250) 13.2 (38)
October 2003 300 44.5 (125) 55.5 (156) 294 86.0 (253) 14.0 (41)
May2004 302 44.4 (115) 55.6 (144) 282 94.0 (265) 6.0 (17)
October 2004 302 45.1 (119) 54.9 (145) 273 96.3 (263) 3.7 (10)
All 1804 44.6(750) 55.4 (933) 1728 89.7 (1550) 10.3 (178)
There were minor increases in prevalence that were sustained in 2003 with prevalence rates of
13.2% in May and 14.0% in October. The decline in malaria transmission was also seen in the
frequency of positive blood smears and clinical malaria episodes in the intervals between cross-
sectional sampling (Table 2.3). During the six-month interval before the first sampling in May
2002, 34.4% children experienced at least one parasitemic episode. Of these children, 52.4% had
at least one clinical mild malaria episode. Between the May 2002 and October 2002 sampling
17.3% had one or more parasitemic episodes. Malaria transmission increased in the following six
months (October 2002 to May 2003) with 52% of the children experiencing parasitaemia. It then
fell steadily in the three six-month intervals between May 2003 and October 2004 from 37% to
12.5% and finally to 2.6%. From October 2003 there were no clinical malaria episodes (Table 2.3).
Sickle trait and a-thalassemia prevalence data was also available for this cohort. 13.1% of the
children had the sickle trait (HbAS) compared to 86.9% of the normal (HbAA) phenotype. 18.4%
of the children were homozygous for a-thalassemia compared to 48.6% heterozygotes and 33.0%
normal children.
Table 2.2 Mean and median age at each cross sectional bleed (longitudinal study)
Age (years)
Bleed
Mean (SO) Median (IQR)
May 2002 299 3.8 (2.1) 3.7 (2.0, 5.6)
October 2002 292 4.0 (2.3) 3.9 (2.1, 5.9)
May 2003 288 4.4 (2.4) 4.3 (2.4, 6.4)
October 2003 295 4.6 (2.5) 4.6 (2.6, 6.8)
May 2004 281 4.9 (2.6) 4.9 (2.8, 7.1)
October 2004 273 5.2 (2.7) 5.3 (2.8, 7.6)
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Table 2.3 Proportion of children experiencing different numbers of episodes of parasitaemia and mild
malaria in the intervals between cross-sectional sampling points (longitudinal study)
Number of episodes'
Proportion % In)
Mild malaria"Parasitaemia I
October 2001- May 2oo2In=305)
o 65.6 (200)
21.0 (67)
8.9 (27)
2.6 (8)
0.7 (2)
0.3 (1)
4
May 2002 - October 2002 (n=255)
o 82.8 (211)
12.9 (33)
3.9 (10)2
4 0.4 (1)
October 2002 - May 2003 (n=256)
o 48.1 (123)
2
23.4 (60)
16.8 (43)
5.5 (14)
5.1 (13)
0.4 (1)
3
4
6
7 0.8 (2)
May 2003 - October 2003 (n=262)
o 63.0 (165)
21.4 (56)
10.7 (28)
4.2 (11)
4 0.8 (2)
October 2003 - May 2004 (nz256)
o 87.5 (224)
9.8 (25)
2.3 (6)
0.4 (1)
May 2004 - October 2004 (n=235)
o 97.5 (229)
2
2.1 (5)
0.4 (1)
82.0 (250)
15.4 (47)
1.6 (5)
1.0(3)
91.4(233)
6.7 (17)
1.6 (4)
0.4 (1)
61.3 (157)
23.1 (59)
10.2 (26)
4.7 (12)
0.4 (1)
0.4 (1)
76.7 (201)
17.9 (47)
4.2 (11)
1.2 (3)
100 (256)
100 (235)
Notes
1 Number of episodes recorded during weekly surveillance In the interval between cross sectional bleeds.
1Recorded parasitaemia accompanied by fever ~ 37.S·C.
1I Malaria definitions: detectable parasitaemia and fever ~ 37.5·C In children < 1 year, parasitaemia ~ 2500h.li
and fever 2: 37.5·C In children 2: 1 vear.
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2.13.2 Ngerenya September 1998 Cohort
130 serum samples collected in September 1998 from Ngrerenya residents aged 0-85 years were
used in this study. 53.4% were female and 45.7% were male. Data was analysed in five age groups
(0-4,5-8,9-12, and l3+). 39.3% of the cohort was parasitemic at sampling (Table 2.4)
Table 2.4 Parasite status and age distribution in the Ngerenya September 1998 cohort
Parasite Status % In)
Age group (years) n
Positive Negative
O· 29 27.6 (8) 72.4 (21)
5- 40 57.5 (23) 42.5 (17)
9- 30 53.3 (16) 46.7 (14)
13+ 51 23.5 (12) 76.5 (39)
All 150 39.3 (59) 60.7 (91)
2.13.3 Chonyi October 2000 Cohort
In total 276 serum samples from Chonyi were collected in October 2000 from individuals 0-55
years of age. 51.4% were female and 48.6% were male. All individuals were monitored weekly
by active and passive surveillance for symptomatic illness and malaria. 42.6% of the samples were
from individuals with concurrent parasitaemia (Table 2.6). More than half of the samples from
individuals 7 years of age or older were parasitemic at sampling.
Table 2.5 Parasite status and age distribution in the Chonyi October 2000 cohort
Parasite Status % (n)
Age group (years) n
Positive % Negative %
0- 20 10.0 (2) 90.0 (18)
1- 51 29.4 (15) 70.6 (36)
3- 52 46.2 (24) 53.9 (28)
5- 52 46.2 (24) 53.9 (28)
7- 53 50.9 (27) 49.1 (26)
9- 20 90.0 (18) 10.0 (2)
11+ 27 25.9 (7) 74.1 (20)
All 275 42.6 (117) 57.5 (158)
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3 Identification of factors determining the acquisition
and levels of antibodies to AMAI and MSP2, and the
influence of changing malaria transmission intensity
3.1 Introduction
The presence of malaria antigen specific antibodies in endemic populations is an important
correlate of immunity (Riley et al. 1992; Hogh et al. 1995; AI-Vaman et al. 1996; Egan et al. 1996;
Branch et al. 1998; Conway et al. 2000; Polley et al. 2003; Cavanagh et al. 2004; Perraut et al.
2005; Dodoo et al. 2008; Osier et al. 2008; Stanisic et al. 2009; Fowkes et al. 2010). That antibody
levels rise with age - often reaching saturation in adulthood - along with the rarity of malaria-
related deaths in adults in populations exposed to endemic malaria indicates that protective
antibody responses are acquired with cumulative exposure. In most areas of sub-Saharan Africa,
the most active phase of immunity acquisition occurs in children below the age of 10 years, after
which malaria related morbidity becomes rare. It is hypothesised that immunity to severe malaria
is acquired after a small number of episodes, followed by broader immunity to mild malaria, and
finally anti-parasite immunity (Marsh and Snow 1997; Gupta et al. 1999).
The overwhelming evidence of increasing antibody responses with age - both in magnitude and
prevalence - that has been produced by a large body of serological studies often leads to over
simplification of the understanding of the antibody acquisition process in childhood. One of the
tenets in malaria immunology is that antibodies will always increase with age in malaria endemic
populations as individuals get more exposure to the pathogen. This is typically seen in cross-
sectional studies and sometimes leads to age being used as a proxy of exposure which is corrected
for in protective association studies. Although it is acknowledged that age and exposure are two
related factors associated with immunity, only a few studies have successfully separated the two
and shown that age has an independent effect on antibody responses (Baird et al. 1991; Kurtis et al.
2001; Hudson Keenihan et al. 2003; Keenihan et al. 2003). These studies compared the antibody
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responses in adults and children; to date there is no study that investigates age independently of
exposure at the time when acquisition of immunity to malaria is at its highest rate (childhood) in
malaria endemic populations.
Antibody titres increase with increasing endemicity and drop significantly after an episode of
severe malaria (Jakobsen et al. 1997; Kinyanjui et al. 2007). In areas of seasonal malaria
transmission, antibody levels appear to be maintained as long as parasite exposure continues (Fruh
et al. 1991; Ramasamy et al. 1994; Cavanagh et al. 1998; Soares et al. 1999b; John et al. 2002).
These two observations are evidence of a differential antibody induction rate which is poorly
described in the published malaria literature. Malaria in Africa is currently typified by both a
reduction in malaria transmission in parts as well as a wide range of malaria transmission
intensities (Hay et al. 2000; Bhattarai et al. 2007; Fegan et al. 2007; O'Meara et al. 2008; Okiro et
al. 2009). Classic models of antibody acquisition in childhood assume fixed transmission
intensities which are unlikely to capture this dynamic effect, and often assume highly stable
antibody levels.
Antibody levels are higher in parasitized individuals and can drop more than 10-fold in the absence
of parasites (Soares et al. 1997; Soares et al. 1999a). But even though antibody prevalence is
associated with parasitaemia, the significant increase is seen predominantly in children rather than
adults (AI-Yaman et al. 1994; AI-Yaman et al. 1995b). Studies of the association of antibody
responses with protection from clinical disease often stratify by parasite infection status in order to
separate the effect of circulating parasites on antibody responses (Bull et al. 2002; Polley et al.
2004). Though this may help with defining an individual's overall responsiveness, it does not give
us much detail into whether the response we are measuring is made up of the response to both the
cumulative and current exposure or whether it is an overwhelming response to the concurrent
parasitaemia.
Two haemoglobinopathies - sickle trait, and alpha-thalassemia - affect the incidence of malaria in
endemic populations. The sickle trait (HbAS) confers a considerable resistance to severe and
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complicated malaria in children below the age of five years as well as to mild symptomatic malaria
(Willcox et at. 1983; Hill et at. 1991; Aidoo et at. 2002; Williams et at. 2005b). Up-regulation of
cell-mediated responses to malaria antigens in HbAS individuals from Sudan and the Gambia has
been observed (Marsh et at. 1989; Bayoumi et at. 1990; Abu-Zeid et at. 1992). That protection
from clinical malaria increases with age at a more rapid pace in HbAS children than in HbAA
children also implies a role for HbAS in regulation of the adaptive immune response (Williams et
at. 2005a). Though two studies have shown differences in antibody responses between HbAA and
HbAS individuals, they have not been in complete agreement (Sarr et at. 2006; Verra et at. 2007).
Due to the paucity of results, it remains unclear whether the presence of the sickle trait leads to a
reduction or increase in the antibody response to malaria antigens.
Studies in Papua New Guinea and Kenya showed that homozygotes for alpha-thalassemia were
more protected than normal individuals from severe malaria (Alien et at. 1997; Williams et at.
2005c). This was contrary to a smaller study in Ghana which showed the same protective effect in
heterozygotes but not in homozygotes (Mockenhaupt et at. 2004). Although inhibition of parasite
growth and invasion have been suggested as mechanisms for the protective action of alpha-
thalassemia, this seems unlikely as the parasite densities measured in the Kenyan and Papua New
Guinean studies were no different in homozygotes and normal individuals, and there is no
consistent protective association observed for mild symptomatic malaria (Williams et at. 2005c;
Wambua et at. 2006; Fowkes et at. 2008). Though the mode of action of protection attributed to
antibodies with regards to alpha-thalassemia remains unclear, there still remains a dearth of basic
information on the acquisition of antibody responses in individuals with alpha-thalassemia.
To date, there is an insufficient amount of information on the direct effect that the above mentioned
factors have on antibody levels. This type of information is important for thorough interpretation
of antibody responses that are often measured in malaria-endemic populations and interpreted
without detailed knowledge of which factors have been instrumental in giving the result obtained.
When antibody responses begin to be seen as a result of other factors that may be dynamic in
nature rather than simply a baseline measurement of immunity, one can see why there is conflicting
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data in studies associating antibody responses with protection from malaria. The association of
antibody responses with protection is beyond the scope of this chapter and will be discussed in later
chapters. In this chapter I will identify factors and quantify their effect on the acquisition and
maintenance of antibody responses to merozoite antigens in children from Kilifi district in Kenya.
Using a unique cohort with repeated sampling that covered a period when malaria transmission was
on the decline (parasite prevalence dropped from 17% in May 2002 to 4% in October 2004 and
incidence of mild malaria from 12% in between October 2001 and May 2002 to 0% from October
2003 onwards), I will compare the acquisition of antibody responses to various alleles of AMAI
and MSP2 as representative merozoite antigens.
3.2 Methods
3.2.1 Study population, sample collection, and surveillance
Serum samples were collected from an observational longitudinal cohort study with 6 sampling
points approximately six months apart from May 2002 to October 2004 with continuous active
weekly case detection, as described in chapter 2.
3.2.2 Enzyme-linked immunosorbent assay (ELISA)
Total IgG responses to recombinant proteins representing three AMA 1 variants (W2mef, HB3, and
307) and two MSP2 variants (307 and FC27) were measured by high throughput ELISA according
to the protocol described in chapter 2. IgG responses to schizont extract and tetanus toxoid were
also measured by ELISA. Antibodies were tested at sera concentrations of 1:4000 (AMA 1
variants), 1:1000 (MSP2 variants and schizont protein extract), and 1:500 (tetanus toxoid).
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3.2.3 Statistical Analysis
All data analyses were performed with STAT A version 9.2 (Stata Corp, College Station, TX USA).
All samples were used in the analyses unless stated. The chi2 test for trend was used to assess the
acquisition of antibodies to AMA 1 and MSP2 in different age groups and at different sample times.
As the antibody data was non-normally distributed, non-parametric methods (Kruskal-Wallis and
Mann-Whitney tests) were used to compare antibody titres. Spearman rank correlation coefficients
were used to examine the association between antibody titres to different antigens. Significance
was reached at the 0.05 level for all tests.
To investigate the factors affecting antibody titres; univariate and multivariable linear regression
was carried out with age, parasite infection status, sickle trait, alpha-thalassemia, and prior
parasitaemia or prior illness as covariates. All the data was fitted into the multivariable model and
then repeated after stratifying by parasite status as concurrent parasitaemia at sample time modifies
the effects of antibodies to P. falciparum blood-stage antigens (Bull et al. 2002; Polley et al. 2004;
Polley et al. 2006; Osier et al. 2008).
The probability of a high antibody response (above the 75th centile) to each antigen after recorded
exposure to P. falciparum was estimated by logistic regression, fitting the number of recorded
parasitaemic episodes in the 6 months prior to sample time as a factor. These odds were converted
into the probability of a high antibody response (Mitchell and Chen 2005). The probabilities were
then plotted using the LOWESS smoothing technique to filter fluctuations and highlight the overall
trend. This same analysis was employed to estimate and plot the probability of being sera-positive
to the various antigens.
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3.3 Results
3.3.1 The prevalence and magnitude of JgG responses to AMAI and MSPl increase with
age
Overall sero-prevalence of the IgG response to AMA1 and MSP2 variants was investigated using
cut-off values determined by a panel of negative controls. Children were grouped according to
their age at sampling and the sero-prevalence was determined at each bleed separately. More than
15% of all children below the age of one had detectable IgG responses to the AMA1 variants tested
(W2mef, HB3, 307) (Tables 3.1-3.3). This was in contrast to sero-prevalence values ranging from
o to 13% in May 2002 (MSP2(FC27» with regards to the IgG response to MSP2 variants (307 and
FC27) in children less than a year old (Tables 3.4-3.5). The prevalence of detectable antibodies
then dropped in one year-olds before increasing with age in the same manner for all three AMAI
variants, with over 70% sero-positivity by 9 years of age (Tables 3.1-3.3). The prevalence of
antibodies to both MSP2 variants in one year-olds remained similar to that in children below one
year and did not begin to rise until 3 years of age (Tables 3.4-3.5). From that age there was a
steady increase in antibody prevalence but only 37.5% (95% Cl: 12.9 -62.2%) and 50% (95% Cl:
24.6 -75.5%) of 9 year olds had detectable antibodies to MSP2(3D7) and MSP2(FC27) in May
2004 respectively, and only 28% (95% Cl: 10-46.1%) and 36%(95% Cl: 16.8-55.3%) in October
2004 respectively (Tables 3.4-3.5). Overall, there was a significant increase (p ~ 0.05, chi2 test for
trend) in the prevalence of detectable antibodies to AMA1 and MSP2 variants with increasing age.
Antibodies to AMA1 appeared to be acquired at a faster rate and were more prevalent than those to
MSP2 (Tables 3.1-3.5). Maternal antibodies to AMAI variants appeared to be more prevalent than
those to MSP2 (as indicated by the prevalence in children below the age of one year).
Representative graphs of the prevalence oflgG responses to each antigen in May 2002 also showed
the slower acquisition of antibody responses to MSP2 variants in comparison to that of AMAI
variants (Figure 3.1).
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Table 3.1 Prevalence of detectable IgG responses to AMA 1 (W2mef) by age and cross sectional bleed in
the Ngerenya cohort.
Antl-AMA1(W2mef) IgG sero-prevalence (95% Cl)
Age (years)
May 2002' October 2002' May 2003' October 2003' May2004' October 2004' P-value'
0 26.7 (10.6 - 42.9) 67.6 (52.3 - 83) 26 (9.1- 42.9) 43.5 (22.7- 64.3) 19.1 (1.8 - 36.4) 33.4 (8.6 - 58.2) 0.182
14.6 (4.5 - 24.8) 21.9 (7.3 - 36.5) 34.7 (15.9 - 53.4) 11.8 (0.8 - 22.9) 16 (1.3 - 30.8) 8.4 (-3.1-19.7) 0.385
2 33.4 (18.3 - 48.4) 48.8 (32.8 - 64.7) 11.4 (1.9 - 20.9) 15.7 (2.8 - 28.5) 6.5 (-2.4 - 15.3) 3.2 (-3.1- 9.3) <0_001
3 48.8 (33.3 - 64.4) 59 (43.3 - 74.7) 34.4 (17.6 - 51.2) 43.3 (27 - 59.5) 32.5 (17.1- 47.8) 17.9 (3.4 - 32.4) 0.002
4 50 (32.4 - 67.7) 76.7 (61.3 - 92.2) 40 (24.6 - 55.5) 47.7 (32.3 - 63) 17.3 (3.2 - 31.3) 33.4 (16.1- 50.6) 0.001
5 61.8 (47.6 - 75.9) 71.5 (58.6 - 84.3) 48.3 (29.7- 66.9) 46.2 (26.6 - 65.8) 45.5 (28.2 - 62.8) 42.5 (25.3 - 59.7) 0.007
6 65.8 (50.5 - 81.2) 75.9 (60 - 91.8) 52.8 (36.2 - 69.4) 62 (47 - 76.9) 54.2 (33.8 - 74.7) 41.7 (21.5 - 62) 0.032
7 74 (55.5 - 92.4) 82.9 (70.2 - 95.6) 71 (54.7 - 87.3) 52 (32 - 72.1) 57.9 (42 - 73.9) 55.3 (39.2 - 71.4) 0.007
8' 100 (0 - 0) 75 (55.5 - 94.6) 81.9 (68.4 - 95.3) 72 (54 - 90.1) 41.7 (21.5 - 62) 0.005
9' 81.3 (61.5 - 101.1) 72 (54 - 90.1) 0.506
P-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
1 Cross sectional bleed.
1P.values calculated uslne a chl1 test for trend for JIG prevalence In the same ale 8rOUPat different cross sectional bleeds (P-values SC.OS/ndlcated In bold type),
) s-vefues calculated usloS a chl1 test for trend for riG prevalence In different age groups at the same cross sectional bleed (P-values Si 0,05 Indicated In bold type),
(Missing values are due to a lack of children In that age eroup.
All samples included in analysis.
Table 3.2 Prevalence of detectable IgG responses to AMA 1 (HR3) by age and cross sectional bleed in
the Ngerenya cohort.
Antl-AMA1(HB3) IgG sero-prevalence (95% Cl)
Age (years)
May2002' October 2002' May 2003' October 2003' May 2004' October 2004' P-value'
0 26.7 (10.6 - 42.9) 56.8 (40.6 - 73.1) 37.1 (18.4 - 55.7) 34.8 (14.8 - 54.8) 23.9 (5.1- 42.6) 33.4 (8.6 - 58.2) 0.361
14.6 (4.5 - 24.8) 9.4 (-1- 19.7) 34.7 (15.9 - 53.4) 14.8 (2.6 - 26.9) 12 (-1.1- 25.1) 8.4 (-3.1- 19.7) 0.619
2 33.4 (18.3 - 48.4) 20.6 (7.7 - 33.5) 25 (12.1- 38) 21.9 (7.3 - 36.5) 9.7 (-1- 20.4) 3.2 (-3.1- 9.3) 0_001
3 46.4 (30.9 - 61.9) 46.2 (30.3 - 62.1) 31.3 (14.9 - 47.7) 43.3 (27 - 59.5) 32.5 (17.1- 47.8) 17.9 (3.4 - 32.4) 0.017
4 53.2 (35.5 - 70.8) 66.7 (49.5 - 83.9) 55 (39.4 - 70.7) 45.3 (30 - 60.6) 27.6 (11 - 44.3) 30 (13.3 - 46.8) 0.002
5 68.1 (54.6 - 81.7) 57.2 (43.1- 71.3) 62.1 (44.1- 80.2) 46.2 (26.6 - 65.8) 45.5 (28.2 - 62.8) 39.4 (22.4 - 56.4) 0.004
6 79 (65.8 - 92.2) 55.2 (36.7- 73.7) 61.2 (44.9 - 77.4) 57.2 (42 - 72.4) 54.2 (33.8 - 74.7) 37.5 (17.7 - 57.4) 0.004
7 74 (55.5 - 92.4) 77.2 (63 - 91.4) 83.9 (70.7 - 97.1) 52 (32 - 72.1) 52.7 (36.5 - 68.8) 52.7 (36.5 - 68.8) 0.002
8' 100 (0 - 0) 85 (68.9 - 101.2) 84.9 (72.4 - 97.4) 80 (64 - 96.1) 45.9 (25.4 - 66.3) 0.002
9' 75 (53 - 97.1) 76 (58.9 - 93.2) 0.943
P-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
I Cross sectional bleed.
1P-values calculated using a chll test for trend for IgG prevalence In the same age group at different cross sectional bleeds (P-values.s 0.05 Indicated In bold type).
) P-values calculated using a chl2 test for trend for igG prevalence in different age groups at the same cross sectional bleed (P-values.s 0,05 Indicated In bold type).
e Mlsslna values are due to a lack of children In that age group.
All samples Included In analysis,
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Table 3.3 Prevalence of detectable IgG responses to AMAI (307) by age and cross sectional bleed in
the Ngerenya cohort.
Anti-AMA1(307) IgG sero-prevalence (95% Cl)
Age (years)
MayZOOZ' October ZOOZ' MayZ003' October Z003' ,MayZ004' October Z004' P-value
0 23.4 (7.9 - 38.8) 48.7 (32.3 - 65.1) 29.7 (12.1- 47.3) 26.1 (7.7 - 44.6) 23.9 (5.1- 42.6) 26.7 (3.4 - 50) 0.384
1 8.4 (0.4 - 16.3) 3.2 (-3.1- 9.3) 34.7 (15.9 - 53.4) 20.6 (6.8 - 34.5) 8 (-3 -19) 12.5 (-1.1- 26.1) 0.386
Z 35.9 (20.6 - 51.3) 20.6 (7.7- 33.5) 13.7 (3.4 - 24) 18.8 (5 - 32.6) 13 (0.9 - 25) 6.3 (-2.4 - 14.9) O.OOZ
3 46.4 (30.9 - 61.9) 35.9 (20.6 - 51.3) 28.2 (12.3 - 44.1) 37.9 (22 - 53.8) 29.8 (14.8 - 44.8) 17.9 (3.4 - 32.4) 0.OZ7
4 40.7 (23.3 - 58) 63.4 (45.8 - 81) 47.5 (31.8 - 63.3) 40.5 (25.4 - 55.6) 17.3 (3.2 - 31.3) 33.4 (16.1- 50.6) 0.017
5 63.9 (49.9 - 77.8) 49 (34.8 - 63.2) 51.8 (33.2 - 70.4) 46.2 (26.6 - 65.8) 39.4 (22.4 - 56.4) 30.4 (14.4 - 46.3) 0.003
6 71.1 (56.4 - 85.8) 55.2 (36.7 -73.7) 50 (33.4 - 66.7) 57.2 (42 - 72.4) 41.7 (21.5 - 62) 33.4 (14 - 52.7) 0.004
7 65.3 (45.3 - 85.3) 68.6 (53 - 84.3) 77.5 (62.4 - 92.5) 52 (32 - 72.1) 50 (33.9 - 66.2) 50 (33.9 - 66.2) O.OZZ
S" 100 (0 - 0) 75 (55.5 - 94.6) 87.9 (76.6 - 99.3) 76 (58.9 - 93.2) 41. 7 (21.5 - 62) 0.003
9' 81.3 (61.5 - 101.1) 72 (54 - 90.1) 0.506
P-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
1 Cross sectional bleed.
2P-values calculated using a chi2 test for trend for IIG prevalence in the same aBe group at different cross sectional bleeds (P-values S 0.05 indicated in bold type).
] P-values calculated uslns a chi2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P-values S 0.05 indicated in bold type).
e MissinS values are due to a lack of children in that age group.
All samples Included in analysis.
Table 3.4 Prevalence of detectable JgG responses to MSP2(3D7) by age and cross sectional bleed in the
Ngerenya cohort.
Antl-MSPZ(307) IgG sero-prevalence (95% Cl)
Age (years)
May200Z' October 200Z' May2003' October Z003' May2004' October 2004' P-value'
0 10 (-1- 21) 2.8 (-2.7 - 8.1) 3.8 (-3.6 - 11) 0(0 - 0) 0(0-0) 6.7 (-6.5 - 19.8) 0.246
10.5 (1.7 - 19.2) 3.2 (-3.1- 9.3) 3.9 (-3.8 - 11.5) 0(0- 0) 4 (-3.9 - 11.9) 4.2 (-4.1- 12.4) 0.150
Z 15.4 (3.9 - 27) 0(0- 0) 6.9 (-0.8 - 14.4) 3.2 (-3.1- 9.3) 6.5 (-2.4 - 15.3) 3.2 (-3.1- 9.3) 0.156
3 31.8 (17.3 - 46.2) 10.3 (0.6 - 20) 0(0- 0) 16.3 (4.2 - 28.4) 13.6 (2.3 - 24.8) 3.6 (-3.5 -10.7) 0.013
4 18.8 (5 - 32.6) 13.4 (1- 25.8) 20 (7.4 - 32.7) 19.1 (7 - 31.2) 6.9 (-2.6 - 16.4) 10 (-1- 21) 0.249
5 49 (34.5 - 63.5) 14.3 (4.4 - 24.3) 13.8 (1- 26.7) 3.9 (-3.8 - 11.5) 9.1 (-1- 19.1) 6.1 (-2.3 - 14.4) <0.001
6 47.4 (31.3 - 63.6) 27.6 (11 - 44.3) 27.8 (12.9 - 42.7) 31 (16.8 - 45.2) 8.4 (-3.1-19.7) 0(0-0) <0.001.
7 52.2 (31.3 - 73.2) 20 (6.5 - 33.6) 22.6 (7.6 - 37.7) 28 (10 - 46.1) 23.7 (10 - 37.5) 10.6 (0.6 - 20.5) 0.009
S" 0(0-0) 30 (9.4 - 50.7) 27.3 (11.8 - 42.8) 28 (10 - 46.1) 25 (7.3 - 42.8) 0.860
9' 37.5 (12.9 - 62.2) 28 (10 - 46.1) 0.529
P-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
I Cross sectional bleed.
2P-values calculated using a chi2 test for trend for IgG prevalence In the same age group at different cross sectional bleeds (P·values S0,05 indicated in bold type),
3 s-velues calculated using a chl2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (s-vafues S0,05 indicated in bold type),
eMissing values are due to a lack of children In that age group.
All samples Included In analysis.
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Table 3.5 Prevalence of detectable IgG responses to MSP2(FC27) by age and cross sectional bleed in
the Ngerenya cohort.
Antl-MSP2(FC27) IgG sero-prevalence (95% Cl)
Age (years)
May 2002' October 2002' May 2003' October 2003' May2004' October 2004' P-value'
0 13.4 (1 - 25.8) 5.5 (-2.1- 12.9) 7.5 (-2.8 -17.6) 4.4 (-4.3 - 13) 4.8 (-4.7- 14.2) 0(0-0) 0.113
18.8 (7.6 - 30) 6.3 (-2.4 - 14.9) 7.7 (-2.8 -18.2) 0(0 - 0) 0(0- 0) 8.4 (-3.1-19.7) 0.012
2 12.9 (2.2 - 23.5) 10.3 (0.6 - 20) 6.9 (-0.8 - 14.4) 3.2 (-3.1- 9.3) 6.5 (-2.4 - 15.3) 0(0- 0) 0.026
3 31.8 (17.3 - 46.2) 15.4 (3.9 - 27) 9.4 (-1- 19.7) 24.4 (10.3 - 38.4) 16.3 (4.2 - 28.4) 3.6 (-3.5 -10.7) 0.026
4 18.8 (5 - 32.6) 40 (22.1 - 58) 20 (7.4 - 32.7) 21.5 (8.9 - 34.1) 6.9 (-2.6 - 16.4) 10 (-1- 21) 0.024
5 23.5 (11.2 - 35.7) 18.4 (7.4 - 29.4) 20.7 (5.7 - 35.8) 23.1 (6.5 - 39.7) 9.1 (-1- 19.1) 6.1 (-2.3 - 14.4) 0.031
6 31.6 (16.6 - 46.7) 20.7 (5.7- 35.8) 27.8 (12.9 - 42.7) 26.2 (12.7- 39.8) 0(0-0) 4.2 (-4.1-12.4) 0.003
7 39.2 (18.7 - 59.7) 34.3 (18.3 - 50.4) 35.5 (18.3 - 52.7) 20 (4 - 36.1) 10.6 (0.6 - 20.5) 10.6 (0.6 - 20.5) 0.000
81 0(0-0) 50 (27.5 - 72.6) 45.5 (28.2 - 62.8) 36 (16.8 - 55.3) 12.5 (-1.1- 26.1) 0.012
9' 50 (24.6 - 75.5) 36 (16.8 - 55.3) 0.381
P-value' 0.033 0.004 <0.001 <0.001 <0.001 0.001
Notes
1 Cross sectional bleed.
2P-values calculated using a chl2 test for trend for laG prevalence In the same age group at different cross sectional bleeds (P-values S 0.05 indicated In bold type).
1 s-values calculated using a chl2 test for trend (or riG prevalence In different age groups at the same cross sectional bleed (P""Values S 0.05 Indicated In bold type).
eMissing values are due to it lack of children In that age group.
All samples included In analysis.
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Figure 3.1 Proportion of children with detectable IgG responses to P. falciparum merozoite antigens by
age group. Representative graphs showing prevalence at the May 2002 cross sectional bleed. All samples
tested by ELISA. Error bars indicate 95% Cl. Chi2 test for trend excluding age 0 years for AMA I variants.
Chi2 test for trend including age 0 years for MSP2 variants. (A) AMA I(W2mef) p <0.001, (B) AMA I(HB3)
P <0.001, (C) AMA 1(3D7) p <0.001, (D) MSP2(3D7) p <0.001, (E) MSP2(FC27) p = 0.033.
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The magnitude of the antibody response to both AMA 1 and MSP2 variants was analysed in four
age groupings (children less than a year, 1-3 years, 4-6 years, and 7-10 years) at each cross
sectional bleed. For all antigens at each cross sectional bleed, there was an increasing magnitude of
response with increasing age (p<O.OOI, Kruskal-Wallis test) (Appendix I Tables 1-5). Analysis of
actual OD values indicated that in all age groups there were a number of individuals who made
very low responses to the various AMA I and MSP2 variants, but the upper range of these
responses tended to rise with increasing age (Figure 3.2, Table 3.6, Appendix I Tables 1-5). For all
antigens tested there was a significant (p <0.001, Wilcoxon rank sum test) difference in the median
IgG response between 1-3 year olds and 7-10 year olds (Table 3.6, Appendix I Tables 1-5). This
was also true of the IgG response to A4 schizont extract which was used as a proxy of exposure
(discussed later in this chapter). Conversely, the IgG response to a non-malaria antigen (tetanus
toxoid) significantly declined with increasing age (Table 3.6), possibly because younger children
would have received booster immunisations for tetanus over the study period.
3.3.2 Acquisition of IgG responses to AMAI and MSP2 increase with measures of exposure
IgG responses to schizont protein extract were measured as a proxy for overall exposure to blood-
stage P. Jalciparum. This measure was split into tertiles that indicated low, medium, and high
levels of reactivity. The antibody response to AMA I and MSP2 variants was then analysed with
regards to these categories. Median IgG responses to all AMA I variants increased with increasing
exposure (p ~ 0.05, Kruskall Wallis test) at all cross-sectional bleeds (Figure 3.3) except those to
AMAI(HB3) in May 2004 (p = 0.70) (Appendix 3 Tables 7-9). A similar increase in IgG
responses to MSP2 with increasing exposure was seen, except in the response to MSP2(FC27) in
May 2004 (p = 0.208) (Appendix I Tables 10-11). Significant differences in the median IgG
response between categories (p ~ 0.05, Wilcoxon rank sum test) was observed for all antigens at
each cross-sectional bleed except in those two cases mentioned above (Appendix I Tables 7-11).
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Figure 3.2 Magnitude of the IgG response to P. fatciparum merozoite antigens by age group.
Representative graphs showing IgG levels at the May 2002 cross sectional bleed. All samples tested by
ELISA. Kruskal-Wallis test for equality of medians in all four age groups; p <0.001 for all antigens.
Wilcoxon rank sum test for equality of medians between children ages 1-3 years and 7-10 years; p <0.001 for
all antigens. (A) AMA I(W2mef), (B) AMA I(HB3), (C) AMA I(3D7), (D) MSP2(3D7), (E) MSP2(FC27).
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Figure 3.3 Magnitude of the IgG response to P. falciparum merozoite antigens by reactivity to A4
schizont extract protein. Representative graphs showing IgG levels at the May 2002 cross sectional bleed.
All samples tested by ELISA. Kruskal-Wallis test for equality of median responses in all three categories; p
<0.00 I for all antigens. Wilcoxon rank sum test for equality of median responses between two categories; p
<0.00 I for all antigens. (A) AMA I(W2mef), (8) AMA I(HB3), (C) AMA I(307), (0) MSP2(307), (E)
MSP2(FC27) .:
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3.3.3 Declining malaria transmission affects the acquisition of IgG responses to AMAI and
MSP2
Median IgG responses to all the AMA I and MSP antigens tested, along with those to schizont
extract for all samples were different at each cross sectional bleed (p :s 0.05, Kruskal Wallis test)
which could reflect differences in the malaria transmission levels at each time point (Table 3.7).
As described in chapter 2, malaria transmission was on the decline over the duration of this tudy,
particularly in the last year. Parasite prevalence fell from 17.1% in May 2002 to 3.7% in October
2004.
Table 3.7 Median IgG levels for each antigen over the study period
IgGlevels to merozoite antigens. median (IQRI
AMA1(W2mef)' AMA1(HB31' AMA1(3D71' MSP2(3D71' MSP2(FC271' Schizont extract
May 2002' (3081 0.08 (0·0.59) 0.09 (·0.01· 0.65) 0.07 (0 • 0.471 0.2 (0.05·0.671 0.1 (0.01· 0.411 0.37 (0.14·0.91
October 2002' (2941 0.4 (0.1- 1.371 0.1 (0.01· 0.441 0.06 (0-0.291 0.08 (0.03 • 0.211 0.08 (0.02·0.32) 0.13 (0.05·0.44)
May 2003' (293) 0.05 (-0.01· 0.49) 0.11 (0.01· 0.61) 0.07 (0.01· 0.48) 0.09 (0.03· 0.27) 0.09 (0.03·0.28) 0.17 (0.05·0.531
October 2003' (2991 0.07 (0.01·0.59) 0.05 (-0.04 -0.57) 0.07 (0-0.43) 0.12 (0.04 • 0.35) 0.1 (0.02 • 0.37) 0.2 (0.07·0.71)
May 2004' (2991 0.04 (0-0.341 0.05 (-0.01- 0.371 0.04 (·0.01· 0.27) 0.07 (0.02·0.24) 0.07 (0.02· 0.23) 0.09 (0.03 ·0.29)
October 2004' (302) 0.02 (·0.D2- 0.26) 0.01 (-0.05-0.24) 0.02 (-0.01- 0.2) 0.07 (0.02 • 0.18) 0.05 (0.02 . 0.19) 0.08 (0.03 ·0.22)
P.value' < 0.001 < 0.001 < 0.001 < 0.001 0.02 < 0.001
Notes
1 Cross sectional bleed. numbers In brackets indicate samples tested by ELISA.
2 Recombinant merozoite antigens tested.
lP-values calculated using a Kruskal Wallis test (P-values S 0.05 indicated In bold type).
All samples tested
To examine whether antibody acquisition might be dependent on the levels of malaria transmission
at the time that a serum sample was taken, sero-prevalence to all AMA 1 and MSP2 variants was
analysed in different age groups (0 to 9 years of age, in one year intervals) at different cro
sectional bleeds and a test for trend carried out in each separate age group (Tables 3.1-3.5). At all
cross sectional bleeds there was a significant rise (p :s 0.05, chi2 test for trend) in IgG prevalence as
mentioned in an earlier section. Although there was a trend for reduced antibody prevalence in
each age group over the study period this trend was only significant (p :s 0.05, chi2 test for trend)
in 2-8 year olds for AMA 1 variants (Tables 3.1-3.3), 3 year olds and 5-8 year olds for MSP2(3D7)
(Table 3.4), and 1-8 year olds for MSP2(FC27) (Table 3.5). AMA I(HB3) (Table 3.2), 2- and 5-
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year olds for AMAl(3D7) (Table 3.3), and 7-year olds for MSP2(FC27) (Table 5). Overall, a
reduction in malaria transmission (inferred by a reduction in parasite prevalence at sample time)
was accompanied by a reduction in antibody prevalence in all age groups.
3.3.4 CODcurreDtparasitaemia is assoeiated with higher IgG respenses to AMAI aad MSPl
For all the malaria antigens tested, children with concurrent parasitaemia at sampling had higher
IgO responses than those in the same age group without concurrent parasitaemia. The IgG
response to AMA1 and MSP2 variants and shizont extract at each cross sectional bleed increased
significantly (p < 0.001, Kruskal Wallis test) with age in aparasitaemic children, with a significant
difference between children ages 1-3 years and 7-10 years (p ~ 0.05, Wilcoxon rank sum test)
(Table 3.6, Appendix 3 Tables 1-6). This was not the case for children with concurrent
parasitaemia. The presence of parasites appeared to boost IgG responses in all children to the point
that any age related increases were not seen (Table 3.6, Appendix 3 Tables 1-6). To show that the
effect of parasites was specific to the malaria antigen response, examination of IgG responses to
tetanus toxoid showed no differences in aparasitaemic or parasitaemic children (Table 3.6).
3.3.S DlmlDished IIG responses are observed in the presence of both the sickle trait and
alpha-thalassemia
Both the sickle trait and alpha-thalassemia are associated with protection from clinical malaria,
particularly severe malaria. The IgG response to AMAI and MSP2 variants was investigated with
regards to the mentioned haemoglobinopathies by comparing these responses to those in normal
children. IgG levels to AMAI variants in children with the sickle trait (HbAS) were lower than in
their normal (HbAA) counterparts (Figure 3.4, Table 3.8, Appendix I Tables 12-14), though this
difference was significant only in a few cross sectional bleeds. When the entire cohort was
analysed at each bleed, only in May 2003 were the median IgG responses to all three AMA1
variants significantly lower in HbAS children (p ~ 0.05, Wilcoxon rank test) (Appendix 1 Tables
12-14). IgG responses to the MSP2 variants in HbAS children had marginally reduced median
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levels which were not significant at any of the cross-sectional bleeds (Figure 3.4, Table 3.8,
Appendix 1 Tables 15-16).
The protection that is conferred by this alpha-thalassemia is only evident in homozygous
individuals. IgG responses to AMA 1 variants were similar in normal and heterozygous children
(Figure 3.4, Table 3.8, Appendix 1 Tables 12-14) whereas those of the homozygotes were lower at
four of the six cross sectional bleeds (October 2002 through to May 2004) (p :s 0.05, Wilcoxon
rank test) (Appendix I Tables 12-14). In contrast, though the IgG responses to MSP2 variants
were consistently lower in range in homozygotes compared to heterozygotes and normal children
(Figure 3.4, Table 3.8, Appendix 1 Tables 15-16), there was no difference in the median IgG
responses between the three categories.
Reduced IgG responses to A4 schizont extract were seen in HbAS children only at the May 2002
cross sectional bleed (p = 0.34, Wilcoxon rank test) (Figure 3.5, Table 3.8, Appendix 1 Table 17).
Though levels tended to be lower, there was no significant difference in the IgO response to A4
schizont extract by alpha-thalassemia homozygotes compared to the other two groups except at the
October 2002 cross sectional bleed (p :s 0.05, Wilcoxon rank test comparing median IgG levels in
heterozygotes and homozygotes) (Appendix I Table 17). IgG responses to a non-malarial antigen
were also measured in order to clarify that these antibody responses were specific to P. falciparum.
There was no difference in antibody titres to tetanus toxoid in both HbAS and alpha-thalassemia
homozygotes compared to their normal counterparts (Figure 3.5, Table 3.8, Appendix I Table 18)
though there was an unusual significant increase in IgG responses to tetanus toxoid in homozygotes
compared with heterozygotes (p :s 0.05, Wilcoxon rank test) at the October 2003 cross sectional
bleed (Appendix 1 Table 18). However it was not possible to account for tetanus immunisations
that may have been given during the study which may be confounding these associations.
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Figure 3.4 Magnitude of the antibody (lgG) response to P. falciparum merozoite antigens in the
presence or absence of haemoglobinopathies (sickle trait and a-thalassemia). AA=Nonnal, AS=Sickle
trait, Norm=Normal, He =Heterozygous, Hom=Homozygous. Representative graphs showing IgG levels at
the May 2002 cross sectional bleed. All samples tested by ELISA. Kruskal-Wallis test for equality of
median responses in a-thalassemia categories non-significant for all antigens. Wilcoxon rank sum test for
equality of median responses between two sickle trait categories non-significant for all antigens except
MSP2(FC27). (A) AMA I(W2mef), (B) AMA I(HB3), (C) AMA I(3D7), (D) MSP2(3D7): p = 0.059,
Kruskal-wallis test on a-thalassemia medians, (E) MSP2(FC27): p = 0.052, Wilcoxon rank sum test on
HbAA and HbAS medians.
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Table 3.8 JgG responses in the presence or absence of haemoglobinopathies at the May 2002 cross
sectional bleed.
May2002'
Sickle trait Alpha- Thalassemia
HbAA HBAS P-value' Norm Het Homo P-value4
AMA1(W2mef)' N2 258 41 93 152 52
Median 0.09 0.05 0.215 0.09 0.09 0.07 0.521
IQR (-0.01- 0.72) (0 - 0.23) (-0.01- 0.72) (0 - 0.72) (0- 0.25)
AMA1(HB3)1 N2 258 41 93 152 52
Median 0.10 0.05 0.258 0.09 0.12 0.05 0.169
IQR (-0.01- 0.75) (-0.02 - 0.3) (-0.03 - 0.85) (0 - 0.65) (-0.02 - 0.27)
AMA1(3D7)1 N2 258 41 93 152 52
Median 0.07 0.04 0.162 0.06 0.08 0.04 0.357
IQR (0-0.6) (0 - 0.15) (-0.01 - 0.59) (0.01 - 0.51) (0.01- 0.21)
MSP2(3D7)1 N2 258 41 93 152 52
Median 0.24 0.13 0.141 0.26 0.23 0.12 0.059
IQR (0.05 - 0.69) (0.02 - 0.58) (0.07 - 0.68) (0.05 - 0.78) (0.03 - 0.34)
MSP2(FC27) 1 N2 258 41 93 152 52
Median 0.11 0.01 0.052 0.14 0.09 0.06 0.397
IQR (0.01- 0.47) (0 - 0.22) (0.01 - 0.42) (0.01- 0.5) (-0.01 - 0.28)
Schizont extract' N2 257 41 92 153 51
Median 0.41 0.25 0.034 0.43 0.41 0.33 0.273
IQR (0.16 - 0.92) (0.08 - 0.72) (0.15 - 0.95) (0.16 - 0.91) (0.09 - 0.68)
Notes
1Antigens tested.
2 Number of samples tested by ELISA
3 P·values calculated using a Wilcoxon rank test (P-values S 0.05 indicated In bold type).
4P-I/alues calculated us/nK a Kruskal Wallis test (P-values S 0.05 indicated In bold type).
6. Cross-sectional sampling time.
: Signtflcant difference (P S0.05 Wilcoxon rank test) in median JgGlevels between normal children and children heterozvgous for a-thalass.mla (P-values not shown).
Significant difference (P S0.05 Wilco)(on rank test) in median IgG levels between normal children and children homozvgous for a·thallssemla (P-values not shown).
t Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children heteroavgous and homozvgous for a-thalassemia (P-values not shown).
Possible effects of sickle trait and alpha-thalassemia on the acquisition of antibodies was also
investigated. Samples were grouped according to the age of the individual at sample time (less
than one year, 1-3 years, 4-6 years, and 7-10 years). JgG responses to AMA 1 and MSP2 were then
analysed.
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Figu re 3.5 Magnitude of the antibody (lgG) response to P. falciparum merozoite antigens in the
presence or absence of haemoglobinopathies (sickle trait and a-thalassemia). AA=Normal, AS=Sickle
trait, Norm=Normal, Het=Heterozygous, Hom=Homozygous. Representative graphs showing IgG levels at
the May 2002 cross sectional bleed. All samples tested by ELISA. Kruskal-Wallis test for equality of
median responses in a-thalassemia categories non-significant for all antigens. CA)A4 schizont extract: p =
0.034, Wilcoxon rank sum test on HbAA and HbAS medians, (B) tetanus toxoid.
For all AMA 1 and MSP2 variants, there was a significant increase in antibody titres in normal
(HbAA) children with increasing age at all cross-sectional bleeds (p <0.001, Kruskal Wallis test; p
::s 0.05, Wilcoxon rank test comparing median levels between children ages 1-3 years and 7-10
years) (Figure 3.6, Table 3.9, Appendix I Tables 19-23). These levels were in contrast to HbAS
children who did not appear to exhibit the same age related acquisition oflgG to the antigens tested
at most cross sectional bleeds. Only in a few cases was there a significant association of antibody
responses with age. HbAs children ages 7-10 had significantly higher IgG responses to
A MA I(W2mef) compared to 1-3 year olds in May 2003 (p ::s 0.05, Wilcoxon rank test) (Appendix
I Table 19). There was an age related increase in IgG responses to MSP2(3D7) and MSP(FC27) in
October 2003 and May 2002 respectively (p < 0.05, Kruskal Wallis test) (Figure 3.6, Table 3.9,
Appendix I Tables 22-23).
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Figure 3.6 Magnitude of the antibody (lgG) response to P. falciparum merozoite and schizont antigens
in the presence and absence of sickle trait by age group. HbAA = Normal, HbAS = Sickle trait.
Representative graphs showing IgG levels at the May 2002 cross sectional bleed. All samples tested by
ELISA. Kruskal-Wallis test for equality of median responses in HbAA: p <0.001 for all antigens. Wilcoxon
rank sum test for equality of median responses between children aged 1-3 years and 7-10 years in HbAA: p :S
0.05 for all antigens. No significant associations for HbAS. Detail of further tests in Table 3.9. (A)
AMA I(W2met), (8) AMA I(HB3), (C) AMA 1(307), (D) MSP2(3D7), (E) MSP2(FC27), (F) A4 Schizont
proteins.
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Though children with HbAS exhibited lower IgG responses to AMA I and MSP2 overall, this
difference was significant in only in a particular number of cases. HbAA (normal) children aged 1-
3 and 4-6 years had significantly higher IgG responses to AMA I(W2mef) when compared to
HbAS children in May 2003 (p :s 0.05, Wilcoxon rank test) (Appendix I, Table 19). This was also
the case for IgG responses to AMAI(HB3) and AMAI(3D7) in children aged 4-6 years, along with
that to AMA I(307) in 1-3 year olds also in May 2003 (Appendix I Tables 20-21). Only in 4-6
year olds at the May 2002 bleed was the difference in IgG responses to MSP2(FC27) significantly
higher in HbAA children compared to HbAS children (p :s 0.05, Wilcoxon rank test) (Figure 3.6,
Table 3.9, Appendix I Table 23). IgG responses to schizont extract also exhibited the same
characteristics, with a significant increase in acquisition of antibody responses with age at all cross
sectional bleeds in HbAA children (p < 0.001, Kruskal Wallis test). Only in October 2004 did
HbAS children aged 7-10 years have significantly higher IgG responses to schizont extract when
compared to 1-3 year olds (p :s 0.05, Wilcoxon rank test) (Appendix I Table 24). Interestingly, at
the May 2004 cross sectional bleed, children ages 1-3 years had higher IgG responses to schizont
extract than 7-10 year olds (p ~ 0.05, Wilcoxon rank test) (Appendix I Table 24).
All normal and alpha-thalassemia heterozygous children exhibited increasing IgG responses to all
three AMA 1 variants and schizont extract with increasing age at all the cross-sectional bleeds (p ~
0.05, Kruskal Wallis test) (Figure 3.7, Table 3.10, Appendix I Tables 26-28 and 31). This was also
the case with the IgG response to MSP2 variants in normal and alpha-thalassemaia heterozygous
children (Figure 7, Table 10, Appendix I Tables 29-30). In every one of the above mentioned
cases, children ages 7-10 years had significantly higher responses than those ages 1-3 years (p :s
0.05, Wilcoxon rank test) (Figure 3.7, Table 3.10, Appendix I Tables 26-31). Children who were
alpha-thalassemia homozygous also exhibited an age dependent acquisition of IgG responses to all
AMA I variants and schizont extract at most of the cross sectional bleeds though it was not always
accompanied by a significant difference in levels between 7-10 year olds and 1-3 year olds due to
small numbers in each category (Figure 3.7, Table 3.10, Appendix ITables 26-28 and 31). Unlike
the case for AMA I, alpha-thalassemia homozygotes did not exhibit a significant age related
acquisition of IgG responses to MSP2 variants except in May 2002 (p = 0.009, Kruskal Wallis test)
and May 2004 (p :s 0.05, Wilcoxon rank test comparing median levels between children ages 1-3
103
years and 7-10 years) for MSP2(3D7) (Figure 3.7, Table 3.10, Appendix 1 Table 29) and October
2002 (p = 0.018, Kruskal Wallis test) and both May 2003 and October 2003 (p ~ 0.05, Wilcoxon
rank test comparing median levels between children ages 1-3 years and 7-10 years) for
MSP2(FC27) (Appendix 1Table 30).
3.3.6 Age, concurrent parasitaemia, haemoglobinopathies, and prior P. falciparum exposure
have variable efl'ects on JgG responses which are dependent OD malaria transmission levels
Previous sections of this chapter have highlighted the different factors that affect antibody levels.
Age, concurrent parasitaemia, erythrocyte polymorphisms, and prior exposure have different
effects on the antibody outcome. In order to investigate this further I carried out a series of
univariate and multivariable linear regression analyses on the antibody levels to all AMA1 and
MSP2 variants at different samples times to try to quantify the effect of different variables on IgG
responses in this cohort. IgG levels to each antigen were analysed at separate time points rather
than pooling them as malaria transmission dropped over the study period as it was thought that this
could confound the results.
Age in years, parasite status at sample time, alpha-thalassemia status, sickle trait, and recorded
episodes of parasitaemia and clinical malaria in the prior six months were fitted into univariate
linear regression models to determine their inclusion into a multivariable linear regression model.
All the dependent variables were fitted as categorical variables except age which was a continuous
variable, and parasite status which was fitted as a binary variable.
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Figure 3.7 Magnitude of the antibody (IgG) response to Pi falciparum merozoite and schizont antigens
in the presence and absence of alpha-thalassemia by age group. Norm = Normal, Het = Heterozygous,
Hom = Homozygous. Representative graphs showing IgG levels at the May 2002 cross sectional bleed. All
samples tested by ELISA. Kruskal- Wallis test for equality of median responses in normal, heterozygotes and
homozygotes by age: p :::;0.05 for all antigens except the MSP2(FC27) response in homozygotes. Detail of
further tests in Table 10. (A) AMA I(W2mef), (B) AMA I(HB3), (C) AMA 1(307), (D) MSP2(3D7), (E)
MSP2(FC27), (F) schizont proteins.
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3.3.6.1 Univariate analysis of factors associated with IgG responses
In the univariate analysis at different sample times, age (in years) increased antibody levels to
AMA I(W2mef) (~ range: 0.07 in October 2004 to 0.12 in May 2002, all p <0.00 I) (Tables 3. II A
and 3.IIF), AMAl(HB3) W range: 0.07 in October 2004 to 0.13 in May 2002, all p <0.001), and
AMA 1(307) ~ range: 0.06 in October 2004 to 0.11 in May 2002, all p <0.001) (Appendix I Tables
33A, 33F, 34A, and 34F). The effect of age was slightly lower on antibody levels to MSP2
resulting in lower p coefficients; MSP2(307) (~ range: 0.05 in October 2004 to 0.12 in May 2002,
all p <0.001), and MSP2(FC27) W range: 0.04 in October 2004 to 0.08 in October 2003, all p
<0.00 I) (Appendix I Tables 35A, 35F, 36A, and 36F).
The effect of parasitaemia at sample time in on antibody titres in univariate analyses was quite
marked. Concurrent parasitaemia had a considerable effect (all p <0.00 I) and increased antibody
titres greatly for all the antigens measured (AMA 1(W2mef) p maximum = 1.14 in October 2003
(Table 3.110); AMAl(HB3) ~ maximum = 1.09 in October 2003 (Appendix I Table 330);
AMAI(307) ~ maximum = 1.04 in October 2003 (Appendix I Table 340); MSP2(307) P
maximum = I.OS in October 2004 (Appendix I Table 35F); MSP2(FC27) P maximum = 0.S4 in
October 2002) (Appendix 1 Table 36B).
Both alpha-thalassemia and the sickle trait reduced antibody titres in the univariate analyses to all
antigens (maximal reduction seen in AMA I(W2mef) for sickle trait with a p coefficient of -0.32, p
= 0.013 in May 2003 (Table 3.11 C, Appendix I), although not all of these effects were statistically
significant. Prior parasitaemia raised antibody titres to all antigens in the univariate analyses (all p
<0.001) with a maximum p coefficient of 0.32 for AMA 1(HB3) in May 2003 (Appendix I Table
33C), with prior episodes of mild malaria also increasing (all p <0.00 I) antibody titres to all
antigens with a maximum B coefficient of 0.36 for AMA I(HB3) in May 2002 (Appendix I Table
33A).
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Table 3.11A Effect of different facton on JgG responses to AMAl(W2mef) in the May 2002 cross
sectional bleed.
AMA1(W2mef) May 2001'
11(95"0)' l'-vllue'
UnlVlrIIte"
Aie (years) 0.12 (0.09-0.16) <0.001
Parasltlemlll 0.73 (0.53-0.93) <0.001
A1pha-tIIIl HET -0.06 (-0.24-0.13) 0.549
Alpha-thai HOM -0.29 (-0.53-0.04) 0.02
Slcldetralt -0.23 (-0.47-0) 0.054
PrIor peresltaemla 0.31 (0.22-0.39) <0.001
PrIor episode 0.34 (0.19-0.49) <0.001
Multlverllte (previous p8l'11s1tHmle)'
AJlsemples
Aie (years) 0.08 (0.05-0.12) <0.001
Parlsltlemla 0.48 (0.28-0.68) <0.001
Alpha-thai HET -0.04 (-0.2-0.12) 0.625
Alpha-thai HOM -0.18 (-0.39-0.03) 0.099
SIcIcIe trait -0.2 (-0.41-0) 0.053
PrIor paraslteemla 0.19 (0.11-0.28) <0.001
PlI'IISIta neptlw7
Ale (years) 0.07 (0.04-0.1) <0.001
A1ph.thal HET -0.03 (-0.19-0.13) 0.745
A1ph.thal HOM -0.17 (-0.37-0.03) 0.093
Sickle trait -0.12 (-0.33-0.09) 0.253
PrIor paraslteemla 0.28 (0.19-0.37) <0.001
PlI'IISIta positive"
Ale (years) 0.12 (-0.03-0.27) 0.124
Alpha-thai HET -0.29 (-0.88-0.3) 0.325
Alpha-thai HOM -0.39 (-1.38-0.59) 0.424
Sickle trait -0.44 (-1.09-0.21) 0.177
PrIor parasitaemia -0.04 (-0.32-0.23) 0.742
Muhlverllte (previous episodes)'
Allsemples
Ale (years) 0.1 (0.06-0.13) <0.001
Parasitaemia 0.52 (0.31-0.72) <0.001
A1~thaIHET -0.06 (-0.23-0.1) 0.457
Alpha-thai HOM -0.18 (-0.4-0.03) 0.094
Sickle trait -0.2 (-0.41-0.01) 0.061
PrIor episode 0.21 (0.06-0.35) 0.006
PlI'IISIte neptlve7
Ale (years) 0.09 (0.06-0.13) <0.001
Alpha-thai HET -0.04 (-0.21-0.13) 0.642
AlphHhal HOM -0.18 (-0.39-0.03) 0.097
Sickle trait -0.15 (-0.37-0.06) 0.165
Prior episode 0.27 (0.11-0.43) 0.001
Plreslte positive·
Ale (years) 0.13 (-0.03-0.28) 0.11
Alpha-thai HET -0.26 (-0.83-0.32) 0.374
Alpha-thai HOM -0.37 (-1.39-0.64) 0.463
Sickle trait -0.44 (-1.11-0.23) 0.191
Prior episode 0.01 (-0.41-0.43) 0.954
298
298
297
299
304
304
289
239
so
289
239
so
~
1Ant"n tested .t Indicated cross sectional bleed.
2 L1 r Ion P coefficients with 95% confidence Intorv.l.
• P"",I for Indicated foetor (p-v.I .... s 0.05 Indlc.tod In bold).
• Numbor of .. mplos Included In tho model.
, UnlYoriote 1I r Ion.
I MultlYoriablo 11 r Ion with Inclu.lon of elthor recorded episodes of p.rosltHmla or m.l.rla In the 6 months prior to sompll ...
7 Strattfled multivari.blllll.,..r ,.....olon, pllraslte ne•• tlve sampl.s onty.
• Stratified multlvlrl.blo 1I.... r ....... Ion. poroslte positive somples only.
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Table 3.118 Effect of different factors on IgG responses to AMA I(W2mef) in the October 2002 cross
sectional bleed.
AMA1(W2mef) Oct 2002
IS (9S" CI)2
Univariate'
Age (years) 0.12 (0.08-0.16)
Parasitaemia 0.51 (0.12-0.89)
Alpha-thai HET 0.06 (-0.17-0.28)
Alpha-thai HOM -0.26 (-0.55-0.02)
Sickle trait -0.27 (-0.58-0.03)
Prior parasitaemia 0.28 (0.09-0.47)
Prior episode 0.38 (0.13-0.62)
Multlv.rl.te (previous pa ... sltaeml.)'
All samples
Age (years) 0.19 (0.15-0.23)
Parasitaemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitaemia
Par.slte neg.tlve'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitaemia
P.... slte positive"
Age (years)
0.41 (0.07-0.76)
0.01 (-0.2-0.22)
-0.19 (-0.45-0.07)
-0.26 (-0.54-0.02)
0.23 (0.07-0.4)
0.2 (0.15-0.24)
0.05 (-0.16-0.26)
-0.12 (-0.39-0.14)
-0.24 (-0.53-0.04)
0.25 (0.08-0.42)
0.09 (-0.28-0.46)
Alpha-thai HET 0 (-1.58-1.57)
Alpha-thai HOM -1.02 (-2.94-0.9)
Sickle trait -0.62 (-2.34-1.1)
Prior parasitaemia -0.16 (-1.18-0.87)
Multivariate (previous episodes)'
All samples
Age (years)
Parasitaemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
P.... slte neg.tlve'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
P.... slte positive"
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
0.19 (0.14-0.23)
0.44 (0.09-0.78)
0(-0.2-0.21)
-0.19 (-0.45-0.07)
-0.28 (-0.56-0.01)
0.3 (0.08-0.51)
0.19 (0.15-0.24)
0.03 (-0.18-0.24)
-0.13 (-0.39-0.13)
-0.26 (-0.54-0.03)
0.31 (0.1-0.53)
0.11 (-0.23-0.46)
-0.1 (-1.56-1.36)
-1.02 (-2.95-0.91)
-0.57 (-2.26-1.13)
-0.02 (-1.11-1.08)
P-value" N'
<0.001 291
0.011 291
0.63 284
0.071
0.081 292
0.004 254
0.003 254
<0.001
0.018
0.915
0.158
0.07
0.006
<0.001
0.64
0.353
0.093
0.003
0.602
0.996
0.272
0.449
0.745
<0.001
0.013
0.972
0.151
0.055
0.007
<0.001
0.757
0.327
0.075
0.005
0.491
0.887
0.274
0.482
0.974
251
232
19
251
232
19
Notes
1 Antlc_" tested ilt indiated cross Mette".1 ble.d.
2 Linear relression ~ coeffldents with 95% confidence intervals
3 P-value for indicated hlttor tp.v.lues :s 0.05 Indic.ted In bold) .
• Number of samples Included In the model.
s Univariate llneilr rearesslon.
6 Multlvarlable llne,r ",.", .. Ion with Inclusion of either recorded episodes of parasitaemia or mallrla In the 6 months prior to Slmpll"l.
r Stratified multiy,rloble llnelr ",.",sslon, parasite nI.ltlve SImples only.
• Str.tifl.d multivariabl. llne.r relress60n, p.rastt. positive Hmples only.
109
Table 3.11C Effect of different factors on JgG responses to AMAI (Wlmef) in the May 2003 cross
sectional bleed.
AMA1(W2mef) MIY 2003
UnMIrt.te"
Ap(yelrs)
flllrasltaemil
Alphe-thli HET
Alphe-thli HOM
Slddenlt
0.11 (0.08-0.14)
0.54 (0.3-0.78)
0.05 (-O.14-().24)
-0.14 (-0.39-0.11)
-0.32 (-0.57-0.07)
PrIor parasltaemll 0.07 (0-0.14)
PrIor episode 0.13 (0.03-0.22)
Mu (prwIous PlresItHmIII)'
M ......
Ap(yelrs)
PllrlsltHmil
Alpha-thll HET
Alphe-thll HOM
Sickle nit
PrIor peruItIemll
hnsIIa MIf/IIIIJIve'
Ap(yelrs)
Alpha-thel HET
Alpha-thel HOM
Slddenlt
PrIor pemltaemll
fill ....... positive'
Ap(yelrs)
Alpha-thel HET
Alpha-thll HOM
Slcldetrllt
PrIor parasltlemll
Multlvlrt.te (previous episodes,'
M.......
Ap(yelrs)
Plraslteemla
Alpha-thll HET
Alpha-thll HOM
Sickle trllt
PrIor episode
fill ....... neptIve'
Ale (yelrs)
Alpha-thai HET
Alpha-thel HOM
Sickle trllt
PrIor episode
fill ....... positive'
Ap(yelrs)
Alpha-thll HET
Alpha-thai HOM
Sickle tr,1t
PrIor episode
0.1 (0.06-0.14)
0.41 (0.16-0.66)
0.04 (-0.16-0.23)
-O.OS(-0.3-0.2)
-0.3 (-0.56-0.04)
O.OS (-0.02-0.11)
0.09 (0.05-0.13)
0.11 (-0.1-0.31)
-0.04 (-0.29-0.21)
-0.21 (-0.47-0.05)
0.07 (0.01-0.14)
0.15 (0.02-0.29)
-0.21 (-0.84-0.42)
0.55 (-0.61-1.71)
-0.94 (-2.06-0.17)
-0.14 (-0.4-().11)
0.1 (0.06-0.14)
0.44 (0.19-0.69)
0.04 (-0.16-0.23)
-0.05 (-0.3-0.19)
-0.29 (-0.55-0.03)
0.1 (0.01-0.19)
0.08 (0.Q4-().12)
0.11 (-0.09-0.31)
-0.04 (-0.29-0.2)
-0.21 (-0.47-0.05)
0.12 (0.03-0.21)
0.16 (0.03-0.29)
-0.25 (-0.87-0.38)
0.7 (-0.53-1.93)
-1.11 (-2.24-0.03)
-0.28 (-0.75-0.19)
<0.001
<0.001
0.6
0.272
0.013
0.053
0.009
285
285
279
283
253
253
cO.OOl
0.002
0.717
0.687
0.024
0.177
247
<0.001
0.297
0.753
0.118
0.031
213
0.026
0.499
0.343
0.094
0.269
34
cO.OOl
0.001
0.701
0.673
0.029
0.035
247
cO.OOl
0.296
0.731
0.112
0.009
213
0.02
0.427
0.253
0.055
34
0.234
fH!lu
I AnI"n tested It Indicated c..... sectlonol_.
, u ion IIcoefflclento w~h 95" confld.... Int.IV.ls
•P_ for Indicated fKtor (p-v.I.... s 0.05 Indle.ted Inbold).
• Number of IImpies Included In the mod.l.
• U.... rtote Ilnnr Ion.
• Multlvorloble linear 1IIon w~h Inclusionof .~her recorded .plsodes of peros_mlo or molorlo In the 6 months prior to Slmpli...
7 5trotlflad mu~iv,rIoble Ii r Ion. pe ... ~ _,tiv. IImples only.
a 5trotlflad multlvorloblellnnr ulan. pe .. _ posltiv. SImpleS only.
110
Table 3.11D Effect of different factors on IgG responses to AMA1(W2meO in the October 2003 cross
sectional bleed.
AMA1(WZmef) Oct 2003
P(95"CI,' P-valu.' N'
UnlvarlateS
Age (years) 0.12 (0.09-0.15) <0.001 294
Parasitaemia 1.14 (0.93-1.34) <0.001 293
Alpha-thai HET -0.08 (-0.27-0.12) 0.436 285
Alpha-thai HOM -0.29 (-0.54--0.05) 0.02
Sickle trait -0.23 (-0.48-0.03) 0.078 284
Prior parasitaemia 0.24 (0.14-0.34) <0.001 261
Prior episode 0.24 (0.09-0.39) 0.002 261
Multivariate (previous paraslheml.,·
All Hmples
Age (years) 0.11 (0.08-0.14) <0.001 248
Parasitaemia 0.95 (0.74-1.15' <0.001
Alpha-thai HET -0.09 (-0.25-0.07) 0.259
Alpha-thai HOM -0.11 (·0.31-0.1) 0.298
Sickle trait -0.28 (-0.48-0.07) 0.008
Prior parasitaemia 0.17 (0.09-0.25) <0.001
Parasite nee.tlve7
Age (years) 0.1 (0.07-0.13) <0.001 212
Alpha-thai HET -0.06 (-0.22-0.11) 0.504
Alpha-thai HOM -0.04 (-0.23-0.16) 0.721
Sickle trait -0.12 (-0.33-0.08) 0.24
Prior parasitaemia 0.2 (0.12-0.29) <0.001
Parasite positive'
Age (years) 0.21 (0.07-0.36) 0.005 36
Alpha-thai HET -0.22 (-0.76-0.31) 0.402
Alpha-thai HOM -0.34 (-1.42·0.74) 0.522
Sickle trait ·1.12 (·1.81··0.43) 0.002
Prior parasitaemia 0.12 (-0.17-0.42) 0.402
Multivariate (previous episodes,'
All Hmples
Age (years) 0.11 (0.08-0.14) <0.001 248
Parasitaemia 1.01 (0.8-1.21) <0.001
Alpha·thal HET -0.09 (-0.25-0.08) 0.29
Alpha·thal HOM -0.08 (-0.29·0.13) 0.451
Sickle trait -0.27 (-0.48--0.06) 0.011
Prior episode 0.19 (0.08-0.31) 0.001
Par.slte negatlve7
Age (years) 0.1 (0.07-0.13) <0.001 212
Alpha·thal HET ·0.07 (-0.24-0.1) 0.42
Alpha·thal HOM -0.03 (-0.23-0.18) 0.776
Sickle trait -0.1 (-0.31-0.11) 0.361
Prior episode 0.21 (0.09-0.33) 0.001
Parasite positive'
Age (years) 0.21 (0.07-0.34) 0.004 36
Alpha·thal HET ·0.19 (-0.7-0.33) 0.464
Alpha·thal HOM -0.18 (·1.2-0.85) 0.725
Sickle trait ·1.18 (·1.85-0.51) 0.001
Prior episode 0.22 (·0.2-0.64) 0.288
~
1Ant •• " tested at Indicated cross sectlon.1 bleed.
2linear "'."'55io" P coefficients with 95" confidence Intervals
, P·•• I.,. fo, Indle.ted facto, ("",.Iues S0.05 Indle.ted Inbold).
4 Number of samples included in the mod.1.
~Univariate linelr sslon.
6 Muitivlrillbht IIn•• r ,..ssion with Inclusion of either recorded episodes of p",.,tt •• mia or ma"rlli In the 6 months prior to umplil'll.
7 St",tified multlv.ri.ble lin.. , Ion. "",,,sit. _.tlve Ample. only.
• Stratlfl.d multlvariablellne.r re sslo", plrllStt. positive Amples only.
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T.ble 3.t tE Effeet of different faetors on JgG responses to AMAl(W2mef) in the May 2004 cross
sectlon.1 bleed.
AMA1(W2rnef) M-v 2004
11(95"0)' P-velue·
u........ "
Ale (yem) 0.1 (0.07-0.13) <0.001
... rultHrniII 0.87 (0.57-1.17) <0.001
Alph8-thIIl HET -0.03 (-0.21-0.14) 0.705
Alph8-thIIl HOM -0.31 (-0.53-0.09) 0.006
Slckletrllt -0.2 (-O.43.().03) 0.081
PrIor PlflsltHmle 0.24 (0.06-0.41) 0.008
PrIor episode
MuItlVlr11t8 (prwIous PlfllltMrniII)'
All ........
Ale (yelrs) 0.09 (0.06-0.13) <0.001
PerultHrniII 0.56 (0.25-0.87) <0.001
Alpha-thll HET -0.03 (-0.19-0.14) 0.729
Alpha-thill HOM -0.2 (-0.41-0) 0.055
Slddetrllt -0.2 (-0.41-0.02) 0.071
PrIor Plrasltaemll 0.16 (0-0.33) 0.05
... ,.... nepthle7
Ace (yelrs) 0.09 (0.05-0.12) <0.001
Alph8-thIIl HET -0.02 (-0.18-0.15) 0.85
Alphl-thill HOM -0.18 (-0.39-0.03) 0.088
SIckle trait -0.2 (-0.42-0.02) 0.068
PrIor PlflsltHmll 0.23 (0.04-0.41) 0.019
... ,.... posIIIve"
Ace (yelrs) 0.23 (-0.04-0.51) 0.086
Alpha-thll HET -0.52 (-1.7-0.67) 0.348
Alphl-thal HOM -1.42 (-3.4-0.56) 0.139
5Iddetrllt -0.29 (-2-1.41) 0.708
PrIor PlflSltHmle 0.1 (-0.68-0.88) 0.782
MultlVlr11t8 (previous episodes).
All ........
Ale (yelrs) 0.1 (0.07-0.13) <0.001
ParlsltHmle 0.61 (0.31-0.92) <0.001
Aipha-thill HET -0.04 (-0.21-0.12) 0.595
Alpha-thill HOM -0.21 (-0.42-0) 0.046
Sickle trllt -0.19 (-0.41-0.02) 0.074
PrIor episode
... ,....,...atIve7
Ace (yem) 0.09 (0.06-0.12) <0.001
Alphl-thal HET -0.03 (-0.2-0.14) 0.748
Alpha-thel HOM -0.18 (-0.39-0.03) 0.088
SlckJetrllt -0.19 (-0.41-0.03) 0.083
PrIor episode
...rIIItIposIIIve'
Ace (years) 0.21 (0.01-0.41) 0.04
Alpha-thai HET -0.57 (-1.62-0.48) 0.256
Alpha-thel HOM -1.49 (-3.27-0.28) 0.09
5Iddetfllt -0.41 (-1.73-0.9) 0.501
PrIor episode
279
280
261
266
254
239
224
15
239
224
15
HIzIH
I Antlpn telted ot lndiCIIled Croll sectional bIHd.
, Llnnr ....... Ion ~ caefftclents with 95" confldenco Interv.1s
I ' .... Iue for indicated foetor (p-y.I .... S 0.05 Indicated In bold).
• Number of Ample. Included In lhe model.
• Unlvartote lI_r uIon.
• Multlvartable IIne.r ..ulon with inclusion of either recorded episode. of paras_mill or molarla In the 6 months prior to somplins.
7SIrailflod multiv.rtable line......... Ion. parasite _.Iive IImple. only.
• Stratlflod multiv.rtable line.. ~. parasite positive IImpIe. only.
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Table 3.11F Effect of different factors on IgG responses to AMAl(W2mef) in the October 2004 cross
sectional bleed.
AMA1(W2mef) Oct ZOO4
14(95"CI)' P-vlliue' N'
Univariate'
Age (years) 0.07 (0.05-0.09) <0.001 273
Parasitaemia 0.55 (0.24-0.86) 0.001 273
Alpha-thai HET -0.02 (-0.16-0.13) 0.838 268
Alpha-thai HOM -0.17 (-0.36-0.01) 0.067
Sickle trait -0.11 (-0.29-0.07) 0.239 270
Prior parasitaemia 0.23 (-0.12-0.58) 0.196 235
Prior episode
MultlVllrlate (previous parasitaemia)'
All samples
Age (years)
Parasitaemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitaemia
Parasite nelatlve'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitaemia
Parasite positive'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitaemia
Multivariate (previous episodes)'
All samples
A8e (years)
Parasitaemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Parasite ",sative'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Parasite positive'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
0.09 (0.06-0.12)
0.62 (0.25-0.99)
<0.001
0.001
0.736
0.062
0.121
0.137
216
-0.03 (-0.17-0.12)
-0.17 (-0.36-0.01)
-0.14 (-0.33-0.04)
0.24 (-0.01-0.56)
0.09 (0.06-0.12)
-0.05 (-0.19-0.1)
-0.19 (-0.38--0.01)
-0.1 (-0.29-0.01)
0.25 (-0.07-0.57)
209<0.001
0.531
0.042
0.274
0.126
0.12 (-0.42-0.65)
0.28 (-3.03-3.6)
0.56 (-3.7-4.83)
-0.69 (-3.84-2.45)
70.45
0.75
0.626
0.443
0.09 (0.06-0.12) <0.001
0.62 (0.25-0.98) 0.001
-0.02 (-0.16-0.13) 0.834
-0.16 (-0.34-0.03) 0.091
-0.14 (-0.33-0.04) 0.12
0.09 (0.06-0.12) <0.001
-0.04 (-0.18-0.11) 0.623
-0.17 (-0.36-0.01) 0.064
-0.1 (-0.29-0.01) 0.273
0.12 (-0.42-0.65) 0.45
0.28 (-3.03-3.6) 0.75
0.56 (-3.7-4.83) 0.626
-0.69 (-3.84-2.45) 0.443
216
209
7
Notes
I Anti._" tested .t indicated cross sectional b~.d.
2 linear re.ression t5 coeffidents with 95%confidence intervlls
aP-v.lue for Indlcat.d factor (p-v.lue. S0.05 indlc.t.d in bold).
• Number of samples included in the model.
S Univariate linear relression.
6Multlvlriabl. lin•• r re.r.5510n with Inclus~n of either recorded episodes of PIU'lIstt•• mlil or millirillin the 6 months prior to slmpUnl.
1Stratified mu~iv.rlable lin", ,.."55lon. para.~ ...... tiv mple. only.
, Stratified mu~iv.rI.ble lino.r rol .... lon. para.~. po.~Iv mples only.
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3.3.6.2 Multivariable aualysis of faetors associated with JgG responses
Age, parasite status at sample time, and recorded episodes of parasitaemia and clinical malaria in
the prior six months all affected antibody titres significantly throughout the study period (p<O.OOl);
therefore they were all included in the multivariable linear regression. Though not as marked in
their effect on antibody levels; both sickle trait and alpha-thalassemia were included in the model
as well due to their protective effect against clinical malaria. Comparison of multivariable linear
models showed that the best fitting model was one with all the dependent variables above included
in the ways in which they had first been designated; age as a continuous variable, parasitaemia as a
binary variable, and the rest as categorical variables. As prior clinical malaria episodes are a subset
ofparasitaemic episodes, they were fitted into the model separately.
In each multivariable model that included prior parasitaemia as a cofactor, concurrent parasitaemia
had the greatest effect on IgO responses to AMA I and MSP2 variants at every cross sectional bleed
(all p <0.001). Maximal p coefficients observed due to concurrent parasitaemia were 0.95 for
AMAI(W2mef) in October 2003(Table 3.IID), 0.89 for AMAI(HB3) in October 2003 (Appendix
I Table 330), 0.86 for AMA1(307) in October 2003 (Appendix I Table 34D), 1.25 for
MSP2(307) in October 2004 (Appendix I Table 35F), and 0.70 for MSP2(FC27) in October 2002
(Appendix 1 Table 36B). Concurrent parasitaemia was followed by prior parasitaemia and age as
the factors with significant positive effects on antibody levels (Tables 3.IIA-3.IIF, Appendix 1
Tables 33A-36F).
Due to the fact that presence of parasitaemia at the time of sampling is associated with higher
antibody levels and may confound the effects of other variables, the muItivariable linear regression
was stratified by parasite infection status. In the case of children with concurrent parasitaemia at
sample time the multivariable model could not reliably predict the effect of the dependent variables
on antibody levels due to the small number of children with concurrent parasitaemia at each bleed
(Tables 3.IIA-3.IIF, Appendix 1 Tables 33A-36F). When there were sufficient numbers for the
multivariable model to work correctly, age was consistently the factor most strongly associated (p
~ 0.05) with antibody levels for all the antigens tested. Increasing age was associated with a
maximum unit increase in antibody levels of 0.21 to AMA 1(W2met), 0.19 to AMA 1(HB3), 0.24 to
114
AMA I(3D7), and 0.15 to MSP2(FC27) all in October 2003 (Table 3.11 D, Appendix I Tables 33D,
34D,36D). Sickle trait was associated with a significant reduction (p ~0.01) in antibody titres
with P coefficients of -1.12 for AMAI(W2mef), -0.99 for AMAI(HB3), -0.95 for AMAI(3D7),
and -1.81 for MSP2(3D7) in October 2004 and October 2003 for all AMA I antigens (Table 3.11 D,
Appendix I Tables 33D, 34D, and 35F). Being alpha-thalassemia homozygous was associated
with a significant (p ~ 0.05) reduction in antibody titres with P coefficients of -0.29 in May 2002
and October 2003, and -0.31 in May 2004 for AMA I(W2mef) (Tables 3.11 A, 3.11 C, 3.11 E). This
polymorphism was also associated with significant (p ~ 0.05) reduction in antibody titres to
AMAI(HB3) and AMA 1(3D7) with P coefficients of ranging from -0.2 to -0.31 in May 2002,
October 2002, October 2003, and May 2004 and those to both MSP2 variants by -0.14 to -0.24 in
the same months (Appendix I Tables 33A-36F). Recorded incidences of parasitaemia in the 6
months prior to the sample time did not appear to have any effect on antibody titres to any antigen
when parasites were present at sampling.
In children who did not have parasites at sample time, the effects of the dependent variables were
different from those with concurrent parasitaemia. Both prior parasitaemia and age significantly
increased (p <0.00 I) antibody titres to all the antigens tested. Prior parasitaemia consistently
increased antibody titres to a greater extent than age with maximum unit increases in May 2003 of
0.28 for AMAI(W2mef), 0.3 for AMAI(HB3), 0.27 for AMAI(3D7), 0.26 for MSP2(3D7), and
0.2 for MSP2(FC27) (Table 3.IIC, Appendix I Tables 33C, 34C, 35C, and 36C). The effect of
age, though significant (p <0.001), was lower than that of prior parasitaemia with maximum unit
increases also occurring during the May 2003 cross-sectional bleed of 0.07 for AMA I(W2mef),
0.08 for AMAI(HB3), 0.07 for AMAI(3D7), and 0.06 for MSP2(3D7) (Table 3.IIC, Appendix I
Tables 33C, 34C, and 35C). Although both the sickle trait and being homozygous for alpha-
thalassemia reduced antibody levels to both AMA I and MSP2 in children without concurrent
parasitaemia, this effect was not significant.
When prior clinical episodes were substituted for prior episodes of parasitaemia in the above
mentioned models, the same effects were seen for all antigens. Age had the most significant effect
in increasing antibody titres in children with concurrent parasitmeia whereas prior episodes were
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most important in children without parasites at sample time (Tables 3.IIA-3.lIF, Appendix 3
Tables 33A-36F). These results indicate that age, prior parasitaemia/clinical malaria, and
concurrent parasitaemia at sample time all have independent effects on antibody titres to AMA I
and MSP2 in this cohort.
In summary, concurrent parasitaemia had the greatest effect on raising IgG responses to AMAI and
MSP2 regardless of the levels of malaria transmission at the time of sampling (Table 3.12). Prior
parasitaemia (or episodes) also positively affected IgG responses, but this effect was much more
pronounced in aparasitaemic children. The positive effect of increasing age on IgG responses to
AMA I and MSP2 depended on both the infection status of the child at sampling and also the levels
of malaria transmission at sampling. When transmission was high, age played a smaller role in
raising IgG levels in parasitaemic children. The effect of age was similar in aparasitaemic children
at high malaria transmission intensities as in both parasitaemic and aparasitaemic children at lower
transmission intensities. Presence of the sickle trait or being homozygous for alpha-thalassemia
reduced the IgG response to AMA I and MSP2 in all cases although this effect was greatest In
parasitaemic children at higher malaria transmission intensities (Table 3.12).
Table 3.12 Summary of the effect of various ,factors on IgG responses at different malaria transmission
intensities in parasitaemic and aparasitaemic children.
Malaria transmission level'
'High' 'Low'
Parasltaemic' Aparasitaemic' Parasitaemic' Aparasitaemic'
Concurrent 1'1'1"1'+ 1'1'1'1'1'parasitaemia'
Prior parasitaemia' l' 1'1'1'1' 1'1' 1'1'1'
Age' 1'1' 1'1'1' 1'1'1' 1'1'1'
Haemoglobinopathies • ,j.._j,,j.._j, ,j..,j..,j.. _j,_j,_j, ,j..,j..
~
tJ. Malaria transmission levels indicated by parasite prevalence at cross sectional bleed.
e Status of the child at sampling.
I Concurrent parasitaemia at sampling.
2 Recorded parasitaemia In the 6 months prior to sampling.
1 Age in years .
• Presence of sickle trait or being homozygous for alpha-thalassemia.
l' Raises 'KG levels (number of arrows is indicative of the strength of the effect) .
.J... lowers ilG levels (number of arrows is indicative of the strength of the effect),
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3.3.7 Increased prior P. !alc;parum exposure does not always result in a high titre antibody
response to AMAI and MSPl
In order to assess how likely prior exposure to P. falciparum was going to result in high IgG
responses, the probability of antibody levels above the 75th centile were estimated by logistic
regression by fitting the number of prior parasitaemic episodes along with age as covariates. The
log its of these models were then converted into probabilities and plotted to compare the effects of
increasing prior exposure on antibody levels. These probabilities were worked out for al1 samples
as well as stratified by parasite status at sampling time and by the age of the children at sampling.
Details of the number of parasitaemic episodes that were recorded in the 6 months prior to
sampling can be found in Table 2.3. Briefly, the proportion of children who did not have any
parasitaemic episodes in the 6 months prior to sampling ranged from 48% before the May 2003
sampling to 97.5% before the Ocotber 2004 sampling. Those with 1-3 episodes ranged from 2.6%
in before the October 2004 sampling to 45.7% before the May 2003 sampling. Children with 4-5
episodes ranged from 0.8% (2 children) before the October 2003 sampling to 5.5% (14 children)
before the May 2003 sampling. Only 2 children had 7 parasitaemic episodes in the 6 months prior
to the October 2003 cross sectional bleed.
For all antigens (three AMAI and two MSP2 variants), the probability of antibody levels above the
75th centile increased in a linear manner from 20% when no parasitaemic episodes were
experienced in the prior 6 months to 43% for AMA1(HB3), AMA1(3D7), and MSP2(FC27) after 2
recorded episodes of parasitaemia in the prior 6 months (Figure 3.8A). The probabilities of a high
antibody response to AMAl(W2met) and MSP2(3D7) also rose from 20% without any prior
exposure to 40% after 2 recorded parasitaemic episodes. The probabilities of developing a high
response to these five antigens changed on further exposure. The probability of a high response to
AMAI(3D7) continued to rise up to 47% after 5 recorded episodes compared to the others.
Regardless of further exposure, the probability of high responses to AMA I(W2mef) and
AMAI(HB3) remained at 40% even after 5 episodes (Figure 3.8A). Following a peak of 45%
probability of a high response to MSP2(3D7) after 3 recorded episodes which dropped to 40% on
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the fourth episode, the probability ofa high anti-MSP2(3D7) response dropped slowly to 37% after
7 recoded episodes (Figure 8A); The probability of a high response to MSP2(FC2) also dropped
on further exposure to 37% after 4 episodes. Regardless of further exposure, the probability of
high responses to AMAl(W2mef) and AMAl(HB3) remained at 40% even after 5 episodes (Figure
3.8A). This may indicate that there is s subgroup of children who are non-responsers.
A similar pattern was seen for the children who were parasite negative at the time of sample
collection. Probabilities rose in association with increasing numbers of episodes at a similar rate
for all antigens and then began to separate after 2 recorded episodes from 30-35% (Figure 3.8C).
The probability of a high anti-AMAl(3D7) response continued to rise on further exposure to 45%
after 7 recorded episodes of parasitaemia. In children who were parasitaemic at sample time, the
probability of antibody titres above the 75th centile when there were no prior episodes recorded was
between 600A,and 70010for all antigens tested. These probabilities declined at a similar constant
rate for all three AMA 1 variants to 43-48% after 7 recorded episodes of parasitaemia (Figure
3.88). The probability of a high response to MSP2(FC7) declined at a slower rate than that of
other antigens from a high of 70% when there were no prior episodes to 60% after 2 episodes and
remained relatively stable with a slight decline to 58% after 7 episodes. The probability of a high
response to MSP2(3D7) was different to that of MSP2(FC27). The probability declined rapidly
from 67% at baseline to 38% after 4 episodes and remained constant even on further exposure
(Figure 3.8B). These observations suggest that if children were parasitaemic at sample collection
time, antibodies were at high levels and were not further increased by a history of prior episodes.
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4
Parasitemia in prior 6 months
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4
Parasitemia in prior 6 months
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-- MSP2(307) -- MSP2(FC27)
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4
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Figure 3.8 The predicted probability of IgG responses to P. falciparum merozoite antigens above the
75th centile by the number of recorded parasitaemic episodes in the 6 months prior to sampling. Each
antigen is represented by a single line on each graph; dark blue = AMA I(W2mef), maroon = AMA I(HB3),
green = AMAI(307), yellow = MSP2(307), light blue = MSP2(FC27). (A) Predicted probability of
antibody titres above the 75th centile in all samples, (B) parasite positive at sample time, and (C) parasite
positive at sample time. Predicted probability of antibody titres above the 75th centile in children ages 0-4
years (0) and ages 5-9 years (E) at sampling.
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To gain further insight into the acquisition of antibody responses with age, the same analysis was
stratified by age. Children were divided into two groups; those ages 0 - 4 years who are actively
acquiring immunity against severe disease and high parasitaemia, and those 5-9 years who have
more established immunity. The younger children had a probability of less than 10% at baseline
(no parasitaemic episodes in the prior six months) of a high antibody response to all three AMAI
variants tested along with MSP2(307) (Figure 3.80). The probability increased at a similar rate
for all these antigens to 30% after two recorded episodes. The probability of high responses to
AMA(W2met) and AMAl(HB3) were very similar. Unlike those of AMAI(W2met) and
AMAl(HB3), the probability ofa high response to AMA1(307) continued to rise at the same rate
and reached 48% after 4 episodes. Following a peak of 38% after three episodes, the probability of
a high response to MSP2(3D7) in younger children remained constant around 35% after four
episodes. This was not the case for the probability of a high response to MSP2(FC27) in the
younger age group. Unlike all the other antigens tested, younger children had a 13% probability of
a high response to MSP2(FC27) at baseline (Figure 3.80). The probability increased at a similar
rate to that of the other antigens but peaked after two recorded episodes at 35% and then dropped to
28% after 4 episodes.
In contrast to the younger children, those aged 5-9 years had a 33-37% probability of a high IgG
response to all the AMAI variants and MSP2(307) in the absence of prior episodes (Figure 3.8E).
The probability rose to 53%, 51%, and 48% for AMAl(HB3), AMAl(307), and AMA1(W2met)
respectively after 3 episodes of parasitaemia and remained at the same level after 3 episodes. The
probability of a high response to the AMA1 variants then declined steadily on further exposure to
28% for AMAl(W2mef) and AMAI(HFB3), and 25% for AMAl(307) after seven episodes. The
probability of a high response to MSP2(3D7) had a similar profile to that ofthe AMA1variants but
with more modest increases and declines (Figure 3.8E). Following a peak of 46% after four
episodes, the probility of a high response to MSP2(307) declined to levels similar to that at
baseline (34%) after seven episodes.
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3.3.8 The probability of antibody positivity is dependent on antigen tharaderistits
In order to assess the probability of being considered antibody positive (levels above the
mean+3SD value of a panel of negative controls), a similar analysis to that described above was
carried out. The probability of being considered IgG positive to A4 schizont extract was also
included in this analysis. The probabilities for this occurrence appeared to cluster into two groups
designated by their antigen (AMA I and MSP2). For AMA I, the probability of being considered
antibody positive after no recorded parsitemia in the prior 6 months was between 30% and 45%
(Figure 9A). This probability increased to 75% for AMAl(HB3), 70% for AMAl(3D7), and 65%
for AMA 1(W2mef) after 3 parasitaemic episodes. This increase occurred at the same rate for all
AMA 1 variants. The probability remained relatively stable for AMA I (HB3) but dropped slightly
for AMA1(W2mef) and AMA1(3D7) to 50% after 7 episodes. The probability of being considered
sero-positive for MSP2 was around 15% when there were no prior episodes and increased to almost
40% for MSP2(FC27) after four parasitaemic episodes and 30% for MSP2(3D7) after two episodes
(Figure 3.9A). Although the probabilities were much lower for MSP2(3D7) when compared to the
AMAI variants, the rates of induction followed a similar profile (Figure 3.9A). Both the
probability of an antibody response and the rate of induction of this response to schizont extract
was the same as that to the AMA 1 variants.
Among children without concurrent parasitaemia at sample time, the probabilities of a positive
antibody response showed similar rates of induction of responses to AMA I and MSP2 variants as
in the analysis described above (Figure 3.9C). The same was also seen for schizont extract in
children without parasites at sampling. These patterns were very different in the children with
concurrent parasitaemia (Figure 3.9B). The probability of a positive antibody response to all three
AMA 1 variant was 78-83% when there were no prior episodes. Regardless of the number of
episodes of prior exposure, the probability of being antibody positive to AMA I(W2mef) did not
change. This was in contrast with AMA1(HB3) and AMAl(3D7). The probabilities of an
antibody response to these two antigens declined steadily on every exposure to 60% for
AMAl(3D7) and 50% for AMAl(HB3) after seven prior episodes of parasitaemia (Figure 3.9B).
The probability of an antibody response to MSP2 was between 57% and 60% without prior
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episodes, which was lower than that for AMA1. Whereas this probability did not change markedly
for MSP2(FC27) even after 7 episodes, the probability of an antibody response to MSP2(3D7)
declined to 40010by four episodes and remained steady even after more episodes of parasitaemia.
The probability of an antibody response to schizont extract was around 80% at baseline and
increased to 90010after 2 episodes (Figure 3.9B). It then declined steadily to baseline levels after
seven episodes.
Stratification by age, as described in the earlier section gave further insight into the induction of
antibody responses to AMA1 and MSP2. Children ages 0 - 4 years had a similar pattern of
induction to that seen when all the samples were analysed together (Figure 3.90). Younger
children had probabilities between 18% and 23% of an antibody response to the AMAI variants
and schizont extract when no prior episodes were recorded. The rates of induction increased at a
similar rate and peaked after 3 episodes for AMAI(W2met), AMAI(307), and schizont extract at
WIG, 60010,and 70% respectively. The rate of induction of an antibody response to AMA1(HB3)
slowed after 3 episodes but continues to rise to 80% after 7 episodes (Figure 3.90). The
probability of an antibody response to AMA1(W2met) remained steady after 3 episodes but
declined to 50% for AMA1(307). More than three episodes resulted in a similar decline in the
probability of an antibody response to schizont extract. Though the probability of antibody
responses to the MSP2 variants were lower than AMA1 when there were no prior episodes (less
than 10%), they rose at the same rate to around 20% after two episodes of parasitaemia and then
remained steady on further exposure (Figure 3.90).
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Figure 3.9 The predicted probability of positive IgC responses to P. falciparum merozoite antigens by
the number of recorded parasitaemic episodes in the 6 months prior to sampling. Each antigen is
represented by a single line on each graph; dark blue = AMA I (W2mef), maroon = AMA I (H 83), green =
AMA I (307), yellow = MSP2(3D7), light blue = MSP2(FC27), red = A4 schizont extract (A) Predicted
probability of sero-positive responses in all samples, (8) parasite positive at sample time, and (C) parasite
positive at sample time. Predicted probability of sero-positive responses in children ages 0-4 years (D) and
ages 5-9 years (E) at sampling.
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Although the probability of a positive antibody response displayed similarities for each antigen as
observed in the younger children also appeared in the older children, there were a number of
differences in the probability of an antibody response in this group. Older children had a higher
probability of an antibody response at baseline. The probability of an antibody response to the
AMAI variants was between 40% and 50010 at baseline and increased at slightly different rates
associated with increasing numbers of episodes of parasitaemia (Figure 3.9E). The probability
peaked at 64% after two episodes for AMAl(W2met) then fell to 40% after seven episodes. A
similar rate of increase peaking at 75% after three episodes was seen for both AMA(HB3) and
AMAl(3D7), though the probabilities declined at different rates to 65% for AMAl(HB3) and 50%
for AMAl(3D7) after seven episodes of parasitaemia. The induction of an antibody response to
schizont extract was similar to that of AMAI with a peak of 83% after three episodes followed by a
decline to 70% after seven episodes. Though the probability of an antibody response to the two
MSP2 variants was 20% when there were no episodes, their rates of induction were different with
increasing exposure. The probability of an antibody response to MSP2(FC27) increased to 40%
after three episodes and remained the same on increased exposure (Figure 3.9E). In contrast, that
to MSP2(3D7) increased modestly to 25% after three episodes and fell to zero after 7 episodes.
3.3.9 Antibody responses to AMAI correlate with those to MSPl
Antibody titres to all five antigens tested were compared in pair-wise Spearman rank correlations.
As expected, the antibody responses to different AMAI variants were significantly correlated with
correlation coefficients between 0.87 and 0.91. The response to the two MSP2 variants was not as
strongly correlated, with a correlation coefficient of 0.62 though this was highly significant
(p<O.OOI)(Table 3.13). This may indicate that antibodies to MSP2 are more allele-specific than
antibodies to AMAI (Stanisic et al. 2009). High antibody responses to AMA1were all associated
with a comparable level of anti-MSP2 responses with significant (p<O.OO1) correlation coefficients
from 0.59 to 0.64 for AMAIIMSP2 pair-wise comparisons. Spearman rank correlations comparing
the IgG response to the same antigen at each cross sectional bleed showed that the antibody
responses at consecutive bleeds were more strongly associated with each other. Correlations
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between antibody responses at different bleeds were more strongly correlated for the AMA 1
variants than the MSP2 variants (Tables 3.14-3.15, Appendix 1 Tables 37-39).
Table 3.13 Correlations between IgG responses to AMAI and MSP2.
AMAl (W2mef)' MSP2(FC27) ,AMA1(HB3)' AMA1(3D7)' MSP2(3D7)'
AMAl (W2mef)'
AMA1(HB3)' 0.89'
AMA1(3D7)'
MSP2(3D7)'
MSP2(FC27) ,
0.87'
0.61'
0.59'
0.91'
0.62
0.59'
0.64'
0.59' 0.62'
Notes
Spearman rank correlation coefficients for IgG responses.
2100 samples in each comparison.
1 Antigens tested by ELISA.
, P-value <0.001
Table 3.14 Correlations between IgG responses to AMA1(W2mel) at each cross sectional bleed,
IgG responses to AMA1 (W2mef)
May 2002'
May 2002'
October 2002' 0.68' (308)
May 2003' 0.57' (263)
October 2003' 0.59' (249)
May 2004' 0.6' (231)
October 2004' 0.6' (226)
October 2002' May 2003' May2004' October 2004'October 2003'
0.53' (294)
o.si' (259)
0.55' (242)
0.53' (236)
0.59' (293)
0.53' (259)
0.58' (255)
0.72' (278)
0.74' (274) 0.75' (277)
Notes
Spearman rank correlation coefficients for IIG responses.
Number of samples in each comparison indicated In brackets.
I Cross sectional bleed .
• P-value <0.001
Table 3,15 Correlations between IgG responses to MSP2(3D7) at each cross sectional bleed,
IgG responses to MSPZ (307)
May 2002'
May 2002'
October 2002' 0.53' (308)
May 2003' 0.47 (263)
October 2003' 0.42' (249)
May 2004' 0.47 (231)
October 2004' 0.41' (226)
October 2002' May2003' October 2004'October 2003' May 2004'
0.59' (294)
0.49' (259)
0.54' (242)
0.62' (236)
0.53' (293)
0.56' (259)
0.56' (255)
0.61' (278)
0.58' (274) 0.72' (277)
~
Spearman rank correlation coefficients for JgGresponses.
Number of samples in each comparison indicated in brackets.
I Cross sectional bleed.
P~vaJue <0.001
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3.4 Discussion
Cross sectional studies are the simplest way to collect data from a population sample and make
inferences on the entire population. Whilst this method is valid for observations that either remain
relatively constant or change slowly over time, it may not be reliable when the outcome under
question is dynamic in nature. A good example of a dynamic outcome is the antibody response to
malarial antigens. Antibody responses are dependent on a number of factors that include the age of
the individual as well as the level of exposure to malaria. With the extra knowledge that
antibodies to various malarial antigens may be short-lived, it is important to note that methods
which take into the account the dynamic nature of the outcome will likely be the best in
investigating antibody responses to malarial antigens (Kinyanjui et al. 2007). The ideal framework
for this outcome is one that is longitudinal (which will be discussed in later chapters), but barring
the possibility of a longitudinal framework, a number of repeated cross sectional surveys will give
insight into the nature of the antibody response. This study is unique in the fact that it was made up
of a set of six repeated cross sectional surveys in which the same parameters were recorded in
almost 300 children per survey, with close to two-thirds of them having been sampled at all six
surveys. Here, I was able to identify the major factors that influence induction and maintenance of
antibody responses to AMAI and MSP2. These factors were age, recent or current malarial
exposure and the presence of haemoglobinopathies.
In agreement with previously published findings antibody prevalence and titres to both AMA I
(W2mef, HB3 and 307) and MSP2 (307 and FC27) consistently rose significantly with age in this
study (Taylor et al. 1998; Johnson et al. 2004; Polley et a1.2004; Cortes et al. 2005; Polley et al.
2006). This can be attributed to increasing cumulative exposure to malaria the longer individuals
live in malaria endemic areas resulting in higher and possibly more durable antibody responses.
Also, when responses to schizont extract (thought to reflect total P. falciparum blood-stage
exposure) were considered, the antibody response to merozoite antigens rose with increasing
exposure. Both of these results are reassuring because they confirm that the responses we were
measuring were specific to P. falciparum. Consistent increases in antibody titres to all merozoite
antigens tested with concurrent parasitaemia at sample time were observed and have also been
126
noted in numerous publications (Al- Yaman et al. 1995a; Bull et al. 2002; Metzger et al. 2003;
Kinyanjui et al. 2004; Polley et al. 2006). The presence of parasites activates both a naive and
previously exposed immune system to produce significant levels of P. falciparum antigen-specific
antibodies in what is probably the most measurable immune response to malaria infection.
Due to the nature of this study, I was able to investigate the effect of changing malaria transmission
on the antibody responses in the same population. Whereas it is already established that antibody
levels are dependent on malaria transmission; it has not been studied in the detail that was carried
out in this study (Vande Waa et al. 1984; Fruh et al. 1991; Ramasamy et al. 1994; Jakobsen et al.
1997; Cavanagh et al. 1998; Giha et al. 1998; Soares et al. 1999b; John et al. 2002; Nebie et al.
2008). Here I showed that in children between the ages of 1 to 10, antibody prevalence to AMA I
and MSP2 fell in concert with reducing malaria transmission over 2.5 years when measured at 6
month intervals.
Age and previous exposure to malaria are two factors that are often difficult to separate and are
usually combined when trying to explain their effect on protection from clinical disease. In many
studies carried out in malaria-endemic areas, the age of a child is often used as a proxy for
cumulative exposure. This may not be a correct assumption. Age alone has been shown to have an
effect on incidence of malaria separate from any other malaria-related variables and also in relation
to antibody responses to pre-erythrocytic and erythrocytic P. falciparum antigens (Baird et al.
1991; Baird et al. 1993; Kurtis et al. 2001; Hudson Keenihan et al. 2003; Keenihan et al. 2003).
Contrary to the general assumption of cumulative exposure with increasing age, it may be better to
assume that although exposure will increase with time spent in a malaria-endemic area, the
exposure will not be homogenous in its distribution or frequency. Studies carried out in malaria-
endemic areas show that the incidence of clinical disease is heterogenous and often occurs in
clusters within these exposed populations (Carter et al. 2000; Creasey et al. 2004; Clark et al. 2008;
Mwangi et al. 2008). Due to active surveillance of the cohort in this study, most incidences of
exposure to P. falciparum could be caught and recorded on a week by week basis over the entire
study period. With this information it was possible to investigate the effect of episodes of prior
recorded exposure/parasitaemia in the 6 months before each sample time. As antibodies to malaria
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antigens are generally short-lived, limiting the period of prior exposure to 6 months would
hopeftally include the antibody response to a recent exposure as well as any relatively long-lived
responses that could be elicited in these children. Also, the decline in malaria transmission over the
study period would allow for further separation of the effects of age and exposure on antibody
responses to AMAI and MSP2. It should be noted that not all episodes of asymptomatic
parasitaemia may have been detected during follow-up as blood smears were only performed if the
child was unwell, or if there was another clinical indication in which a blood sample was collected.
Furthermore, sub-microscopic parasitaemia which is detectable by PeR-based methods does OCcur.
Unfortunately PCR detection of parasitaemia is not available for this cohort at present.
Throughout the study period, concurrent parasitaemia at sample time was the greatest contributor to
higher antibody levels. As this effect overshadowed the contribution of other factors to antibody
levels, the analyses were stratified by parasite status at sample time. When this was done, the
effect of age could be seen throughout the study period with increasing age being associated with
higher antibody titres to AMA1 and MSP2. In children who did not have detectable parasitaemia
at sample time, recorded episodes of parasitaemia and mild malaria increased antibody levels more
than age at the beginning of the study period when malaria transmission was higher (parasite
prevalence at sample time above 10%). As malaria transmission dropped over the study period, the
effect of age on antibody levels became more pronounced. In children with concurrent
parasitaemia at sample time, age had a much less obvious effect on antibody levels. It appears that
the circulating parasites activate the immune response to such a degree that any effects of age are
overwhelmed. As malaria transmission dropped over the study period, age began to have more of
an effect even in children who were parasite positive. Age and prior exposure affect antibody titres
in an independent manner that is dynamic and dependent on the overall malaria transmission
intensity. When circulating parasites are present in previously exposed individuals, it could be that
the antibody titres are mainly a response to concurrent parasitaemia that masks the effect of other
factors. As suggested in other studies, this response in the presence of activating parasites could be
an indication of the individual's overall responsiveness to malaria antigens (Bull et al. 2002; POlley
et al. 2004).
128
Both the sickle trait and alpha-thalassemia were associated with a reduction in antibody titres
though these associations were not significant at every sampling point. Comparison in different
age groups also showed a trend for lower antibody titres associated with the haemoglobinopathies.
The results seen in the HbAA and HbAS children are both in agreement with and contrary to other
studies. A study in Kenya showed that protection from clinical malaria increased with age at a
more rapid pace in HbAS children than in HbAA children, thus implying a role for HbAS is
regulation of the adaptive immune response (Williams et al. 2005a). Antibody-related protection
against variant surface antigens in relation to haemoglobinopathies was observed in two studies but
was not in other studies (Marsh et al. 1989; Luzzi et al. 1991; Allen et al. 1992; Alien et al. 1993;
Le Hesran et al. 1999). A more recent study that measured antibody titres to MSP2 (307 and
FC27) found that Senegalese children with the sickle trait (HbAS) had significantly lower levels of
total IgG, IgG 1 and IgG3 than their normal counterparts (Sarr et al. 2006). Another recent study
showed slightly higher levels of antibodies to AMA1(3D7) and MSP2(D2d) in adults from a low
transmission setting in Burkina Faso but no difference in antibody titres to the same antigens in
children living in a high transmission setting (Verra et al. 2007). The results from the Sarr et al
study are in agreement with this one. The same antigens from the same source were used in both
studies on children of similar ages (2-10 years in the Sarr et al compared to 0-10 years in this
study) from areas of comparable transmission intensity (EIR of 9-12 in the Sarr et al study
compared to lOin this study). This study adds to evidence that the antibody responses to merozoite
antigens in individuals with haemoglobinopathies may be lower compared to their normal
counterparts. It has been suggested that lower antibody responses seen in HbAS and alpha-
thalassemic individuals may be an effect of protection from clinical malaria (Bayoumi 1997).
Reduced parasite densities due to erythrocyte physiology along with increased splenic clearance of
defective erythrocytes could lead to a reduction in the amount of malaria antigens that are
presented to B cells and lead to a lower antibody response.
Antibody responses to different AMA I variants and MSP2 variants were significantly correlated
both within the different antigenic alleles and between the different antigens. This result is
expected as both AMA I and MSP2 have conserved regions that will elicit a similar antibody
response. The correlation between MSP2 and AMA 1 can also be explained by exposure to a
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number of P. falciparum antigens which results in an antibody response to all possible antigens. In
order to further compare the responses to AMA 1 and MSP2, the probability of a sero-positive
response after recorded exposure to P. falciparum was investigated. Without any recorded
exposure in the prior 6 months - which may not include all asymptomatic exposure - the
probability of an antibody response considered positive was lower for MSP2 than for AMA 1. Even
after four recorded episodes of exposure the probability of a positive antibody response to MSP2 is
on average 25% compared to 7()oA,for AMAI. These results may indicate that AMAI is more
immunogenic than MSP2 in this cohort and therefore elicits a stronger response than that to MSP2;
samples were tested at a lower concentration for AMA 1 compared to MSP2. All antigens were
expressed and purified using similar methods, were of high purity, and were coated on ELISA
plates at saturating concentrations (Beeson, unpublished data).
The probability of a high antibody response (above the 75th centile) after recorded exposure was
also investigated and the patterns were very similar for all AMA I and MSP2 variants. The
probability of a high antibody response increased in a linear manner in relation to number of
episodes to more than 40% after three episodes of recorded exposure. When only those without
parasites at sample time were considered a similar pattern was observed. When those with
concurrent parasitaemia were considered alone, the probability of a high response was above 60%
in the absence of prior episodes and dropped for all antigens with increasing prior exposure. These
results suggest that in children with ongoing exposure, a high antibody response to AMA 1 and
MSP2 is likely to be generated after 3 episodes of exposure which may parallel the immunity to
severe non-cerebral malaria that is generated after 2-3 episodes of disease (Gupta et al. 1999). If a
child has not generated a high antibody response to AMA 1 or MSP2 after three episodes, it is
unlikely that they will after more episodes. The effect of concurrent parasitaemia was very clear
with high probabilities of high antibody titres even without any exposure in the six months prior to
sample time. The fact that more episodes of exposure were predictive of lower antibody levels
may indicate that those children who were parasitaemic at sample time could include a group of
more susceptible children who cannot generate a high antibody response to AMA 1 and MSP2 even
after considerable exposure.
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Overall antigen immunogenicity appears to influence whether an individual will have a
seropositive response after a number of P. Jalciparum exposures regardless of age. Both older (5 -
9 years) and younger (0 - 4 years) children were between 60% and 80% likely to have measurable
antibody responses to AMA I after three recorded parasitaemic episodes compared with 20% to
40% for MSP2. This was regardless of the fact that the likelihood of a measureable antibody
response was much lower in younger children without any exposure in the prior six months
compared to older children. Even though antigen characteristics will influence whether there is any
antibody response, the individual's age appears to further implicate whether this response will be in
the higher percentiles or not. If an older child has not produced a high level antibody response
after 2-3 parasitaemeic episodes, they are less likely to produce this response on further exposure
compared to their younger counterparts. These results could be indicative of the fact that older
children who experience numerous parasitaemic episodes do so due to overall lower antibody
and/or immune responses and may actually be the susceptible members of the population in which
malaria transmission and disease actively occurs. An alternative explanation may be the shift from
allele-specific to cross-reactive malaria immunity that occurs with aging. In this study both cross-
reactive and allele specific antibodies were measured by ELISA. Younger children had different
rates of acquiring a high antibody responses on increasing prior exposure, with similar rates for
AMAl(W2met) and AMAl(HB3) when compared to those of AMAl(3D7). There was also a
difference between MSP2(3D7) and MSP2(FC27). In older children the differences tended to be
antigen-specific rather than variants specific; likely explained by the existence of cross-reactive
IgG responses specific to AMAI and MSP2 respectively.
Though detailed in its approach, a limitation of this study is the small number of antigens tested.
But even with this limited antigen repertoire, I have shown that the effects of different factors on
antibody acquisition are dynamic in nature. We intend to extend this study with other merozoite
antigens as immunity to malaria is dependent on responses to a number of antigens (Meraldi et al.
2004; Gray et al. 2007; Osier et al. 2008). As antibody levels are often used as a proxy for the
immune response to malaria in protection studies, it is important to note that the extent to which
age, prior exposure, concurrent parasitaemia, and haemoglobinopathies influence antibody levels to
AMA 1 and MSP2 also change over time. The acquisition of antibodies to malaria antigens in
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childhood is also dependent on changing states of these factors. Here I show that when antibody
responses are measured during higher malaria transmission intensities, the effect of age can only be .
clearly seen when children are aparasitaemic. Only when malaria transmission drops does the
antibody response begin to better represent cumulative exposure in both parasitaemic and
aparasitaemic children. Age also begins to playa bigger role in predicting antibody levels at lower
transmission intensities. The fact that antibody responses are intimately linked to malaria
transmission intensity means that interpretation of antibody data must include this confounder.
These antibody properties are already being used in the sero-epidemiological prediction of malaria
transmission intensity (Drakeley and Cook 2009). Longitudinal analysis of this data will allow for
deeper understanding of the acquisition of antibody responses in this population (see Chapter 4).
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4 Longitudinal patterns of IgG responses to AMAI and
MSP2
4.1 Introduction
The successful treatment of clinical malaria in children by the passive transfer of immunoglobulins
from adults in the 1960s may have over-simplified the interpretation of the role of naturally
acquired antibodies to malaria antigens (Cohen et at. 1961). To date, most - if not all- studies that
investigate the role of antibodies in malaria immunity are founded on the hypotheses that the
presence or absence of anti-malaria antibodies is reflective of immunity or lack of, and that
immunity is relatively stable over the period of follow-up in question. It is most interesting that
these premises persist in the face of growing evidence that antibody responses to malaria antigens
often appear to be short-lived in children (Le. present at detectable levels for only a few weeks) and
that adults who move away from malaria endemic areas for extended periods are more susceptible
to disease on their return to these areas (Deloron and Chougnet 1992; Branch et at. 1998; Cavanagh
et at. 1998; Soares et at. 1999; Kinyanjui et at. 2007). The traditional method of measuring
antibody responses at baseline and then associating them with protection or susceptibility over
follow-up is both logistically and statistically simpler than multiple sampling over an extended
period, which may contribute to the popularity of these studies. The varying results seen in
comparable studies using the same antigens along with disappointing results from vaccine trials
may indicate some unreliability for these types of studies to assign immune status. A more
complete picture of the development of malaria immunity will be by repeated sampling and
surveillance of the same individuals over an extended period of time.
Longitudinal studies allow the individual development of dynamic outcome variables to be studied
over time. A number of longitudinal studies investigating the acquisition of various antibodies to
malarial antigens in endemic populations have been carried out in children (Fruh et at. 1991;
Branch et al. 1998; Cavanagh et at. 1998; Giha et at. 1999; Udhayakumar et at. 2001; Kinyanjui et
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al. 2007; Akpogheneta et al. 2008; Biswas et al. 2008). To date two studies - both in adults have
shown a stable persistence of antibody levels to MSPI and AMA1(Riley et al. 1993;Udhayakumar
et al. 2001). Most of the studies showed that antibodies to PjMSP1, PvMSP1, PfAMA1, PvAMAI
and PjEMPI are frequently short-lived and decline significantly over the study period although
antibodies to PvAMAI could be detected in a few individuals up to 7 years after an outbreak of P.
vivax malaria in Brazil (Branch et al. 1998; Cavanagh et al. 1998; Giha et al. 1999; Soares et al.
1999; Morais et al. 2006; Kinyanjui et al. 2007; Akpogheneta et al. 2008; Biswas et al. 2008).
Whilst the studies above have shown that antibody responses to merozoite antigens are often short-
lived and boosted by concurrent parasitaemia or recent infection, they have not examined the
acquisition of antibody responses in children below the age of 10 years over an extended period.
Also lacking in published literature is the effect of changing covariates such as age and exposure on
the longitudinal patterns of antibody acquisition and maintenance.
As shown in the previous chapter, antibody responses to AMAI and MSP2 are dynamic and are
affected by a number of different factors. Age, concurrent parasitaemia, and prior exposure all had
considerable effects on the antibody levels exhibited by children in this study. Utilisation of both
bi-annual antibody measures and weekly surveillance data over 2.5 years allows for patterns of
antibody acquisition and maintenance to be examined in depth. The effects of increasing age,
variable incidents of concurrent parasitaemia, and overall exposure over a period with declining
malaria transmission can now be investigated more fully. Antibody levels at a single time point are
not only a result of the factors already mentioned, but are also affected by antibody levels
previously exhibited by the same individual (unless measured after primary Plasmodium exposure,
which is difficult to assess in endemic populations). Therefore, what may be described as a high
response at a single time point may not be the case over a longer period of time. The opposite
could also be true; perhaps antibody measures at a single time point could give great insight into
their magnitude over time.
This chapter aims to investigate the acquisition and maintenance of antibody responses to AMA1
and MSP2 as well as the factors affecting them throughout the study period. As already stated,
both these antigens elicit antibody responses in malaria-endemic populations and are likely to be
targets of protective immunity. It is hoped that the results from this chapter may shed more light
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on the dynamic antibody response that is typical of naturally acquired malaria immunity and will
aid in the interpretation of the sero-epidemiological data that is used as a measure of immunity in
ongoing observational studies and malaria vaccine trials.
4..2 Methods
4.2.1 Statistical Analysis
All data analyses were performed with STATA version 9.2 (StataCorp, College Station, TX USA).
All samples were used in the analyses unless stated. Tracking is used to investigate the stability of
outcome variables over time. Rather than calculating a tracking coefficient for each individual, a
simpler method of visualizing relative change over time was used. I analysed an individual's
antibody response as a rank within the study population and investigated its stability over the study
period using adjusted z-scores (the standard normal deviate). The equation used is described in
Chapter 2. The z-score was adjusted for age and sample time to take into account the increasing age
of the children over the study period and the reduction in malaria transmission over the same.
Stability of the IgG response over the study period was assessed by calculating the difference in z-
scores for each child from bleed to bleed.
In order to reduce the large number of data points at each time point to a longitudinal pattern, mean
antibody levels were calculated and graphed using locally weighted scatter-plot smoothing
(LOWESS). LOWESS fits a low-degree polynomial to a determined subset of the data at each
point with explanatory variable values near the point where the response is being estimated
(Cleveland 1979; Cleveland and Devlin 1988). 80% of the data at each point was used to fit each
local polynomial using weighted least squares which gives less weight to points further away from
the point whose response is being estimated. LOWESS does not require the specification of a
function to fit a model to all of the data in the sample and requires large densely sampled data sets
to produce good models. With over 250 data points at each sample point, this model gave a
reasonable population mean.
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To test for differences in antibody levels over the study period MANOVA for repeated measures
was carried out. This statistical test is carried out for the T - 1 absolute differences between
subsequent measurements. Details of this test can be found in Chapter 2. MANOV A for repeated
measures assumes that observations on different subjects at each of the time points are independent
and are multivariate normally distributed.
To investigate the effect of different predictor variables on antibody levels. generalised estimating
equations (OEE) were used. OEE allow for the analysis of longitudinal relationships using all
available longitudinal data without summarizing the longitudinal outcome into a single value. This
model allows for simultaneous analysis between variables at different time points. Repeated
observations on the same subject are not independent so a correction needs to be made for this
within-subject correlation. GEE was also used to investigate the decline in antibody responses
between May and October 2004. Details can be found in Chapter 2.
Antibody measures were entered into the model as continuous variables, age was a categorical
variable defined by age at the start of the study. parasitaemia was also a categorical variable
defined by the number of times an individual had concurrent parasitaemia at sample time. Prior
exposure was a count variable defined by the number of times each individual had an episode of
recorded parasitaemia in six months prior to sample time. Sickle trait and alpha-thalassemia were
both entered as categorical variables.
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4.3 Results
4.3.1 Fluctuating IgG responses to AMAI and MSP2 parallel the decline in malaria
transmission
In order to get a clearer picture of antibody patterns over the study period; standardized measures
of relative antibody levels were plotted over the entire period for each child present in the study
(Figure 4.1). For ease of interpretation, the sample time (May 2002 to October 2004) was indicated
on the x-axis rather than the actual date of sample collection (which varied widely for each cross-
sectional sample time due to the number of study participants involved). These individual antibody
plots revealed a number of occurrences. The overall antibody patterns for AMA I were different
from those of MSP2 within the same group of children. A small number of children maintained a
high antibody response to all variants of AMA 1 throughout the study period (Figure 4.1A-C)
compared to MSP2 (Figure 4.1D-E). A second group of children had highly fluctuating antibody
responses that spanned the upper and lower limits of detection for both AMA 1 and MSP2 variants,
though these patterns were exhibited less with regards to MSP2 compared to AMA I. For both
AMAI and MSP2 there were a considerable number of children who maintained a low antibody
response (below 0.5 OD units) over the entire study period compared to other children. Though
there was some fluctuation in the antibody response in these children, it was small. Overall, the
antibody response to AMAI appeared to be stronger than that to MSP2, with more children
exhibiting OD values to AMAI greater than 1 OD unit compared to MSP2 (anti-AMA 1 responses
were tested at a sera dilution of I :4000 and those to MSP2 at a I: I000 dilution). When the same
data was plotted for those 186 children who were present at all six cross-sectional bleeds the same
patterns described above were evident (Appendix 2, Figure I).
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Figure 4.1 Longitudinal antibody (lgG) responses to merozoite antigens. Each line represents an
individual. (A) AMAI(W2mef), (B) AMAI(HB3), (C) AMA1(307), (D) MSP2(307), (E) MSP2(FC27).
To further investigate the relative stability of the antibody response to AMAI and MSP2 over time ,
z-scores stratified by age and sample time were calculated for all the children present at all six
sample times and each child's z-score was plotted over the study period (Figure 4.2). Both the
AMA I and MSP2 antibody data showed a considerable level of stability over time. The children
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with low antibody responses (corresponding z-scores below zero) generally maintained their rank
over time within the group compared to other children whose ranking changed over the study
period. There were a few children with higher antibody responses who also showed a considerable
level of tracking with z-scores above 1, but they were present only with regards to AMA I (Figure
4.2 A-C). Detailed interpretation of the z-score using the graphs in Figure 4.2 is difficult due to the
large number of observations in this dataset. Differences in the z-score from one cross sectional
bleed to the next were used as a way to gain further insight into the relative IgG response 'position'
of anyone child compared to the cohort mean. The fold difference in z-scores was calculated and
then categorised into five groups. For all the antigens tested, the greatest amount of change was up
to 2-fold decline in a-scores between each bleed (Table 4.1). Between 40% and 70% of the
children had declining IgG responses to AMA 1 and MSP2 during anyone interval between cross-
sectional bleeds. The proportion of children who maintained their ranking ranged from I7% to
34% for MSP2 and 19% to 38% for AMAI (Table 4.1). Generally, the largest decline in z-scores
(up to 70% of children had up to a 2-fold decline in their z-scores) occurred during the May 2004
cross sectional bleed. This occurred at the same time as there was a sharp decline in the number of
children with parasitaemia in the intervals between cross sectional bleeds. Between May and
October 2003 37% of the children had parasitaemia compared with the following period of October
2003 to May 2004 when 12% had parasitaemia.
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Figure 4.2 Tracking of antibody responses to merozoite antigens for children present at all six sample
times. Each line represents an individual's 'response ranking' over the study period represented by their
adjusted z-score (adjusted for age and sample time). (A) AMAI(W2mef), (B) AMAl(HB3), (C)
AMAI(3D7), (D) MSP2(3D7), (E) MSP2(FC27).
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Table 4.1 Changes in z-score from one cross sectional bleed to the next over the study period.
Antl·AMA1 and antl·MSP2 antibody response chanles from previous sample point. proportion (n)
Change in z-score4
October 2002 May2003 October 2003 May2004 October 2004
AMA1(W2mef) > Hold decline 8.2 us) 5.0 (9) 6.6(12) 2.2 (4) 3.8 (7)
S 2·fold decline 40.2 (74) 67.6 (123) 47.5 (87) 66.3 (122) 50.5 (93)
No chanle 3S.6 (71) 19.2 (35) 3S.8 (71) 25.5 (47) 3S.0 (70)
S 2-fold increase 7.6(14) 1.7 (3) 3.S (7) 2.2 (4) 6.0(11)
> 2-fold increase 5.4 (10) 6.6(12) 3.3(6) 3.S (7) 1.6 (3)
AMA1(HB3) :> 2-fold decline 6.0 (11) lOA (19) 5.5 (10) 2.2 (4) 3.3 (6)
S 2-fold decline 55.4 (102) 53.3 (97) 50.3 (92) 66.9 (123) 51.6(95)
No change 29.4 (54) 2604 (4S) 37.7 (69) 26.1 (4S) 34.2 (63)
S 2-fold increase 4.9 (9) 5.5 (10) 3.3(6) 2.7 (5) 7.1 (13)
> 2-fold increase 4.4 (S) 4.4 (8) 3.3(6) 2.2 (4) 3.8 (7)
AMA1(3D7) > 2-fold decline 6.0(11) S.S (16) 7.1 (13) 1.1 (2) 2.2 (4)
S 2-fold decline 53.3 (9S) 4S.4 (8S) 48.6(S9) 65.2 (120) 53.S (99)
No change 34.2 (63) 34.1 (62) 37.2 (6S) 28.3 (52) 34.S (64)
S; 2-fold Increase 3.3 (6) 5.5 (10) 4.4(S) 3.3 (6) 4.9 (9)
> 2-fold increase 3.3 (6) 3.3 (6) 2.7(5) 2.2 (4) 4.4 (S)
MSP2(3D7) > 2-fold decline 6.5 (12) 8.8 (16) 10.4 (19) 4.9(9) 2.7 (5)
S Hold decline 65.S (121) 45.6 (S3) 43.2 (79) 63.0 (116) 53.S (99)
No change 17.4 (32) 33.0 (60) 33.3 (61) 23.9 (44) 33.2 (61)
S 2-fold increase 5.4 (10) S.8 (16) 8.7(16) 4.9 (9) 6.0 (11)
> 2-fold increase 4.9 (9) 3.9 (7) 4.4 (8) 3.3 (6) 4.4 (8)
MSP2(FC27) > Hold decline 5.4 (10) 8.2 (15) 6.6(12) 2.2 (4) 7.1 (13)
S Hold decline 51.1 (94) 52.8 (96) 51.9 (95) 70.1 (129) 50.0 (92)
No change 34.2 (63) 27.5 (50) 27.3 (50) 23.4 (43) 31.5 (SS)
S 2-fold increase 5.4(10) 7.1 (13) 8.2(15) 2.2 (4) 6.0(11)
> 2-fold Increase 3.8(7) 4.4(8) 6.0 (11) 2.2 (4) 5.4 (10)
Notes
4 Difference in a-score between cross-sectional bleeds (z-score= (antibody response, OD - mean response1! standard deviation),
Table shows data for all children who were sampled at all cross sectional bleeds.
Though the IgG response to a single merozoite antigen variant from one cross-sectional bleed to
the next was highly correlated (see chapter 3 for details; AMA I r > 0.85 and MSP2 r > 0.62, all
p<O.OOl Spearman Rank); not all younger children exhibited this similarity in antibody responses
to the AMA I and MSP2 variants over the study period. Antibody profiles to AMA I (W2mef,
HB3, 23D7) and MSP2 (307, FC27) variants in a selection of children were plotted and only a few
displayed profiles which clustered according to the antigens (Figures 4.3-4.5).
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Figure 4.3 Longitudinal antibody (lgG) responses to merozoite for selected individuals between the
ages of 0 and 2 years at the start of the study. Each line on the plots represents the antibody levels
corresponding to a single antigen. Dark blue - MSP2(3D7), red - MSP2(FC27), green - AMA I(W2met),
yellow - AMAI(HB3), light blue - AMA 1(307).
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Figure 4.4 Longitudinal antibody (lgG) responses to merozoite for selected individuals between the
ages of 2 and 5.5 years at the start of the study. Each line on the plots represents the antibody levels
corresponding to a single antigen. Dark blue - MSP2(3D7), red - MSP2(FC27), green - AMA I(W2met),
yellow - AMA I(HB3), light blue - AMA I(307).
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Figure 4.5 Longitudinal antibody (lgG) responses to merozoite for selected individuals between the
ages of 6 and 7.5 years at the start of the study. Each line on the plots represents the antibody levels
corresponding to a single antigen. Dark blue - MSP2(3D7), red - MSP2(FC27), green - AMA I(W2met),
yellow - AMA I(HB3), light blue - AMA I(307).
Most children who were 0-2 years at the start of the study exhibited antibody responses that were
very similar to both AMA I and MSP2 throughout the study period with responses to a single
antigenic variant sometimes differing considerably from the other responses (Figure 4.3C-4.3D).
Similarities in the antibody response to variants of the same antigen exhibited in concert with
differences between antigens were seen in children who were older than 2 years of age at the start
of the study period (Figure 4.4A-4.4C and 4.SB-4.SC). Antibody responses that were similar for all
the antigens tested were also commonly seen in older children.
Even with what appear to be relatively stable antibody levels in many children when plotted
individually (Figure 4.1), there was a significant overall decline in antibody levels over the study
period within the study population (Figure 4.6). Though AMA I (W2mef) showed a slight increase
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in mean antibody levels from May 2002 to October 2003, this increase was not maintained and
antibody levels had declined to a point comparable to those of AMA I (HB3) by October 2003. The
multivariate test of differences (MANOVA repeated measures) in antibody levels between cross-
sectional bleeds using the Wilks Lambda criteria showed statistically significant differences in
mean antibody levels over the study period for AMA 1(W2mef) (Wilks Lamba statistic = 0.63,
p<O.OOI), AMAl(HB3) (Wilks Lambda statistic = 0.73, p<O.OOI), AMAl(3D7) (Wilks Lambda
statistic = 0.71, p<O.OOI), MSP2(3D7) (Wilks Lambda statistic = 0.73, p<O.OOl), and MSP2(FC27)
(Wilks Lambda statistic = 0.76, p<O.OOI). Each of the F-ratio transformations of the Wilks criteria
was exact.
Mean smoothed Ab levels
- MSP2 3D7 -- MSP2 FC27 - AMA1 W2mef
- AMA1 HB3 - AMA 3D7
Lowess smoothing
Figure 4.6 Mean antibody (IgG) titres to merozoite antigens over the study period. Plots were created
using locally weighted scatter plot smoothing (LOWESS) with all the samples in the study. Each line on the
plots represents the antibody levels corresponding to a single antigen. Dark blue - MSP2(3D7), red -
MSP2(FC27), green - AMA I(W2mef), yellow - AMA I(HB3), light blue - AMA I(3D7).
To quantify the change in antibody levels over the study period, univariate GEE (generalised
estimating equation) with exchangeable correlation structure was carried out with sample time as
the dependent variable. GEE was used because it takes into account the inherent correlation
(autocorrelation) between measurements carried out on the same subject repeatedly. Each
successive sample time was associated with a significant decline in antibody levels of 0.06 for
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AMA I(W2mef), 0.03 for AMAI (HB3), 0.02 for AMA 1(3D7) and MSP2(FC27), and 0.04 for
MSP2(3D7) (all p<O.OOI)(Table4.2).
Table 4.2 Changes in antibody responses to AMAI and MSP2 in Ngerenya.
P(95%CI)' p
AMA1(W2mef) -0.06 (-0.07, -0.05) <0.001
AMA1(HB3) -0.03 (-0.04, -0.02) <0.001
AMA1(3D7) -0.02 (-0.03, -0.01) <0.001
MSP2(3D7) -0.04 (-0.05, -0.03) <0.001
MSP2(FC27) -0.02 (-0.03, -0.01) <0.001
J::!Qlli
Univariate leneralized estlmatlne equation (GEE) with exchangeable correlation structure.
'Reduction In antibody levels at each cross sectional bleed over the entire study period.
This decline in antibody levels appears to parallel the decline in malaria transmission from 17% to
4% parasitaemia between May 2002 and October 2004. Analysis of median IgG levels at each
cross sectional bleed compared to those during the May 2002 sampling showed that by October
2004 the median IgG responses to AMAI (W2mefand 3D7) were 30% and 33% of those in May
2002, and for AMA 1(HB3) it was 7% of that in May 2002 (Table 4.3). This is in contrast to the
median response to MSP2 (3D7 and FC27) which were 34% and 57% of the May 02 levels
respectively. The single noticeable increase in median responses during the entire period of the
study was observed between May and October 2002 when the median IgG response to
AMA 1(W2mef) increased over 450%. Responses to other AMA 1 variants were roughly the same
over this period. Generally the trend was towards declining antibody responses with intervals of
stability midway through the study period with most of the decline occurring over the final year of
the study (Table 4.3).
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Table 4.3 Changes in median IgG responses to AMAI and MSP2 compared to the baseline cross
sectional bleed.
Proportional change in median antibody levels compared to May 2002 (n=308)
AMA1(W2mef) AMA1(HB3) AMA1(3D7) MSP2(3D7) MSP2(FC27)
October 2002 (294) 4.86 1.09 0.92 0.39 0.85
May 2003 (293) 0.64 1.19 0.98 0.44 0.93
October 2003 (299) 0.86 0.52 1.06 0.61 1.03
May 2004 (299) 0.52 0.56 0.61 0.35 0.79
October 2004 (302) 0.30 0.07 0.33 0.34 0.57
Notes
Difference in median IgG responses compared to responses during the May 2002 cross sectional bleed.
4.3.2 Longitudinal patterns of IgG responses to merozoite antigens do not increase in
magnitude with increasing age
Children were divided into three age groups defined by their age at the start of the study period
(May 2002); 0-2 years, 3-5 years, and 6-7 years. Antibody levels to all five antigens were plotted
individually for each child who was present at all six sample times (Figures 4.7 and 4.8; Appendix
2 Figures 2-4). Antibody responses to all three AMA I variants were similar in the different age
groups. All three age categories contained children who exhibited low antibody levels throughout
the study period. Contrary to expectations and already noted in Figure 4.1, none of the children
exhibited an overall increase in antibody levels regardless of their age at the start of the study.
Those children who were 3-5 years of age at the start of the study exhibited more fluctuating IgG
responses to AMAI than the 0-2 year aids (Figure 4.78; Appendix 2, Figures 2B and 38). Within
the highest age category there appeared a group of children with consistently high antibody levels
to AMAI throughout the study period (Figure 4.7C; Appendix 2, Figures 2B and 38). High
antibody responses that were maintained over the study period were not as prevalent with regards
to MSP2, even in the highest age category (Figure 4.8C; Appendix 2, Figure 4C). Most children in
this age category actually exhibited very low antibody responses to both MSP2 variants. Similar to
the response to AMA 1, there were a number of children with widely fluctuating antibody responses
to MSP2 in the 3-5 year age category, though like their older counterparts most had a low antibody
response (Figure 4.88; Appendix 2, Figure 48).
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AAMA 1(W2mef) 0-2 years in May 2002
on
N
c
AMA1(W2mef) 6-7 years in May 2002
B
AMA 1(W2mef) 3-5 years in May 2002
PreMnt In 6 conseelfive bleeds, n=81
Figure 4.7 Longitudinal antibody (lgG) responses to AMA1(W2mef) for children present at all sample
times. Each line represents an individual. Plots grouped by age of the child at the start of the study. (A) 0-
2 years, (8) 3 - Syears, (C) 6 - 7 years.
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Figure 4.8 Longitudinal antibody (lgG) responses to MSP2(3D7) in children present at all sample
times. Each line represents an individual. Plots grouped by age of the child at the start of the study. (A) 0-
2 years, (B) 3 - 5years, (C) 6 - 7 years.
To better understand the effect of age on anti-AM A 1 and anti-MSP2 antibodies, mean antibody
levels were plotted for each of the three age categories using LOWESS smoothing techniques and
differences in antibody levels throughout the study period were analysed by GEE (Figure 4.9,
Table 4.4). Antibody levels to all merozoite antigens tested were highest in children who were 6-7
years at the start of the study followed by those in 3-5 year olds with the youngest children
maintaining the lowest antibody levels throughout the study period. Though the children were
getting older - with the 0-2 year olds being up to 4 years old in October 2004 and those who were
3-5 years in May 2002 being 7 years old at the end of the study - none of the antibody responses
showed an increase with age over the study period. The increase in antibody levels with increasing
age grouping was significant for all antigens (GEE: p<O.OO1). Antibody levels increased from one
age group to the next on average by 0.39 OD units (95% Cl: 0.30, 0.48) for AMA I(W2mef)
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(Figure 4.9A), 0.35 OD units (95% Cl: 0.26, 0.43) for AMAl(HB3) (Figure 4.9B), 0.33 OD units
(95% Cl: 0.25, 0.40) for AMA 1(307) (Figure 4.9C), 0.22 OD units (95% Cl: 0.15, 0.29) for
MSP2(3D7) (Figure 4.90), and 0.22 OD units (95% Cl: 0.15, 0.28) for MSP2(FC27) (Figure
4.9E). Exclusion of those children without detectable parasitaemia at any of the cross sectional
bleeds did not affect the pattern described.
Comparison of differences in antibody levels in the two older age groups with the youngest
children showed a significant increase (GEE: p~0.005) in antibody levels of up to 0.79 (95% Cl:
0.62,0.97) between 0-2 year olds and 6-7 year olds for AMA 1(W2mef) (Table 4.4). The effect of
age on anti-MSP2 antibodies was of a lower magnitude but still significant; there was an increase
of 0.45 OD units (95% Cl: 0.31,0.58) in 6-7 year olds compared to 0-2 year olds.
Table 4.4 The effect of age on IgG responses to AMAI and MSP2
Age group' ~(9S%CI)' P·value
AMA1(W2mef) 3-5 years 0.33 (0.18, 0.48) <0.001
6-7 years 0.79 (0.62, 0.97) <0.001
AMA1(HB3) 3-5 years 0.29 (0.15, 0.43) <0.001
6-7 years 0.71 (0.54, 0.88) <0.001
AMA1(3D7) 3-5 years 0.23 (0.1, 0.36) 0.001
6-7 years 0.68 (0.52, 0.84) <0.001
MSP2(3D7) 3-5 years 0.22 (0.11, 0.33) <0.001
6-7 years 0.44 (0.31, 0.57) <0.001
MSP2(FC27) 3-5 years 0.16 (0.05, 0.27) 0.005
6-7 years 0.45 (0.31, 0.58) <0.001
Notes
Unlvarlate generalized estimating equation (GEE)with exchangeable correlation structure (n=299).
eAle group during May 2002 sample time.
IGEE resression coefficients indicating reduction/increase in the antibody response compared to children age 0-2 years.
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Figure 4.9 Mean antibody (lgG) titres to merozoite antigens over the study period. Plots were created
using locally weighted scatterplot smoothing (LOWESS) with all the samples in the study. Each line on the
plots represents the antibody levels corresponding to an age grouping at the start of the study; 0-2 years
(blue), 3-5 years (red), 6-7 years (green). (A) AMA I(W2mef), (B) AMA 1(HB3), (C) AMA I(307), (D)
MSP2(3D7), (E) MSP2(FC27).
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4.3.3 Concurrent parasitaemia at sampling positively influences the longitudinal IgG
response patterns to merozoite antigens
The previous chapter reported that concurrent parasitaemia at sample time had a significant
positive effect on antibody levels to all the merozoite antigens tested. In order to investigate the
effect of concurrent parasitaemia longitudinally, study participants were divided into three groups
that identified their parasitaemic status at sample times over the study period. For this analysis.
categorization only included those children present at all six cross-sectional sample times. The
groups are as follows: (i) never parasitaemic at sample time (n=11 5), (ii) concurrent parasitaemia
once (n=47), and (iii) concurrent parasitaemia more than once (n=24). The mean antibody levels
throughout the study period were plotted using LOWESS smoothing techniques and a clear pattern
became evident for all the antigens tested. All those children who had recurrent concurrent
parasitaemia (group iii) had significantly higher antibody titres throughout the study period and
those without concurrent parasitaemia at any sampling point consistently exhibited the lowest
antibody titres (Figure 4.10). The increase in antibody levels with from one group to the next was
significant for all antigens (GEE: p<0.001). Antibody levels increased by 0.41 OD units (95% Cl:
0.33, 0.49) for AMAl(W2met) (Figure 4.l0A), 0.39 OD units (95% Cl: 0.31, 0.47) for
AMAl(8B3) (Figure 4.10B), 0.35 OD units (95% Cl: 0.28,0.42) for AMA1(3D7) (Figure 4.10C),
0.34 OD units (95% Cl: 0.28, 0.39) for MSP2(3D7) (Figure 4.10D), and 0.33 OD units (95% Cl:
. 0.27, 0.38) for MSP2(FC27) (Figure 4.1OE).
Compared to those without concurrent parasitaemia, recurrent parasitaemia was associated with
significantly increased antibody levels by up to 0.9 OD units (95% Cl: 0.71, 1.08; P<O.OOI, GEE)
for AMAl(W2met) and 0.82 OD units (95% Cl: 0.70, 0.93; p<O.OOI,GEE) for MSP2(3D7) (Table
4.5).
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Figure 4.10 Mean antibody (lgG) titres to merozoite antigens over the study period. Plots were created
using locally weighted scatterplot smoothing (LOWESS) with all the samples in the study. Each line on the
plots represents the antibody levels corresponding to the number of times concurrent parasitaemia was
recorded at sample time; never parasitaemic (blue), concurrent parasitaemia at one sample time (red),
concurrent parasitaemia more than once (green). (A) AMA I(W2mef), (8) AMA 1(HB3), (C) AMA I(3D7),
(D) MSP2(3D7), (E) MSP2(FC27).
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Table 4.5 The effect of concurrent parasitaemia on IgG responses to AMAI and MSP2
Concurrent parasltaemlaA p (95%CI)' P-value
AMA1(W2mef) Once 0.29 (0.15, 0.43) <0.001
Recurrent 0.9 (0.71, 1.08) <0.001
AMA1(HB3) Once 0.3 (0.17, 0.43) <0.001
Recurrent 0.84 (0.67, 1.02) <0.001
AMA1(3D7) Once 0.25 (0.12, 0.38) <0.001
Recurrent 0.77 (0.6, 0.93) <0.001
MSP2(3D7) Once 0.12 (0.04, 0.21) 0.006
Recurrent 0.82 (0.7,0.93) <0.001
MSP2(FC27) Once 0.14 (0.05, 0.24) 0.003
Recurrent 0.78 (0.66, 0.9) <0.001
Notes
Univariate generalized estimating equation (GEE) with exchangeable correlation structure (n=398).
"Number of times with recorded concurrent parasitaemia at sampling times during the study.
'GEE regression coefficients indicating reduction/increase in the antibody response compared to children without any recorded concurrent parasitaemia at sampling times.
As the groupings described above did not take into account whether the children were exposed to
P. falciparum in the six month intervals between blood sampling; it was clear that a definition that
included interval exposure would be necessary to further understand the effects of parasitaemia on
longitudinal antibody responses. Weekly surveillance of all study participants allowed for most, if
not all instances of exposure to be recorded as identified by a positive slide (a blood smears was
carried out if the child had a temperature greater than 37 .5°C, or reported a fever or being unwell).
When the earlier categories of concurrent parasitaemia (never, once, recurrent) were investigated it
was clear that a considerable amount of P. falciparum exposure was happening even in the group
that never exhibited concurrent parasitaemia at sample time. The total number of recorded
episodes of parasitaemia in the intervals throughout the study period ranged from 0 to 8. Of the
total 392 children who were enrolled in the study at different times, 51.3% (201/392) of the
children did not have any recorded parasitaemia in the intervals between sampling times
throughout the study period (Table 4.6). Of these children 85.1% (171/201) were categorized as
never having any concurrent parasitaemia at sample time. 9% (18/201) of these children had
concurrent parasitaemia only once and 6% (12/201) of those who had recurrent concurrent
parasitaemia didn't experience any recorded parasitaemia in the intervals. Within each of these
three categories the proportion of children with one or more parasitaemic episodes in the intervals
was high in the group of children with concurrent parasitaemia once (76.9%) and those with
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recurrent concurrent parasitaemia (70%). These proportions contrasted with that in the group of
children who never had detectable parasitaemia at cross sectional bleeds or in the intervals of
which 37.6% had recorded parasitaemia in the intervals (Table 4.6). Thus even in the group of
children without concurrent parasitaemia had experienced one or more recorded parsitemic
episodes during the intervals. This data regarding the total number of recorded parasitaemic
episodes during the study was used along with the concurrent parasitaemia data to categorise the
children according to their overall P. falciparum exposure. The groupings were as follows: (i) No
recorded exposure, (ii) recorded exposure during the intervals only, (iii) exposure during the
intervals and at sampling time, and (iv) recorded exposure at sample time only.
Table 4.6 Number of parasitaemic episodes experienced by children in the intervals categorised by
concurrent parasitaemia at cross sectional bleeds
Parasltaemlc episodes'
Concurrent parasitaemia at sample time, percent (n)
o
Never Once Recurrent
62.4 (171) 23.1 (18) 30 (12)
13.9 (38) 9(7) 37.5 (15)
8.4 (23) 18 (14) 12.5 (5)
4 (11) 15.4 (12) 7.5 (3)
5.5 (15) 16.7 (13) 5 (2)
3.7 (10) 9(7) 2.5 (1)
1.1 (3) 5.1 (4) 0(0)
0.4(1) 2.6 (2) 2.5 (1)
0.7(2) 1.3 (1) 2.5 (1)
4
6
Notes
IJ.Total number of parasitaemic episodes during the entire study recorded during weekly surveillance.
The risk of experiencing a parasitaemic episode in the intervals showed that children who had
concurrent parasitaemia once (RR = 1.95, 95% Cl: 1.65 - 2.30) and recurrently (RR = 1.51, 95%
Cl: 1.20 - 1.90) were at a significantly higher risk (p<O.OOI) of parasitaemia throughout the study
period than those who did not have any concurrent parasitaemia at time of sampl ing. When median
IgG responses at a single bleed (October 2002) were analysed by both age and the number of times
they had detectable concurrent parasitaemia at sampling, those with concurrent parasitaemia once
or recurrently showed an increase in antibody responses with age (Appendix 2, Table 4 and 5).
Median IgG responses to AMA I and MSP2 were higher in the oldest children with recurrent
parasitaemia when compared to their peers who had only one instance of concurrent parasitaemia
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(p ~ 0.05, Wilcoxon rank sum) (Appendix 2, Table 4 and 5). These differences were only apparent
when all the samples were analysed together only when children who were aparasitaemic during
the October 2002 cross sectional bleed were considered.
Longitudinal plots of mean antibody responses within these groupings showed that those children
without exposure during the study period had consistently low antibody levels to all the merozoite
antigens tested (Figure 4.11). Those with exposure recorded during the intervals only had slightly
higher antibody titres than those without any recorded exposure. The highest antibody responses to
both AMAI and MSP2 were seen in children who were parasi .... ic only at sample time (Figure
4.11). Investigation into the difference in antibody levels throughout the study period by GEE in
different exposure categories showed that antibody levels to both MSP2(3D7), AMA 1(W2met) and
AMA 1(307) were no different in the group without exposure and the group with exposure only
during the intervals (Table 4.7). Only in the case of anti-AMAl(HB3) antibodies was a significant
increase of0.13 OD units (95% CI:O, 0.26; p=O.OS) over the study period in the group with interval
exposure only compared to that without any recorded exposure. Antibody responses to all the
antigens were significantly higher (p<O.OOl) over the study period when individuals had concurrent
parasitaemia regardless of their exposure to P.falciparum in the intervals (Table 4.7).
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Figure 4. J J Mean antibody (lgG) titres to merozoite antigens over the study period. Plots were created
using locally weighted scatterplot smoothing (LOWESS) with all the samples in the study. Each line on the
plots represents the antibody levels with regards overall recorded P. falciparum exposure throughout the
study; no exposure (blue), exposure during the intervals only (red), exposure during the intervals and at
sample time (green), exposure at sample time only (yellow). (A) AMA I(W2mef), (B) AMA I(HB3), (C)
AMA1(307), (D) MSP2(3D7), (E) MSP2(FC27).
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Table 4.7 The effect of recorded Pi falciparum on IgG responses to AMAI and MSP2
Exposure levell p (95% Cl)' P_value4
Intervlls onty 0,1 (-0,04, 0.25) 0,152
Intorvlls Ind X-Bleed 0.51 (0,36, 0,66) <0.001
X-Blood only 0,67 (0.43, 0,9) <0.001
Intervals only 0,13 (0, 0,26) 0.05
Intervals and X-Bleed 0.51 (0,37, 0,65) <0.001
X-Bleed only 0,64 (0,42, 0,86) <0.001
Intervals only 0,1 (-0,03, 0,22) 0.13
Intervills Ind X-Bleed 0.44 (0,31, 0,57) <0.001
X-BI.ed only 0.57 (0,36, 0.78) <0.001
Intervals only 0.08 (-0,02. 0.18) 0.097
Intervals and X-Bleed 0.36 (0.26, 0.46) <0.001
X-Bleed only 0.53 (0.37, 0.69) <0.001
Intorvlls only 0.1 (0, 0.2) 0.054
Intervals and X-Bleed 0.37 (0.27, 0.48) <0.001
X-Blood only 0.51 (0,34, 0.67) <0.001
AMA1(W2mef)
AMA1(H83)
AMA1(3D7)
MSP2(3D7)
MSP2(FC27)
Notes
Univariate generalized estimiltlne equation (GEE)with exchangeable correlation structure (n=389).
I Overall level of P./aJciporum exposure as indicated by recorded parasitaemia in the intervals and at cross sectional bleeds (X-bleeds),
IGEE regression coefficients indicatinl reduction/increase in the antibody response compared to children without P.jalciparum exposure .
• s-vatoes s 0,05 Indicated in bold type.
4.3.4 The sickle trait and alpha-thalassemia results in lower longitudinal antibody responses
to AMAI and MSP2
When the antibody responses to AMAI and MSP2 in HbAA (normal) and HbAS (sickle trait) were
plotted longitudinally, they revealed a pattern than had been alluded to in the cross-sectional
analysis in the previous chapter. Antibody levels were higher in HbAA individuals throughout the
study period (Figure 4.12). The sickle trait was associated with a reduction in antibody levels for
all the antigens tested of approximately 0.1 00 units for MSP2 variants and 0.2 OD units for
AMA I variants; these differences were statistically significant only for AMA I (Table 4.8).
Longitudinal plots of antibody levels in normal, heterozygous, and homozygous alpha-thalassemic
individuals revealed that the normal and heterozygous children had longitudinal antibody levels
that were very similar (Figure 4.13). In comparison, children who were homozygous for alpha-
thalassemia had visibly lowered antibody levels throughout the study period which declined in
concert with the reduction in malaria transmission over the study period. Analysis by GEE
showed that there was no significant difference in antibody levels between the heterozygotes and
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normal individuals (Table 4.9). Being alpha-thalassemia homozygous was associated with
significantly reduced antibody responses by 0.2 OD units (p<0.05, GEE) for all three AMA I
variants tested. This significant reduction in antibody responses was also observed in the response
to MSP2(3D7) but of weak significance for MSP(FC27).
Table 4.8 The effect of sickle trait (HbAS) on IgG responses to AMAI and MSP2
~ (95% Cl)' P-valueA
AMA1(W2mef) -0.23 (-0.43, -0.04) 0.017
AMA1(HB3) -0.2 (-0.38, -0.02) 0.027
AMA1(3D7) -0.19 (-0.36, -0.02) 0.031
MSP2(3D7) -0.05 (-0.19, 0.08) 0.4S2
MSP2(FC27) -0.1 (-0.24, 0.03) 0.132
Notes
Univariate generalized estimating equation (GEE) with exchangeable correlation structure (n=355).
'GEE regression coefficients indicating reduction/increase in the antibody response compared to children without the sickle trait (HbAA).
boP-values S 0.05 indicated in bold type.
Table 4.9 The effect of alpha-thalassemia on IgG responses to AMAI and MSP2
Alpha-thalassemia ~ (95% Cl)' P_valueb.
AMA1(W2mef) Heterozygous .Q.03 (.Q.18, 0.12) 0.656
Homozygous .Q.24 (.Q.43, -0.04) 0.016
AMA1(HB3) Hete razygous .Q.06 (.Q.2, O.OS) 0.377
Homozygous -0.23 (.Q,42, -0.05) 0.012
AMA1(3D7) Heterozygous .Q.04 (.Q.17, 0.09) 0.565
Homozygous .Q.21 (.Q.3S, -0.04) 0.017
MSP2(3D7) Heterozygous .Q.06 (-0.16, O.OS) 0.276
Homozygous -0.16 (-0.29, -0.02) 0.024
MSP2(FC27) Heterozygous .Q.Ol (.Q.12, 0.09) 0.S32
Homozygous .Q.13 (.Q.26, 0.01) 0.062
Notes
Univariate generalized estimating equation (GEE) with exchangeable correlation structure (n=349).
:GEE regression coefficients indicating reduction/increase in the antibody response compared to normal children.
s-velues s 0.05 indicated in bold type.
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Figure 4.12 Mean antibody (lgG) titres to merozoite antigens over the study period in "bAA and
HbAS chidren. Plots were created using locally weighted scatterplot smoothing (LOWESS) with all the
samples in the study. Each line on the plots represents the antibody levels with regards to sickle trait; normal
(blue), and sickle trait (red). (A) AMAI(W2mef), (B) AMAI(HB3), (C) AMAI(3D7), (D) MSP2(3D7), (E)
MSP2(FC27).
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Figure 4.13 Mean antibody (lgG) titres to merozoite antigens over the study period in children with
and without alpha-thalassemia. Plots were created using locally weighted scatter plot smoothing
(LOWESS) with all the samples in the study. Each line on the plots represents the antibody levels with
regards to alpha-thalassemia; normal (blue), heterozygous (red), homozygous (green). (A) AMA 1(W2mef),
(B) AMA 1(HB3), (C) AMA 1(307), (D) MSP2(3D7), (E) MSP2(FC27).
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4.3.5 Age aDd recurreDt parasitaemia exert the greatest effects ODlongitudinal patterns of
JgG responses to merozoite antigens
Multivariable GEE was carried out to investigate the overall effect of all the factors discussed in
earlier sections on antibody levels to three AMAI and two MSP2 variants. For all three AMAI
variants, recurrent parasitaemia at sample time had the greatest positive effect (p<O.OOI,GEE) on
antibody levels followed by being in the highest age category (6-7 years in May 2002) (P<O.OOI,
GEE) (Table 4.10). Being a carrier of the sickle trait also significantly lowered antibody responses
to AMAI variants (p<O.OS,GEE). Though recorded parasitaemia in the six months prior to
sampling time was significantly associated with increased antibody levels (~ = 0.08 - 0.13;
p<O.OO1), its effect was not as great as that of concurrent parasitaemia at sample time (~ = 0.18 _
0.71; p<0.01).
With regards to antibody responses to MSP2, recurrent parasitaemia positively affected antibody
levels to a much greater extent than age (~ = 0.69 - 0.72; p<0.001 compared to ~ = 0.13 - 0.31;
p<0.001) (Table 4.11). Increasing age also led to higher antibody responses to both MSP2 variants
but only for MSP2(3D7) was it significant in children 3-5 years of age (p = 0.004). Both sickle
trait and malaria transmission had non-significant effects of similar magnitude on MSP2 as for
AMA whereas the effect of prior parasitaemia on anti-MSP2 responses was less, though
significant, when compared to AMA1.
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Table 4.10 Factors affecting anti-AMAI JgG responses throughout the study period
AMA1(W2mefj
AMA1(HB3)
AMA1(307)
Factor p (95% Cl)' P-value'"
Age (3-5 years) 0.26 (0.12, 0.4) <0.001
Age (6-7 years) 0.67 (0.5, 0.83) <0.001
Parasitaemic once 0.25 (0.1, 0.39) 0.001
Recurrent parasitaemia 0.71 (0.52, 0.91) <0.001
Sickle Trait -0.25 (-0.43, -0.07) 0.006
alpha -ThaI. Heterozygous 0(-0.14, 0.14) 0.968
alpha -ThaI. Homozygous -0.06 (-0.24, 0.12) 0.496
Prior Parasitaemia 0.08 (0.05, 0.11) <0.001
Age (3-5 years) 0.22 (0.09. 0.35) 0.001
Age (6-7 years) 0.59 (0.43, 0.75) <0.001
Parasitaemic once 0.23 (0.09, 0.37) 0.001
Recurrent parasitaemia 0.64 (0.46, 0.82) <0.001
Sickle Trait -0.2 (-0.37, -0.03) 0.019
alpha -ThaI. Heterozygous -0.03 (-0.16, 0.1) 0.657
alpha -ThaI. Homozygous -0.07 (-0.24, 0.1) 0.409
Prior Parasitaemia 0.13 (0.11, 0.15) <0.001
Age (3-5 years) 0.17 (0.04, 0.29) 0.007
Age (6·7 years) 0.57 (0.42, 0.72) <0.001
Parasitaemic once 0.18 (0.04, 0.31) 0.008
Recurrent parasitaemia 0.57 (0.4, 0.74) <0.001
Sickle Trait -0.18 (·0.34, ·0.02) 0.026
alpha -Thal, Heterozygous -0.01 (-0.13, 0.12) 0.896
alpha -ThaI. Homozygous -0.06 (-0.23, 0.1) 0.437
Prior Parasitaemia 0.12 (0.1, 0.15) <0.001
Notes
Multivariable generalized estimating equation (GEE) with exchangeable correlation structure, adjusted for changes in malaria transmission (n:287).
t GEE regression coefficients indicating reduction/increase in the antibody response.
I) s-velues S; 0.05 indicated in bold type.
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Table 4.11Factors affecting anti-MSP2 IgG responses throughout the study period
MSPZ(3D7)
Factor p (95% Cl)' P-value'"
Ac. (3-5 y.ars) 0.13 (0.04, 0.22) 0.004
Ac. (6-7 y•• rs) 0.3 (0.19, 0.41) <0.001
Parasit.lmic once 0.08 (-0.02, 0.17) 0.109
Recurrent parasitaemia 0.72 (0.59, 0.84) <0.001
Sickl. Trait -0.07 (-0.19, 0.05) 0.246
alpha -ThaI. Het.rozYlouS 0.02 (-0.Q7, 0.11) 0.626
aiph. -ThaI. HomolYlouS -0.02 (-0.14, 0.1) 0.792
Pr/or Parasitaemi. 0.08 (0.06, 0.11) <0.001
A" (3-5 veers) 0.07 (-0.03, 0.17) 0.158
AI' (6-7 veers) 0.31 (0.19, 0.43) <0.001
Parasltaemic once 0.07 (-0.03, 0.18) 0.174
Recurrent parasitaemia 0.69 (0.56, 0.83) <0.001
Sickle Trait -0.11 (-0.24, 0.02) 0.093
alpha -Thal. Heterozygous 0.06 (-0.04, 0.16) 0.24
alpha -Thai. Homozygous -0.01 (-0.13, 0.12) 0.937
Prior Parasitaemia O.OS (0.06, 0.1) <0.001
MSPZ(FC27)
Notes
Multlvarlable generalued estimating equation (GEE)with exchangeable correlation structure, adjusted for changes in malaria transmission (n=287).
t GEEregression coefficients Indicating reduction/increase In the antibody response .
• P-vaiues S 0.05 indicated in bold type.
4.3.6 Antibody responses to merozoite antigens are better maintained by older children in
the face of declining malaria transmission
With an overall decline in antibody responses over the study period, 1decided to investigate the
effect of the various factors described above on the maintenance/decay of IgG responses in the later
parts of the study when malaria transmission had fallen considerably. Parasite prevalence during
the May 2004 cross sectional bleed was 6.0% and dropped to 3_7% in October 2004. In the months
between sampling 98% of the children did not exhibit any detectable parasitaemia during the
weekly surveillance visits. GEE models were used to quantify the decline in antibody levels in
only those children who where sero-positive for the antigen tested in May 2004 and did not have
any detectable parasitaemia in the subsequent interval. In general, the decline in malaria
transmission resulted in a reduction of antibody levels of around 0.2 OD units for anti-AMA 1
responses and 0.3 OD units for anti-MSP2 responses (Tables 4.12 and 4.13; Appendix 2, Tables 1-
3). Univariate analysis indicated that the youngest children (0-2 years) had the greatest reduction
in antibody levels to both AMA1(W2mef) (0.50 OD units, p=0.005) (Table 12) and MSP2(3D7)
(0.91 OD units, p<O.OOI) (Table 4.13). This was also the case for the other AMA I and MSP2
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variants tested (Appendix 2, Tables 1-3). Conversely, the oldest children (6-9 years) better
maintained their antibody levels to both AMA 1 and MSP2 (p<O.OS) (Table 4.12 and 4.13;
Appendix 2, Tables 1-3). It was only the 6-9 year olds who maintained their antibody responses to
AMA 1 variants at significantly higher levels compared to 0-2 year-olds (p<O.OS) (Table 4.12;
Appendix 2, Tables 1 and 2). This was not the case for the antibody responses to MSP2 variants
(Table 4.13; Appendix 2, Table 3).
Table 4.12 Differences in the rate of anti-AMAI(W2met) IgG decay between May and October 2004
Antl·AMA1(W2mef) IgG
13(95%CI)' P-value4 N'
Sample time' -0.21 (-0.27, -0.15) <0.001 86
Age 0-2 years -0.5 (-0.85, -0.15) 0.005 8
Age 3-5 years -0.27 (-0.37, -0.17) <0.001 24
Age 6-9 years -0.15 (-0.22, -0.08) <0.001 54
Compared to 0-2 year olds
... Age 3-5 years 0.33 (-0.18, 0.84) 0.209 86
... Age 6-9 years 0.56 (0.08, 1.03) 0.021
HbAA (Normal) -0.22 (-0.29, -0.15) <0.001 74
HbAS (Sickle trait) -0.15 (-0.32, 0.02) 0.088 9
Compared to HbAA children
..... HbAS -0.19 (-0.64, 0.27) 0.421 83
Alpha-thalassemia NORM' -0.23 (-0.32, -0.15) <0.001 31
Alpha-thalassemia HET' -0.21 (-0.33, -0.09) <0.001 41
Alpha-thalassemia HOM' -0.11 (-0.15, ·0.07) <0.001 10
Compared to normal children
.... Alpha-thalassemia HET ·0.02 (-0.33, 0.28) 0.876 82
.... Alpha-thalassemia HOM -0.35 (-0.81, 0.11) 0.136
Notes
Univariate generalized estimating equation (GEE)with exchangeable correlation structure.
:GEE regression coefficients indicating reduction/increase in the rate of antibody decay between May and October 2004.
/.values:s 0.05 indicated in bold type.
Number of samples included in the model.
lChange in IgG response between May and October 2004.
2Alpha·thalassemia genotypes: NORM = normal, HET = heterozygous, HOM == homozygous.
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Table 4.l3 Differences in the rate ofanti-MSP2(3D7) IgG decay between May and October 2004
Antl-MSP2(3D7) IgG
P(9S" Cl)' P-valueA N'
Sample time' -0.34 (-0.52, -0.15) <0.001 32
Age 0-2 years -0.91 (-1.41, -0.41) <0.001 3
Age 3-5 years -0.56 (-1.07, -0.06) 0.030 7
Age 6-9 years -0.19 (-0.35, -0.02) 0.032 22
Compared to 0-2 year olds
... Age 3-5 years -0.34 (-US, 0.47) 0.412 32
... Age 6-9 years 0.06 (-0.66, 0.79) 0.863
HbAA (Normal) -0.41 (-0.58, -0.25) <0.001 27
HbAS (Sickle trait) 0.08 (-0.61, 0.76) 0.830 5
Compared to HbAA children
..... HbAS -0.32 (-0.9, 0.27) 0.286 32
Alpha-thalassemia NORM' -0.31 (-0.57, -0.05) 0.021 14
Alpha-thalassemia HEr -0.29 (-0.58, -0.01) 0.043 14
Alpha-thalassemia HOM' -0.27 (-0.57, 0.03) 0.083 3
Compared to normal children
.... Alpha-thalassemia HET -0.06 (-0.49, 0.38) 0.804 31
.... Alpha-thalassemia HOM -0.76 (-1.5, -0.02) 0.043
Notes
Univariateleneralized estimating equation (GEE)with exchangeable correlation structure.
'GEE re,rassion coefficients Indlcatl". reduction/Increase in the rate of antibody decay between May and October 2004.
'P..,alues S O.OSlndlcated In bold type.
'Number of samples Included in the model.
IChanl' in leG response between Mayand October 2004.
2Alpha-thalassemlilllenotypes: NORM = normal, HET == heterozygous, HOM = homozygous.
There was no difference in the decay rate of antibody responses to AMA I and MSP2 in children
with the sickle trait compared to those without the trait (Tables 4.12 and 4.13; Appendix 2, Tables
1-3). When analysed separately, children who were homozygous for alpha-thalassemia appeared to
maintain their antibody response to AMA 1 better (reduction of 0.08-0.11 OD units, P<0.05) than
normal (reduction of 0.17-0.23 OD units, p<O.OO1) or heterozygous children (reduction of 0.21-
0.23 OD units, p<O.OO1) (Table 4.12; Appendix 2, Tables I and 2). When this difference seen in
homozygous children was further analysed, it was not significantly different to the decay rates of
antibody responses to AMA I seen in normal children. Interestingly, children homozygous for
alpha-thalassemia had significant declines in their antibody response to MSP2(3D7) (P=0.043)
(Table 4.13) but not to MSP2(FC27) (Appendix 2, Table 3) when compared to normal children.
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4.4 Discussion
Longitudinal analysis of antibody responses to AMAI and MSP2 revealed three overall patterns:
(i) consistently high antibody responses, (ii) fluctuating antibody responses, and (ii) consistently
low antibody responses. A large proportion of the study participants had consistently low antibody
responses to both AMA I and MSP2. Children with consistently low IgG responses may have not
been exposed at sufficient levels to Plasmodium over the study period and therefore did not have a
measurable antibody response to the antigens tested. These children could also include a subgroup
of non- or poor-responders as a result of host genetic or other factors. An alternative explanation
could be that the sampling interval of six months could result in a loss of detection of significant
antibody responses due to short IgG half-life, as suggested in some studies. More children had
persistent antibody responses to AMA 1 above 2 OD units compared to the MSP2 antibody
response. In the analysis of cross-sectional data (chapter 3), an overall lower antibody response
was seen with regards to MSP2 compared to AMA 1. With these results in mind, it is not surprising
to observe a lower antibody response over the study period. As these are the same children, this
result may be indicating a relative lower immunogenic capacity of MSP2 compared to that of
AMA 1. AMA I is a structurally constrained antigen whereas MSP2 is not so these results may
indicate that the conformations adopted by the recombinant MSP2 antigen on the ELISA plate
could be less common than the conformations presented to the immune system in natural infection,
which would lead to less recognition of this antigen in the assay. As IgG responses to MSP2 were
tested at serum dilutions of I: 1000 as opposed to those to AMA 1 variants which were tested at
1:4000 dilutions, I am reasonably confident that the responses to MSP2 were genuinely of a lower
magnitude than those to AMAI. Both antigens were of high purity (J. Beeson and R. Anders,
personal communication) and were used to coat ELISA plates at a saturating concentration. The
higher IgG titres to MSP2(3D7) is likely to reflect a greater incidence of infections with isolates
having the MSP(3D7) allelic type compared to FC27. This is in agreement with a study carried
out in the same area that found type A msp2 alleles in 86.9% of asymptomatic infections in
children below the age of II years compared with 41.3% for type B msp2 alleles (Farnert et al.
2009).
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Antibody responses to merozoite antigens in endemic populations have been measured in other
studies and are generally reported to be short-lived in children (Fruh et al. 1991; Branch et al. 1998;
Cavanagh et al. 1998; Soareset al. 1999; Udhayakumar et al. 2001; Kinyanjui et al. 2007;
Akpogheneta et al. 2008; Biswas et al. 2008). Though the exact half life of anti-merozoite
antibodies is unknown. studies indicate a range of a week to 4 months (Kinyanjui et al. 2007;
Akpogheneta et al. 2008). The sampling framework in this study was approximately every 5-6
months which inevitably made it impossible to pick up fine trends in IgG boosting as suggested by
other studies (Branch et al. 1998; Cavanagh et al. 1998; Kinyanjui et al. 2007; Akpogheneta et al.
2008). However, findings from this cohort suggest that at least a proportion of children sustained
antibodies for several months after malaria transmission reduced substantially.
Antibody 'response rankings' within this study population were steadier with regards to AMA 1
compared to MSP2 as observed in the tracking plots (Figure 4.2). Most children appeared to
maintain their response (whether high or low) relative to others in the same age group though a
small number did have widely varying responses. Assuming that the population of circulating
parasites over the study period displayed all the antigens tested in comparable frequencies with
comparable exposure, one could infer that the increased prevalence of stable responses above the
cohort mean to AMA 1 could be indicative of higher AMA 1 immunogenicity and better
maintenance of the anti-AMAI response. Children were as equally able to mount an immune
response to AMAI as to MSP2 that was dependent on their overall 'responsiveness' and levels of
exposure. Though AMAlwas more immunogenic than MSP2 (eliciting higher IgG titres), the
study population was not predisposed to responding more to one merozoite antigen than the other.
That anti-AMA I IgG responses saturate faster in endemic populations and appear to be maintained
better than those to MSP2 has been noted in other studies (Udhayakumar et al. 2001; Drakeley et
al. 2005; Morais et al. 2006; Akpogheneta et al. 2008). When the responses to both AMAI and
MSP2 were investigated in selected children, the responses to AMA 1 and MSP2 tended to be
similar across variants in older children. Though not implicit, this could imply a trend towards
antibody responses to conserved epitopes on both AMAI and MSP2 as children get older, or that
greater exposure leads to the larger repertoire of antibodies to different antigens and their variants.
Some data suggests that a substantial component of antibodies to recombinant AMA I measured by
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ELISA is against conserved epitopes, whereas antibodies to MSP2 show a higher degree of allele-
specific reactivity (Stanisic et al. 2009). This has also been suggested by unpublished data by
Beeson J et al. Due to time constraints, it was not possible to address this issue in this thesis using
competition ELISAs with different alleles or other approaches.
At a population level, mean antibody levels to all five antigens tested declined over the study
period. These responses paralleled the decline in malaria transmission seen over the same period.
Antibody responses to AMA I(W2mef) increased from May 2002 before declining and reaching
levels comparable to those of the other two AMA 1 variants in October 2003. Though no data on
circulating parasites is available for this period, this antibody response may indicate an increase in
the frequency of parasites with this AMA I variant. There was an increase in the incidence of both
recorded parasitaemia and clinical disease in this area between May 2002 and May 2003 which
could possibly be due to new circulating parasite isolates that may have been carrying an AMA 1
variant similar to, if not the W2meftype. Whilst parasite frequencies cannot be determined simply
by examining antibody data, this data may give some insight into the circulating parasite strains as
seen in other longitudinal studies (Branch et al. 1998; Cavanagh et al. 1998; Giha et al. 1999).
Presently there is little data published on the sero-epidemiology of different alleles of AMA 1,
particularly with respect to understanding population exposure to different alleles. This knowledge
will be important for advancing vaccine development of AMA 1.
Individual plots of antibody levels showed more stability in the responses to all three AMA 1
variants as children aged compared to MSP2, although fluctuating antibody responses were still
observed in older children. These results were in agreement with two studies which showed
persistent and stable antibody responses to AMA 1 and MSP2 (Riley et al. 1993; Udhayakumar et
al. 2001). Though these prior studies were both carried out in adults, the results described here
show that a stable antibody response to AMA 1 can be detected over time from as early as 5 years
of age. The difference observed with MSP2 compared to AMA I could be due to both its relative
immunogenicity and the nature of the recombinant protein, as mentioned earlier. The mean
smoothed antibody patterns showed that older children always had higher antibody responses to
AMA I and MSP2 over time. This occurred without any noticeable increase over time in the mean
antibody responses exhibited by the younger children. All children showed a decline in antibody
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responses over the study period that implied a strong effect of malaria transmission, particularly for
the last year of the study. As cross-sectional studies show an increase in antibody responses with
age, we may expect some sort of positive trajectory in longitudinal antibody levels over time as
children get older. Although antibody responses to AMAI and MSP2 were indeed higher in older
children than younger ones, there was no increase in the antibody response of younger children
with time. This could indicate a lack of cumulative exposure as malaria transmission declined over
the study period and separated the effect of age from cumulative exposure which has not been
possible to quantify in cross-sectional studies. Only one study that measured anti-MSPI responses
in infants over their first year of life has also shown no change in the magnitude of antibody
responses with age (Branch et al. 1998). Children with the sickle trait as well as those homozygous
for alpha-thalassemia had consistently lower antibody responses than their normal counterparts
throughout the study period. This could also be an effect of the overall reduced exposure to
Plasmodium that was discussed in chapter 3.
Cross-sectional studies all show that concurrent parasitaemia at sampling time is associated with
higher antibody levels (AI-Yaman et a1. 1995; Bull et a1.2002; Metzger et al. 2003; Kinyanjui et al.
2004; Polley et al. 2006). This was also the case when analysed longitudinally. Children who had
concurrent parasitaemia more than once at sample time had higher antibody responses throughout
the study period compared to those with concurrent parasitaemia only once or never. These results
were further corroborated when investigation into recorded parasitaemia in the intervals was
carried out. Children who had recorded parasitaemia in the intervals and also had concurrent
parasitaemia once at the cross sectional bleeds were also the children with very high antibody
responses to both AMA1 and MSP2. The levels were only higher in those children who were
parasitaemic at more than one sample point though the difference was not statistically significant.
In the case of all antigens, higher exposure led to a higher antibody response. A limitation of the
study is that we may have missed some instances of exposure. During the weekly surveillance,
blood smears were only carried out when children had fever or a history of fever or other illness so
any asymptomatic parasitaemia - other than that caught at sample time - cannot be identified in
this analysis. Additionally, parasitaemia was only defined as detected by microscopy, which is
known to miss low level parasitaemias that are detectable by peR (Okell et al. 2009). One could
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argue that this is not a problem as only those instances that have led to a child mounting a
significant immune response (fever being an indication of an active immune response) nteans that
the particular incident of exposure is important and is probably the type that would result in
measurable antibody responses, though we cannot rule out the contribution of sub-patent
parasitaemia to antibody induction. On the other hand asymptomatic parasitaemia could be
reflective of effective humoral and cellular immune function. In this particular case, significant
antibody responses were only detected when parasitaemia was actually present (at sample time as
well as the intervals) which could indicate that longitudinal antibody responses give an overall
indication of levels of exposure. The finding that the factor with the greatest effect on antibody
levels to AMA I and MSP2 was concurrent exposure, as well as the fact that children with
concurrent parasitaemia were 1.5 times more likely to be parasitaemic in the intervals adds to the
evidence that antibody levels are a marker of exposure. These results are comparable to those seen
in a study which found that those children who were parasitaemic at baseline went on to experience
more instances of parasitaemia over the study period (Polley et al. 2004; Akpogheneta et al. 2008).
The finding that children with concurrent parasitaemia were also more likely to have parasitaemic
episodes in the intervals is in agreement with published data on this population which showed that
20% of the children had (those parasitaemic at cross-sectional bleeds) experienced 56% of all
malaria episodes (Mwangi et al. 2008).
With the apparent decline in malaria globally, it is important to understand how this affects the
acquisition and maintenance of antibodies, and there is considerable interest in this question in the
field. The extended duration of this cohort and repeated sampling provided important early insights
into the potential effects of declining malaria on the acquisition and maintenance of responses that
are believed to playa role in immunity. As the incidence of malaria and prevalence of P.
falctparum infections declined in the latter part of the study, there was a reduction in the levels and
prevalence of antibodies to all three AMA I variants and the two MSP2 alleles. By October 2004,
the prevalence of antibodies to AMAI had declined to 36.1% (W2mef), 35.8% (HB3), 34.1%
(307) and those to MSP2 to 8.9% (307) and 8.6% (FC27) , compared to 45.5%, 48.1 %, 43.2%,
28.6%, and 23.1% respectively in May 2002. The difference in the prevalence and levels of
antibodies at the start compared to the end of the study was particularly evident among young
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children. Although there was a lengthy period between cross sectional bleeds, it is possible to make
broad comparisons and quantification in the rate of decay of IgO responses to AMA 1 and MSP2.
The results here showed that anti-MSP2 antibodies declined at a higher rate than those to AMA 1
which is in agreement with a recent study carried out in The Gambia on children less than 6 years
of age (Akpogbeneta et al. 2008). In agreement with the study mentioned, the rate of anti-AM A 1
(gO decay was lower in older children but this was not the case for anti-MSP2 antibodies. These
results point both to differential effects of age on antibody decay and antigen-specific effects. The
fact that antibody responses to AMA 1 and MSP2 were maintained at significantly higher levels in
older children throughout the study duration gives further support to an independent effect of age.
Older children may have a larger population of long-lived plasma B cells which is in agreement
with the fact that both T-helper cell function and antigen presentation increases with age in children
(Clerici et al. 1993). Akpogheneta et al suggested that the tandem repeated epitope sequences in
MSP2 (which AMAI does not contain) could reduce the effectiveness of MSP2 to induce B cell
memory responses.
A number of limitations of this study are (i) the long periods between cross sectional bleeds, (ii) the
lack of isolate typing, and (iii) the possibility that a number of episodes of P. falciparum exposure
could have been missed in the intervals due to the inclusion criteria for blood smears. Only those
children with fever or with a history of fever in the last week had blood smears made. This means
that we may have missed a considerable number of asymptomatic episodes over the 2. 5 years of
this study. A major strength of this study was the dynamic shift of malaria transmission in the
study area. Without the effects of continuous infection (or superinfection) which is found in areas
of high transmission, it was possible to investigate the acquisition of anti-merozoite antibodies in a
situation that may be very relevant to the emerging malaria epidemiology in Africa today. Falling
malaria transmission rates along with increased use of bednets across the continent has led a
significant decline in the incidence of malaria (Bhattarai et al. 2007; Fegan et al. 2007; Okiro et al.
2007). Though the predicted effect of this decline on acquisition to malaria is a corresponding
decline in the immunity to malaria in endemic populations, it has yet to be presented in detail. To
my knowledge, this study is the first to do so during the time when children are actively acquiring
immunity to Plasmodium.
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Antibody levels are dynamic outcomes that are dependent on a number of changing factors. Cross-
sectional studies attempt to assign a static category of responsiveness according to antibody levels
measured at baseline. This study has used established statistical methods to quantify the amount of
change occurring over time which is a truer representation of an individual's immune response to
malaria. An important question that this study addresses is whether antibody responses measured
at a single time point sufficiently capture enough information to assess an individual's antibody
responsiveness or immune status compared to longitudinal measurement. Antibody responses to
merozoite antigens (MSPI and MSP2) at a single time point have been suggested to reflect age-
related cumulative exposure over an extended period, although it was acknowledged that this may
not be the case for highly immunogenic antigens such as AMA 1 (Drakeley et al. 2005). Indeed, the
present study suggests that antibody responses to AMA 1 in children may be highly indicative of
recent exposure and parallel ongoing changes in malaria transmission. The observation that mean
anti-AMA 1(W2met) antibodies increased in the population when there was a higher incidence of
malaria, and then declined with decreasing transmission, supports this theory.
Studies of protection from clinical disease in association with antibody levels give conflicting
results. For some, antibodies are associated with protection, whereas for others it is not the case.
These results may be due to the fact that the groupings used - high or low responders, tertiles,
parasitaemic or aparasitaemic - are each made up of individuals with varying amounts of exposure
and responsiveness. The antibody levels at a single time point are affected by not only age and
concurrent parasitaemia, but also by the prior exposure and their prior antibody responses. Low
antibody levels could be due to a lack of exposure or an appropriate immune response (humoral
and cellular) sometime in the past which has led to control of parasitaemia to levels that don't
activate a high antibody response. This study found that children with more exposure maintained
high antibody responses to merozoite antigens which fell as malaria transmission declined.
Increasing age and parasitaemia at a sampling were also associated with higher antibody responses.
Malaria transmission appeared to have a great effect on the antibody response as the younger
children in the cohort failed to mount increasing antibody responses as they aged. The association
of these antibody responses with protection against malaria will be assessed in the following
chapter.
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5 The association of anti-merozoite antibody responses
with protection from clinical malaria
5.1 Introduction
The inferred role of antibodies in protection against malaria in endemic settings has traditionally
been elucidated by the measurement of antibodies in serum at a single time point followed by
surveillance of study subjects over a period of time for incidence of malaria disease. These
association studies have been carried out in various settings examining antibody responses to
several different Plasmodium - predominantly merozoite - antigens. Published results often
conflict in their assessment of the protective capacity of antibodies to merozoite antigens in
protecting against clinical malaria. To date, most of the published data on the association of anti-
merozoite antibodies with protection against malaria is on MSPI. Antibodies to the C-terminal
(MSPI19 and MSPI42) and N-terminal regions (Kl-Iike, MAD20-like, and R033-like) have been
associated with protection against malaria in numerous studies (Riley et a1. 1992; Hogh et al. 1995;
AI-Yaman et al. 1996; Egan et al. 1996; Branch et al. 1998; Conway et al. 2000; Polley et al. 2003;
Cavanagh et al. 2004; Perraut et al. 2005; Dodoo et al. 2008; Osier et al. 2008; Stanisic et al. 2009).
This is not always the case; other studies have associated the same antibody responses with an
increased risk of malaria (Dodoo et al. 1999; Conway et al. 2000; Polley et al. 2003; Cavanagh et
al. 2004; John et al. 2005; Gray et al. 2007; Nebie et al. 2008; Osier et al. 2008). A recent
systematic review and meta-analysis of prospective cohort studies that investigated the protective
effects of antibody responses to merozoite antigens (AMA I, EBA 175, GLURP, MSPI, MSP2, and
MSP3) showed that antibody responses to MSP119 and the C-terrninus of MSP3 reduced the risk of
P. falciparum malaria by 18% and 54% respectively, and antibodies to AMA I were associated with
protection in most studies (Fowkes et al. 20 I0). In this meta-analysis, there was no significant
overall association of antibody responses to MSP2, full length MSP3, or N-terrninal regions of
MSPI with protection from malaria.
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Two studies carried out in the same part of Kenya provide evidence that antibodies to AMA 1 are
associated with protection. Anti-AMAI antibodies to the 307 and FVO variants were associated
with protection from clinical malaria in children and adults over 6 months of follow-up (Polley et
al. 2004). A later study on samples from the same area on children showed that high levels of
antibody reactivity was associated with a reduced risk of hospital admission over 8 months of
follow-up (Osier et at. 2008). Although antibodies to AMA 1 were predictive of protection in this
study; it was only when anti-AMA 1 antibodies were analysed in combination with those to MSP2
or MSP3 that the protection was significant. A similar result had also been obtained from a study
canied out in The Gambia where antibody reactivity to both AMA 1 and MSP2 in combination was
more predictive of protection (Gray et al. 2007). In a study with 4 months of follow-up that was
canied out on children aged 6 months to 15 years, total IgG responses to AMA1(FVO) were not
associated with protection against malaria yet IgG 1 responses to the same antigen were associated
with protection (Nebie et at. 2008). Though high levels of IgG to AMA 1 were also associated with
protection in a study performed in Papua New Guinea, the association with protection was
significant for 1803, but not J80 1 (Stanisic et at. 2009). Subclass responses to merozoite antigens
will be discussed in detail in the following chapter.
The earliest evidence of anti-MSP2 antibodies being associated with protection against malaria
came from studies in Papua New Guinea. High antibody levels to MSP2 were associated both
with fewer episodes of fever and less anaemia (AI-Yaman et al. 1994). A later study in the same
place showed that anti-MSP2 (307) antibodies were associated with a reduced risk of clinical
malaria in the subsequent year (AI-Yaman et al. 1995). In Kenya, high antibody levels to MSP2
were associated with protection from malaria over 28 weeks (Polley et al. 2006). Interestingly, a
single study showed an association with protection when high anti-MSP2 IgG3 antibodies were
present and an increased risk of malaria with high anti-MSP2 IgG 1 levels (Taylor et al. 1998)
whereas another study showed protection from clinical disease for both JgG1 and JgG3 responses
to MSP2 (Metzger WG et al, 2003). More evidence for the protective effect of anti-MSP2 total
IgG and JgG3 was seen in a study carried out in Senegal (Sarr et al. 2006). Another recent study
has also shown that anti-MSP2 antibodies were associated with a reduced risk of malaria but are
not associated with protection from re-infection per se (Stanisic et al. 2009).
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This chapter aims to investigate the association between antibody responses to merozoite antigens
and protection against malaria. Two representative merozoite antigens were selected for
investigation here; AMAI, which is located in the apical organelles and plays an important role in
invasion, and MSP2, which is an abundant merozoite surface antigen. Additionally, both antigens
are leading vaccine candidates. The malaria literature is generally in agreement that antibodies
contribute a large part of the natural defence against disease. A major issue has been the lack of
agreement on the protective effects of different antibody responses to malarial antigens.
Contradictory results between studies could be attributed to several factors including cohort and
antigen differences, malaria transmission, follow-up time, and analysis methods. Very few studies
have examined antibody responses over an extended period of time (such as over several seasons)
and analysed associations between antibodies and protective immunity using data from multiple
sampling points. Due to the extended longitudinal nature of this study, along with the changes in
malaria transmission described in previous chapters, this study provides a unique opportunity for
investigating the role of antibody responses in protection from malaria. As immunity to malaria
develops over time and is dependent on the malaria transmission intensity (Marsh and Kinyanjui
2006) this study will attempt to assess the acquisition of immunity under different malaria
transmission intensities. This will be done by first identifying factors other than antibody
responses that affect the risk of malaria and then two different methods will be used to analyse
whether antibody responses to AMAI and MSP2 may be protective in this cohort.
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5.1 Methods
S.2.1 Statistical Aaalysls
Two different analytical approaches were used to investigate the association between antibody
responses and protection from clinical malaria. The first utilised the data in a cross sectional cohort
format and analysed antibody responses at baseline with the risk of malaria on follow-up. The
second method investigated the association between antibody responses throughout the study with
the risk of malaria during the study. The results from these two analysis methodologies were then
compared. SignifICance was reached at the 0.05 level for all tests. P values ranging from 0.06 to
0.1 were considered as borderline significance, providing weaker evidence for the association being
examined.
5.1.1.1 RIsk aaalysis with crollscctional data format
In order to investigate whether the association between antibodies and risk of disease was
dependent on the time that sampling occurred, univariate and multivariate generalised linear
models (OLM) were used with data collected and antibody measurements at the May and October
2002 bleed times as well as those taken during the May 2003 bleeds. From October 2003 there
were no recorded episodes of clinical malaria in this cohort so antibody measures for samples
collected after the May 2003 bleed were not included in the analysis. Univariate analysis was first
carried out to assess the non-antibody factors that affected the risk of clinical disease. These
factors were age, concurrent parasitaemia, and haemoglobinopathies. Each was included in the
model in different ways. Age was a continuous variable, concurrent parasitaemia was coded as
both a binary variable (at sample time) and also as a categorical variable when it described an
individual's ongoing parasitaemic status over the study period (never parasitaemic, parasitaemic
once, and recurrent parasitaemia). Sickle trait was a binary variable and alpha-thalassemia a
categorical variable (normal, heterozygous, homozygous). As mentioned earlier, univariate
analysis was carried out on the May and October 2002 samples as well as the May 2003 samples.
It was then carried out on all the samples in the study using the same model but including a
clustering indicator that identified repeated sampling on the same individuals but ignored the
longitudinal nature of the sampling. Each antibody response was inputted into the model as a
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continuous variable. MuItivariable GLM analysis for the risk of a clinical episode was carried out
on the antibody responses for the May 2002 to May 2003 bleeds as well as for all samples and was
adjusted for age, concurrent parasitaemia, and haemoglobinopathies.
5.2.1.2 Risk analysis with longitudinal data format
The overall risk of a clinical episode of malaria in this study was assessed using Generalised
Estimating Equations (GEE) for 'count' outcome variables. GEE allow for the analysis of
longitudinal relationships using all available longitudinal data without summarizing the
longitudinal outcome into a single value. The GEE for 'count' outcomes is comparable to a
poisson regression analysis except that within-subject correlation is taken into account.
Exchangeable correlation structure which assumes that correlations between subsequent
measurements are assumed to be the same irrespective of the length of the time interval was used in
this case. Univariate GEE analysis on antibody responses and the non-antibody factors that may
affect the risk of clinical malaria was carried out followed by multivariable analysis on the adjusted
effect of antibody responses to AMA I and MSP2. Recently published results from a separate study
carried out in Kilifi has shown that removal of those individuals without any exposure strengthened
the protective effects of some malarial antigens against clinical disease (Bejon et a1. 2009). With
this in mind, I carried out the multivariable analysis on only those children who had recorded
exposure to Plasmodium over the study period (as indicated by a positive blood smear in during the
weekly surveillance or at sample time). All the antibody data obtained was included in the GEE
model and was inputted as a continuous variable.
5.3 Results
5.3.1 Factors affecting the risk of malaria six months post-sampling
In order to investigate the protective effects of antibody responses to AMA 1 and MSP2, this study
was divided into 6-monthly intervals based on the timing of cross-sectional bleeds. Protection was
assessed from each sample time for a period of six months until the next sampling, which is similar
to the approach that has typically been used in the literature (Fowkes et a1. 2010). Each sample
time was considered baseline with no regard being taken of antibody measures or exposure before
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each sampling &arne. From October 2003 no children in this cohort experienced any clinical
malaria due to dropping malaria transmission in the community. As the outcome was absent from
October 2003, only the first three sampling times were used in this analysis. In the six months post
sampling in May 2002 there were 29 episodes of malaria. Following the October 2002 cross
sectional bleed there were 156 episodes of malaria. This number fell to 78 episodes after the May
2003 cross sectional bleed.
Facton other than antibody responses that could affect the risk of clinical malaria were first
investigated using univariate models. For all three sampling times key demographic characteristics
remained the same. Females made up 44.5%, 44.4%, and 44.5% of the cohort respectively. The
mean and median ages at each sampling was; 3.8/3.7 years, 4.0/3.9 years, and 4.4/4.3 years
respectively. The only difference at each sampling time was the levels of malaria transmission
(inferred by the proportion parasitaemic at sampling); 51%, 21%, and 38%.
When examined at the three sampling times mentioned, key factors that are known to influence the
risk of clinical malaria had similar effects. Age had little or no effect on the risk of malaria in May
2002 (IRR 1.11, 95% Cl 0.93-1.32, p = 0.26), October 2002 (lRR 1.07, 95% Cl 1.00-1.15,P =
0.05), or May 2003 (IRR 1.02,95% Cl 0.93-1.12,p = 0.63) (Table 5.1). Concurrent parasitaemia
at time ofsampling at May 2002 (IRR 1.58,95% Cl 0.68-3.71,p = 0.29), October 2002 ORR 1.11,
95% Cl 0.63-1.96, p = 0.71) and May 2003 (IRR 0.99, 95% Cl 0.51-1.92, P = 0.98) had no
significant effect on the risk of malaria in the subsequent six months. At all three sampling times
the presence of the sickle trait was associated with a reduced risk of clinical malaria, however, this
was significant only in October 2002 - May 2002 ORR 0.27, 95% Cl 0.04-1.98,p = 0.20), October
2002 (IRR 0.49, 95% Cl 0.26-0.92, p = 0.03), and May 2003 (lRR 0.52, 95% Cl 0.23-1.20, p =
0.13). Interestingly, being alpha-thalassemia homozygous was associated with a decreased risk of
malaria subsequent to the May 2002 (IRR 0.39,95% Cl 0.11-1.37, P = 0.14) and the May 2003
(IRR 0.52, 95% Cl 0.26-1.06, p = 0.07) cross sectional bleeds though this association was only of
borderline significance in May 2003. The association between both these haemoglobinopathies
and a reduced risk of malaria in this cohort has been previously reported (Williams et al. 2005a;
Williams et al. 2005b; Williams et al. 200Sc).
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Table 5.1 Factors affecting the risk of clinical malaria in the 6 months subsequent to sampling time
Malaria episodes' P-valueUnivariate analysis' IRR(9S% Cl)
All samples· 273 (132)
MayZOOZ' 29 (22)
October 2002' 156 (99)
May 2003' 78 (61)
Age (years) 0.99 (0.93, 1.04) 0.61
Parasitaemial 1.12 (0.71, 1.76) 0.62
- Parasitaemic once' 2.05 (1.49, 2.83) <0.001
- Recurrent parasitaemia' 1.00 (0.60, 1.68) 0.99
Sickle trait 0.45 (0.24, 0.84) 0.Q1
Alpha-thai HET' 0.91 (0.64, 1.32) 0.63
Alpha-thai HOM' 0.74 (0.46, 1.19) 0.22
Age (years) 1.11 (0.93, 1.32) 0.26
Parasitaemia' 1.58 (0.68, 3.71) 0.29
Sickle trait 0.27 (0.04, 1.98) 0.20
Alpha-thai HET' 0.65 (0.30, 1.4) 0.27
Alpha-thai HOM' 0.39 (0.11, 1.37) 0.14
Age (years) 1.07 (1.00, 1.15) 0.05
Parasltaernla' 1.11 (0.63, 1.96) 0.71
Sickle trait 0.49 (0.26, 0.92) 0.03
Alpha-thai HET' 1.04 (0.74, 1.47) 0.83
Alpha-thai HOM' 0.96 (0.6, 1.51) 0.85
Age (years) 1.02 (0.93, 1.12) 0.63
Parasitaemia' 0.99 (0.51, 1.92) 0.98
Sickle trait 0.52 (0.23, 1.20) 0.13
Alpha-thai HET' 0.76 (0.48, 1.21) 0.25
Alpha-thai HOM' 0.52 (0.26, 1.06) 0.07
Notes
l Total number of malaria episodes recorded, numberof children experiencing malaria indicated in brackets.
Malaria definition: Temperature 237.S·C with patent parasitaemia in <1 year-aids or parasitaemia ~2500 parsrtes/u! in children >1 year of age.
oUnivariate poisson regression.
11 Analysis of all samples (a1l6 sampling points) with the addition of an indicator for those children contributing more than one observation to the analysis,
t Analysis covering the 6 month period subsequent to the cross sectional bleed indicated.
No analysis for October 2003, May 2004, and October 2004 cross-section bleeds due to lack of malaria episodes after the October 2003 sampling.
1 Concurrent parasitaemia at sampling.
aNumber oftimes with concurrent parasitaemia at sampling over entire study period; once and recurrently (more than once).
Aipha-thalasssemia: HET = heterozygous, HOM = homozygous.
P-values SO.1 indicated in bold.
A second analysis using all the samples in the study (May 2002 to October 2004) with the inclusion
of an identifier that indicated individuals had been sampled repeatedly was carried out. As a
number of the children had concurrent parasitaemia at more than one of the cross sectional bleeds,
it was possible to group the children according to this. This grouping of parasitaemia was an
indicator of each child's level of exposure. The children were categorised as never parasitaemic,
parasitaemic once, and recurrently parasitaemic at cross sectional sampling. This analysis showed
that presence of concurrent parasitaemia at least once over the study period was associated with a
significantly increased risk of clinical malaria (IRR 2.05, 95% Cl 1.49-2.83, P < 0.00 I) whereas the
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presence of the sickle trait was associated with a reduced risk of clinical malaria (IRR 0.45, 95% Cl
0.24-0.84,p· 0.01) (Table 5.1).
5.3.2 The auoelation of antibody resPODSeswith protection from malaria six months post-
ISmpUna is dependent on malaria transmission at sampling
Univariate analysis of the effect of antibodies to AMA1 and MSP2 on the risk of clinical malaria
over six months post-sampling was carried out on the May 2002, October 2002, and May 2003
samples. As indicated in previous chapters, a major determinant of the antibody responses to
AMAI and MSP2 in this cohort was the intensity of malaria transmission. Therefore, any
differences in the association of antibody responses to the same antigen with the risk of clinical
malaria at different time points could be attributed to changes in malaria transmission at sampling
(Table 5.2).
When each cross sectional bleed was analysed separately, only at the May 2002 bleed were there
any antibody responses that were weakly associated with the risk of malaria. The strongest
association was that of antibody responses to MSP2(FC27). These antibodies were associated with
an increased risk of malaria though this was of borderline significance (IRR 1.52, 95% Cl 0.97-
2.40, p = 0.07). Responses to MSP2(3D7) appeared to reduce the risk of malaria (IRR 0.54, 95%
Cl 0.26-1.15, p = 0.11) whereas those to AMAI(HB3) appeared to increase the risk (IRR 1.36,
95% Cl 0.88-2.12, p = 0.17), though both of these associations were not significant. Though not
significant, antibodies to all three AMA1 variants tested appeared to be associated with an
increased risk of malaria in the six months following the May 2002 bleed (Table 5.2). This was not
the case for MSP2; antibodies to one variant appeared to be associated with protection _
MSP2(3D7) - whereas antibodies to MSP2(FC27) appeared to be associated with an increased risk
of malaria.
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Table 5.2 The associations between totallgG to AMAland MSP2 and the risk of clinical malaria in the
6 months subsequent to sampling time
Univariate analysis' iRR (95% Ci) P·value
All samples·
May 2002'
October 2002'
May 2003'
AMA1(W2mef) 1.46 (1.23, 1.72) <0.001
AMA1(HB3) 1.11 (0.89, 1.38) 0.36
AMA1(307) 1.09 (0.87, 1.38) 0.46
MSP2(307) 0.77 (0.59, 1.01) 0.06
MSP2(FC27) 1.20 (0.94, 1.55) 0.15
AMAl(W2mef) 1.33 (0.86, 2.06) 0.21
AMA1(HB3) 1.36 (0.88, 2.12) 0.17
AMA1(307) 1.36 (0.85. 2.16) 0.20
MSP2(307) 0.54 (0.26, 1.15) 0.11
MSP2(FC27) 1.52 (0.97, 2.40) 0.07
AMAl(W2mef) 1.08 (0.9, 1.28) 0.42
AMAl(HB3) 1.04 (0.8, 1.35) 0.76
AMAl(307) 1.03 (0.79, 1.36) 0.81
MSP2(307) 0.96 (0.64, 1.44) 0.85
MSP2(FC27) 1.10 (0.80, 1.51) 0.55
AMAl(W2mef) 1.06 (0.79, 1.42) 0.70
AMAl(HB3) 1.08 (0.80, 1.44) 0.63
AMAl(307) 1.09 (0.80, 1.47) 0.59
MSP2(307) 1.05 (0.70, 1.58) 0.80
MSP2(FC27) 1.2 (0.83, 1.73) 0.34
Notes
oUnivariate poisson regression.
1I Analysis of all samples (a116sampling points) with the addition of an indicator for those children contributing more than one observation to the analysis.
t Analysis covering the 6 month period subsequent to the cross sectional bleed Indicated.
No analysis for October 2003, May 2004, and October 2004 cross-section bleeds due to lack of malaria episodes after the October 2003 sampling.
P-values SO.l indicated in bold.
Univariate analysis of the association between antibody responses and risk of malaria using all the
samples with the inclusion of a repeated sampling identifier gave different results to those from
single sampling analysis. Antibody responses to AMA 1(W2mef) were significantly associated
with an increased risk of clinical malaria (JRR 1.46, 95% Cl 1.23-1.72, p < 0.00 I) whereas those to
AMA 1(HB3) and AMA 1(307) had no effect on the risk of clinical malaria (Table 5.2). Antibodies
to MSP2(307) had a borderline association with protection from clinical malaria (IRR 0.77, 95%
Cl 0.59-1.01, p = 0.06) whereas those to MSP2(FC27) were somewhat associated with an increased
risk of malaria though this was not significant (IRR 1.20,95% Cl 0.94-1.55, p = 0.15).
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Table 5.3 The adjusted association between antibody responses to merozoite antigens and the risk of
clinical malaria in the 6 months subsequent to sampling time
May 2003'
Multlvarlable analysis' IRR (95% Cl) P-value
AMA(W2mef) 1.54 (1.28, 1.85) <0.001
AMA(HB3) 1.1 (0.85, 1.43) 0.46
AMA(3D7) 1.08 (0.83, 1.42) 0.57
MSP2(3D7) 0.7 (0.5, 0.96) 0.03
MSP2(FC27) 1.2 (0.9, 1.61) 0.22
AMA(W2mef) 1.12 (0.67, 1.87) 0.67
AMA(HB3) 1.16 (0.69, 1.93) 0.57
AMA(3D7) 1.14 (0.67, 1.94) 0.64
MSP2(3D7) 0.38 (0.17, 0.86) 0.02
MSP2(FC27) 1.36 (0.83, 2.22) 0.23
AMA(W2mef) 0.98 (0.81, 1.19) 0.85
AMA(HB3) 0.92 (0.7, 1.22) 0.58
AMA(3D7) 0.9 (0.67, 1.21) 0.49
MSP2(3D7) 0.81 (0.52, 1.27) 0.36
MSP2(FC27) 0.94 (0.65, 1.36) 0.73
AMA(W2mef) 1.01 (0.72, 1.4) 0.96
AMA(HB3) 1.03 (0.74, 1.44) 0.85
AMA(3D7) 1.05 (0.74, 1.48) 0.79
MSP2(3D7) 1.04 (0.65, 1.66) 0.87
MSP2(FC27) 1.23 (0.78, 1.94) 0.37
Allsamples·
May 2002'
Octobar 2002'
I:t!21!.!
o Multlvarlable poisson regression.
(I Analysis of III samples (a1l6 sampHn. points) with the addition of an Indicator for those children contributing more than one observation to the analysis,
• Analysis cO\lerlnl the 6 month period subsequent to the cross sectional bleed indicated.
No analysis for October 2003, May 2004, and October 2004 cross-section bleeds due to lack of malaria episodes after the October 2003 sampling,
P·,.lues SO.llndlcated In bold.
The adjusted risk of clinical malaria was investigated by multivariable analysis that included the
factors mentioned earlier (age, parasitaemia, and haemoglobinopathies). For the single time point
analysis, only antibody responses to MSP2(3D7) in May 2002 were significantly associated with
protection from clinical malaria (adjusted lRR 0.38, 95% Cl 0.17-0.86, p = 0.02) (Table 5.3).
Though anti-MSP2(FC27) responses had been weakly associated with an increased risk of malaria
in the univariate analysis, the weak association was lost in the multivariable analysis. None of the
other antibody responses at all three sampling points were associated with an increased or
decreased risk of malaria, When all the samples were used in the multivariable analysis along with
the inclusion of a repeated sampling identifier, anti-AM A1(W2mef) antibodies were strongly
associated with a higher risk of malaria (adjusted lRR 1.54, 95% Cl 1.28-1.85, p < 0.00 I) (Table
5.3). In contrast, anti-MSP2(3D7) antibodies were associated with protection from clinical malaria
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(adjusted IRR 0.70, 95% Cl 0.5-0.96, P = 0.03). Antibody responses to AMAI(HB3),
AMA1(3D7), and MSP2(FC27) had no significant effect on the risk of malaria.
5.3.3 Longitudinal analysis of factors affecting the risk of malaria
The associations between antibody responses and the risk of malaria in the six months after
sampling - as described in the previous sections - was important for informing us when antibodies
had their greatest effect on malaria risk and also allowed for comparison with published literature.
In the single time point analysis the inclusion of a repeated sampling indicator permitted use of all
the samples at once but did not take into account the chronological nature of the sampling or the
interdependency of both the covariates and outcome. The best way to take all these into account
was by using generalised estimating equations (GEE).
To assess the contribution of non-antibody factors on the risk of clinical malaria over the entire
study period, univariate poisson GEE was carried out on age, concurrent parasitaemia and the
haemoglobinopathies. Age had a minor effect on reducing the risk of malaria over the study period
(IRR 0.93, 95% Cl 0.88-0.98,p = 0.01) compared to the sickle trait which significantly reduced the
risk of malaria to a much greater degree ORR 0.41, 95% Cl 0.24-0.70, p = 0.001) (Table 5.4).
Those children who had concurrent parasitaemia at only one cross sectional bleed were at a 2-fold
higher risk of malaria compared to those without any concurrent parasitaemia (IRR 2.05, 95% Cl
1.56-2.69, P < 0.001). Concurrent parasitaemia at more than one cross sectional sampling point
and alpha-thalassemia had no association with the risk of malaria.
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Table 5.4 Factors affecting the risk of clinical malaria over the study
Univariate analysis' IRR(95% Cl) P-value
AI_(yean) 0.93 (0.88, 0.98) 0.01
Parasltaemlc once' 2.05 (1.56, 2.69) <0.001
Recurrent paraslta_mla' 0.95 (0.61, 1.5) 0.84
Sickle trait 0.41 (0.24,0.7) 0.001
Alpha-thel HET 0.95 (0.72, 1.26) 0.72
Alpha-thai HOM' 0.76 (0.51, 1.12) 0.17
t:l2!!!
• Univariate generalised estimating equation (GEE), exchangeable correlation structure.
All samples.
1 Concurrent parasitaemia at one cross sectional bleed during the study.
1 Concurrent parultaemla at more than one cross sectional bleed durlna: the study.
'Alpha4thalasssemla: HET = heteroZVlouS, HOM = homozygous.
P-velues sO.1Indle.ted Inbold.
5.3.4 Contrasting associations between anti-merozoite antibody responses and protection
against malaria
Univariate analysis of the association of antibody responses to AMA 1 and MSP2 with the risk of
clinical malaria was analysed by GEE with exchangeable correlation structure using all the samples
in the cohort. Increasing antibody responses to AMAI(HB3), AMAI(3D7), MSP2(3D7)and
MSP2(FC27) were not associated with risk of malaria over the study period (Table 5.5).
Interestingly, antibody responses to AMA(W2met) were significantly associated with an increased
risk of malaria over the study period (IRR 1.56,95% Cl 1.34-1.80, P < 0.001).
Table 5.5 The effect of antibody responses to merozoite antigens on the risk of clinical malaria over the
study
Univariate analysis' IRR(95% Cl) P-value
AMA1(W2mef) 1.56 (1.34, 1.8) <0.001
AMA1(HB3) 1.1 (0.91, 1.32) 0.34
AMA1(3D7) 1.07 (0.88, 1.31) 0.50
MSP2(3D7) 0.86 (0.64, 1.15) 0.32
MSP2(FC27) 1.15 (0.91, 1.46) 0.25
Notes
• Univariate generalised estimating equation (GEE), exchangeable correlation structure.
All samples.
P-values SO,l indicated In bold.
Multivariable analysis of the protective associations of antibody responses to AMA I and MSP2
that adjusted for the factors above was then performed. As seen in the univariate analysis, antibody
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responses to AMA1(HB3) and AMA1(307) were not associated with the risk of clinical malaria
(Table 5.6). Antibody responses to MSP2(307) were associated with protection though this effect
was not statistically significant (IRR 0.88, 95% Cl 0.62-1.23, p = 0.44) whereas those to
MSP2(FC27) were associated with an increased risk of malaria (IRR 1.31, 95% Cl 0.98-1.75, p =
0.07). As seen in the univariate analysis, antibody responses to AMA 1(W2met) were associated
with a significantly increased risk of malaria over the study (IRR 1.75, 95% Cl 1.47-2.09, p <
0.001). Recent studies report that the removal of individuals without any exposure from analysis
strengthened the protective associations of some merozoite antibodies against clinical disease
(Bejon et al. 2009). Multivariable analysis was therefore repeated using only those children who
had recorded exposure to Plasmodium over the study period. This analysis also showed that higher
antibody responses to AMAl(W2met) were associated with an increased risk of malaria (IRR 1.56,
95% CI1.32-2.1.64,p <0.001) (Table 5.6). The protective effect ofanti-MSP2(307) antibodies on
clinical malaria was suggested by a reduced risk ratio of borderline statistical significance (IRR
0.75, 95% Cl 0.55-1.04, P = 0.08) although the increased risk of malaria associated with anti-
MSP2(FC27) responses was lost. Even with the removal of non-exposed children from the
analysis, antibody responses to AMA 1(HB3) and AMA 1(307) had little association with the risk
of clinical malaria.
Table 5.6 The adjusted effect of antibody responses to merozoite antigens on the risk of clinical
malaria over the study period
All children' Exposed children .
Multlvarlable analyslsO
IRR195%CI) P-value IRR195%Cl) P-value
AMA(W2mef) 1.7511.47,2.09) <0.001 1.56 (1.32, 1.84) <0.001
AMA(HB3) 1.05 10.84, 1.3) 0.68 110.82,1.22) 0.99
AMA(3D7) 1.0410.82, 1.31) 0.75 1.01 (0.81, 1.25) 0.94
MSP2(3D7) 0.8810.62, 1.23) 0.44 0.7510.55,1.04) 0.08
MSP2(FC27) 1.3110.98, 1.75) 0.G7 1.0410.79,1.37) 0.79
Notes
: Multivariable generalised estimating equation (GEE). exchangeable correlation structure.
All samples.
t Only those children with recorded P.falciparum exposure during the study.
s-vatues ~O.l indicated in bold.
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5.4 Discussion
This study is particularly effective in both highlighting and demonstrating the contrasting results
that are reported in the published literature. Published studies have often taken the simplest
approach to infer the protection accorded by antibodies to malaria antigens due to the logistics of
setting up extended longitudinal studies. Those that have sampled antibody levels in a repeated
longitudinal manner have either then not included all available data or have instead broken down
the longitudinal data into a series of cross-sectional queries. This study is unique in the approaches
used to investigate associations between antibodies and protective immunity using all available
data. In order to compare this study with the published literature logistic regression was performed
with clinical malaria as the outcome over a period of six months post sampling.
Analysis of the effect on malaria immunity of antibody responses measured at a single time point
showed that it is possible to get different associations with protection or risk that are simply
dependent on the time that the study is performed. As indicated in chapter 4, a number of children
maintained a similar antibody profile to all AMA 1 and MSP2 variants throughout the study period
with minor fluctuations in their responses. Analysis suggests that a major contributor to the
relationship between antibodies and protection lies in the level of malaria transmission during the
period in question. Because one particular antibody response is protective over a certain period
does not mean that the same response will be at a different time. Looking at the data in this
'snapshot' fashion allowed it to be compared with published literature as most association studies
measured antibodies at baseline and then calculated protection over a define period (often six
months). Results presented here suggest that using a single sample collection and follow-up to
assess protective associations has its limitations. It is believed that the antibody response at any
one time encompasses the capacity of an individual to respond as well as their response to previous
malaria exposure and therefore makes single time point sampling a valid method (Drake ley et al.
2005). Contrary to this; the results discussed in previous chapters indicate that in children in this
cohort, a large portion of the antibody response recorded at anyone time is largely a response to
antigen currently in or very recently in the system. This is likely to be due to declining malaria
transmission levels.
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The loss of statistical significance of the associations between MSP2 antibody responses and risk of
malaria at some time-points could be due to declining malaria transmission. The falling malaria
incidence then resulted in anti-MSP2(3D7) antibodies being associated with high reductions in risk
which were not statistically significant. Had the incidence of malaria been higher in this cohort,
these associations may have reached statistical significance. This limitation was addressed in part
when all the samples were analysed together or when longitudinal analysis was used. Use of all the
samples with an indicator of repeated sampling led to better use of the data available. By doing so,
the model took into account that the same individuals can have different antibody responses and
outcomes. What it could not encompass was that the measures were related to each other in time
and therefore lost the impact of changing malaria transmission on both the antibody levels and the
outcomes. This method tended to result in associations that were different when compared to those
of the single-time point analysis. For example, the multivariate analysis in May 2002 showed that
antibody responses to AMA(W2mef) were associated with an increased risk of malaria and yet this
was not the case in October 2002 and May 2003. The results indicated that protection from clinical
malaria in this cohort was both antigen and variant specific. Antibodies to AMA 1 were
significantly associated with an increased risk for the W2mef variant though this was not the case
for the HB3 and 3D7 variants. Antibodies to MSP2 (307) were significantly associated with
protection yet those for MSP(FC27) were associated with an increased risk of malaria though this
was not statistically significant. The results from the combined cross sectional risk analysis are
very similar to those seen in an earlier study carried out in the same area with regards to MSP2
(Polley et al. 2006). Antibodies to type A and type B MSP2 were analysed in a cohort of
individuals 0-85 years of age in October 2000. The authors found that antibodies against type A
MSP2 were associated with a reduced risk (OR = 0.87, p = 0.64) and those to type B with an
increased risk of malaria in the 6 months post sampling (OR = 1.23, P = 0.48). These results are
comparable to those seen in the study described here where antibodies to MSP2(3D7) were
associated with a reduced risk (lRR 0.70, P = 0.03) and those to MSP2(FC27) with a higher risk
(IRR = 1.20, P = 0.22) of malaria in the 6 months post sampling. Antibody responses to
AMA1(3D7) had no effect on the risk of malaria in this study (lRR = 1.08, p = 0.57) although
earlier studies in the same area showed that there could be a protective effect by anti-AMA I(307)
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antibodies (RR - O.73,p= 0.075) (Polley et al. 2004). The differences in the earlier study from the
one described in this chapter included a wider age distribution, higher rates of malaria transmission,
and possibly the inclusion of schizont extract responses in the multivariable analysis. Schizont
extract was not included in the multivariable model in this study as it is not independent of the
antibody responses being evaluated. As schizont extract proteins include both AMAI and MSP2, it
does not meet the definition of a confounder. Inclusion of schizont extract into the models used in
this analysis had little effect on the associations found in this chapter. Both sickle trait and alpha-
thalassemia were adjusted for in the multivariable models as they were independently associated
with lower antibody levels and reduced risks of malaria.
The longitudinal model used not only took into account that the independent and dependent
variables changed over time, it also accounted for any changes in covariates such as age or
concurrent parasitaemia. Both the univariate and multivariable analysis indicated that antibodies to
AMAI(W2mef) were significantly associated with an increased risk of clinical malaria over the
study period (p <0.001). In both the univariate and multivariable GEE analysis antibodies to
AMAI(HB3), AMAl(3D7), and MSP2(FC27) had no association with clinical disease. The only
antibody response to be associated with protection from malaria was that to MSP2(3D7) when
children without recorded Plasmodium exposure were removed from the analysis, though this
association was of borderline significance (p = 0.08). The results from the longitudinal GEE
analyses were in agreement with those from the GLM analyses with a clustering indicator. This
agreement underscored the importance of multiple measurements when a dynamic variable such as
antibody levels is being evaluated.
As indicated in previous chapters, antibody levels were also dependent on a number of dynamic
factors that change with time, such as age, cumulative and recent malaria exposure, and malaria
transmission levels. These changing covariates are intrinsically accounted for in longitudinal
analysis with GEE. Following the earliest definitive studies that antibodies are involved in
immunity to malaria, more recent immune-epidemiological studies often fail to discuss in depth the
reasons that an antibody response could be associated with clinical disease, rather than protection.
An explanation for this could be that the lack of information on exposure and/or parasitaemic or
malaria episodes over a considerable period of time makes it difficult to assess a result that is
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contrary to published results. Though it has been observed and is accepted that antibody levels are
dynamic, the idea that the presence of antibodies to the same malarial antigen can indicate either
protection or susceptibility in the same individuals is not widely explored.
Antibodies to any malarial antigen will only be induced on exposure. Some of these antibodies
will protect against further infection from the same strain, or may contribute to protection against
many strains due to the existence of conserved epitopes. Other antibodies will be directed against
'non-immunity' epitopes. That is, epitopes that even when bound to, will not affect the function of
the antigen or parasite survival adversely. Every exposure and re-exposure results in a combination
of all three types of antibody to each antigen. As cumulative exposure leads to immunity to
malaria, it could be hypothesised that the majority of the initial antibody response is made up of
those antibodies directed to 'non-immunity' epitopes and therefore act as a marker of
disease/infection. Additionally, antibodies may need to reach a threshold concentration or affinity
before they have significant activity against parasites in vivo. Each successive exposure to that
particular antigen results in antibody response that is decreasingly made up of these 'non-
immunity' antibodies and increasingly of 'immunity' antibodies. How fast or after how many
exposures this occurs is still unknown and would be dependent on a number of factors that are
dependent on both the host and the antigen in question. This idea may shed some light on the fact
that antibodies to different malarial antigens are variously associated with protection from or risk of
clinical malaria in the published literature. As it was not possible to investigate the infective
genotype or phenotype of each infection in this study, I can only speculate. What this study did
show was that malaria transmission will have an effect on inferred protection or risk associations.
In this case, a reduction in transmission may have an effect on the number of circulating P.
/alciparum strains in the population. The reduction in strains would leave larger gaps in each
individual's antibody repertoire therefore leading to the production of more 'non-immunity'
antibody responses on exposure. This could explain how the high antibody response to
AMA I(W2met) seen in the population may reflect recent exposure to this antigen which appeared
low before May 2002 (see chapter 4). This interpretation might explain why higher anti-
AMA I(W2met) antibodies were associated with an increased risk of disease in this study.
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The·finding that parasitaemia was longitudinally associated with increased risk suggests that these
are the most exposed children. Indeed, the factor of differences in exposure has already been
suggested in recent publications (Polley et a1. 2004; Bejon et a1. 2009). When exposure was
factored into the analysis, the increased risk of disease with anti-AMA1(W2met) antibodies
remained significant. The removal of non-exposed children in the analysis led to a stronger
association between antibodies to MSP2(3D7) and protection from disease which approached
statistical significance. This result is also in agreement with the assessment made in the previous
chapter. It was noted that 67.9% of the children who had concurrent parasitaemic once at cross-
sectional bleeds had more than one incident of recorded parasitaemia in the intervals. This is a
much larger proportion than those seen in the group who never had concurrent parasitaemia at
sampling (23.7%) or those who had recurrent parasitaemia at sampling (32.5%). That children
with high antibody responses to A4 schizont proteins were at an increased risk of malaria suggests
that these children had greater Plasmodium exposure which translates to a higher risk of disease.
Only in the longitudinal analysis was it possible to see the small but significant effect that older age
in childhood had on the reduction of malaria. Although the effect of age is commonly observed by
falling rates of parasitaemia and severe illness, its effect has not been identified independently of
cumulative exposure as was possible in this analysis. In both the single time point and the
longitudinal analysis the sickle trait was associated with a reduced risk of malaria in this cohort.
This is in agreement with published findings on this cohort as well as in other studies (Willcox et
al. 1983; Hill et al. 1991; Aidoo et al. 2002; Williams et aI. 2005a; Williams et aI. 2005b). This
immunity appears in part due to the physical nature of the erythrocytes as well as regulation of the
immune response in HbAS children (Marsh et a1. 1989; Bayoumi et aI. 1990; Abu-Zeid et aI. 1992;
Williams et al. 2005a). In this study, alpha-thalassemia did not confer significant protection
against malaria. This finding is also in agreement with published data on children from the same
study area (Wambua et al. 2006).
A recent study carried out in Papua New Guinea showed that although antibodies to merozoite
antigens were associated with protection from malaria they were not associated with protection
from re-infection (Stanisic et a1.2009). Re-infection and parasite density thresholds are rarely used
as an outcome in immune-epidemiological studies yet finding those antibody responses that protect
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against them could be very important in identifying the particular antigens targeted in those
individuals who maintain sub-patent infections. This study - with its intensive weekly surveillance
- could have led to further insight into this process. Unfortunately as there was no active
surveillance for parasitaemia - only for clinical illness - it was not possible to do so in the analysis.
This study revealed that assessment of the protective effects of antibodies measured at a single time
point assists in informing when the antibody response in question is exerting its greatest effect.
This was the case for anti-MSP2(3D7) which were most protective in the six months following the
May 2002 bleed. But it must be noted that without the other cross sectional bleeds to compare
with, the interpretation of this association may have been incomplete. The advantage of the
longitudinal method was that it allowed for a more complete picture of the role of antibody
responses in protection against malaria. As malaria immunity is a dynamic process that is affected
by a number of factors of which some are dynamic (such as ongoing malaria transmission and age)
and others are static (such as haemoglobinopathies), analysis methods that include all these
variables in their entirety are probably the best options for studying the role of anti-malarial
antibodies in protection. Longitudinal sampling will need to be an important consideration in
future studies. In this study, antibody responses to AMAl(W2met) were associated with an
increased risk of clinical disease whereas those to MSP2(3D7) were possibly associated with
protection from clinical disease in children below the age of 10 years.
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6 Acquisition and maintenance of isotype and subclass
antibody responses to AMAl(3D7) and their association
with protection against clinical malaria
6.1 Introduction
Functional differences may exist in antibodies of the same specificity and one reason for these
differences may be subclasses. It was not until the early 1990s that differences in antibody isotypes
and subclasses were reported in susceptible and protected individuals (Bouharoun- Tayoun and
Druilhe 1992). In this study, immunoglobulin 01 (IgOl) and immunoglobulin 03 (lg03) were the
dominant antibody subclasses in protected individuals. IgO 1 and Ig03 are cytophilic antibodies
that mediate complement fixation and phagocytosis (Bredius et al. 1994). In the study described
earlier; IgM - a low affinity antibody that is produced on primary exposure to antigen -
predominated in younger children who were susceptible to disease (Bouharoun- Tayoun and
Druilhe 1992). Further studies in Africa and Asia have also showed that IgG 1 and IgG3 are the
predominant antibody responses to merozoite antigens (Taylor et al. 1995; Shi et al. 1996;
Rzepczyk et al. 1997; Polley et al. 2006; Nebie et al. 2008; Stanisic et al. 2009).
A number of factors including host genetics, antigen type, cumulative exposure, and age have been
implicated in determining the predominant subclass response to merozoite antigens. An example
of host genetic influence on subclass responses was a study carried out in Burkina Faso which
showed that related individuals tended to display similar subclass antibody profiles (Aucan et al.
2001). Whereas the predominant IgO response to MSP2 is Ig03 in normal individuals, three
studies showed that individuals with the sickle trait (HbAS) had measurable IgG2 responses to
MSP2 in comparison to their normal (HbAA) counterparts (Aucan et al. 2000; Ntoumi et al. 2002;
Ntoumi et al. 2005). The type of Plasmodium exposure that individuals experience may also have
an effect as shown by the in vitro stimulation of peripheral blood mononuclear cells from
Senegalese adults with complete parasite extract that resulted in a mixed IgG subclass response
whereas stimulation with a single recombinant antigen always resulted in a single IgG subclass
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response (Garraud et al. 2002). Studies carried out in Senegal and Gambia indicated that there was
an exposure-related preponderance for IgGl or IgG3 responses to MSPI and MSP2 but these
results remained unconfirmed in a later Brazilian study (Nguer et a1. 1997; Taylor et a1. 1998;
Scopel et a1. 2005). Increasing age has also been suggested to polarize the antibody response to
IgG3 for MSPI and MSP2, and to JgG 1 for AMA 1 though this was not seen in a more recent study
(Scopel et al. 2006; Tongren et al. 2006; Stanisic et a1. 2009). In fact, this recent treatment re-
infection study that compared the subclass response to different AMAI and MSP2 variants in
children showed that the main factor influencing the subclass response was the antigen rather than
the host (Stanisic et al. 2009).
Anti-AMAI antibodies in malaria endemic populations are predominantly JgG 1 and IgG3 with
very little IgG2 or IgG4 detected (Riley et a1. 2000; Polley et al. 2004; Metenou et al. 2007; Nebie
et a1. 2008; Stanisic et a1. 2009). IgG 1 responses predominated over IgG3 responses both in
prevalence and intensity (Riley et al. 2000; Nebie et a1. 2008), but titres of both increased with age
and exposure to malaria (Stanisic et a1. 2009). To date, there have been no studies examining the
longitudinal acquisition and maintenance of subclass antibodies to AMA I or other merozoite
antigens.
It has been suggested that age and exposure skews the antibody response to AMA 1 towards a
predominantly IgG 1 response. The implication here is that at a young age both IgG 1 and IgG3 are
similarly induced. The structure of this study allows for investigation into the balance of IgG 1 and
IgG3 responses over time. Here, I describe the patterns of subclass (IgG I, IgG3) and isotype (IgG,
IgM) antibody responses to AMA1(3D7) and compare the effects of various factors (host genetics,
cumulative exposure, and age) on the magnitude of the antibody response. In particular, this
chapter examines whether repeated exposure or increasing age leads to changes in the pattern of
IgG subclass responses and investigates whether specific isotype or subclass responses to
AMAl(3D7) are associated with protection against clinical malaria in this cohort of children.
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6.2 Methods
6.2.1 Enzyme-linked immunosorbent assay (ELISA)
IgGI, IgG3 and IgM antibody levels to AMAI(3D7) were measured in all samples by high
throughput ELISA. The details of this assay can be found in chapter two but will be described
briefly here. Nunc Maxisorp 384 well plates (Nunc) were coated with SOIlI per well of
AMAI(3D7) diluted in phosphate buffered saline (PBS) at a concentration of'u.Sug/rnl. The plates
were sealed and incubated overnight at 4°C. Plates were then washed twice using PBS with 0.25%
Tween 20 (wash buffer). Non-specific binding was blocked by addition of 100111per well of PBS
with 0.1% Casein (Pierce) and 0.05% Tween 20. The plates were then sealed and incubated
overnight at 4°C. The plates were washed once before addition of sera. SOIlIof sera diluted in PBS
with 0.1% Casein and 0.05% Tween 20 was added to each well and incubated for 2 hours at room
temperature. IgG I, IgG3, and IgM were measured at a sera concentration of I: 100. After the sera
incubation, the plates were washed five times using wash buffer. Detection of IgM was done using
SOJ.lIof a 1:2500 dilution of HRP-conjugated polyclonal goat anti-human IgM (Chemicon,
Melbourne Australia) in PBS with 0.1% Casein and 0.05% Tween 20 as the secondary antibody.
HRP-conjugated monoclonal mouse anti-human IgG (lgG 1 clone HP6069A, Calbiochem-
Novabiochem Corp, CA USA) and HRP-conjugated monoclonal mouse anti-human IgG3 (lgG3
clone HP6047, Calbiochem-Novabiochem Corp, CA USA) were also used at 1:2500 dilutions to
detect IgGI and IgG3 responses to AMA1(3D7). The plates were then washed five times in wash
buffer and 50J.lI of ABTS (A3219, Sigma) was added to each well. The plates were incubated for
30 minutes in the dark to allow for sufficient colour change. Addition of 50lll of 1% SDS per well
stopped the reaction and absorbance was read at 405nm using an Envision plate reader (Perkin
Elmer). Antibody levels were expressed as an absorbance value (OD).
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6.2.2 Statlstleal Analysis
All data analyses were performed with STATA version 9.2 (StataCorp, College Station, TX USA).
Statistical analysis was carried out as described in detail in chapters 2 - 5 and will only be
described briefly here. All samples were used in the analyses unless stated. Significance was
reached at the 0.05 level for all tests. The chi2test for trend was used to assess the acquisition of
antibodies in different age groups, and the Kruskal-Wallis test to compare antibody levels. The
probability of a high antibody response (above the 75th centile) after recorded exposure to P.
falciparum was estimated by logistic regression, fitting the number of recorded parasitaemic
episodes in the 6 months prior to sample time as a factor and adjusting for age. The logits from
these models were converted into probabilities to give estimates of risk and then plotted using the
lowess smoothing technique. This same analysis was employed to estimate and plot the probability
of being sero-positive. The association between antibody responses to AMAI(3D7) and the risk of
malaria was investigated by two methods which are described in detail in chapters 2 and 5.
Univariate and multivariable generalised linear models (GLM) were used to investigate the
relationship between antibody levels at a single time point ant the risk of malaria in the subsequent
six months. Univariate and multivariable generalised estimating equations (GEE) were used to
investigate relationship between antibody levels at several time points and the risk of malaria over
the entire study period.
6.3 Results
6.3.1 The predominant IgG response to AMAI in Ngerenya is of the IgG 1 subclass and is
&Ssociatedwith age and active parasitaemia
Using cut-offvalues determined by a panel of negative controls, the acquisition of different isotype
and subclass antibody responses to AMAI(3D7) was investigated by examining the prevalence of
total IgG, IgGI, IgG3 and IgM. In all age groups (in one year intervals), sero-positivity ranged
widely with the lowest prevalence seen for IgM followed by IgG3 responses, and highest for IgG1.
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Prevalence of sero-positivity of all antibodies increased with age following a decline in maternal
antibodies from the age of one year (Figure 6.1).
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Figure 6.1 Proportion of samples with detectable antibody responses to AMAl(3D7) by age group. All
samples in the study were included, defined by age at sampling.
By the age of one year, when all maternal antibodies have disappeared from the child's circulation,
only 8.3% (95% Cl: -3% - 19.7%) of children tested positive for IgM in May 2004 (Table 6.4),
compared with 34.7% (95% Cl: 15.9% - 53.4%) for total IgG in May 2003 (Table 6.1). In
comparison with the lower prevalence of IgM responses, 15.4% (95% Cl: 1.2% - 29.6%) and
12.5% (95% Cl: -1.1% - 26.1%) of one year olds had IgG I and IgG3 antibody responses to
AMA I(3D7) in May 2003 and May 2004 respectively (Tables 6.2 and 6.3). By the age of 8 years,
all children had total IgG and IgG 1 responses to AMA I in October 2002 (Tables 6.1 and 6.2). This
was never the case for IgG3 and IgM which had maximal prevalence values of 51.5% (95% Cl:
34.1% - 68.9%) and 12.1% (95% Cl: 0.8% - 23.5%) in October 2003 in children above 7 years of
age (Tables 6.3 and 6.4). For all three TgGresponses tested (total IgG, IgG I and IgG3), there was a
significant increase (p < 0.0 I, chi2 test for trend) in the prevalence of responses with age at all cross
sectional bleeds (Tables 1 - 3). Only during the May 2002 cross sectional bleed was there a
significant increase (p < 0.0 I, chi2 test for trend) in the prevalence of JgM responses with age
(Table 6.4).
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Table 6.1 Prevalence of detectable JgG responses to AMAI (3D7) by age and cross sectional bleed in
the Ngerenya cohort
Antl-AMAl(3D7) IgG sero-prevalence (95% Cl)
Age (years)
May2002' October 2002' May2003' October 2003' May2004' October 2004' P-value'
0 23.4 (7.9 - 38.8) 48.7 (32.3 - 65.1) 29.7 (12.1- 47.3) 26.1 (7.7 - 44.6) 23.9 (5.1- 42.6) 26.7 (3.4 - 50) 0.384
8.4 (0.4 - 16.3) 3.2 (-3.1- 9.3) 34.7 (15.9 - 53.4) 20.6 (6.8 - 34.5) 8 (-3 - 19) 12.5 (-Ll - 26.1) 0.386
2 35.9 (20.6 - 51.3) 20.6 (7.7 - 33.5) 13.7 (3.4 - 24) 18.8 (5 - 32.6) 13 (0.9 - 25) 6.3 (-2.4 - 14.9) 0.002
3 46.4 (30.9 - 61.9) 35.9 (20.6 - 51.3) 28.2 (12.3 - 44.1) 37.9 (22 - 53.8) 29.8 (14.8 - 44.8) 17.9 (3.4 - 32.4) 0.027
4 40.7 (23.3 - 58) 63.4 (45.8 - 81) 47.5 (31.8 - 63.3) 40.5 (25.4 - 55.6) 17.3 (3.2 - 31.3) 33.4 (16.1- 50.6) 0.017
5 63.9 (49.9 - 77.8) 49 (34.8 - 63.2) 51.8 (33.2 - 70.4) 46.2 (26.6 - 65.8) 39.4 (22.4 - 56.4) 30.4 (14.4 - 46.3) 0.003
6 71.1 (56.4 - 85.8) 55.2 (36.7 - 73.7) so (33.4 - 66.7) 57.2 (42 - 72.4) 41. 7 (21.5 - 62) 33.4 (14 - 52.7) 0.004
7 65.3 (45.3 - 85.3) 68.6 (53 - 84.3) 77.5 (62.4 - 92.5) 52 (32 - 72.1) 50 (33.9 - 66.2) 50 (33.9 - 66.2) 0.022
S' 100 (0 - 0) 75 (55.5 - 94.6) 87.9 (76.6 - 99.3) 76 (58.9 - 93.2) 41.7 (21.5 - 62) 0.003
9' 81.3 (61.5 - 101.1) 72 (54 - 90.1) 0.506
p-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
1 Cross sectional bleed.
2 P-values calculated usina a chi2 test for trend for IKG prevalence In the same age group at different cross sectional bleeds (P-values S 0.05 indicated in bold type).
JP-values calculated usln. a chl2 test for trend for IIG prevalence In different age groups at the same cross sectional bleed (P-values s 0.05 indicated in bold type),
t Misslnl values are due to iii lack of children in that ase group.
All samples Included In analysis.
Table 6.2 Prevalence of detectable IgG1 responses to AMA1 (3D7) by age and cross sectional bleed in
the Ngerenya cohort
Antl-AMAl(3D7) IgG1 sero-prevalence (95% Cl)
Age (years)
May 2002' October 2002' May 2003' October 2003' May2004' October 2004' P-value'
0 16.7 (3 - 30.3) 18.9 (6.1- 31.8) 25.9 (9 - 42.8) 17.4 (1.5 - 33.3) 9.5 (-3.4 - 22.4) 20 (-1- 41) 0.759
6.3 (-0.7 -13.2) 3.1 (-3 - 9.3) 15.4 (1.2 - 29.6) 5.9 (-2.2 - 13.9) 4 (-3.9 - 11.9) 4.2 (-4 - 12.4) 0.761
2 20.5 (7.6 - 33.4) 10.3 (0.6 - 19.9) 2.3 (-2.2 - 6.7) 9.4 (-0.9 -19.7) 3.2 (-3.1- 9.6) 6.3 (-2.3 -14.8) 0.028
3 26.8(13 - 40.6) 12.8 (2.1- 23.5) 21.9 (7.3 - 36.5) 27 (12.5 - 41.6) 18.9 (6.1- 31.8) 14.3(1- 27.5) 0.536
4 28.1 (12.2 - 44) 20 (5.4 - 34.6) 30 (15.6 - 44.4) 33.3 (18.8 - 47.8) 13.8 (1- 26.6) 16.7(3 - 30.3) 0.289
5 36.2 (22.2 - 50.1) 24.5 (12.3 - 36.7) 27.6 (11 - 44.2) 30.8 (12.6 - 48.9) 33.3 (16.9 - 49.7) 21.2 (7 - 35.4) 0.452
6 57.9 (41.9 - 73.9) 37.9 (19.9 - 56) 36.1 (20.1- 52.1) 35.7 (21- 50.4) 20.8 (4.2 - 37.5) 25 (7.2 - 42.8) 0.003
7 47.8 (26.9 - 68.8) 48.6 (31.7 - 65.4) 58.1 (40.3 - 75.8) 32 (13.3 - 50.7) 39.5 (23.7- 55.3) 34.2 (18.9 - 49.6) 0.089
8' 100 (0 - 0) 70 (49.3 - 90.7) 78.8 (64.6 - 93) 64 (44.7 - 83.3) 25 (7.2 - 42.8) <0.001
9' 75 (53 - 97) 68 (49.3 - 86.7) 0.635
P-value' <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Notes
1 Cross sectional bleed.
2P-vaIU8Scalculated using a chi2 test for trend for JIG prevalence in the same age group at different cross sectional bleeds (P·values S. 0.05 indicated in bold type).
J P-values calculated using a chi2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P·values S 0.05 indicated in bold type).
eMlssl"1 values are due to a lack of children In that age group.
All samples included in analysis.
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Table 6.3 Prevalence of detectable IgG3 responses to AMAI (3D7) by age and cross sectional bleed in
the Ngerenya cohort
Anti-AMA1(3D7) IgG3 sero-prevalence (95% Cl)
Age (years)
May 2002' October 2002' May 2003' October 2003' May2004' October 2004' P-value'
0 10 (-1- 21) 8.1 (-0.8 -17.1) 3.7 (-3.6 -11) 4.3 (-4.2 - 12.9) 4.8 (-4.6 - 14.1) 6.7 (-6.5 - 19.8) 0.436
6.3 (-0.7 -13.2) 11.5 (-1- 24.1) 8.8 (-0.9 - 18.5) 4 (-3.9 - 11.9) 12.5 (-1.1- 26.1) 0.316
2 17.9 (5.7 - 30.2) 12.8 (2.1- 23.5) 15.6 (2.8 - 28.5) 6.5 (-2.4 - 15.3) 0.020
3 24.4 (11- 37.8) 10.3 (0.6 - 19.9) 9.4 (-0.9 - 19.7) 32.4 (17.1- 47.8) 8.1 (-0.8 - 17.1) 3.6 (-3.5 - 10.6) 0.108
4 25 (9.7 - 40.3) 23.3 (7.9 - 38.8) 10 (0.5 - 19.5) 28.6 (14.7 - 42.5) 17.2 (3.2 - 31.3) 3.3 (-3.2 - 9.9) 0.085
5 23.4 (11.1- 35.7) 18.4 (7.4 - 29.4) 20.7 (5.6 - 35.8) 19.2 (3.7- 34.7) 12.1 (0.8 - 23.5) 9.1 (-0.9 - 19.1) 0.080
6 39.5 (23.7- 55.3) 24.1 (8.2 - 40.1) 25 (10.6 - 39.4) 21.4 (8.8 - 34) 8.3 (-3 - 19.7) 12.5 (-1.1- 26.1) 0.003
7 30.4 (11.1- 49.7) 20 (6.5 - 33.5) 35.5 (18.3 - 52.7) 16 (1.3 - 30.7) 18.4 (5.9 - 31) 13.2 (2.2 - 24.1) 0.081
S' 50 (27.4 - 72.6) 51.5 (34.1- 68.9) 32 (13.3 - 50.7) 12.5 (-1.1- 26.1) 0.005
9' 31.3 (7.7- 54.8) 24 (6.8 - 41.2) 0.614
P-value' 0.001 0.009 <0.001 0.006 0.001 0.008
Notes
1 Cross sectional bleed.
2P-values calculated using a chj2 test for trend for IgG prevalence in the same age group at different cross sectional bleeds (P-values S 0.05 Indicated In bold tvpe].
1 P-values calculated using a chi2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P-values S 0.05 Indicated In bold type).
tMissing values are due to a lack of children in that age group.
All samples included in analysis.
Table 6.4 Prevalence of detectable IgM responses to AMAI (3D7) by age and cross sectional bleed in
the Ngerenya cohort.
Age (years)
Anti-AMA1(3D7) IgM sero-prevalence (95% Cl)
May 2002' October 2002' May2oo3' October 2003' May2004' October 2004' P-value'
0 3.3 (-3.2 - 9.9) 2.7 (-2.6 - 8) 4.3 (-4.2 - 12.9) 0.416
2.1 (-2 - 6.2) 3.1 (-3 - 9.3) 3.8 (-3.7 - 11.4) 4 (-3.9 - 11.9) 8.3 (-3 - 19.7) 0.327
2 7.7 (-0.8 -16.2) 4.5 (-1.7 - 10.8) 12.5 (0.8 - 24.2) 3.2 (-3.1- 9.6) 6.3 (-2.3 - 14.8) 0.382
3 12.2 (2 - 22.4) 2.6 (-2.5 - 7.6) 3.1 (-3 - 9.3) 2.7 (-2.6 - 8) 2.7 (-2.6 - 8) 3.6 (-3.5 - 10.6) 0.107
4 9.4 (-0.9 -19.7) 10 (-1- 21) 5 (-1.9 -11.9) 2.4 (-2.3 - 7.1) 6.9 (-2.5 - 16.3) 0.081
5 4.3 (-1.6 - 10.1) 6.1 (-0.7 - 12.9) 3.4 (-3.3 - 10.2) 19.2 (3.7- 34.7) 12.1 (0.8 - 23.5) 6.1 (-2.2 - 14.4) 0.241
6 15.8 (4 - 27.6) 6.9 (-2.5 -16.3) 5.6 (-2.1- 13.2) 7.1 (-0.8 - 15.1) 4.2 (-4 - 12.4) 4.2 (-4 - 12.4) 0.088
7 26.1 (7.7 - 44.5) 8.6 (-0.9 - 18) 9.7 (-0.9 - 20.3) 4 (-3.9 - 11.9) 2.6 (-2.5·7.8) 2.6 (-2.5 - 7.8) 0.002
8' 5 (-4.8 - 14.8) 12.1 (0.8 - 23.5) 8 (-2.9 - 18.9) 4.2 (-4 - 12.4) 0.744
9' 6.3 (-6.1-18.6) 4 (-3.9 - 11.9) 0.747
P-value' 0.001 0.446 0.415 0.170 0.562 0.479
Notes
1 Cross sectional bleed.
: P~valuescalculated using Cl chj2 test for trend for IgG prevalence in the same age group at different cross sectional bleeds {s-vatues s 0.05 Indicated in bold type).
P-values calculated using a chi2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P·values S 0.05 Indicated in bold type).
tMissing values are due to a lack of children in that age group.
All samples included in analysis,
From 2 - 8 years of age, there was a significant decline in the prevalence of total JgG responses to
AMA 1 as malaria transmission declined (p < 0.05, chi2 test for trend) (Table 6.1). This has already
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been discussed in chapter 3. In comparison, the decline in malaria transmission only appeared to
aff~ct the prevalence of IgO1 and 1803 responses in 2-, 6-, and 8-year olds (p < 0.05, chi2 test for
trend) (Tables 2 and 3). Only in 7-year olds was declining malaria transmission accompanied by a
significant decline (p < 0.01, chi2test for trend) in the prevalence ofIgM responses (Table 6.4).
In agreement with previous findings, total IgG responses were strongly associated with those of
J8O! at every cross sectional bleed (Table 6.5, Appendix 3 Tables 1-5). Correlation coefficients
ranged from 0.67 in May 2003 (Appendix 3 Table 2) to 0.91 in October 2002 and May 2003
(Appendix 3 Tables 1 and 3) (p < 0.001, Spearman rank correlation). Ig03 responses were not as
strongly associated with total JgG with correlation coefficients ranging from 0.49 in May 2003
(Appendix 3 Table 2) to 0.64 in May 2002 (p < 0.001, Spearman rank correlation) (Table 6.5).
JgM responses were weakly associated with total JgO responses at all bleeds with correlation
coefficients never rising above 0.4. IgM responses were most strongly associated with those of
1803, with a correlation coefficient of 0.6 in May 2002 and October 2004 (p < 0.001, Spearman
rank correlation) (Table 6.5, Appendix 3 Table 5). The weakest association between anti-AMAI
and anti-schizont extract protein responses was the IgM response. The correlation coefficient
ranged from a low of 0.01 (p = 0.89, Spearman rank correlation) in May 2004 to 0.28 (p < 0.001,
Spearman rank correlation) in May 2002 (Table 6.5, Appendix 3 Table 4). Of the IgG subclass
responses, 1801 had the strongest association with responses to schizont extract protein.
Interestingly, there was a negative association between schizont extract responses and IgO
responses during the May 2004 cross sectional bleed that was significant for total IgG and IgG1 (p
< 0.01, Spearman rank correlation) (Appendix 3, Table 4).
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Table 6.5 Correlations between antibody responses to AMAl(3D7) and schizont extract for the May
2002 cross sectional bleed.
May 2002 Antibody responses
Schizont extract TotallgG' IgGl' IgG3' IgM'
TotallgG' 0.72
IgGl' 0.61 0.88
IgG3' 0.56 0.64 0.74
IgM' 0.28 0.35 0.5 0.6
Notes
Spearman rank correlation coefficients for IgG responses.
All samples tested .
• Antibody response to AMA1(3D7) .
• P·value <0.001
The magnitude of the IgG isotype and subclass response to AMAI was analysed in four age
groupings (children less than a year, 1-3 yearis, 4-6 years, and 7-10 years) as well as by concurrent
parasiemia at each cross sectional bleed. IgGl, IgG3, and IgM responses increased with age during
the May 2002 cross sectional bleed in all children as well as aparasitaemic children (p < 0.00 I,
Kruskal Wallis test), with children ages 7-10 years having significantly higher antibody responses
than those aged 1-3 years (p :S 0.05, Wilcoxon rank sum test) (Table 6.6). Though this remained
the case for all the responses in May 2002, it was not the same at all cross sectional bleeds for IgG3
and IgM. Antibody responses in aparasitaemic children significantly increased with age (p <
0.001, Kruskal Wallis test) only in May 2002, May 2003, and May 2004 for IgG3 and IgM
compared to all cross sectional bleeds for IgG 1 (Appendix 3 Tables 6-8). In children with
concurrent parasitaemia at sampling, antibody responses were similar in all age groups at all cross
sectional bleeds. The only exceptions were for IgG I in May 2003 and IgM in October 2003 where
antibody responses significantly increased with age (p < 0.001, Kruskal Wallis test) (Appendix 3,
Tables 7 and 8). Although concurrent parasitaemia increased the magnitude of the response to
AMA 1(3D7) with regards to all antibodies measured (all samples pooled regardless of age;
p<O.OOI Wilcoxon rank test), its effect was different for the different antibodies measured. A
marked l6-fold and 13-fold increase in median antibody levels was observed for total IgG and
IgGI, whereas a less marked 7-fold increase was noted for JgG3. In comparison to the effect on
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JgG titres~ there was only a modest 2-fold increase in the median IgM response among children
with the presence of circulating parasites.
Total JgG levels to schizont protein extract were measured as a proxy for exposure to blood stage
P.falciparum and responses were divided into tertiles. The antibody response to AMA1(3D7) was
then analysed with regards to these categories. All four antibody responses measured (total IsO,
JgG 1, JgG3, and JgM) in May 2002 increased in magnitude with increasing exposure to P.
falciparum and showed marked differences in those with high exposure compared to those with
low and medium exposure (Figure 6.2). The IgG3 response was of a lower magnitude compared to
the response to JgG 1 although there was also a marked increase in the response of those with high
prior exposure compared to those with less exposure (Figure 6.2C). Not only was there a very low
magnitude IgM response to AMAl(3D7), the median response in those with the highest prior
exposure was not markedly different from those with less prior exposure (Figure 6.20). Analysis
at each cross sectional bleed revealed a similar pattern except for IgG3 in May 2004 and IgM in
both October 2002 and May 2004 (Appendix 3 Tables 11 and 12).
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Figure 6.2 Magnitude of the antibody response to P. falciparum AMAI(3D7) by reactivity to A4
schizont protein. Representative graphs showing isotype and subclass antibody levels at the May 2002 cross
sectional bleed. All samples tested by ELISA. Kruskal- Wallis test for equality of medians; p<O.OOI for all
antigens. Wilcoxon rank sum test for equality of median responses between two categories all p<0.05 except
between 'Low' and' Med' IgM response. (A) Total IgG, (8) IgG I, (C) IgG3, (D) IgM.
6.3.2 Lower IgG subclass responses are seen among children with alpha-thalassemia
Due to the protective effect of both the sickle trait and alpha-thalassemia on clinical malaria, the
antibody response to AMA I(307) was investigated in children with different erythrocyte
polymorph isms (Figure 6.3 Appendix 3 Tables 13-16). As previously reported in chapter 3,
although total IgG titres in children with the sickle trait (HbAS) were generally lower than in their
normal (HbAA) counterparts, this difference was only significant during the May 2003 cross
sectional bleed (p = 0.02; Kruskal-Wallis test) (Appendix 3 Table 13). Although the overall range
of IgG I responses was wider in HbAA children, there was no difference in the median response
when compared to that in HbAS children at all cross sectional bleeds (Figure 6.38, Appendix 3
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Table 14). Both HbAA and HbAS children had similar ranges of IgG3 responses without
differences in their median values (Figure 6.3C, Appendix 3 Table 15). This observation was no
different from that for IgM responses to AMAI(3D7) (Figure 6.3D, Appendix 3 Table 16). Also
previously reported in chapter 3 was the lower total IgG response in alpha-thalassemia
homozygotes as compared to heterozygote and normal children in October 2002, May 2003, and
May 2004 (p ~ 0.05; Kruskal Wallis test) (Appendix 3 Table 13). The IgG I response in alpha-
thalassemia homozygotes was also significantly lower than that in the heterozygotes in October
2002 and May 2003 (p ~ 0.05; Wilcoxon rank test), and between homozygotes and normal children
in Ocotber 2003 and May 2004 (p ~ 0.05; Wilcoxon rank test) (Appendix 3 Table 14). There was
no difference in IgG3 responses in alpha-thalassemia homozygotes and heterozygotes compared to
normal children at all cross sectional bleeds (Appendix 3 Table 15). Only in May 2003 was there a
significantly lower IgM response in alpha-thalssemia homozygotes compared to the heterozygotes
and normal children (Appendix 3 Table 16).
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Figure 6.3 Magnitude of the antibody (lgG) response to P. falclparum merozoite antigens in the
presence or absence of haemoglobinopathies (sickle trait and a-thalassemia). AA=Normal, AS=Sickle
trait, Norm=Normal, Het=Heterozygous, Hom=Homozygous. Representative graphs showing [gG levels at
the May 2002 cross sectional bleed. All samples tested by ELISA. Kruskal-Wallis test for equality of
median responses in sickle trait and a-thalassemia categories non-significant for all antibody responses
tested. Wilcoxon rank sum test for equality of median responses between two sickle trait categories non-
significant for all antibody responses tested. (A) Total IgG, (B) IgG I, Cc) IgG3, CD)JgM.
6.3.3 The IgGl response to AMAI is predominant over the study period
Standardised measures of antibodies were plotted over the entire period for each child present at all
sample times as described in chapter 5 (Figure 6.4). Similar to the antibody plots for total IgG,
antibody profiles of IgG 1 could be described in three groupings. A number of children maintained
a high antibody response throughout the study period whereas a smaller group had highly
fluctuating antibody responses. The third group was made up of a considerable number of children
who maintained a low antibody response (below 0.5 OD units) over the entire study period (Figure
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6.4A-B). Most IgG3 responses were maintained at low levels throughout the study period with a
few individuals exhibiting minor fluctuations and only two individuals maintaining high antibody
levels throughout the study period (Figure 6.4C). All children had low levels of anti-AMA I(307)
IgM throughout the study with a single child exhibiting a single peak in October 2003 (Figure
6.40).
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Figure 6.4 Longitudinal antibody responses to P.falciparum AMAI(3D7) for children present at all six
sample times. Each line represents an individual. (A) TotallgG, (8) IgG 1, (C) IgG3, (0) IgM.
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Longitudinal antibody profiles of selected children who were below 2 years at the start of the study
were similar with regards to all IgG and IgM responses (Figures 6.sA-B). Only in a few
individuals could a predominant IgGI response that mirrored the total IgO response be observed.
In those children who were aged 2 or above at the start of the study, a predominantly IgGl
response became more common although a number of children still exhibited isotype and subclass
responses that had similar patterns (Figure 6.sC-D). In the oldest age group, most children had
high IgOI responses that were so similar to the total IgO response and Ig03 responses that were
negligible (Figure 6.sE-F), that one could assume that the overall IgO response to AMAI(3D7)
was an IgG1 response.
Although the examples of individual plots described above (Figure 6.5) show most children
maintaining a stable antibody response - whether high or low - over the study period, there was an
overall decline in antibody levels among the cohort (Figure 6.6). Levels of IgG1 followed the total
IgO trend described in chapter 4, and although modest in magnitude there was also a decline in
Ig03 levels over the study period. IgM levels remained low and throughout the study period. To
quantify the age in antibody levels over the study period, univariate OEE with exchangeable
correlation structure was carried out with sample time as the dependent variable. Over the entire
study period each successive sampling time was associated with an average significant decline in
antibody levels with P coefficients ofO.02 for total IgO, and 0.01 for IgG3 (p < 0.001) (Table 6.7).
Though there was a decline of 0.01 for IgGI, it was of borderline significance (p = 0.09). The
borderline significance is probably explained by the marginal increase in mean IgG1 levels
between May 2002 and October 2003 which then dropped at the same rate as the total IgG
responses to levels below those seen at the start of the study.
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Figure 6.5 Longitudinal antibody (IgG) responses to Pi falclparum AMAJ(3D7) for selected individuals
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Figure 6.6 Mean antibody titres to Pi falciparum AMAl(307) over the study period. Plots were created
using locally weighted scatterplot smoothing (LOWESS) with all the samples in the study. Each line on the
plots represents the antibody levels corresponding to a single immunoglobulin isotype or subclass. Dark blue
- TotallgG, red - IgG I, green - IgG3, yellow - IgM.
Table 6.7 Changes in antibody responses to AMAl(307) in Ngerenya
I! (95%Cl)' P·value
AMA1(3D7) Total laG ·0.02 (·0.03, ·0.01) <0.001
AMA1(3D7) IIG1 -0.01 (·0.01, 0) 0.09
AMA1(3D7) IgG3 ·0.01 (·0.01, 0) <0.001
AMA1(3D7) laM 0(0,0) 0.56
~
Univariate generalized estimating equation (GEE) with exchangeable correlation structure.
'Reductlon in antibody levels at each cross sectional bleed over the entire study period.
P-values SO.OS indicated in bold.
To better understand the population trend in antibody responses, the children were divided into
three age groups defined by their age the start of the study period (May 2002); 0-2 years, 3-5 years,
and 6-7 years. Mean antibody levels were plotted for each of the three age categories using
Lowess smoothing techniques and differences in antibody levels throughout the study period were
analysed by GEE (Table 6.8).
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Table 6.8 The effect of age on antibody responses to AMAl (3D7)
Age group' p (95% Cl)' P-value
TotallgG 3-5 years 0.23 (0.10, 0.36) 0.001
6-7 years 0.68 (0.52, 0.84) <0.001
IgG1 3-5 years 0.24 (0.11, 0.37) <0.001
6-7 years 0.72 (0.56, 0.88) <0.001
IgG3 3-5 years 0.02 (-0.03, 0.08) 0.40
6-7 years 0.09 (0.03, 0.16) 0.004
IgM 3-5 years 0.01 (0.00, 0.03) 0.008
6-7 years 0.03 (0.02, 0.04) <0.001
Notes
Univariate generalized estimating equation (GEE) with exchangeable correlation structure (n=299).
t.. Age group during May 2002 sample time.
*GEE regression coefficients indicating reduction/increase in the antibody response compared to children age O~2years.
Antibody responses to AMAl(3D7) were highest in children who were 6-7 years at the start of the
study followed by those in 3-5 year olds with the youngest children maintaining the lowest
antibody levels throughout the study period (Figure 6.7). Even though the children were getting
older - the 0-2 year olds being up to 4 years old in October 2004 and those who were 3-5 years in
May 2002 being 7 years old at the end of the study - none of the antibody responses showed an
overall increase with age over the study period. Although IgG I levels appeared to rise from May
2002 to October 2003, this change was marginal (Figure 6.78). The single marked increase in
antibody responses with age was seen for IgG3 between October 2002 and October 2003 in
children who were 0-2 years at the start of the study (Figure 6.7C). The mean IgG3 levels in these
children eventually matched those of the 3-5 year olds and then declined at a similar rate. The
increase in antibody levels from one age grouping to the next was significant for all antibodies
(GEE: p <0.01). Antibody levels in the two older age groups compared with the youngest children
were significantly higher (GEE: p <0.01) with mean antibody levels increasing up to 0.72 units
(95% Cl: 0.56, 0.88) between 0-2 year olds and 6-7 year olds for JgG I (Table 6.8). As indicated
by the IgG3 plot, there was a slight non-significant difference in the overall antibody response of 3-
5 year olds compared to 0-2 year olds ofO.02 OD units (95% Cl: -0.03,0.08; P = 0040).
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Figure 6.7 Mean antibody (lgG) titres to AMAl(3D7) over the study period in different age groups.
Plots were created using locally weighted scatter plot smoothing (LOWESS) with all the samples in the
study. Each line on the plots represents the antibody levels corresponding to an age grouping at the start of
the study; 0-2 years (blue), 3-5 years (red), 6-7 years (green). (A) Total IgG (B) IgG 1, (C) IgG3, (D) IgM.
6.3.4 Increasing episodes of clinical malaria do not affect the balance of IgG 1 and IgG3
responses to AMAI
To investigate the hypothesis that repeated episodes of malaria leads to a polarisation of the IgG
response from a mixed subclass response to a predominantly IgG 1 response, mean antibody titres
were plotted for children who had no exposure, those who had no clinical episodes, those who had
one clinical episode and those who had two or more clinical episodes during the study (Figure 6.8).
10 all instances IgG I was the predominant response. IgG3 responses remained very low even when
children had been exposed though did not have any clinical malaria (Figure 6.88). Those with one
or more clinical episodes during the study had increasing IgG 1 responses over time with no
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significant change in the IgG3 response (Figure 6.8C-D); this further indicates that exposure to
malaria is mainly inducing IgG I to AMAl. In the last 12 months of the study there were no
recorded episodes of clinical malaria and very little parasitaemia at cross sectional bleeds which
probably explains why all antibody levels declined over that time.
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Figure 6.8 Mean antibody titres to P. falciparum AMAl(3D7) over the study period in children with
different outcomes. CA)No parasitaemia, (B) no clinical episodes, (C) one clinical episode, and (D) two or
more clinical episodes during the study period. Each line on the plots represents the mean antibody level
corresponding to a single immunoglobulin isotype or subclass. Dark blue - Total IgG, red - IgG I, green -
IgG3, yellow - IgM.
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6.3.5 Effect of P./alc/ptl,,,,,. infection on boosting and induction of antibodies to AMAI
Assessment of the likelihood that recorded episode of P. falciparum infection in the six months
prior to sampling results in high antibody titres was carried out by logistic regression as detailed in
chapter 3. The probability of a positive antibody response above the 75th centile was calculated for
all samples, and stratified by the presence or absence of concurrent parasitaemia at sampling and
by age group.
For both IgO subclass responses the probability of an antibody response above the 75th centile
increased in a linear manner from a baseline of 20% among those who had no infection and peaked
around 4()oA,for IgOI after 2 parasitaemic episodes (Figure 6.9A). The probability remained the
same after more than two episodes. In contrast, the probability continued to rise for both Ig03 and
total IgO with maximum probabilities of 52% and 45% respectively after 5 recorded parasitmeic
episodes. The probability of an IgM response above the 75th centile remained below 25%
regardless of the number of episodes of parasitaemia in the prior 6 months, indicating that there
was no clear induction or boosting of IgM levels in responses to infection. In parasite negative
children a similar pattern to that described above was observed for the IgG subclasses although the
peak probabilities were slightly lower (reduced by 5%) (Figure 6.9C). In contrast to the stable
probability of an IgM response when all samples were included in the analysis; that of a high IgM
response in aparasitaemic tended to decline (from 22% at baseline to less than 20% after 4 recorded
parasitaemic episodes).
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Figure 6.9 The predicted probability of antibodyresponses to AMA 1(307) above the 75th centile by the
number of recorded parasitaemic episodes in the 6 months prior to sampling. Each antibody response is
represented by a single line on each graph; dark blue = Total IgG, maroon = IgG I, green = IgG3, yellow =
IgM. (A) Predicted probability of antibody titres above the 75th centile in all samples, (B) parasite positive at
sample time, and (C) parasite positive at sample time. Predicted probability of antibody titres above the 75th
centile in children ages 0-4 years (D) and ages 5-9 years (E) at sampling.
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Children with concurrent parasitaemia at sampling had a higher probability of being a high
responder and suggested in chapter 3, and the probabilities of high antibody responses after
parasitaemia episodes were substantially different to those in aparasitaemic children. The
probability of a high response among children with no episodes was around 65% for both total IgG
and IgG1. This probability reduced with increasing episodes of parasitaemia in the prior 6 months
to 53% after 2 episodes and less than 40% after 7 episodes for total IgG. In contrast, the
probability of a' high IgG1 response in parasitaemic children increased slightly with further
exposure to 57% after 7 recorded parasitaemic episodes (Figure 6.9B). The probability of a high
IgG3 response among children with no episodes in the prior 6 months was 53% which increased
with prior episodes and peaked at 67% after 2 parasitaemic episodes and then dropped to 38% after
7 recorded parasitaemic episodes. These findings suggest that children with active parasitaemia
already have a significant probability of having high antibody levels and therefore an increasing
number of prior episodes did not have a substantial effect on antibody levels. Children with
concurrent parasitaemia at sampling had a 40% probability of having a high IgM response that
fluctuated somewhat with a 300Alprobability after three recorded parasitaemic episodes and 45%
after 7 recorded episodes (Figure 6.9B). These findings further suggest that there was little
ongoing induction or boosting of IgM responses in response to infection, and that exposure was
mainly boosting IgG responses.
The probability of a high total IgG, IgG1, and IgG3 response to AMA1(307) increased with
increasing prior episodes in children ages 0-4 years at sampling (Figure 6.90). The likelihood of a
high total IgG and IgGI response was below 10% for those who had no prior episodes and
increased to 30% after 2 recorded parasitaemic episodes. On further exposure, the likelihood of a
high IgGI response did not increase as much and peaked at 35% for IgGI and 45% for total IgG
after four episodes. Although the predominant response to AMAI was IgG1, the likelihood of a
high IgG3 response was always greater than that of IgGI. Without any prior exposure in the past 6
months, a child aged 0-4 years had a 14% probability of a high IgG3 response that rose with
increasing exposure to 52% after 4 recorded parasitaemic episodes (Figure 6.90). In contract to
the IgG responses, the probability of a high IgM response fell from 20% at baseline to 13% after 4
recorded parasitaemic episodes. Older children (ages 5-9 years) were more likely to have high
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antibody responses even in the absence of prior exposure (Figure 6.9E). Among this age group, the
likelihood of high total IgG, IgG 1, and IgG3 responses followed a similar pattern with an
increasing probability to a peak after 3 episodes of recorded parasitaemia followed by a decline to
below that for children with no prior episodes for total IgG and IgG 1. The probability of a high
IgG I and total IgG response was 35% at baseline compared to 28% for IgG3. This rose to 55% for
total IgG and 50% for IgG I and IgG3 after 3 parasitaemic episodes and declined to 25% for total
IgG, 27% for IgG I, and 30% for IgG3 after 7 episodes of recorded parasitaemia. This suggested
that there is a subgroup of children who had poor induction of antibodies, reflected by a low
probability of being antibody positive among those children who had multiple recorded episodes of
parasitaemia. The probability of a high IgM response remained stable around 30% regardless of
exposure (Figure 6.9E).
The probability of being classified as antibody positive (titres above the mean+3SD value of a
panel of negative controls) in relation to recorded prior parasitaemia episodes was also analysed.
All IgG isotypes showed an increase in the probability of sero-positivity from no episodes to 2-3
parasitaemic episodes in the prior 6 months (Figure 6.10A). After 3 parasitaemic episodes,
children had a 70% probability of being sero-positve for total IgG compared to 55% for IgG I and
35% for IgG3 after 4 episodes. In contrast, the probability of being IgM sero-positive remained
below 10% regardless of the number of parasitaemic episodes experienced in the prior 6 months,
further indicating a lack of induction or boosting of this response in the cohort. The probabil ity of
a positive antibody response in those with parasitaemia at sampling was different. Among those
with no prior episodes of parasitaemia, children were more likely to have an IgG I response (70%)
compared to an IgG3 response (50%) (Figure 6.1OB). The probability of an IgG I and IgG3
response increased with increasing exposure and peaked at 60% after 2 episodes of recorded
parasitaemia for IgG3 compared with a decline to 60% after 2 episodes for IgG I. Further exposure
increased the probability of an IgG I response to 80% after 7 episodes of recorded parasitaemia. In
contrast, the probability of an IgG3 response declined to 40% after 7 parasitaemic episodes.
Further exposure did not increase the likelihood of an IgG response. The probability of an IgM
response to AMA I(3D7) remained below 20% regardless of concurrent parasitaemia or increasing
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prior exposure, though there was a steady decline in the likelihood with increasing exposure in
parasitaemic children (Figure 6.10B). These findings again suggest that most children with active
parasitaemia already have antibodies and therefore an increasing number of prior episodes does not
have a substantial effect on antibodies.
When stratified by age, the probability of all the tested antibody responses to AMA I(307) were
similar in children ages 0-4 years as those described above when all the samples were analysed
together although the peak probabilities never rose above 65% (Figure 6.100). This was not the
case for older children. Among children aged 5-9 years, the probability of being antibody positive
was 50010, 38%, and 20010for totallgO, IgOl and Ig03 responses respectively, for those with no
prior episodes (Figure 6.10E). The probability of these responses increased at a similar rate to
80%, 60010,and 40% respectively after 3 parasitaemic episodes and declined to 50% for total IgO
and IgO 1 and 20% for Ig03 after 7 episodes. The likelihood of a detectable IgM response in older
children remained around 10% regardless of the amount of prior exposure (Figure 6.1OE).
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Figure 6.10 The predicted probability of detectable antibody responses to AMAI(307) by the number
of recorded parasitaemic episodes in the 6 months prior to sampling. Each antibody response is
represented by a single line on each graph; dark blue = Total [gG, maroon = [gG I, green = IgG3, yellow =
[gM. (A) Predicted probability of sero-positive responses in all samples, (8) parasite positive at sample time,
and (C) parasite positive at sample time. Predicted probability of sero-positive responses in children ages 0-4
years (D) and ages 5-9 years (E) at sampling.
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Further investigations using categories described in previous chapters was carried out. Children
were split into three age groups defined by their age the start of the study period (May 2002) and
the likelihood of an antibody response after recorded exposure was plotted. In all age groups the
probability of a measurable IsO 1 response was the same as that for a total IgG response (Figure
6.11). Without any recorded parasitaemia in the prior six months, the youngest children (0-2 years
at the start of the study) had a 1()oA, predicted probability of having a positive IgOI response
compared to 20% for 3-5 year olds and 55% for 6-7 year olds. The probability of an IgO1 response
increased in a linear manner for the youngest children and was at 48% after 6 recorded episodes
(Figure 6.1IA). In the 3-5 year olds, the probability ofan IgOI response increased linearly to 55%
after two recorded episodes then continued to increase at a slower rate to 60% after 5 recorded
episodes (Figure 6.IIB). The oldest children had an increase from 55% without any parasitaemia
to 75% after three recorded episodes and then declined to 65% after seven recorded episodes
(Figure 6.11C).
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Figure 6.11 Predicted probability ofa positive antibody response to Pi falciparum AMAI(3D7) in each
age group by the number of recorded parasitaemic episodes in the 6 months prior to sampling time.
Antibody titres above the mean+3SD value of a panel of non-exposed negative controls are considered
poisitve. Each immunoglobulin isotype or subclass is represented by a single line; dark blue = total IgG, red
= IgG 1, green = IgG3, yellow = IgM. (A) 0-2 years at the satrt of the study, (8) 3-5 years at the start of the
study, (C) 6-7 years at the start of the study.
The probability of an IgG3 response to AMAl(3D7) was overall lower than that of IgG I. The
youngest children had a 5% probability of an IgG3 response without any recorded parasitaemia in
the prior six months compared to 15% for the 3-5 year olds and 25% for the oldest children. The
probability of an IgG3 response increased at the same rate as that of an IgG I response in the
youngest children but peaked and remained at 30% after two recorded episodes (Figure 6.11 A). In
3-5 year old children, the probability of an IgG3 response increased linearly to 40% after 4
episodes. Like the IgG I response in the youngest children, the probability of an IgG3 response in
3-5 year aids continued to rise with no changes (Figure 6.118). After three recorded episodes, the
probability of an IgG3 response peaked at 50% in the oldest children and fell to 20% after seven
223
recorded episodes (Figure 6.11C). Though the probability of an IgM response was highest in the
oldest children at 1()OAt, it did not change regardless of the number of times that the child
experienced parasitaemia in the prior six months. In contrast and although a minor effect, the
probability of an IgM response declined from 5% without recorded exposure to zero after five
episodes in the youngest children (Figure 6.11A). In the 3-5 year olds there was a corresponding
increase from 7% with no exposure to 10% after three recorded episodes in the probability of an
IgM response (Figure 6.11B). These results suggest that although repeated infections increased the
levels of I~, they did not increase the levels of IgM.
6.3.6 The association between isotype and subclass responses to AMAI and protection from
clinical malaria
As described in chapter 6, different analysis methods (cross-sectional and longitudinal) gave
different associations with risk of or protection from clinical malaria for different antibody
responses when a single sample point was used in the cross sectional analysis. This was also the
case for IgG 1, IgG3, and IgM responses. All three antibody responses were associated with an
increased risk of disease in the subsequent six months when analysed cross-sectionally in May
2002 (Table 6.9). The only association that approached significance was that with the IgG 1
response (IRR 1.52, 95% Cl 0.97 - 2.38, P = 0.(7). There were no statistically significant
associations for IgM (Eg. IRR 0.05, 95% Cl 0.00 - 5.98, P = 0.22 for May 2003). When all the
samples were analysed using a clustering indicator, IgG 1 and IgG3 responses had no association
with the risk of clinical malaria in the six months subsequent to sampling in both the univariate and
multivariable analysis. Though IgM responses appeared to be associated with protection from
malaria in both the univariate and multivariable analysis (lRR 0.27 and 0.53), none of these effects
were statistically significant (Table 6.9).
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Table 6.9 The association between antibody responses to AMAl(3D7) and the risk of clinical malaria
in the 6 months subsequent to sampling time
All samples·
Univariate analysis' Multivarlable analysis'
IRR(95%CI) P-value IRR(95% Cl) P-value
TotallgG 1.09 (0.87, 1.38) 0.46 1.02 (0.78, 1.33) 0.88
IgG1 1.09 (0.85, 1.41) 0.50 1.03 (0.77, 1.38) 0.84
IIG3 1.05 (0.64, 1.7) 0.86 1.05 (0.6, 1.82) 0.87
11M 0.27 (0.01, 5.79) 0.40 0.53 (0.03,8.97) 0.66
TotalllG 1.36 (0.85, 2.16) 0.20 1.2 (0.71, 2.05) 0.50
IIG1 1.52 (0.97, 2.38) 0.07 1.39 (0.83, 2.32) 0.21
IIG3 1.56 (0.57, 4.25) 0.39 1.46 (0.47, 4.61) 0.51
11M 17 (0.1, 2839.3) 0.28 13.89 (0.06, 3182.87) 0.34
Total leG 1.03 (0.79, 1.36) 0.81 0.91 (0.67, 1.23) 0.54
leG1 1.07 (0.82, 1.41) 0.61 0.95 (0.71, 1.28) 0.74
leG3 0.8 (0.24, 2.66) 0.72 0.74 (0.21, 2.59) 0.64
leM 0.95 (0.05, 16.59) 0.97 0.85 (0.04, 16.97) 0.91
Total leG 1.09 (0.8, 1.47) 0.59 1.02 (0.72, 1.44) 0.92
IgG1 1.12 (0.83, 1.51) 0.45 1.07 (0.76, 1.51) 0.71
leG3 1.43 (0.54, 3,79) 0.48 1.64 (0.53, 5.08) 0.40
leM 0,05 (0, 5.98) 0.22 0.14 (0, 15.95) 0.42
May 2002'
October 2002'
May 2003'
Notes
t Univariaable poisson regression.
eMultivariable poisson regression (adjusted for age, concurrent parasitaemia, and haemoglobinopathies)
lI. Analysis of all samples (aU6 sampling points) with the addition of an indicator for those children contributIng more than one observation to the analysis.
t Analysis covering the 6 month period subsequent to the cross sectional bleed indicated.
No analysis for October 2003, May 2004, and October 2004 cross-section bleeds due to lack of malaria episodes after the October 2003 sampling,
P·values :S0,1 indicated in bold,
Multivariable GEE was carried out to investigate the overall effect on antibody levels of all the
factors discussed in chapter 3. Both recurrent parasitaemia at sample time and being in the highest
age category (6-7 years at the start of the study) significantly increased antibody levels to the same
degree (~=O.57, p<O.OOl). Though prior parasitaemia also had a significant association (p<O.OOI)
with total IgG levels, it was not as high as of age and recurrent parasitaemia, In the case of IgG I,
age (6-7 years at the start of the study) and recurrent parasitaemia significantly increased antibody
levels by the greatest degree. Contrasting with the total IgG and IgG I results, age was not
associated with 19G3 responses to the same degree (~=O.07, p=O.02). Recurrent parasitaemia was
the strongest predictor of IgG3 responses W=O.17, p<O.OOl), Though significant, the effects of age
and recurrent parasitaemia on IgM levels were much smaller than those on IgG subclasses (P=O.02
and ~=O.03 respectively, both p<O.OO 1). Though the haemoglobinopathies led to a reduction in all
antibody responses, the only significant effect was that of the sickle trait on total IgG levels
(p=O.03).
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Longitudinal analysis of the association between antibody responses and protection from malaria
gave slightly different results to those seen in the cross-sectional analysis with clustering (Table
6.10). In the multivariable GEE, IgG 1 and IgG3 responses were not associated with a higher or
lower risk of malaria over the entire study period. IgM responses were associated with protection
in both the univariate and multivariable analysis (lRR 0.10 and 0.27) though they were not
statistically significant. Even after removal of those children who had not been exposed over the
study period the relationships remained the same; IgG I, IgG3, and IgM had no significant
association with the risk of malaria (Table 6.10).
Table 6.10 The effect of antibody responses to AMAl(3D7) on the risk of malaria over the study
period.
Univariate analyslsO All children' Exposed children
IRR (95% Cl) P-value IRR (95% Cl) P-value IRR (95% Cl) P-value
Totall,G 1.07 (0.88, 1.31) 0.50 1.04 (0.82, 1.31) 0.75 1.01 (0.81, 1.25) 0.94
IIG1 1.04 (0.84, 1.28) 0.72 1.02 (0.8, 1.29) 0.90
0.98 (0.78,1.22) 0.84
IIG3 0.94 (0.46, 1.89) 0.85 0.92 (0.43, 1.97) 0.83 0.89 (0.43, 1.8) 0.74
I,M 0.1 (0.01, 1.44) 0.09 0.27 (0.02, 3.37) 0.31 0.18 (0.02, 2.19) 0.18
Notes
• Univariate generalised estimating equation (GEE).
11 Multivariable GEE, exchangeable correlation structure. All samples.
I Multivariable GEE, exchangeable correlation structure. Only those children with recorded P. Jalciparum exposure during the study.
P-values SO.llndlcated in bold,
6.4 Discussion
In agreement with published findings (Riley et at. 2000; Polley et at. 2004; Metenou et at. 2007;
Nebie et al. 2008; Stanisic et at. 2009), IgG 1 was the predominant subclass response to
AMAl(3D7) from the age of 3 years. This IgGI predominance was also seen over the entire
duration of the study. lncreasing age led to higher IgG I responses at all cross sectional bleeds
which is in agreement with recent findings in Papua New Guinea (Stanisic et al. 2009). Unlike the
study mentioned, IgG3 levels significantly increased in one year intervals rather than every six
months like IgG I. This result points to a slower acquisition of IgG3 responses to AMA I. In
agreement with Stanisic et al there was no evidence that increasing age led to polarisation of the
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antibody response to AMA 1 as was seen in previous studies (Taylor et al. 1998; Tongren et al.
2006). The longitudinal nature of this study made it particularly good at examining whether
polarisation of IgG subclass responses occurs over time. Although it may be argued that the
reduction in malaria transmission during the course of this study would make it difficult to address
whether polarisation actually occurred, the weekly follow-up allowed us to indentify children with
varying amounts of exposure and plot their IgG 1 and IgG3 responses over time.
The acquisition and maintenance of the IgG 1 response was very similar to that of the overall IgG
response, whereas that of IgG3 differed somewhat. One or two recorded episodes of parasitaemia
in the 6 months prior to sampling time was associated with an increased probability of having high
IgG, IgG 1, and IgG3 levels. More than three prior parasitaemic episodes were associated with a
lower probability of a high titre IgG 1 response. This result appears to indicate that there is a cap on
the probability of a high titre response. In children who are still in the active stages of acquiring
malaria immunity, the propensity to mount an IgG 1 response was similar to that of IgG3 up to two
prior episodes. Further episodes result in a predominantly IgG I response. This could be due to the
relative immaturity of the immune cells which leads to an initial mixed IgG subclass response. On
further exposure the nature of the antigen may have a stronger effect thus leading to a
predominantly IgG 1 response. Above the age of two years children may have accumulated
sufficient exposure to the antigen that would lead to a predominantly IgG I response. Both these
points are supported by the fact that the strongest factor associated with antibody levels was
recurrent exposure.
IgG3 was the minor subclass response to AMA1(3D7). Unlike the dominant IgGI subclass, IgG3
was titres were not reduced in children with haemoglobinopathies. In agreement with published
data, the overall levels remained low throughout the study period. The slight increase in IgG3
levels seen between October 2002 and October 2003 in the youngest children (0-2 years at the start
of the study) could be attributed to the initial stages of exposure in relatively naive immune
systems which result in a mixed response dominated by IgG I but where IgG3 is also present. This
is supported by the fact that prevalence of IgG 1 and IgG3 was similar in children until the age of
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three when IgO 1 began to dominate. Therefore it is possible that the highest IgO antibody levels
would be reached after few exposures and any further exposure would not lead to increased levels.
IgM is induced on primary exposure to antigen therefore low prevalence is expected in areas where
malaria is endemic, as was the case in this study. The fact that IgG and IgM responses to AMA 1
do not strongly correlate with each other is in agreement with the idea that increasing malaria
exposure boosts secondary responses (IgG) and induces a memory response. A high correlation
might suggest that this memory response is not being generated effectively. As the children in this
study were continuously being exposed to Plasmodium, it was unlikely that we were observing
primary exposure except in the youngest children. This would explain the low IgM levels
throughout the study. The higher levels seen in older children were still relatively low when
compared to the IgO response. Because IgM is induced on initial exposure, we did not expect any
further exposure of the same antigen, whether or not it results in clinical disease to induce an IgM
response. This result was in agreement with the concepts of IgM induction on primary exposure
and not evidence of a failure in isotype switching as has been suggested (Scopel et al. 2006;
Tongren et al. 2006). As the disease-causing parasite and its corresponding antigen are more likely
than not to be of a heterologous strain, measurement of the IgM response to one variant _
AMAl(307) in this case - would be unable to capture any induction in IgM that may result from
exposure to new variants. The probability of an IgM response considered sero-positive remained
low regardless parasitaemia episodes. The low IgM titres observed were due to the fact that most
of the children were already exposed at the start of the study and this continued throughout the
study even as transmission dropped. Any IgM peaks could not be detected due to the wide
sampling times. The relatively stable probability of a high titre IgM response on increasing
exposure may indicate that on every exposure to any antigen, regardless of primary or secondary
exposure, there is a certain amount of IgM that is produced by the immune system.
Total IgO responses to AMAl(307) did not have any effect on protection from clinical malaria in
previous chapters so it is not surprising that the IgO 1 response also had no association with
protection as this was the predominant IgO subclass response. This resulted contrasted with that
found in Burkina Faso where IgO 1 was associated with protection from clinical malaria (Nebie et
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al. 2008). The lack of association for IgG I with protection has also been suggested in another
study (Stanisic et al. 2009). Unlike the Stanisic et al study IgG3 was not associated with protection
from malaria. The protection seen with regards to IgG3 in that study is surprising as one would not
expect the minor subclass response to be that which will confer protection. It has been suggested
that differences in population genetics, age groups, and malaria transmission could be the reason
for this result.
Increasing IgG I titres in association with increasing exposure and disease suggest that this
response to AMA 1(3D7) could be a marker of exposure rather than one of protection in th is cohort.
Although statistically non-significant, only IgM responses were associated with protection from
clinical disease. If the low affinity nature of IgM allows it to bind to different variants of the same
antigen then this association with protection could be due to the IgM interacting with another
AMA 1 variant on the disease causing parasite. This non-specific response along with other more
specific IgG responses could end up protecting the individual from disease. Due to time
constraints investigation of the subclass and isotype response in another antigen was not possible.
Future work is planned for MSP2(3D7) as an example of an antigen that induces an IgG3 dominant
response.
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7 Acquisition and prevalence of antibodies to specific
epitopes of AMAI and their association with invasion
inhibition and protection from clinical malaria
7.1 Introduction
Passive transfer of antibodies from immune individuals was first shown to confer protection against
malaria in the 1960s (Cohen et al. 1961). There are numerous Plasmodium spp proteins to which
naturally acquired antibodies have been measured including the blood-stage antigens; apical
membrane protein 1 (AMAI), merozoite surface proteins 1-3 (MSPI - MSP3), and erythrocyte
binding antigen 175 (EBAI75) among others. Immuno-epidemiological studies also provide
further evidence that these above mentioned antigens may be targets of protective immunity
(Conway et al. 2000; Cavanagh et al. 2004; Polley et al. 2004).
Protection from disease in immunization-challenge studies with recombinant AMA I in animal
models has been observed (Deans et al. 1988; Collins et al. 1994; Crewther et al. 1996; Anders et
al. 1998; Narum et al. 2000), although the AMAI needs to be folded in its proper conformation in
order to do so (Collins et al. 1994; Crewther et al. 1996; Anders et al. 1998). Antibodies to AMA I
are also detected in most members of malaria endemic populations (Thomas et al. 1994; Johnson et
al. 2004; Polley et al. 2004; Chelimo et al. 2005; Cortes et al. 2005). Some immuno-
epidemiological studies show that individuals with high levels of AMA 1 specific antibodies are at a
reduced risk of experiencing an episode of clinical malaria (Polley et al. 2004; Gray et al. 2007;
Osier et al. 2008; Stanisic et al. 2009), although a couple have not indicated this protective effect of
anti-AMA 1 antibodies (Roussilhon et al. 2007; Nebie et al. 2008).
Antibodies to AMA 1 are able to inhibit invasion of erythrocytes by merozoites in vitro (Hodder et
al. 2001; Healer et al. 2004), and although most of inhibitory antibodies are targeted to
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polymorphic regions of the protein, and inhibitory antibodies are generally strain specific, there is
some evidence that invasion-inhibitory antibodies could also recognize conserved or less
polymorphic epitopes (Kennedy et al. 2002; Collins et al. 2007). Inhibition of erythrocyte invasion
by parasites appears to be variant specific as well as cross reactive. Antibodies produced by the
immunisation of rabbits with recombinant 307 PfAMAI significantly inhibited invasion of P.
falciparum field isolates and lab strains that share sequence similarity (eg. 0 I0) whereas those
antibodies generated by immunization with recombinant FVO PfAMA 1 were able to inhibit
erythrocyte invasion by field isolates and well lab strains in with divergent AMA1 sequences
(Duan et al. 2008). Though both animal and human antibodies to AMA1 can inhibit invasion of
erythrocytes, most of the antibodies tested interact with strain-specific epitopes in order to exert
this functionality (Hodder et al. 2001).
The crystal structure of AMA1 reveals a long hydrophobic region in domain I that is hypothesised
to be a ligand-binding site. It is surrounded by a region consisting of the highest number of
polymorphic residues in the protein (Bai et al. 2005). These polymorphisms appear to have arisen
due to diversifying selection in order to avoid invasion-inhibitory antibodies (Cortes et al. 2003;
Polley et al. 2003). Invasion inhibitory epitopes in domains II and III have also been described
(Nair et al. 2002; Mueller et al. 2003; Collins et al. 2007). As a primary action of antibodies to
AMAI is inhibition of invasion, we set out to investigate the prevalence and acquisition of
antibodies to specific polymorphic and invasion-inhibitory AMAI epitopes in a malaria-endemic
setting, and to relate these antibodies to protection from clinical malaria.
Monoclonal antibody IF9 is strain specific and inhibits invasion of 307 and 010 P. falciparum
parasites but not HB3 or W2mef, and recognises a polymorphic epitope in domain I (Coley et al.
2001; Coley et al. 2006). The 010 and 307 strains of AMAI are identical in domain I but differ in
domains II and III. The actual binding site of mAb 1F9 appears to be part of the hydrophobic
trough and the surrounding loops on the AMA1 surface (Figure 7.1). This interaction between
AMA I and mAb 1F9 is quite large, conformationally dependent, and substitution of residue 197
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completely inhibits the AMA 1-1F9 interaction (Coley et al. 2006). The interface between AMA 1
and IF9 is made up of a large buried area that the antibody protrudes into. Though this interface is
unusual, binding of mAb IF9 does not significantly affect the structure of AMA I (Coley et al.
2007). Antibodies from exposed individuals from Papua New Guinea compete with mAb IF9 for
binding to AMA 1, whereas antibodies from non-malaria exposed individuals do not (Coley et al.
2007).
A B
Figure 7.1 X-ray structure of P. falciparum AMAI domains I and II showing the hydrophobic trough
and binding sites of mAb 1F9 and mAb 4G2. (A) Base of the hydrophobic trough indicated in green,
disordered loops in purple (Bai et al. 2005), (B) residue 197 that is critical for mAb I F9 binding shown in
blue, mAb 4G2 critical residues in red, and the hydrophobic cleft is in yellow (Coley et al. 2006).
Monoclonal antibody 2C5 also reacts with 3D7 and DI 0 Pi falciparum AMA 1. MAb 2C5 does not
inhibit invasion of erythrocytes by merozoites (Coley et al. 2006). As the entire, correctly folded
AMA I ectad amain is necessary for reactivity, a distinct epitope separate from that of IF9 but
which is common to the 307 and DI0 strains is suggested. MAb 5G8 is not strain specific in its
interactions but only recognizes P. falciparum (Coley et al. 2006). It recognizes a 19 residue linear
epitope in the N-terminal pro-sequence/pro-domain of AMA I (Coley et al. 200 I). As the
prosequence is cleaved from the mature form of AMA I expressed by P. falciparum merozoites we
do not expect much malaria- and age-related reactivity to the mAb 5G8 epitope, but it will serve as
a control.
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Another invasion inhibitory monoclonal antibody that has been studied in detail is 402. Initial
studies showed that 402 exerted its inhibitory effects not by simple steric effects but by binding to
a functionally important part of AMAI. This same study revealed that the mAb 402 epitope was
conserved across all P. falciparum variants and was situated in the domain II loop of AMA1
(Figure I) (Coley et al. 2007). AMAI forms a complex with the essential rhoptry neck protein
RON4 which then associates with the moving junction during invasion. MAb 4G2 appears to exert
its inhibitory effects by binding to the domain II loop before the AMAIIRON4 complex forms and
therefore inhibits downstream invasion actions (Collins et al. 2009).
It has not been possible to directly measure AMAl-specifc inhibitory antibodies in relation to
protection from clinical malaria. With the use of mAbs IF9, 2C5 and 508 and well characterised
cohorts it is possible to investigate the ability of naturally acquired antibodies to inhibit binding of
monoclonal antibodies and use this activity as a surrogate of AMAI-specific invasion-inhibitory
activity, and to understand the acquisition of antibodies to polymorphic epitopes. As yet, it is not
clear whether antibodies to polymorphic or conserved epitopes are responsible for the protection
seen in field studies (Polley et al. 2004; Gray et al. 2007; Osier et al. 2008). Here, we examined
antibodies to two polymorphic epitopes (one inhibitory and another non-inhibitory) and their
relationship with protection against clinical malaria.
7.2 Methods
7.2.1 Study populations, sample collection, and surveillance
Samples were obtained from cohort studies based in Kilifi District; a malaria-endemic area in
Kenya. The study sites were two villages (Ngerenya and Chonyi) that have been part of a
demographic surveillance system since the 1990s. The population is predominantly Mijikenda and
rural. Most of the malaria in the area results from P. falciparum (Mwangi et al. 2003). Biannual
malaria transmission occurs during the rainy seasons of May-July and November-December, with
the shorter rains occurring later in the year. Ngerenya is considered a low-medium transmission
area with an entomologic inoculation rate (EIR) of approximately 10 infective bites per person per
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Mwangi 2003). Venous and/or finger prick blood samples and slide data have been collected from
study participants every 6-12 months. The study samples comprised of 130 serum samples from
Ngrerenya collected in September 1998 (ages 0-85 years) and 294 samples collected in October
2002 (ages 0-10 years). 276 samples from Chonyi were collected in October 2000 from individuals
0-55 years of age. All individuals were monitored weekly by active and passive surveillance for
symptomatic illness and malaria; any febrile episodes were investigated for malaria. Malaria was
defined as a temperature greater than 37.5°C and any parasitaemia in children less than I year of
age. For individuals older than 1 year, malaria was defined as parasitaemia above 2500
paras ites/u I and a temperature greater than 37.5°C. Age-specific malaria and parasitaemia
incidence as well as prevalence rates have been determined in this population (Mwangi et al. 2005).
Serum from 20 non-exposed British and Australian donors were used as reference controls.
7.2.2 Monoclonal antibodies
Monoclonal antibodies were obtained from Anders RF. They were generated using standard
methods (Harlow and Lane 1988). MAb IF9 and 508 were generated by immunization of mice
with recombinant refolded 307 AMA 1. MAb 1F9 was produced in hybridoma cell cultures and
purified by protein 0 chromatography (Coley et al. 2007). The reactivity of the MAb to AMA I
was assayed by ELISA, and immunofluorescence of 307 schizonts and merozoites (Coley et al.
200 I). The 402 mAb was not available to us for use in these studies.
7.2.3 Enzyme-linked immunosorbent assay (ELISA)
7.2.3.1 Standard ELISA
Total IgO to recombinant AMA I(307) and A4 schizont extract proteins was measured by standard
ELISA methods. IgM to recombinant AMAI(3D7) was also measured using the same method.
The protocol is described in chapter 2.
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7.1.3.2 Competltloa ELISA
Antibodies to epitopes specific to three monoclonal antibodies (lF9, 2C5, and 5G8) on
AMAl(3D7) were measured by a competitive ELISA method fully described in chapter 2.
7.1.4. Growtb lablbltioD usay (GIA)
In vitro inhibition of P. laic/porum growth by human serum was tested by GIA with the growth of
parasites expressed as a percentage of the maximal growth achieved in control wells. Details of the
methodology are described in chapter 2. The assays were performed by Fiona McCallum
(McCallum et al. 2008).
7.1.S Statlstleal aDalysis
Differences in median antibody levels were analysed using the Kruskal-Wallis test. Tests for trend
were used to check for patterns in the proportion of the population acquiring a particular response.
Antibody levels to recombinant AMA I (307), the IF9, 2C5, 5G8 epitopes, and parasite growth in
vitro were compared using Spearman rank correlation. Kaplan-Meier survival functions were used
to investigate the failure rates and characteristics of the groups described above. Differences in
survival functions were tested using the Log-rank test. Differences in the likelihood of failure at
any point during follow up between high and low responders was analysed using Cox Proportional
Hazards. Both the unadjusted and age adjusted proportional hazards were investigated. The
relationship between antibody levels and the risk of experiencing a clinical malaria episode in the 6
months post-sampling was analysed using univariate and then multivariate generalised linear
models (GLM) that were adjusted for age (in I year categories) and previous P. falciparum
exposure using reactivity to schizont extract (continuous variable). Risk was expressed as relative
risk/risk ratio as the outcome incidence was above 10%; and was compared between those with
high and low antibody responses (assigned using the median value) in the entire cohort as well as
in groups stratified by parasite status. Significance was reached at a 0.05 level for all tests.
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7.3 Results
7.3.1 Serological prevalence and reactivity to speeffle epitopes of AMAI in malaria endemic
settings
Samples from two areas representing low-medium (Ngerenya) and medium-high (Chonyi) malaria
transmission settings were tested for antibodies that inhibit mAb 1P9, 2C5, and 508. 276 serum
samples were collected in October 2000 from Chonyi (ages 0 - 55 years), 130 samples in
September 1998 from Ngerenya (ages 2 - 81 years), and 294 samples in October 2002 also from
Ngerenya (ages 0 - 8 years). Samples from both Ngrerenya and Chonyi were used in order to
include adults for whom prior associations with protection for anti-AMAI antibodies had been
observed (Polley et al. 2004; Osier et al. 2008), and - as will be mentioned later - pilot assays
showed little 1P9 epitope specific activity in the Ngerenya October 2002 cross sectional bleed
samples.
The prevalence of total AMA-I antibodies was high in Chonyi at 82.3% (95% Cl; 77.6 - 87.1%)
with 42.8% of the cohort parasitaemic (by light microscopy) at sample time. When children below
the age of 11 years were sampled, most had measurable IgG to AMA-l (82.3%, 95% Cl 77.5 -
87.0%). Antibodies to the 1P9 epitope (measured by the ability of antibodies to inhibit binding of
IF9 to AMAI) were less common in individuals from Chonyi. In this cohort, only 20.4% (95% Cl
15.7 - 25.1) for all individuals and 20.7% (95% Cl 15.9 - 25.5%) of children under II years of age
had measureable antibodies to the 1P9-specific epitope. Antibodies to mAbs 2C5 and 5G8 were
also measured in Chonyi. Antibodies to these epitopes appeared more prevalent than to the 1F9
epitope in children less than 11 years. The prevalence in children under 11 years was 52.0% (95%
Cl 45.8 - 58.3%) for 2C5 and 7S.6% (95% Cl 73.5 - 83.8%) for 5GS.
Antibodies to mAb-specfic epitopes were expressed as the percentage inhibition of the mAb in
question. A high level of inhibition therefore implies that there are significant antibodies specific
to the epitope in question. The range of antibody reactivity to the 1F9 epitope varied widely in
Chonyi; from -14.6 to 65.1%. Negative values of inhibition were suggestive of enhanced binding
of the monoclonal antibody to its epitope. Though the Chonyi 2000 cohort also had many
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individuals exhibiting low anti-1F9 activity (median 0.4%, -0.41 - 5.4% IQR), the proportion of
those with measurable antibodies (20.4%) above the negative controls made this cohort ideal for
further study.
Responses to recombinant AMA1, the IF9 epitope, the 2C5 epitope, and the 5G8 epitope were
measured using samples from the Chonyi cohort. The median percent reactivity to the three
specific epitopes was varied (IF9 0.4%, 2C5 8.3%, 5G8 7.1%). Reactivity to the mAb 2C5
epitope had the widest range (-18.0% to 93.6%) with 5G8 reactivity exhibiting the narrowest range
(-11.3% to 29.7%). Wide ranges of reactivity together with low mean values are indicative of only
a few of the individuals in the cohort contributing most of the observed epitope-specific reactivity.
Only 13.4% (95% Cl, 9.4 - 17.4) of the sera had anti-lf9 activity greater than 10%whereas 44.9%
(95% Cl 38.8 - 51.1) had anti-2C5 reactivity above 10% and 34.7% (95% Cl 28.8-40.5) had anti-
5G8 reactivity above 10%.
In the lower transmission setting (Ngerenya), the prevalence of anti AMA-I IgG antibodies was
58.8% (95% Cl 53.2 - 64.5%) and only 6.9% of the individuals were parasitaemic (light
microscopy) at sample time. Prevalence of IF9 epitope reactivity was also lower, with only 15.7%
(95% Cl 11.5-19.8) of the children positive for inhibitory activity. This cohort (Ngerenya 2002)
cohort was not analysed further. Non-malaria exposed individuals were used as negative controls
and had no reactivity to the monoclonal antibodies.
7.3.1 Ale- and exposure-related acquisition of epitope-specific antibodies
All the samples in the Chonyi cohort were grouped according to age at the time of sampling.
Parasite prevalence was below 50% in children between the ages of 1 and 7 years, was highest in
the 9 - 10 age groups (90010), and fell to 26% in the older individuals. The prevalence of antibodies
to recombinant AMAI (307) was above 50% in all age groups. By the age of 3 years 80% of all
children tested positive for antibodies to recombinant AMAI, and the proportion increased with
age (test for trend, p <0.001) (Figure 7.2A). By the age of II all individuals were anti-AMAI IgG
positive. Maternal antibodies probably explain the high proportion (67%) of children under the age
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of 1 with antibodies to the 2C5 epitope (Figure 7.2C). These numbers fell to less than 30% in
children ages I - 2 years and then rose sharply in the next age group (55%). There continued a
gradual increase in numbers with age (test for trend, p= 0.003), up to a maximum value of 70%
amongst the 9 - 10 year olds. Antibodies to 1F9 remained less prevalent than those to recombinant
AMA 1 and the 2C5 epitope (Figure 7.2B). Only 40% of individuals above 10 years tested positive
for these antibodies. There was a significant trend (p <0.001) for increasing numbers acquiring
anti-l19 epitope-specific antibodies with age. The proportion of individuals with anti-SGS epitope-
specific antibodies is relatively constant throughout all age groups at around 80% from 3 years
onwards (Figure 7.2D).
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Figure 7.2 Proportion of individuals with dectecatble reactivity to P. Falciparum AMAl(3D7) by age
group. Antibodies to recombinant AMA1(307) tested by standard ELISA. Antibodies to specific
AMA1(307) epitopes tested by competition ELISA. Error bars indicate 95% Cl. Chi2 test for trend
excluding age 0 years. (A) Recombinant AMA1(307) P < 0.001, (B) 1F9 epitope p <0.00 I, (C) 2C5 epitope
p = 0.028, (D) 5G8 epitope p = 0.178.
As antibody data was not normally distributed; median antibody levels were analysed within each
age group. Acquisition of antibodies to recombinant AMA 1 gradually increased with age
(p<O.OOI, Kruskal Wallis) though a slight decrease in antibodies in children between ages 1 - 2
years possibly indicating a reduction in maternal antibodies (Figure 7.3A). The association
between age and acquisition of anti-2C5 epitope-specific antibodies was not as strong. Though
mean levels were significantly higher in children between ages 9 and 10 years compared to those in
children between 1 and 2 years, there was no corresponding increase between ages 3 and 9 years of
age (Figure 7.3C). The trend of acquisition of antibodies of the 1F9 epitope with age was not as
clear. There was a wide range of inhibitory activity in each age group and there was a trend to
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higher maximal values with age (not significant). There were negative values for 1F9 epitope
reactivity in all the age groups (Figure 7.38) which was due to the monoclonal antibody binding in
greater amounts in the wells. Median antibody reactivity to the 508 epitope was similar from ages
1 through to the oldest individuals at around 8% (Figure 7.30). Children below I had slightly
lower reactivity but it was not significant.
Presence of P. falciparum at the time of sampling was associated with higher antibody levels that
are parasite specific, possibly reflecting boosting. This pattern was observed for AMA 1, 1F9, and
2C5. Individuals without parasites had significantly lower antibody levels than those with parasites
at all ages for AMA 1, 2C5, and IF9. The difference in mean antibody levels between parasitaemic
and aparasitaemic individuals to the 508 epitope was negligible in most of the age groups.
Reactivity to A4 schizont protein was used as a measure of exposure to blood-stage P. falciparum.
Schizont reactivity was divided into tertiles to represent low, medium, and high prior exposure.
The proportion of individuals with antibodies to recombinant AMA 1, the 2C5 epitope, and the I F9
epitope significantly increased (p<O.OOI, test for trend) with increasing prior exposure to P.
falciparum, This pattern was not seen with regards to the 5G8 epitope (p= 0.30, test for trend).
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Figure 7.3 Magnitude of the antibody response to recombinant AMAl(3D7) and specific epitopes.
Graphs represent median reactivity with error bars indicating the interquartile range. Antibodies to
recombinant AMA1(307) tested by standard ELISA and represented in absorbance OD units. Antibodies to
specific AMA I(307) epitopes tested by competition ELISA and represented as percentage activity. Kruskal-
Wallis test of equality of medians. (A) Recombinant AMA 1(307) p < 0.00\, (8) 1F9 epitope p = 0.02, (C)
2CS epitope p < 0.001, (D) SGS epitope p = O.SS.
Median antibody levels were analysed using these groups. Antibody levels to recombinant
AMA 1 and the 2C5 epitope increased with increasing schizont protein reactivity (p <0.001,
Kruskal-Wallis). Although not as reactive as the response to 2C5, there was also a significant
(p=0.002, Kruskal-Wallis) increase in antibody levels to the I F9 epitope with increasing prior
exposure to P. Jalciparum. There was a trend to increasing antibody reactivity with increasing
prior exposure to the 5G8 epitope for low and medium P. Falciparum exposure (p= 0.04, Kruskal-
Wallis) but it was not as marked as that for the other epitopes.
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7.3.3 Relationship between epitope-specitic JgG, anti-AMAI JgG, and JgG responses to
schizont protein extract
There was a significant positive correlation (p<0.001, Spearmans rank correlation) between
reactivity to schizont extract and antibodies to recombinant AMA 1 (r=0.54), the IF9 epitope
(r=0.23), and the 2C5 epitope (r=0.37) (Figures 7.4A-C). The relationship between schizont
reactivity and 1F9 epitope-specific activity appeared to exhibit threshold characteristics. All 1F9
specific-activity remained below 12% until schizont extract reactivity was above 1 OD unit, then
the 1F9 epitope-specific activity increased to 65% (Figure 7.4B). The relationship between
schizont extract and 2C5 epitope reactivity exhibited similar threshold characteristics at I OD unit
(Figure 7.4C). The association between reactivity to schizont extract and to the 5G8 epitope was
weak but approached significance (r=0.13 p=0.054, Spearmans rank correlation) (Figure 7.4D).
These results indicate that prior exposure to P. falciparum is unlikely to affect the acquisition of
antibodies to the 508 epitope as expected, since there should be little to exposure to this epitope
that is contained in the prodomain.
The association between reactivity to recombinant AMA I and IF9 epitope specific reactivity was
correlated (r=0.57, p <0.001 Spearmans rank correlation) (Figure 7.5A). There were several
individuals who exhibited 'negative' reactivities to the 1F9 epitope and yet had high levels of
antibodies to AMA 1, suggesting that some antibodies that bind to AMA 1 may enhance binding of
1F9. This association is stronger than that between antibodies to the IF9 epitope and those to
schizont extract. Antibody levels to AMA 1 do not always correspond with antibodies to the IF9
epitope. Individuals with high anti-AMA 1 IgG levels (>2.5 OD units) had a range of 1F9
inhibitory activity from 0% to 60%. Conversely, individuals with low antibody reactivity to
AMA 1 «0.5 OD units) also exhibited a wide range of 1F9 epitope reactivity (-15% to 40%),
though most remained well below 20% (Figure 7.5A). Increased 1F9 binding in the presence of
high anti-AMA 1 antibodies could be due to conformational changes induced by the anti-AMA 1
antibodies leading to enhanced exposure of the 1F9 binding site. Enhanced IF9 binding in the
presence of low anti-AMA 1 IgG «0.5 OD units) may also be due to presence of undetected IgM.
Further studies were carried out to investigate this and will be discussed later.
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Figure 7.4 Association between antibody reactivity to A4 schizont extract and AMAl(3D7). Spearman
rank correlation. (A) schizont extract and recombinant AMA1 (r = 0.54; p < 0.00 I), (B) schizont extract and
the IF9 epitope (r = 0.23; p < 0.001), (C) schizont extract and the 2C5 epitope (r = 0.37; p < 0.00 I), (D)
schizont extract and the 5G8 epitope (r = 0.13; P = 0.054).
There was a very strong positive association (r=0.79 p<O.OOI, Speannans rank correlation) between
antibody reactivity to AMA I and 2CS epitope reactivity (Figure 7.SB). High anti-AMA I IgG
levels were associated with high 2C5 epitope specific activity with no obvious outliers. There were
far fewer individuals with enhanced 2CS binding and high anti-AMA I antibody levels than those
observed with IF9. The association between antibodies to AMA I and 5G8 epitope reactivity was
weak but remained significant (r=0.19 p=0.003, Spearmans rank correlation) (Figure 7.SC). Many
individuals with negligible anti-AMA I antibodies had SG8 epitope reactivity greater than 10%.
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Figure 7.5 Association between antibody reactivity to recombinant AMAI(307) and specific epitopes.
Spearman rank correlation. (A) Recombinant AMA I and the I F9 epitope (r = 0.57; P < 0.00 I), (B)
recombinant AMAI and the 2C5 epitope (r = 0.79;p < 0.001), (C) recombinant AMAI and the 5G8 epitope
(r = 0.19; P = 0.003).
The correlation between I F9 epitope and 2CS epitope antibodies was reasonably strong (r= 0.S7
p<O.OO1, Spearmans rank correlation) and expected, as the J F9 epitope probably exists within a
part of the larger 2CS epitope, though there were a couple of individuals with high J F9 epitope
reactivity whilst their 2CS epitope reactivity remained below 2S% (Figure 7.6A). There was no
association between I F9 and SG8 epitope specific reactivity (r=0.02 p=737, Spearmans rank
correlation) (Figure 7.68), and although there was a significant association (p=O.O 13, Spermans
rank correlation) between SG8 and 2C5 epitope reactivity, it was weak (r= 0.16) (Figure 7.6C).
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Figure 7.6 Association between antibody reactivity to specific epitopes. Spearman rank correlation. (A)
The 2C5 and the IF9 epitope (r= 0.57; p < 0.001), (8) recombinant AMAI and the 2C5 epitope (r= -0.02; p=
0.737), (C) recombinant AMAI and the 5G8 epitope (r= 0.16;p= 0.013).
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7.3.4 Association of antibodies to AMAI with protection from clinical malaria
Individuals in the Chonyi cohort were analysed for protection from clinical disease. This cohort
was picked due to its higher rate of malaria transmission and higher reactivity to the I F9 epitope.
228 children between the ages of I and 10 years were analysed for episodes of clinical malaria 6
months after the sampling time. Children under Iy were excluded because of the confounding
effect of maternal antibodies, and are unlikely to have acquired much immunity before this age.
Adults were excluded from this analysis to help reduce the confounding effect of age; adults in this
cohort have robust immunity and a broad range of antibodies to different antigens (Polley et al.
2004; Osier et al. 2008). Clinical malaria was defined as parasitaemia >2500 parasites per
microlitre of blood accompanied by a fever >37.5°C in individuals> I year of age. For younger
children; any measurable parasitaemia accompanied by a measured fever was considered a clinical
malaria episode. Any clinical episodes within 14 days of the sampling date were disregarded in
order to account for any ongoing infection at the sampling time. Of the 228 children, there were 34
single failures in the subsequent 6 months. Samples with negative values for competition with the
different monoclonal antibodies were not included in this analysis unless stated.
Kaplan-Meier survival curves for the four antibody responses were plotted in order to investigate
the protection from clinical malaria further. Individuals were followed up weekly for 6 months
after the sampling point and the date of any clinical episodes was recorded. Single failure survival
was analysed with censoring of any clinical episode in the first 14 days post sampling. Only three
episodes of clinical malaria were disregarded by this censoring. Individuals were categorised
according to whether their antibody response was above or below the median as well as by their
parasite status at sampling time.
The rate of failure in individuals with a high AMA I response was similar to that in those with a
low response though the overall number of failures in the high group was significantly less
(p=O.013, Log-rank (Figure 7.7A). When only parasite positive individuals were assessed; a clear
difference in the rate of failure was seen. Most individuals who were parasite positive and had a
low AMA I response failed within the first 75 days of follow up compared to those in the high
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group (p=0.003, Log-rank) (Figure 7.78). There was no difference in failure between the high and
low AMA I responders when parasite negative at sampling time.
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Figure 7.7 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
antibody reactivity to recombinant AMAl(307)_ Graphs show the proportion of individuals remaining
free from clinical malaria over time (days). Individuals are categorized according to whether their response
to recombinant AMA I was above (solid line) or below (dashed line) the median reactivity. All samples with
negative values for reactivity to specific epitopes were excluded from the analysis. Log-rank test for
difference in survival estimates. (A) All individuals (p = 0.013), (B) parasite positive at sampling (p = 0.003),
(C) parasite negative at sampling (p = 0.910).
Individuals with a high antibody response to the invasion inhibitory I F9 epitope had a significantly
lower rate of failure compared to those with low responses (p=0.006; Log-rank) (Figure 7.8A).
The protective effect of making a high response to the I F9 epitope appeared to be lost in parasite
positive individuals (p=0.12; Log-rank). Though individuals with high levels did not experience
any clinical episodes for over 100 days after sampling, their rate of failure in the last 80 days of
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follow-up was similar to that experienced by the low responders at the beginning of follow-up
(Figure 7.8B). Rates of failure in the parasite negative individuals were not significantly different,
though there was only a single failure in the high responders (Figure 7.8C).
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Figure 7.8 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
antibody reactivity to the I F9 epitope. Graphs show the proportion of individuals remaining free from
clinical malaria over time (days). Individuals are categorized according to whether their response to the IF9
epitope was above (solid line) or below (dashed line) the median reactivity. All samples with negative values
for reactivity to specific epitopes were excluded from the analysis. Log-rank test for difference in survival
estimates. (A) All individuals (p = 0.006), (8) parasite positive at sampling (p = 0.120), (C) parasite negative
at sampling (p = 0.110).
The difference in rates of failure between high and low polymorphic 2C5 epitope responders was
marginal (p=0.047; Log-rank) (Figure 7.9A). The greatest difference in rates of failure between
these two groups was seen in parasite positive individuals (p=0.003; Log-rank) with the high group
rarely failing whereas the low group experienced most of their failures within 100 days of follow-
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up (Figure 7.9B). Interestingly, in the parasite negative group; high 2C5 epitope responders had a
marginally non-significant higher rate of failure than the low responders (Figure 7.9C).
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Figure 7.9 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
antibody reactivity to the 2CS epitope. Graphs show the proportion of individuals remaining free from
clinical malaria over time (days). Individuals are categorized according to whether their response to the 2C5
epitope was above (solid line) or below (dashed line) the median reactivity. All samples with negative values
for reactivity to specific epitopes were excluded from the analysis. Log-rank test for difference in survival
estimates. (A) All individuals (p = 0.047), (8) parasite positive at sampling (p = 0.003), (C) parasite negative
at sampling (p = 0.888).
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There was no difference in the rates of failure in both high and low 5G8 epitope responders,
whether they were parasite positive or negative at sampling time (Figure 7.1OA-C).
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Figure 7.10 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
antibody reactivity to the 5G8 epitope. Graphs show the proportion of individuals remaining free from
clinical malaria over time (days), Individuals are categorized according to whether their response to the 5G8
epitope was above (solid line) or below (dashed line) the median reactivity. All samples with negative values
for reactivity to specific epitopes were excluded from the analysis. Log-rank test for difference in survival
estimates. (A) All individuals (p = 0.723), (B) parasite positive at sampling (p = 0.644), (C) parasite negative
at sampling (p = 0.177).
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A published study on the same cohort showed an association with protection from clinical malaria
in those individuals positive for antibodies to AMAI and parasitaemic at sample time (Polley et al.
2004). In light this I investigated the effect of parasites at sampling time and age on associations
with protection. Age (p <0.001) and presence of parasites at the sampling time (p = 0.04) were
associated with significantly lower risks of clinical malaria. The dataset was therefore stratified by
parasite status and multivariate analysis adjusting for age.
As only 20010 (58/276) of individuals in the cohort had IF9 epitope reactivity above the mean +
2SD (of negative controls) cut-off, the dataset was analysed for the protection from malaria in
individuals with antibody reactivity above and below the median value. Antibody reactivity below
zero for the IF9, 2C5, and 5G8 epitopes was disregarded in the assignation of the median as these
negative values are difficult to interpret.
The risk of experiencing a clinical episode at any time within 6 months of sampling was
investigated using Cox proportional hazards. As age had a significant effect of reducing the risk in
this population (HR=O.55, 95% Cl 0.43 - 0.72; p<O.OOI), it was adjusted for in the population,
Antibody responses were divided into two groups above and below the median value as described
earlier. When antibody responses were analysed without taking into account parasite status; those
with a high antibody response to AMAI (HR=0.36, 95% Cl 0.15 - 0.84; p=0.02), and the IF9
epitope (HR=0.21, 95% Cl 0.06 - 0.73; p=O.Ol) were significantly less likely to experience a
clinical malaria episode at any point during the 6 months after sampling (Table 7.1). Only the low
responders to the 1F9 epitope maintained the propensity to experience a clinical episode when the
adjusted hazard ratio was calculated, though it was not significant (Adjusted HR=0.34, 95% Cl
0.09 - 1.31; p=0.12). High responders to the 2C5 epitope were also less likely to experience a
clinical episode at any time. This reduction approached significance (HR=0.38, 95% Cl 0.14 _
1.04; p=O.06) but the advantage was lost when the adjusted hazard ratio was calculated. Overall ,
high responders to the 5G8 epitope were no more protected from experiencing a clinical episode
than their counterparts with a lower response.
High responders to AMAI (HR=0.14, 95% Cl 0.03 - 0.64; p=0.01) and to the 2CS epitope
(HR=O.08, 95% Cl 0.01 - 0.66; p=0.02) who were parasite positive at sampling time were much
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less likely to experience a clinical episode of malaria. They maintained this apparent protection
when adjusted for age but the significance diminished (p=O.08) (Table 7.1). Though high
responders to the IF9 epitope who were parasite positive at sampling were less likely to experience
a malaria episode with and without age adjustment, it was not a significant effect. Interestingly,
those parasitaemic individuals with a high response to the 5G8 epitope were more likely to
experience a malaria episode at any time point compared to those with a low response. In parasite
negative individuals, only those with a high response to the invasion inhibitory IF9 epitope and the
5G8 epitope appeared more likely to experience a clinical malaria episode at any time point. This
effect was not statistically significant but held in both the unadjusted and age-adjusted Cox
proportional hazards regression (Table 7.1).
Table 7.1 Association between antibody responses and the proportional hazard of experiencing a
clinical malaria episode in the 6 months subsequent to sampling in the Chonyi cohort
Antibody reactivity'
Coxproportional hazards Adjusted Coxproportional hazards'
HR(95%CI) P·value HR(95%CI) P·value
0.36 (0.15 • 0.84) 0.02 0.81 (0.31- 2.10) 0.66
0.21 (0.06 - 0.73) 0.01 0.34 (0.09 - 1.31) 0.12
0.38 (0.14 - 1.04) 0.06 0.85 (0.28 - 2.55) 0.77
0.87 (0.40 - 1.88) 0.73 0.96 (0.44 - 2.09) 0.92
0.14 (0.03 - 0.64) 0.01 0.23 (0.05 -1.18) 0.08
0.29 (0.06 - 1.52) 0.14 0.49 (0.09 - 2.74) 0.41
0.08 (0.01- 0.66) 0.02 0.15 (0.02 - 1.27) 0.08
1.32 (0.40 - 4.33) 0.65 2.37 (0.68 - 8.27) 0.18
0.95 (0.37 - 2.44) 0.91 1.55 (0.58 - 4.16) 0.39
0.31 (0.06 - 1.49) 0.14 0.38 (0.08 - 1.85) 0.23
1.09 (0.33 - 3.56) 0.89 1.36 (0.41 - 4.45) 0.61
0.49 (0.17 - 1.44) 0.19 0.51 (0.17 - 1.50) 0.22
Allsamples AMA1
IF9epltope'
2(5 epltope'
5G8 epltope'
Parasltaemlc' AMAl
IF9epltope'
2(5 epltope'
5G8 epitope'
Aparasltaemlc' AMAl
IF9epltope'
2(5 epltope'
5G8 epltope'
t Antibody reactivity divided into two groups at the median value.
1Negative values of activity disregarded in the assignation of the median value.
~Multivariable Cox proportional hazards adjusted for age.
2Parasitaemia detetced by light microscopy.
P-values SO.! indicated in bold.
In order to investigate the effect on protection from clinical malaria in those individuals with
negative anti-I F9 epitope reactivity new categories were formed for further survival analysis. The
three categories were; (I) those with negative anti-I F9 reactivity (i.e. values below zero), (2) those
with anti-I F9 reactivity below the median of the positive reactivity (low positive), and (3) those
with anti-I F9 reactivity above the median of the positive reactivity (high positive). Kaplan-Meier
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survival curves for the three groups were plotted and an unexpected pattern was seen (Figure 7.11).
There was a significant difference in the rate of failure between the three groups (p = 0.025; Log-
rank), with those children who had anti-IF9 reactivity in the low positive group displaying the
highest rate of failure. This pattern was clearest in the parasite positive individuals (p = 0.04; Log-
rank) (Figure 7.11 B).
When the risk of experiencing a clinical episode at any time within 6 months of sampling was
investigated the low positive group was assigned as the baseline group. Children with high anti-I F9
epitope reactivity were less likely to experience a clinical malaria episode in the follow up time
(HR = 0.21, 95% Cl 0.06 - 0.74;p = 0.02), whereas there was no significant association for those
with negative values for IF9 competition (HR = 0.57; 95% Cl 0.28 - 1.18; P = 0.13) (Table 7.2).
When considered in multivariate analysis (adjusted for age), the apparent protection remained
(negative HR = 0.68; high positive HR = 0.41), but was not statistically significant. Univariate
analysis showed considerable protection from clinical malaria in children with high positive anti-
IF9 reactivity who were parasite positive at sampling time (HR =0.15; 95% Cl 0.03 - 0.80; p =
0.03). This significance was not held when adjusted for age.
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Figure 7.11 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
antibody reactivity to the I F9 epitope. Graphs show the proportion of individuals remaining free from
clinical malaria over time (days). Individuals are categorized according to whether their response to the I F9
epitope was below zero, below the median reactivity of positive responses (low positive), and above the
median reactivity of positive responses (high positive). Log-rank test for difference in survival estimates
between the low positive and high positive groups. (A) All individuals (p = 0.025), (8) parasite positive at
sampling (p = 0.04), (C) parasite negative at sampling (p = 0.315).
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Table 7.2 Antibody responses to the epitope of mAb IF9 on recombinant AMAI and the proportional
hazard of experiencing a clinical malaria episode 6 months from the date of sampling (October 2000)
in the Chonyi cohort
Cox Proportional Hazards' Adjusted Cox Proportional Hazards'
Anti-1F9 Epitope Reactivity
HR (95%CI) P-value HR(95%CI) P-value
All Individuals NeBative' 0.57 (0.28 - 1.18) 0.13 0.68 (0.33 -1.38) 0.28
Hieh Positive' 0.21 (0.06 - 0.74) 0.02 0.41 (0.11 -1.49) 0.18
Parasltaemlc' Negative! 0.39 (0.11- 1.36) 0.14 0.70 (0.18 - 2.62) 0.59
Hieh Positive' 0.15 (0.03 - 0.80) 0.03 0.53 (0.09 - 3.15) 0.48
Aparasltaemk' Neeatlve' 0.72 (0.30 -1.73) 0.46 0.77 (0.32 -1.85) 0.56
Hieh Positive' 0.24 (0.03 - 1.90) 0.18 0.32 (0.04 - 2.62) 0.29
Notes
1Antibody reactivity to the lF9 epitope below zero.
2 Antibody reactivity to the lF9 epitope abive te median reactivity of positive responses.
6COXproportional hazards in the assigned groups compared to the low positive group (below median reactivity of positive responses).
t Multivariable Cox proportional hazards adjusted for age.
1Parasitaemia detetced by light microscopy.
P-values SO.! indicated in bold.
For the purpose of comparison with published studies on from this cohort, associations between
antibodies and protection were also performed using risk ratios (Polley et al. 2004; Osier et al.
200S). An earlier study on 537 individuals in this cohort has shown that the presence of parasites
and measurable antibody AMA 1 (307) are associated with protection from clinical malaria
(RR=0.33, 95% Cl 0.17 - 0.61; p<O.OOI) (Polley et al. 2004). Univariate logistic regression
investigating the risk of developing malaria in similar individuals in this smaller cohort also
showed that those individuals with parasites and measurable antibodies were at much lower risk of
having a subsequent clinical malaria episode (RR=0.25, 95% Cl 0.06 - 1.12; p=0.07). The fewer
episodes in this study probably had an effect on the power of the association with protection but the
agreement of the trend towards protection in parasite positive individuals was reassuring.
Antibody reactivity to AMAl, the invasion inhibitory I F9 epitope, and the polymorphic 2C5
epitope above the median decreased the risk of malaria in the subsequent 6 months by univariate
analysis (Table 7.3). The risk was significantly reduced with regards to antibodies to AMA 1
(RR=0.35, 95%CI 0.16 - 0.7S); p=O.Ol) and antibodies to the 2C5 epitope (RR=0.29, 95%CI 0.11
- 0_78; p=O.OI). Though there was also a reduced risk in individuals with reactivity above the
median for the I F9 epitope, it was not statistically significant (RR=0.36, 95%CI 0.1 - 1.27;
p=O_II). When looked at in the multivariate analysis (adjusting for age), though all these antibody
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responses had reduced risks, none of them were significant. Individuals with antibody reactivity to
the 5G8 epitope above the median were at the same risk of experiencing a clinical malaria episode
as those with lower reactivity both in the univariate and multivariate analysis. Among children
who were parasite positive (by light microscopy) at the time of serum collection, high antibody
reactivity to recombinant AMA 1, the IF9 epitope, and the 2CS epitope conferred protection from
malaria in the subsequent 6 months, though this was significant only for 2CS (RR=0.13, 9S%CI
0.02 - 1.0 I; p=O.OS) (Table 7.3). When adjusted for schizont extract reactivity and age in the
multivariate analysis only reactivity to AMA 1 and the 2CS epitope were associated with lowered
risk with clinical malaria though one were significant. Lndividuals were at no less risk from clinical
malaria when high antibody reactivity to the 1F9 epitope was investigated in the multivariate
analysis. Though there was a trend to protection from clinical disease in parasite negative
individuals (though to a lesser degree), it was not significant for any of the responses measured
(Table 7.3).
Table 7.3 Association between antibody responses and the risk of experiencing a clinical malaria
episode in the 6 months subsequent to sampling in the Chonyi cohort
Antibody reactivity'
Univariate analysis Multlvarlable analysis'
RR(95% Cl) P·value RR(95%Cl) P·value
0.35 (0.16-0.78) 0.Q1 0.50 (0.19- 1.32) 0.16
0.36 (0.10-1.27) 0.11 0.56 (0.14-2.27) 0.41
0.29 (0.11- 0.78) 0.01 0.40 (0.13- 1.19) 0.10
1.13 (0.54-2.38) 0.75 1.04 (0.46-2.36) 0.92
0.2510.06- 1.12) 0.07 0.70 (0.11- 4.45) 0.71
0.52 (0.10-2.57) 0.42 1.08 (0.14-8.05) 0.94
0.13 (0.02 . 1.01) 0.05 0.26 (0.03-2.29) 0.23
1.32 (0.43 . 4.09) 0.63 1.04 (0.46-2.36) 0.92
0.47 (0.19, 1.20) 0.12 0.62 (0.20- 1.92) 0.41
0.62 (0.13-3.00) 0.56 0.81 (0.16-4.14) 0.80
0.63 (0.19-2.05) 0.44 0.99 (0.26-3.72) 0.99
0.84 (0.31- 2.31) 0.74 0.73 (0.23-2.35) 0.60
Allsamples AMA1
IF9epltope'
2C5 epltope'
5G8 epltope'
Parasltaemlc' AMA1
IF9epltope'
2C5epltope'
5G8 epltope'
Aparasltaemlc' AMA1
IF9epltope'
2C5epltope'
5G8 epltope'
Notes
t Antibody reactivity divided into two groups at the median value.
1Negative values of activity disregarded in the assignation of the median value.
IMultivariable analysis adjusted for age and reactivity to schizont extract.
2 Parasitaemia detetced by light microscopy.
P-values SO.1 indicated in bold.
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7.3.5 AIsoeiatioD of eomblaed •• dbody responses with proteetioD from eHDieal malaria
In light of the trend towards protection from clinical malaria in the subsequent analyses and the
correlations between anti-AMAI antibodies and antibodies to the IF9 epitope (r=0.57 p<O.OOl,
Spearmans rank), the 2C5 epitope (r=O.79 p<O.OOl, Spearmans rank), as well as between the two
epitopes (r=O.57 p<O.OOI Spearmans rank); an analysis to defme whether those individuals with
combined high responses were protected from malaria was carried out. Individuals were assigned
as high responders if their antibody response was above the median. Then those with high
responses to both AMAI and the IF9 epitope, AMAI and the 2C5 epitope, and both the IF9 ado
2C5 epitopes were compared to those with combined low responses.
Kaplan-Meier survival curves show that the rate of failure in individuals with a combined high
response was significantly lower than that in their low responder counterparts (Figure 7.12). Those
with a high AMAI and high epitope specific response appeared to be better protected (AMAI/IF9
p=0.006; AMAl12C5 p=O.OO8,Log-rank) than those with high IF9 and 2C5 responses (p=0.045,
Log-rank). The risk of experiencing a clinical episode at any time within 6 months of sampling was
also investigated in these three groupings using Cox proportional hazards. Children with high
responses to AMAI and IF9 (HR=O.l5, 95% Cl 0.03 - 0.71; p=0.02) as well as those high
responses to AMAI and 2C5 (HR=0.21; 95% Cl 0.06 - 0.75; p=0.02) were significantly less likely
to experience a clinical malaria episode in the follow up time (Table 7.4). Those with high
responses to the 1F9 and 2CS epitopes were also less likely to experience a clinical malaria episode
though this was not statistically significant (HR=0.23; 95% Cl 0.05 - 1.12; p=0.07). When
considered in multivariate analysis (adjusted for age), the trend for protection remained but lost its
significance for all combinations.
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Table 7.4 Combined antibody responses to recombinant and the proportional hazard of experiencing a
clinical malaria episode 6 months subsequent to sampling in the Chonyi cohort
Antibody Reactivity Cox Proportional hazards
Adjusted Cox proportional hazards'
Combinations HR(95%Cl) P·value HR(95%CI) P-value
.AMA1/1F9 0.15 (0.03 - 0.71) 0.02 0.29 (0.05 -1.61) 0.16
AMA1/2Cs 0.21 (0.06 - 0.75) 0.02 0.36 (0.08 - 1.50) 0.16
2CS/1F9 0.23 (0.05 - 1.12) 0.07 0.34 (0.06 - 2.01) 0.23
Notes
t Antibody reactivity above the median (negative values of activity disregarded in the assignation of the median value).
IMultivariable analysis adjusted for age.
P-values :SO.1 indicated in bold.
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Figure 7.12 Kaplan-Meier estimates for the time to first episode of clinical malaria associated with
combined antibody reactivity to recombinant AMA1(3D7) and different epitopes. Graphs show the
proportion of individuals remaining free from clinical malaria over time (days). Individuals are categorized
according to whether they had high (above the median) or low (below the median) combined responses. All
samples with negative values for reactivity to specific epitopes were excluded from the analysis. Log-rank
test for difference in survival estimates. (A) Recombinant AMA I and the IF9 epitope (p = 0.006), (8)
recombinant AMA I and the 2C5 epitope (p = 0.008), (C) the IF9 and 2C5 epitopes (p = 0.045).
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7.3.6 AssociadoD betweeD epitope-speeific antibodies aDd iDbibitiOD of P.falaclparum growtb
A third group of 139 individuals was analysed to investigate the relationship between the IF9
epitope response and P. falciparum growth inhibition in 'Vitro; there was insufficient serum
available in the Chonyi cohort to perform GlAs. Serum was collected from individuals in
Ngerenya during the September 1998 cross-sectional bleed (there was insufficient sera to carry out
GIA in the Chonyi cohort) Individuals ranged from 2 - 81 years of age with a mean age of 19.9
years (95% Cl 16.3 - 23.5) and a median of9.4 years. Antibodies to recombinant AMAl. the IF9
epitope, and inhibition of parasite growth were measured. Median antibody levels to AMA 1 and
IF9 increased with age. Also observed were higher mean antibody levels in parasitaemic
individuals compared to aparasitaemic individuals.
Functional growth inhibitory antibodies can be measured by the GIA assay. It is expected that high
levels of antibodies to recombinant AMAI should translate to high levels of growth inhibition as
any functional antibodies are a subset of the total response. Results are given as the percentage
growth inhibition relative to a negative control (PBS. growth equals 100%). When the relationship
between growth inhibition and antibodies to AMAI was examined there was no significant
correlation between the two (r=-0.09 p=0.311. Spearman rank correlation) though a negative trend
was suggested (Figure 7.13A). As the functional inhibitory response is only a fraction of the total
response. it could be argued that very high levels of anti-AMA I antibody activity should produce
functional activity. There may be a threshold level at which antibodies to AMAl can mediate
inhibition of invasion. This was suggested in earlier correlations of responses to AMA 1 versus
those to the 1F9 epitope where reactivity to the 1F9 epitope above 10% was seen individuals with
high responses to AMAI (Figure 7.5A).
As the magnitude of the response to AMAI is strongly associated with increasing prior exposure to
P.falciparum (p<O.OOl. Kruskal-Wallis), individuals with a low schizont extract antibody response
were excluded from further correlations. Exclusion of responses to schizont extract below the
median response resulted in strengthening the correlation between inhibition of growth and the
antibody response to AMAl. There was a negative correlation (r=-0.39 p=0.001. Spearmans rank
correlation) between the two variables; high antibody levels generally resulting in low parasite
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growth in vitro (or high levels of inhibition) (Figure 7.13B). However, there were still samples
with high levels of AMA I IgG but little growth inhibitory activity. When this relationship was
further investigated by splitting the group into parasite positive and negative individuals, the
negative association remained and was slightly strengthened in the parasite positive individuals
(r=-0.54 p=O.OOI, Spearmans rank correlation).
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Figure 7.13 Association between antibody reactivity to recombinant AMAI(307) and inhibition of P.
falciparum growth measured by the growth inhibition assay in the Ngerenya cohort. Spearman rank
correlation. (A) Recombinant AMA1 antibody reactivity and parasite growth in all samples (r = 0.09; p =
0.311), (8) recombinant AMAI antibody reactivity and parasite growth in all samples with an A4 schizont
extract response above the median (r = -0.39; p = 0.001).
A negative a correlation between parasite growth and antibody reactivity to the 1F9 epitope was
expected as the monoclonal antibody (1F9) inhibits parasite growth/invasion. Though parasite
growth ranged from 10% - 65%, most of the anti-I F9 epitope activity clustered around 0%.
Though a negative association between the two measures was implied, it was not significant (r=-
0.11 p=O.239; Spearmans rank correlation) (Figure 7.14B). Exclusion of those individuals with
antibody reactivity to AMA I below the median (as the 1F9 response is a subset of this overall
response) resulted in a stronger negative association between parasite growth and IF9 epitope
reactivity (r=-0.25 p=0.042; Spearmans rank correlation) (Figure 7.14C).
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Figure 7.14 Association between antibody reactivity to recombinant AMA1(3D7), IF9 epitope
reactivity, and inhibition of P. Jalciparum growth measured by the growth inhibition assay in the
Ngerenya cohort. Spearman rank correlation. (A) Recombinant AMA I antibody reactivity and 1F9 epitope
reactivity (r = 0.48; p < 0.00 I), (8) IF9 epitope reactivity and parasite growth (r = -0.11; p = 0.239), (C) 1F9
epitope reactivity and parasite growth in individuals with AMA I reactivity above the median value (r = _
0.25; p = 0.042).
7.3.7 Association between anti-AMAI IgM and antibodies to specific mAb epitopes
There were a considerable number (n=57) of individuals who appeared to give enhanced binding of
the monoclonal IF9 antibody to its epitope (anti-I F9 epitope activity less than zero), Some of
these individuals had significant IgG reactivity to AMA 1; 19 samples with negative IF9 activity
had high AMA 1 IgG levels (defined as greater than the median). It is possible these IgG
antibodies may bind to other sites on recombinant AMA I that make the I F9 epitope more
accessible by conformational modification of the recombinant antigen and thereby increase the
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binding of 1F9. However, some individuals with enhanced 1F9 binding had low IgG reactivity to
AMAl. Therefore, we also investigated whether some individuals have high IgM reactivity to
AMAI that could potentially enhancelF9 binding. IgM levels were measured in the Ngerenya
1998 cohort and analysed for association with 1F9 epitope-specific activity. Few individuals had
high IgM responses, which is normal in a malaria endemic population. There was a positive
correlation between IgG and IgM reactivity to AMA I (r=0.48 p<O.OOI, Spearmans rank
correlation) (Figure 15A). The association between (gM responses to AMA I and 1F9 epitope
reactivity was not strong (r=0.22 p=O.OI, Spearmans rank correlation) (Figure 15B). Some
individuals with enhanced mAb binding had significant (gM reactivity; 26 samples with negative
IF9 activity had high AMA 1 JgM levels (defined as greater than the median). Togther these results
suggest that among some individuals IgG and IgM to AMA 1 may enhance the binding of 1F9 to its
epitope.
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Figure 7.15 Association between IgG and IgM antibody reactivity to recombinant AMAI(3D7), and
1F9 epitope reactivity in the Ngerenya cohort. Spearman rank correlation. (A) Recombinant AMA I IgG
and IgM antibody reactivity (r = 0.479; p = 0.001), (8) 1F9 epitope reactivity amd recombinant AMA I IgM
antibody reactivity (r = 0.22; p = 0.0 I0).
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7.4 Discussion
AMAI appears to be highly immunogenic in malaria endemic populations (Thomas et al. 1994;
Johnson et al. 2004; Polley et al. 2004; Chelimo et al. 2005; Cortes et al. 2005). As seen, the
prevalence of measurable antibodies to AMA 1 reaches 8()o,4by the age of lOin this particular
population (Polley et al. 2004). As AMAt is also under diversifying selection, it is logical that
antibodies to this antigen would have some measurable effect on merozoite invasion of the
erythrocyte or are relevant to immunity. Both polyclonal and monoclonal antibodies to AMAI
have been shown to be inhibitory to merozoite invasion. Mapping of the epitope of an inhibitory
monoclonal antibody has allowed for further investigation on naturally acquired antibodies to
AMAI. Monoclonal antibody IF9 significantly inhibits invasion of 307 and 010 P. falciparum
parasites in vitro (Coley et al. 200t; Coley et al. 2006). Whether antibodies to this epitope are
abundant and associated with protection in malaria endemic areas was unknown.
Here, we measured antibodies to polymorphic and inhibitory epitopes and compared them with
antibodies to total anti-AMAI IgG. Antibodies to the IF9 epitope were relatively uncommon in all
the cohorts that we looked at. Their prevalence did not rise above 25% in all the individuals
studied. When compared to the very high total anti-AMA IgG response (above 75%), one may
logically infer that this response is a relatively small part of the total response to AMA 1. The
individual response to this epitope is also quite wide ranging in all age groups and whilst the trend
of increasing levels with age is not as strong as with total anti-AMA 1 antibodies, the relationship of
increasing levels with increased exposure is significant. The rarity of antibodies to the 1F9 epitope
may be explained by the nature of this epitope. Though the antibody footprint is quite large, the
majority of the epitope is within a deep hydrophobic cleft (Coley et al. 2007). Binding of other
antibodies close by or further away from this site may have conformational effects on this cleft·,
making it harder to measure antibodies to it. As these are both polymorphic epitopes many
children may not have been exposed to them. The affinity of mAbs I F9 and 2C5 appears to be
high (K. Persson, J. Beeson, R. Anders, unpublished data); therefore only those samples with high
affinity antibodies to the epitopes may inhibit binding of the respective monoclonal antibodies.
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The low prevalence of antibodies to these epitopes could also imply that they are not highly
immunogenic.
Antibodies to the mAb IF9 epitope correlated with increased exposure to Plasmodium falciparum,
anti-AMAI antibodies, and antibodies to the 2C5 epitope. Both the increase in antibody
prevalence and magnitude of the response to the IF9 epitope rose with increasing prior exposure to
P. falciparum. This indicated that though not the 'preferred' antibody response (as overall
prevalence is quite low) in this population, recognition of this epitope may confer some protective
advantage in malaria endemic settings. As the invasion inhibitory IF9 epitope is encompassed by
the multi-domain polymorphic 2C5 epitope, it was expected that the response to the 2C5 epitope as
well as the overall anti-AMA I response would be positively correlated to that of the IF9 epitope.
Antibodies to the 2C5 epitope (which covers parts of all three domains) were more common than
those to the IF9 epitope, as well as being associated with increasing age and exposure. The
presence of maternal antibodies in the children's serum probably explains the high proportion
(67%) of children under the age of 1 with antibodies to the polymorphic 2C5 epitope. These
antibodies were also more highly correlated with total anti-AMA I antibodies and schizont extract
than antibodies to the IF9 epitope. The nature of the 2C5 epitope makes it more accessible to
antibodies as it is made up of all three domains and does not include the deep hydrophobic cleft
that characterises that of 1F9.
High levels of anti-I F9 epitope reactivity are associated with inhibition of erythrocyte invasion by
Plasmodim Jalciparum merozoites. In agreement with earlier studies that established the role of
specific AMAI epitopes in erythrocyte invasion inhibition (Coley et al. 2001; Coley et al. 2006),
we were able to show that serum with high IF9 epitope reactivity was more likely to inhibit
invasion. Though there was a trend for increasing levels of inhibition with increased IF9 epitope
reactivity the level of inhibition seen was not as high as in other studies. This could be due to the
polyclonal nature of the natural immune response; antibodies that block binding to this epitope may
be present in the serum of individuals from malaria-endemic areas.
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High antibody levels to both polymorphic (2C5) and inhibitory (IF9) epitopes were associated with
a reduced risk of clinical disease though this association was not always significant. This indicates
that antibodies to these defined epitopes may be involved in contributing to protective immunity.
High total IgO levels to recombinant AMAI were also associated with a reduced risk of clinical
disease which is in agreement with published studies on the same cohort (Polley et al. 2004; Osier
et al. 2008). It is therefore not surprising that when a combination of antibodies to AMA I and the
2CS or IF9 epitopes was investigated; those children were at a significantly reduced risk of clinical
malaria in the 6 months of follow-up. Though the trend of reduced risk remained, it lost
significance when adjusted for age with regards to all the antibody responses investigated. As
antibodies are associated with age, the loss of significance is not unusual.
In agreement with other studies on the same cohort; the reduced risk of infection was significant in
parasite positive rather than slide negative individuals. It has been suggested that a non-humoral
component of immunity that is stimulated by circulating parasites may be necessary and will work
in concert with the measured antibodies in effectively controlling parasitaemia and thusly reducing
the risk of clinical malaria (Polley et al. 2004). Comparison of this study with that of Polley et ai,
reveals that antibodies to AMAI (307) were two times more protective in our study (RR=0.35
compared to 0.71) in the univariate analysis. There are two differences in our study and
methodology that may explain these findings. We compared antibody levels above and below the
median whereas Polley et al compared antibody positive and antibody negative individuals. Also,
our study was confined to children below the age of 11 whereas Polley et al included adults in their
analysis. With an overall reduction in risk of clinical malaria as individuals age the percentage of
individuals experiencing malaria in the antibody positive and antibody negative group may not be
very different due to intrinsic immune actions honed by both age and cumulative exposure.
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This study confirmed the presence of naturally acquired polymorphic and invasion inhibitory
antibodies in children from a malaria endemic area, and found they were associated with protection
from symptomatic malaria and growth-inhibitory activity by serum antibodies. Presently it is not
possible to measure AMA l-specific invasion-inhibitory activity in samples other than by affinity
purification of antigen-specific antibodies which requires large sample volumes (typically >20mls
are needed). The competition ELISA using MAb IF9 appears to be a proxy for antibodies to
AMA I inhibitory epitopes and AMA I-specific invasion-inhibitory antibodies. This assay may be
valuable for use in AMA I vaccine trials to indicate the induction of functional and polymorphic
antibodies.
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8 Concluding Remarks
This study aimed to investigate the dynamics of acquisition and maintenance of antibody responses to
P. falciparum AMAI and MSP2 in childhood and examine their role in protective immunity.
Investigation of the protective role of antibodies to functional epitopes of AMAI was an additional aim
of this study. Previous studies have shown that antibody responses to merozoite antigens are both
short-lived and fluctuant in young children and are affected by malaria transmission levels (Trape
1987; Ramasamy et al. 1994; Jakobsen et al. 1997; Snow et al. 1997; Branch et al. 1998; Marsh and
Snow 1999; John et al. 2002; Kinyanjui et al. 2007). Also, longitudinal studies show that antibody
levels to different antigens are associated with parasitaemia at the time of sampling or an episode prior
to sampling time (Branch et al. 1998; Cavanagh et al. 1998; Giha et at. 1999; Soares et at. 1999;
Morais et at. 2006; Biswas et al. 2008). With six cross sectional sampling points over 2.5 years and
weekly surveillance of participants, this study was well suited to perform a detailed longitudinal
evaluation of acquired immunity and identify factors determining the acquisition and maintenance of
antibodies to merozoite antigens and the effects of declining malaria transmission. AMA 1 and MSP2
were used as representative merozoite antigens. To facilitate the testing of all samples in the cohort to
multiple antigens, a high throughput ELISA using automated robotics was developed and optimised.
Age, prior exposure, and concurrent parasitaemia at sampling were identified as factors affecting the
antibody response to AMA 1 and MSP2. Malaria transmission levels at the time of sampling not only
affected the antibody responses measured, but also the strength of the effect of the above mentioned
factors on the overall antibody response. The variability of the effect on antibody levels by age,
concurrent parasitaemia, and prior parasitaemia has not been clearly evaluated in the published
literature. Here, the decline in malaria transmission allowed for this analysis in a systemic manner and
enabled the separation of the effects of age and previous exposure. A model of the effect on antibody
responses could then be approximated (Figure 8.1 ).
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Figure 8.1 Factors affecting antibody responses to AMA I and MSP2 at different malaria transmission
intensities. Antibody levels in parasitaemic and aparasitaemic children are indicated by the relative size of and
direction of the arrow. Arrows pointing upwards indicate an increasing effect; arrows pointing downwards
indicate a decreasing effect. The contributions of different factors is also indicated by the size of the arrows; blue
- concurrent parasitaemia, green - exposure in the six months prior to sampling, yellow - age, and purple -
haemoglobinopathies. Reduction in transmission intensity is indicated by the red triangle.
The greatest effect on antibody responses was that of concurrent parasitaemia though previous
exposure and age had significant effects. In the case of higher levels of malaria transmission, age had
the greatest effect in aparasitaemic children followed by prior exposure; presumably age is reflective of
prior exposure. Though both age and prior exposure did have an effect on antibody levels in
parasitaemic children, the antibody response appeared to be predominantly related to the presence of
active blood-stage parasitaemia. In contrast to the period of higher transmission, age played a much
larger role in predicting antibody responses to AMA I and MSP2 during periods of reduced
transmission. In aparasitaemic children, prior exposure played a much larger role in predicting
antibody responses together with age. Only when malaria transmission dropped did the antibody
response to AMA I and MSP2 begin to largely reflect cumulative exposure in both parasitaemic and
aparasitaemic children. In both periods of higher and lower transmission, both alpha-thalassemia and
sickle trait led to lower antibody responses to AMA I and MSP2 although this reduction was significant
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only in a few cases. The sickle trait led to significantly (p:S 0.05) lower antibody responses to all three
AMA 1 variants tested in 4-6 year olds in May 2003 as well as to the W2mef variant in 1-3 year olds.
There was no significant reduction in MSP2 antibody responses. In contrast, alpha-thalassemia
homozygotes between the ages of 1-3 year had significantly lower antibody responses to both AMA 1
and MSP2 in May 2002 and May 2004 with the same being seen in the oldest children in October
2004. This could be due to reduced immune activation and antigen presentation to B cells as a result of
lower parasite densities and/or reduced incidence of clinical malaria episodes associated with those
haemoglobinopathies. However it should be noted that although alpha-thalassemia is associated with
reduced risk of severe malaria, it has not been consistently associated with reduced parasitaemia or risk
of mild malaria.
The probability of a high anti-AMA 1 or anti-MSP2 antibody response after recorded exposure in the 6
months prior to sampling increased with increasing exposure up to 3 episodes or did not increase
among those with greater exposure. This indicated that a high antibody response was achievable
following few exposures and those children who did not exhibit this response may represent non-
responders. These children appear to be the more susceptible ones in the population.
Investigation of individual antibody responses to AMA 1 and MSP2 over time revealed children with
consistently high antibody responses, those with fluctuating antibody responses, and a third group
made up of those with consistently low antibody responses. The sampling framework in this study was
approximately every 5-6 months which inevitably made it impossible to pick up fine trends in IgG
boosting as seen in other studies (Branch et at. 1998; Cavanagh et at. 1998; Kinyanjui et at. 2007;
Akpogheneta et al. 2008). This means that the two groups of children described above as those with
consistently high or low antibody responses may have included those with fluctuating responses. At a
population level, mean antibody levels to all antigens declined in concert with falling malaria
transmission rates seen over the same period. Older children always had higher antibody responses
without any noticeable increase over time in the antibody responses exhibited by the youngest children.
There was a decline in median antibody responses over the study period that implied a strong effect of
the declining malaria transmission in the population. Children who had concurrent parasitaemia more
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than once at sample time had higher antibody responses throughout the study period compared to those
with concummt parasitaemia only once or never. These results indicated that the antibody responses
that were measured in this study were markers of exposure and were maintained by regular exposure to
blood-stage parasites. The fact that children with concurrent parasitaemia were 1.5 times more likely
to be parasitaemic in the intervals adds to the evidence that antibody levels are a marker of exposure.
This study suggests that antibody responses to AMA 1 may highly indicative of recent exposure and
parallel ongoing changes in malaria transmission.
Antibodies to AMA I and MSP2 have been associated with protection from malaria in some studies but
not in others (AI-Yaman et al. 1994; AI-Yaman et al. 1995; Taylor et al. 1998; Metzger et al. 2003;
Polley et al. 2004; John et al. 2005; Polley et al. 2006; Gray et al. 2007; Roussilhon et al. 2007; Nebie
et al. 2008; Osier et al. 2008). Even though antibodies contribute a large part of the natural defence
against disease, a major issue in understanding immunity to malaria as well as development of vaccines
has been the lack of agreement on the protective effects of different antibody responses to malarial
antigens. This study showed that antibody responses to AMAI and MSP2 could be associated with
both an increased or decreased risk of malaria in the same cohort of children and that these results were
influenced by malaria transmission at sampling and the study framework utilised. In both the cross-
sectional and longitudinal analyses, parasitaemia at sampling was associated with an increased risk of
disease. The longitudinal association of parasitaemia with increased risk could be indicative of a group
of more exposed children. This factor of differences in exposure has been suggested in recent
publications (Polley SO et al, Vaccine 2004; Bejon P et al, Infec Imm 2009). This study allowed for
identification of the small but significant effect increasing age in childhood had on the reduction of
malaria. Although the effect of age is commonly observed by falling rates of parasitaemia and severe
illness, its effect has not been identified independently of cumulative exposure. Here, total IgG
responses to AMAI(W2mef) were associated with an increased risk of clinical disease whereas those
to MSP2(307) were associated with possible protection from clinical disease in children.
In both the cross-sectional and longitudinal analyses, parasitaemia at sampling was associated with an
increased risk of disease. Exposure to Plasmodium can result in three states; symptomatic malaria,
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asymptomatic parasitaemia. and lack of detectable parasitaemia. The first is an indicator of an immune
system that cannot control the infection and is therefore in the process of acquiring immunity to the
infective strain. The second is an indicator of a system with functional immunity to the infective
strain. When parasite positivity at baseline response results in protection from future clinical episodes,
the implication is that the exposure at baseline was successful in inducing the acquisition of a
protective future response. But when the parasitaemia at baseline is accompanied by more disease then
the implication is either that the individual cannot mount a protective response, may have a slower rate
of acquisition of immunity, or may be exposed to Plasmodium strains outside their immune repertoire.
Conversely, exposure without resultant parasitaemia would imply a truly protected individual. The
above mentioned published results are therefore possibly a snapshot in this acquisition process whereas
longitudinal sampling attempts to account for the dynamic process.
IgGl was the predominant subclass response to AMAI(3D7) in all age groups and throughout the
study which is in agreement with published findings (Riley et al. 2000; Polley et al. 2004; Metenou et
al. 2007; Nebie et al. 2008; Stanisic et al. 2009). There was little evidence that increasing age led to
polarisation of the antibody response to AMA I as suggested in previous studies (Taylor et al. 1998;
Tongren et al. 2006). The longitudinal nature of this study made it particularly valuable at examining
whether polarisation of IgG subclass responses occurred with increasing exposure though the reduction
in malaria transmission possibly affected this analysis. These findings are consistent with the nature of
the antigen being the major determinant of the IgG subclass response (Egan et at. 1995; Taylor et al.
1995; Rzepczyk et al. 1997; Metzger et al. 2003; Tongren et al. 2006; Nebie et al. 2008; Stanisic et al.
2009).
In order to complement the longitudinal studies of antibodies to AMA I, an assay was developed to
measure antibodies to functional and polymorphic epitopes of AMA I using monoclonal antibodies in
competition ELISAs. Antibodies to a functional invasion inhibitory epitope of AMAI(3D7), defined
by mAb IF9, were of low prevalence in malaria endemic populations from Kilifi district, including
those with high malaria transmission rates. Though antibodies to the mAb 1F9 epitope correlated with
increased exposure to P. jalciparum (as represented by the response to schizont protein extract) they
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did not significantly increase with age. High levels of anti-I F9 eptope reactivity were associated with
a reduced risk of clinical disease. This study suggests that functional inhibition of erythrocyte invasion
by merozoites could be one of the mechanisms involved in protection against malaria and suggest that
this assay may be valuable in vaccine trials of AMA I.
A number of factors that may affect antibody responses were not included in this study for various
reasons. Exposure to Plasmodium is heterogeneous and can be affected by both location (proximity to
mosquito breeding sites) and bed net use. Although weekly surveillance gave a strong indication of
whether a child had been recently infected, additional information from location and bed net use may
have helped properly define those children currently identified as non-exposed. The fact that drug
treatment occurred during the study period may have also affected antibody titres. Rapid drug-related
clearance of parasites could lead to a lowered antibody response due to reduced exposure of the
parasite to the immune system. As anti-malarial medication is widely in use in malaria endemic
populations inclusion of the number of times a child received drug treatment may have given a truer
picture of the acquisition of antibody responses to AMA 1 and MSP2. The above mentioned factors
would have assisted in the interpretation of these antibody responses. The underlying effect of each
individual's nutritional status would also confound any results obtained in this study. Unfortunately
this data was not available.
This study gives compelling evidence of the need for true longitudinal studies (with multiple sampling
of antibodies rather than longitudinal surveillance for clinical episodes alone) in the analysis of
antibody responses to malaria antigens and their role in protection against malaria. This work could be
extended in future studies by measuring responses to additional merozoite antigens, or antigens
expressed by other parasite stages, including IgG subclass responses to different antigens. The
::ndings here have significant implications for understanding the targets of protective immunity and the
factors determining the acquisition and maintenance of anti-malarial antibodies and immunity.
Insights from these studies may be valuable for advancing malaria vaccine development and testing as
well as aiding in the development of approaches for measuring exposure to malaria among populations.
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APPENDIX 1
The following appendix includes all results not included in Chapter 3 but mentioned in the text.
Tables 1-6: IgG responses to AMAI, MSP2, and schizont extract by age group and parasite status
at each cross-sectional bleed.
Tables 7-11: IgG responses to AMA 1 and MSP2 by reactivity to A4 schizont extract at each cross-
sectional bleed.
Tables 12-18: IgG responses to AMAI, MSP2, A4 schizont extract, and tetanus toxoid in the
presence or absence of haemoglobinopathies at each cross-sectional bleed.
Tables 19-25: IgG responses to AMA 1, MSP2, A4 schizont extract, and tetanus toxoid in the
presence and absence of the sickle trait in different age groups.
Tables 2~32: IgG responses to AMA I, MSP2, A4 schizont extract, and tetanus toxoid in the
presence and absence of the alpha-thalassemia in different age groups.
Tables 33A - 36F: The effect of different factors on IgG responses to AMA I and MSP2 at each
cross sectional bleed.
Tables 37-39: Correlations between IgG responses to AMA I(HB3), AMA I(3D7), and
MSP2(FC27) at each cross sectional bleed.
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Table 7 IgG responses to AMAl(W2mef) by reactivity to A4 schizont extract.
AMA1(W2mef)
P-value'
Reactivity to Schizont extract
Low Medium High
May20021
October 20021
May20031
October 20031
May20041
October 20041
N' 102 100 101
Median -0.01 0.09 0.75
lOR (-0.03 - 0.03) (0.01- 0.35) (0.2 -1.93)
N' 99 98 97
Median 0.10 0.39 1.54
IQR (0.01- 0.29) (0.16 - 1.01) (O.73 - 2.37)
N' 97 98 95
Median 0.01 0.03 0.39
IQR (-0.03 - 0.07) (-0.01- 0.18) (0.06 -1.7)
N' 96 95 95
Median 0,01 0.07 1.23
IQR (-O,O1- 0.05) (0.01 - 0.28) (0.25 - 2.07)
N' 95 93 95
Median 0.07 0.04 0.02
IQR (O- 0.87) (0 - 0.26) (-O.Ol - 0.23)
N' 101 101 100
Median -0.01 0.01 0.49
IQR (-0.03 - 0.01) (-0.02 - 0.07) (O.16 - 1.18)
<O.OOlt·'
<O.OOlt·,
<O.OOlt·'
<0.001'"
0.020'
<0.001'"
Notes
1Cross sectional bleed.
2 Number of samples tasted by ELISA
, P-values calculated uslnl a Kruskal Wallis test (P-values S 0.05 indicated in bold type).
• SIKnlflcant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with high schizont reactivity (P-values not Shown).
Sianificant difference (P S 0.05 Wilcoxon rank test) in median JIG levels between children with low and children with medium schizont reactivity (P-values not shown).
t Sllnlflcant difference (P.s 0.05 Wilcoxon rank test) in median IIG levels between children with medium and children with high schizont reactivity (P-values not shown).
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Table SlgG responses to AMAl(HB3) by reactivity to A4 schizont extract.
AMA1(HB3)
Reactivity to schizont extract
Low Medium High
May 2002'
October 2002'
May 2003'
October 2003'
May 2004'
October 2004'
N2 102 100 101
Median -0.02 0.11 0.83
lOR (-0.04 - 0.03) (0.01 - 0.37) (0.25 - 1.87)
N2 99 98 97
Median 0.02 0.10 0.55
IQR (-0.03 - 0.08) (0.02 - 0.33) (0.2 - 1.46)
N2 97 98 95
Median 0.03 0.08 0.50
lOR (-0.01 - 0.13) (0.01- 0.2) (0.12 - 1.83)
N2 96 95 95
Median -0.04 0.06 1.23
IQR (-0.06 - 0.01) (-0.03 - 0.28) (0.19 - 2.05)
N2 95 93 95
Median 0.08 0.05 0.02
IQR (0 - 0.91) (-0.D1- 0.25) (-0.02 - 0.31)
N2 101 101 100
Median -0.04 -0.02 0.51
lOR (-0.07 - -0.01) (-0.05 - 0.08) (0.15 - 1.24)
<0.001*"
<0.001*"
<0.001*"
<0.001*"
0.070*
<0.001*"
Notes
1Cross sectional bleed.
2 Number of samples tested by ELISA
3 P-vaduescalculated using a Kruskal Wallis test (P-values SO.OSlndicated In bold type).
t Significant difference (P S 0.05 Wilcoxon rank test) in median JIG levels between children with low and children with hl,h schizont reactivity (P-values not shown),
• Significant difference (P S 0,05 Wilcoxon rank test) In median fgG levels between children with low and children with medium schizont reactivity (P-values not shown).
t Significant difference (P S 0,05 Wilcoxon rank test) in median IgG levels between children with medium and children with h1ah schizont reactivity (P-Vllues not shown),
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Table 9 IgG responses to AMAl(3D7) by reactivity to A4 schizont extract.
AMA1(3D7)
Low Medium High
Reactivity to schizont extract
P-value3
May2oo2'
October 2002'
May 2003'
October 2003'
May2004'
October 2004'
N2 102 100 101
Median 0.00 0,07 0.61
IQR (-0.02 - 0.03) (0.02 - 0.32) (0.16 - 1.76)
N2 99 98 97
Median 0.00 0.05 0.38
lOR (-0.02 - 0.04) (0 - 0.22) (0.15 - 1.34)
N2 97 98 95
Median 0.02 0.04 0,45
lOR (0-0.09) (0 - 0.17) (0.07 - 1.68)
N2 96 95 95
Median -0.01 0.08 0.96
lOR (-0.D2 - 0.03) (0 -0.23) (0.18 - 1.97)
N2 95 93 95
Median 0.06 0.05 0.02
lOR (0 - 0.74) (-0.01- 0.22) (-0.02 - 0.18)
N2 101 101 100
Median -0.01 0.01 0.36
lOR (-0.03 - 0.02) (-0.01- 0.07) (0.11 - 0.95)
<0.001'"
<0.001'"
<0.001*'
<0.001'"
0.016'
<0.001'"
Notes
ICross sectional bleed.
2 Number of samples tested by ELISA
3P.vllues calculated uslna a Kruskal Wallis test lP-values So 0.05 indicated in bold type).
• 511nlficlnt difference (P ~ 0.05 Wilcoxon rank test) in median iKG levels between children with low and children with high schizont reactivity Is-vatuas not shown),
• Sllnlflcant difference (P S 0,05 Wilcoxon rank test) In median laG levels between children with low and children with medium schizont reactivity (P-values not shown).
I Silnltlcant difference (P S 0,05 Wilcoxon rank test) In median laG levels between children with medium and children with hiah schizont reactivity (P·values not shown).
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Table 10 IgG responses to MSP2(3D7) by reactivity to A4 schizont extract.
MSP2(3D7)
Reactivity to schizont extract
Low Medium High P-value'
May2002' N' 102 100 101
Median 0.06 0.16 0.86 <0.001'"
IQR (0.02 - 0.18) (0.05 - 0.42) (0.35 - 1.81)
October 2002' N' 99 98 97
Median 0.03 0.07 0.26 <0.001'"
IQR (0.01 - 0.07) (0.03 - 0.14) (0.1- 0.68)
May 2003' N' 97 98 95
Median 0.03 0.07 0.26 <0.001'"
IQR (0.01 - 0.09) (0.03 - 0.15) (0.1- 0.89)
October 2003' N' 96 95 95
Median 0.04 0.13 0.41 <0.001'"
IQR (0.01 - 0.08) (0.05 - 0.25) (0.17 - 0.91)
May 2004' N' 95 93 95
Median 0.12 0.07 0.05 0.012'
IQR (0.03 - 0.36) (0.02 - 0.18) (0.01- 0.2)
October 2004' N'
Median
101
0.03
101
0.06
100
0.21 <0.001'"
IQR (0.01- 0.06) (0.02 - 0.12) (0.09 - 0.51)
Notes
1Cross sectional bleed.
2 Number of samples tested by ELISA
1 P~values calculated using a Kruskal Wallis test (P-values S0.05 indicated In bold type).
: Significant difference (P S 0,05 Wilcoxon rank test) In median fKG levels between children with low and children with hleh schizont reactivity (P-Vllues not shown).
Sllnlflcant difference (P:so 0 05 Wilcoxon rank test) in median ilG levels between children with low and children with medium schizont r.lctlvlty (P-v.luls not shown)
t Slgnlflcant difference (P S 0.05 wttcoxcn rank test) in median IKG levels between children with medium and children with hllh schizont reactNltv (p..yalues not shown).
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Table 11 IgG responses to MSP2(FC27) by reactivity to A4 schizont extract.
MSP2(FC27)
Low Medium P-value'
Reactivity to schizont extract
High
May20021
October 20021
May 20031
October 20031
October 20041
N' 102 100 101
Median 0.01 0.06 0.56
lOR (-0.02 - 0.06) (0.01 - 0.22) (0.2 - 1.6)
N' 99 98 97
Median 0.03 0.06 0.40
IQR (0 - 0.07) (0.02 - 0.15) (0.17 - 0.85)
N' 97 98 95
Median 0.04 0.Q7 0.32
IQR (0.01- 0.09) (0.03 - 0.17) (0.14 - 0.96)
N' 96 95 95
Median 0.03 0.08 0.46
IQR (0.01 - 0.08) (0.02 - 0.16) (0.18 - 1.4)
N' 95 93 95
Median 0.07 0.06 0.05
lOR (0.03 - 0.34) (0.02 - 0.15) (0.01- 0.18)
N' 101 101 100
Median 0.03 0.04 0.19
IQR (0.01- 0.05) (0.02 - 0.11) (0.09 - 0.41)
<0.001'·'
<0.001'·'
<0.001'·'
<0.001'·'
0.208
<0.001'·'
Notes
1Cross sectional bleed.
'Number of sampl .. tested by ELISA
, P-vllues c.lcul.ted usln, I Kruskal Wallis test (P·values S 0.05 Indicated in bold type).
, Sianificant difference (P S 0,05 Wilcoxon rank test) in median IIG levels between children with low and children with high schizont reactivity (P-values not shown),
• SIa:nlflclnt difference (P S 0.05 Wilcoxon rank test) In median IIG levels between children with low and children with medium schizont reactivity (P-values not shown).
t Sllnlflcant difference (P S 0.05 Wilcoxon rank test) in median laG levels between children with medium and children with high schizont reactivity Is-values not shown),
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Table 12 IgG responses to AMAl(W2mef) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha- Thalassemia
AMA1(W2mef)
P-value' P-value'HbAA HBAS Norm Het Homo
May2002' N' 258 41 93 152 52
Median 0.09 0.05 0.215 0.09 0.09 0.07 0.521
IQR (-0.Q1- 0.72) (0 - 0.23) (-0.01- 0.72) (0-0.72) (0 - 0.25)
October 2002' N' 258 34 92 138 54
Median 0.44 0.36 0.141 0.40 0.50 0.21 0.042'
IQR (0.11 - 1.47) (0.05 - 0.98) (0.1- 1.36) (0.16 - 1.53) (0.04 - 0.66)
May 2003' N' 246 37 90 137 52
Median 0.06 0.01 0.012 0.05 0.07 0,01 0.04'
IQR (0-0.69) (-0.03 - 0.21) (-0.01- 0.44) (0-0.73) (-0.02 - 0.1)
October 2003' N' 246 38 97 136 52
Median 0.07 0.09 0.908 0.09 0.09 0.03 0.067
IQR (0 - 0.69) (0.02 - 0.24) (0.02 - 0.85) (0.01- 0.58) (-0.01- 0.21)
May 2004' N' 231 35 88 124 49
Median 0.05 0.04 0.584 0.06 0.05 0.02 0.029"
IQR (0-0.46) (0 - 0.17) (0.01- 0.78) (0-0.41) (-0.01 - 0.09)
October 2004' N' 232 38 92 126 50
Median 0.Q3 0.03 0.905 0.04 0.03 0.01 0.401
IQR (-0.02 - 0.3) (-0.02 - 0.21) (-0.01- 0.35) (-0.02 - 0.34) (-0.02 - 0.17)
Notes
I Cross sectional bleed.
2 Number of samples tested by ELISA
3 s-velues calculated using a Wilcoxon rank test (P-values!l 0,05 indicated in bold type).
4 P-values calculated using a Kruskal Wallis test (P-values S0.05 Indicated In bold type).
• Slloiflcant difference (P S 0.05 Wilcoxon rank test) in median IIG levels between normal children and children heterozv&ouS for a-thalassemia (p..yllues not shown),
Significant difference (P S 0.05 Wilcoxon rank test) In median liG levels between normal children and children homozVlous for a~thalasseml. (P-valuls not shown).
'SiKnificant difference (P S 0.05 Wilcoxon rank test) in median IKG levels between children heterozygous and hcmczvgous for a-thalassemia (P·valuls not shown).
321
Table 13 IgG responses to AMA1(HB3) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha·Thalassemia
AMA1(HB3)
HbAA HBAS P-vaiue' Norm Het P-value'Homo
May2002' N2 258 41 93 152 52
Median 0.10 0.05 0.258 0.09 0.12 0.05 0.169
iQR (-0.01- 0.75) (-0.02 - 0.3) (-0.03 - 0.85) (0 - 0.65) (-0.Q2 - 0.27)
October 2002' N2 258 34 92 138 54
Median 0.10 0.08 0.454 0.11 0.12 0.04 O.OOg·t
IQR (0.02 - 0.5) (0.01 - 0.38) (0.02 - 0.47) (0.03 - 0.5) (-0.02 - 0.19)
May2003' N2 246 37 90 137 52
Median 0.12 0.03 0.013 0.11 0.14 0.04 0.026t
IQR (0.02 - 0.79) (0 - 0.3) (0 - 0.58) (0.03 - 0.83) (0-0.14)
October 2003' N2 246 38 97 136 52
Median 0.04 0.08 0.684 0.13 0.05 -0.Q1 0.068'
IQR (-0.04 - 0.75) (-0.Q3 - 0.2) (-0.Q2 - 0.91) (-0.04 - 0.66) (-0.04 - 0.17)
May 2004' N2 231 35 88 124 49
Median 0.06 0.03 0.511 0.09 0.05 0.02 0.058·
iQR (-0.01- 0.53) (0 - 0.2) (0 - 0.79) (-0.01- 0.57) (-0.02 - 0.11)
October 2004' N2 232 38 92 126 SO
Median 0.01 0.03 0.68 0.03 0.02 -0.02 0.344
IQR (-0.05 - 0.31) (-0.05 - 0.28) (-0.04 - 0.39) (-0.05 - 0.29) (-0.04 - 0.24)
Notes
t Cross sectional bleed.
2 Numbe, 01 samples tested bV ELISA
'P·values calculated uslna a Wilcoxon rank test (P·values S 0.05 indicated In bold type),
4 P-values calcullted usin. ill Kruskal Wallis test (P-values S 0.05 Indicated in bold type).
• Sllnificant difference (P S 0.05 Wilcoxon rank test) in median 'IG levels between normal children ilnd children heterozygous for a-thalassemia {P-values not shown},
Silniflcant difference (P S; 0,05 Wilcoxon rank test) in median IIG levels between normal children and children homozygous for a-thalassemia (P-values not shown).
I Sicnificant difference (P S 0,05 Wilcoxon rank test) in median laG levels between children heterozygous and homozygous for a-thalassemia (P·values not shown),
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Table] 4 IgG responses to AMAl(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha- Thalassemia
AMA1(3D7)
P-value' P-value'HbAA HBAS Norm HbAA HBAS
May 2002' N' 258 41 93 152 52
Median 0.07 0.04 0.162 0.06 0.08 0.04 0.357
IQR (0-0.6) (0 - 0.15) (-0.01- 0.59) (0.01- 0.51) (0.01- 0.21)
October 2002' N' 258 34 92 138 54
Median 0.06 0.05 0.368 0.05 0.09 0.02 0.051"
IQR (0 - 0.33) (0 - 0.19) (0- 0.31) (0 - 0.38) (-0.01- 0.14)
May 2003' N' 246 37 90 137 52
Median 0.08 0.02 0.02 0.06 0.08 0.03 0.02'
IQR (0.01- 0.6) (-0.01- 0.24) (0 - 0.5) (0.01 - 0.65) (-0.01- 0.13)
October 2003' N' 246 38 97 136 52
Median 0.08 0.07 0.843 0.10 0.08 0.02 0.07
IQR (-0.01- 0.46) (0.01 - 0.19) (0- 0.74) (0 - O.4S) (-0.01- 0.13)
May 2004' N' 231 35 88 124 49
Median 0.04 0.04 0.47 0.07 0.04 0.00 0.032"
IQR (-0.01- 0.36) (-0.01- 0.14) (-0.01- 0.6) (-0.01- 0.36) (-0.01 - 0.08)
October 2004' N' 232 38 92 126 50
Median 0.02 0.04 0.728 0.03 0.04 0.02 0.721
IQR (-0.01- 0.22) (-0.02 - 0.18) (-0.01 - 0.27) (-0.02 - 0.24) (-0.01 - 0.18)
Notes
1 Cross sectional bleed.
2 Number of samples tested by ELISA
3 P-values calculated using a Wilcoxon rank test (P-values S 0.05 Indicated In bold type).
4 P-values calculated using a Kruskal Wallis test (P-values S 0.05 indicated in bold type).
: Significant difference (P S 0.05 Wilcoxon rank test) in median IIG levels between normal children and children heterozveous for a-thalassemia IP·values not shown).
Significant difference (P S 0.05 Wilcoxon rank test) in median liG levels between normal children and children homozvgous for a-thalassemia (P"Valuu not shown).
t Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children heterozygous and homozygous for a-thalassemia IP-valuls not shown).
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Table 15 IgG responses to MSP2(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
MSP2(3D7)
HbAA HBAS P-value' Norm P·value"Het Homo
May 2002' N' 258 41 93 152 52
Median 0.24 0.13 0.141 0.26 0.23 0.12 0.059
IQR (0.05 - 0.69) (0.02 - 0.58) (0.07 - 0.68) (0.05 - 0.78) (0.03 - 0.34)
October 2002' N' 258 34 92 138 54
Median 0.07 0.09 0.884 0.08 0.08 0.07 0.633
lOR (0.03 - 0.23) (0.03 - 0.17) (0.03 - 0.25) (0.03 - 0.26) (0.03 - 0.16)
May 20031 N' 246 37 90 137 S2
Median 0.09 0.07 0.4 0.10 0.09 0.07 0.762
IQR (0.03 - 0.29) (0.02 - 0.2) (0.02 - 0.33) (0.03 - 0.26) (0.03 - 0.2)
October 2003' N2 246 38 97 136 S2
Median 0.13 0.09 0.626 0.15 0.10 0.09 0.487
lOR (0.03 - 0.36) (0.05 - 0.17) (0.04 - 0.39) (0.04 - 0.35) (0.03 - 0.31)
May2004' N2 231 3S 88 124 49
Median 0.08 0.07 0.517 0.08 0.07 0.08 0.779
IQR (0.02 - 0.26) (0.02 - 0.22) (0.03 - 0.29) (0.02 - 0.27) (0.03 - 0.17)
October 2004' N2 232 38 92 126 SO
Median 0.07 0.07 0.89S 0.07 0.08 0.06 0.738
lOR (0.02 - 0.22) (0.04 - 0.17) (0.03 - 0.26) (0.02 - 0.23) (0.03 - 0.21)
Notes
1Cross sectional bleed.
'Number of ,amples tested by ELISA
3 P-\Illues calculated uslna a Wilcoxon rank test (P-values S 0,05 indicated in bold type).
4 P-values calculated u,ln, a Kru,kal Walli, test lP-values S O.05lndicated In bold type).
: Sllnlficant dlfferencelP s 0,05 Wilcoxon rank test) in median leG levels between normal children and children heterozygous for a-thalassemia Is-values not shown),
Sllnlflcant difference (P Si 0,05 Wilcoxon rank test) In median IKG levels between normal children and children homozygous for a-thalassemia (P-values not shown),
, Sllnificant dIfference \p Si 0.05 Wilcoxon rank test) in median IIG levels between children heterozygous and hcmozvgous for a-thalassemia (P-values not shown).
324
Table 16 IgG responses to MSP2(FC27) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha- Thalassemia
MSP2(FC27)
P-value' P-value·HbAA HBAS Norm Het Homo
May 2002' NZ 258 41 93 152 52
Median 0.11 0.Q1 0.052 0.14 0.09 0.06 0.397
IQR (0.01 - 0.4 7) (0 - 0.22) (0.01- 0.42) (0.01- 0.5) (-0.01- 0.28)
October 2002' NZ 258 34 92 138 54
Median 0.09 0.06 0.593 0.09 0.08 0.07 0.309
IQR (0.02 - 0.34) (0.03 - 0.23) (0.02 - 0.28) (0.02 - 0.4) (0.03 - 0.17)
May2003' NZ 246 37 90 137 52
Median 0.09 0.06 0.19 0.11 0.10 0.06 0.151
IQR (0.03 - 0.32) (0.03 - 0.19) (0.03 - 0.47) (0.03 - 0.32) (0.03 - 0.14)
October 2003' NZ 246 38 97 136 52
Median 0.10 0.07 0.276 0.10 0.10 0.08 0.365
IQR (0.02 - 0.41) (0.04 - 0.17) (0.02 - 0.42) (0.02 - 0.39) (0.02 - 0.24)
May 2004' NZ 231 35 88 124 49
Median 0.08 0.05 0.379 0.08 0.07 0.05 0.22
IQR (0.02 - 0.25) (0.02 - 0.15) (0.03 - 0.34) (0.02 - 0.24) (0.02 - 0.14)
October 2004' NZ 232 38 92 126 50
Median 0.07 0.06 0.721 0.07 0.07 0.03 0.363
IQR (0.03 - 0.2) (0.03 - 0.19) (0.03 - 0.24) (0.03 - 0.18) (0.02 - 0.18)
Notes
ICross sectional bleed.
2 Number of samples tested by ELISA
3 s-velues calculated using a Wilcoxon rank test (P-values S0.05 indicated In bold type),
" P-values calculated using iii Kruskal Wallis test (P-values S 0.05 Indicated In bold type).
• Slgnfflcant difference (P S 0.05 Wilcoxon rank test) In median leG levels between normal children and children heterozYlouS for a-thalasslmla (P-vllu.s not shown).
Significant difference (P S 0.05 Wilcoxon rank test) in median riG levels between normal children and children homozvgous for a-thalassemia (P-values not shown).
t Significant difference (P S 0.05 Wilcoxon rank test) in median tgG levels between children heterozygous and homozygous for a-thalusemla IP-.... lu.s not shown).
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Table 17 IgG responses to A4 schizont extract in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
Schizont extract
P-value'HbAA HBAS Norm Het Homo P-value'
MayZOOZ1 N2 257 41 92 153 51
Median 0.41 0.25 0.034 0.43 0.41 0.33 0.273
IQR (0.16 - 0.92) (0.08 - o.n) (0.15 - 0.9S) (0.16 - 0.91) (0.09 - 0.68)
October ZOOZl N2 259 34 92 139 54
Median 0.13 0.12 0.702 0.13 0.16 0.09 0.15'
IQR (0.05 - 0.44) (0.03 - 0,48) (0.05 - 0,41) (0.05 - 0.49) (0.03 - 0.21)
MayZ0031 N
2 249 37 93 137 52
Median 0.17 0.13 0.291 0.18 0.19 0.11 0.188
iQR (0.06 - 0.54) (0.04 - 0,42) (0.06 - 0.48) (0.05 - 0.S7) (0.05 - 0.31)
October 2003' N' 239 38 95 132 SO
Median 0.21 0.18 0.218 0.24 0.25 0.14 0.174
IQR (0.07 - 0.82) (0.04 - 0,49) (0.09 - 0.9) (0.06 - 0.7) (0.07 - 0,48)
MayZ0041 N2 234 35 89 125 49
Median 0.09 0.06 0.157 0.10 0.09 0.Q7 0.865
IQR (0.02 - 0.31) (0.02 - 0.23) (0.02 - 0.29) (0.02 - 0.27) (0.03 - 0.7)
October 20041 N2 232 38 92 126 50
Median 0.09 0.10 0.839 0.11 0.10 0.06 0.271
IQR (0.04 - 0.25) (0.05 - 0.22) (0.03 - 0.35) (0.04 - 0.25) (0.04 - 0.17)
Notes
1Cross sectional bleed.
] Number of samples tested by ELISA
1 P.values calculated usin. a Wlico)(on rank test (P·values S 0.05 indicated in bold type) .
.. P-values calculated uslna a Kruskal Wallis test lP-values S 0.05 Indicated In bold type).
, Sllnlficlnt difference (P S 0.05 Wllco)(on rank test) In median ilG levels between normal children and children heterozvgcus for a-thalassemia (P-values not Shown) .
• Sllniflclnt difference (P S 0,05 Wilcoxon rank test) In median IIG levels between normal children and children hcmczvgous for a-thalassemia (P-values not shown).
I Slenificant difference (P S 0.05 Wilcoxon rank test) in median leG levels between children heterozvgous and homozygous for a-thalassemia (P-values not shown).
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Table 18 IgG responses to tetanus toxoid in the presence or absence of hemoglobinopathies.
Sickle trait Alpha- Thalassemia
Tetanus toxoid
P-value'HbAA HBAS P-value' Norm Het Homo
May 2002' NZ 258 41 93 152 52
Median 0.54 0.60 0.95 0.60 0.55 0.64 0.543
IQR (0.29 - 0.93) (0.28 - 0.85) (0.3 - 0.93) (0.29 - 0.87) (0.33 - 1.09)
October 2002' NZ 258 34 92 138 54
Median 0.58 0.60 0.616 0.59 0.58 0.72 0.298
IQR (0.33 - 1.03) (0.37 - 1.13) (0.35 - 1.1) (0.3 - 0.95) (0.36 - 1.27)
May 2003' NZ 246 37 90 137 52
Median 0.54 0.53 0.69 0.61 0.49 0.86 0.208
IQR (0.28 - 1.13) (0.27 - 0.99) (0.33 - 1.13) (0.27 - 1.04) (0.31- 1.63)
October 2003' NZ 246 38 97 136 52
Median 0.48 0.53 0.954 0.55 0.44 0.70 0.1'
IQR (0.26 - 0.99) (0.22 - 0.98) (0.22 - 1.06) (0.26 - 0.86) (0.42 - 1.08)
May 2004' NZ 231 35 88 124 49
Median 0.45 0.53 0.527 0.58 0.44 0.53 0.485
IQR (0.26 - 0.91) (0.37 -1) (0.28 - 0.92) (0.27 - 0.79) (0.32 - 1.05)
October 2004' NZ 232 38 92 126 50
Median 0.50 0.58 0.869 0.58 0.46 0.61 0.499
IQR (0.29 - 0.99) (0.28 - 1.03) (0.3 - 1.05) (0.28 - 0.94) (0.33 - 1.04)
Notes
ICross sectional bleed.
2 Number of samples tested by ELISA
] P-values calculated using a Wilcoxon rank test (P-values S 0.05 indicated In bold type).
4 P-values calculated using a Kruskal Wallis test (P-values.s 0.05 indicated in bold type).
: Slgnlflcant difference (P.s 0.05 Wilcoxon rank test) in median IgG levels between normal children and children heterozvgous for a-thalassemia lP-values not shown).
Slgnfflcant difference (P S 0.05 Wilcoxon rank test) In median jgG levels between normal children and children hornozvgous for a-thalassemia Ip..yalues not shown).
t Significant difference (P S; 0.05 wtlccxcn rank test) in median fgG levels between children heterozygous and homozygous for a-thalassemia (P·values not shown),
327
.s
Q
Q,je
N
~-<:;
<
o-TIl
Q,j
TIl=o
C.
TIl
~
o
!!
0\
e
'"~
M
I...
~
'"~
Cl...
I,...
~
'"~
M
I...
00...
m
N
00
LI'I
N
d
Cl
N
d
r-,
o
d
...o
d
No
d
....
g
clv
Cl....
,...
LI'I
d
No... Nmd
Clo....
No
d
c:
re
'ti
QJ
:2
LI'Io
2.
M
N
d...q
2.
M
N
d
No
1
'"....
2.
M
ID
...i
'"o
2.
No
~
iD
N
d...
q
~
a:
Q'Z
N....
LI'I....
'"
~N
g
N...
III
.rJ
~o
N
ID
d
r-,...
d
N
'"...i
....
s
cl
v
N
'"
ID
Cl
Cl
ID
d
q-
Cl
.........
d
m
m
ID
ID
d
c:
re
'ti
QJ
:2
u:;-
LI'I
...i
00...
2.
m
o
2.
'"
Mo
N
N
2.
....
o
2.
N
N
............
d
'"~o
Cl
N
d
....
g
cl
v
.....q-
...
00
d
....
ID ...
00 d
.....
00 0
00 d
....
o
d
N
o
2.
N
d
00m ...o
1
<0
ID
d
N
o
1
c;:;-
o
N
0'>
o
2.
No:t
c;:;-
o
d
mo:t
ID
'"
....
o
2.
N....
d
0'>
m
r-,
d
....
d
........
d
....
g
c:)
v
N
U')
ID
ID
c:i
....
Cl
00....
d
00
00
N
o
d
'"....
m
o
d
c:
ro
'ti
Cli
:2
N
N
d
m
o
2.
~
N
d
....
o
2.
N
ID
d
Mo
:t
00q
2.
....
o:t
00-
o
c:i
....
o
2.
00
o...
N
........
d
0'>
N....
d
U'\
o
d
...
o
d
...
o
d
....
s
cl
v
........ Nq-d
III
o
d
0'>..... o
q-
m ...
o
2.
~o
d
....o:t
m-o
d
....
o
1
IDo
2.
~o
d
q-
N ID
o
~
o '"o1
N
00....
d
N.... 0'>od ....o:t
00-m
d
2.
mo
9
iDo
d
N'Io
1
o.....
.....
s
clv
00....
d
c;:;-
O'>
d
No
2.
N'I
o
d
<0
N
d
N
o
1
N
o
d
m
o
9
m-o
9
m
o
:f_
a:
Q 'Z
a:
Q
~8
N...
Jj
o
t:io
~..
~
<:>...
I,...
e..
~
m
I...
~..
~
o...
I,...
~..
~
m
I...
'"....
N
o....
'"o....
m
N
IJ'l
m....o
r-,
o
si.
N....
c:i
00....
....
o
9
mo
c:i
00-o
c:i
N
o
:t
....
g
civ
m
IJ'l
c:i 00....
8.
o
....
o
c:i
a;-
No
mo
1
Nm
m
m
~N
g
N..
CII
..0o
to
"'"o
'"'"c:i '"o
:t
M
00o
'"....
IJ'l....
m
....
g
ci
v
"....c:i
mo
c:i
N
M
c:i
C
rn
'6
OJ~
~....
c:i
IJ'lo
c:i
00-....
c:i
....o
si.
m...
c:i
en~o
00o
8.
'"00,..;
'"....
8.
IJ'l
o
si.
........
00
00
'"'"
~m
g
N
>..
:!:
....
g
civ
'",...
c:i
c
'"'6
OJ~
'"....o
m
'"c:i
iDo
c:i
o
No
~
M
'"c:i
mo
8.
00-o
N
IJ'l
M
si.
~
N
,..;
mo
si.
m
M
c:i
....
o
1
....
'"
00
00
m....
~m
g
N..
IIo
t:o
........
c:i
00....
........
c:i
........ '"oc:i
....
g
ci
v
'"~o
'"o
c:i
....
o
9
No
9
N
c:i
IJ'l
M ....o
~
N
c:i
M
IJ'l
c:i
00o
~
No
N
IJ'lo
si.
M....
c:i
IJ'lo
~
rx:
Q'Z
o....
N
M
"
....,...
'",...
N
'"Mc:i
00
~
M
c:i
M
m
c:i
S
00o
c:i
o
No
~
No
c:i
o
Mo
~
....
g
c:i
v
,...
o
c:i
00-o
c:i
o
No
~
....o
9
M....
o
C
rn
'6
OJ~
o.....
00...
mo
N
M
M....
c:i
00o
c:i
IJ'lo
9
....
g
ci
v
"....
c:i
M
'"c:i
S
No
c:i
a;-
N
c:i
;;-
o
c:i
~o
~
00o
9
00-o
9
00o
1
r;-
o
Co...
c(
:E
c(
s...
d
e
"'~
til
I...
c
"'III>-
Q
~
"'~
Q...
I,..
c
"'III>-
ID
I~
~
"'~
'"I...
00...
'"....
No....
NI
N
....
o
d
....
8
ci
v
o.n
NI
d
~
N
d
No
d
NIo
d
00...
d
No
£
...
o
d
u:;-....
d,...o
~
00
00
...i
,..
o
£
00
N
...i
N....
d...o
:?
a:
Q'Z
N...
NI
N
NI
1.0
'"
NI
NI
"N
8
N..
III...
~o
o.n
NI
NI
d
'"....d
o.n...
....
8
civ
o
,....
o
d
No
£
00
o
d
NIo
d
...
NI ...
o
:?
r-,...
d
u:;-
N
d
....
o
£
NI
o:t
d
NI...
d
r;-
o.n
d
No
£
r;-
o
d
No
:?
NI
N
d
1.0
00
00
00
N
N
r-,....
d
o
NI
....
g
ci
v
00
ID
d
...
d
NIo
d
No
d
N
N
d
8.
;v;-
a
d
No
1
....o
£
No
£
....o
1
~....
d
8.
N
U"")
00
00
NI...
o:t...
d
00....
......
NI
....
8
ci
v
...
'"
...
o
ci
o
....
d
00....
d
NI
o
£
oN ....
C!
2:
NIo
d
r;-
o.n
d
00
<:t:
a
....
'"""!
o
No
:?
a:
Q 'Z
00
N
....r--
'"NINI
d
,.......
d
NI
N
d...
o
:t
II)...
e;;-
o
d
....
a
£
...
o
d
u:;-
o
d
No
:?
...
o
d ....o
:?
....
8
civ
o.n
NI
d
...,....
e;;-
N
d
o.... r--
a
1
;:0-
o
d
o
....
o
d NIa
:?
N....
....
"8
N..
III...o
tio
r-,
r-,
m
d
IDo
d
~
N
d...
o
:?
<.0o
d
No
9 No
:?
.....
8
civ
o
M
M
;:0-
r--
d
No
£
N
o
d
;:::;-
N
d
....
a
~
No
d
o
NIo
~
No
9
No
9
N
o
~
~
to
~
o...
I,...
00...
~
to
OJ
>
o...
I,...
'"...
No...
~
to
~
M
I...
'"D...
en
N
'"<Doo
en
No ...
2.
N...o ...o
2.
'"
enoo
'"oo...
o
2.
....
g
o
v
,...
'"o en...
2.
'"eno
00-o,..;
N...
2.
'"oo No
2.
N...
'"...
N
en
en
en
N
8
N..
1:og
'"'"No
.....oo
<D
oo
...
o
....
8o
v
<t...o
enoo
c
"''0
Q)
~
00-
00o
N
D
2.
...
en ...
o
2.
N
eno
00o
2.
<Do
2.
00-oo
No
2.
a;-
Do
00...
<D
00
00
00
('oj
N
M
8
N
>to
:E
'"oo
......o
<Doo
('oj...
o
....
8o
v
00...
o
en...o
c
"''0
Q)
~
...
o
2.
;::::-
oo
('oj
o
2.
N.....o
'"o2.
'"o2.
iVi
N
ci...
o
2.
00...
......
N
'"
...
0>
00
00
en...
"M
8
N..
1:o
1::o
'M
Noo
en
No
<Doo
....
8ov
en
N
ci
en...o
'"Dci
.....oo
c
"''0
Q)
~
00-
eno
<Do
2.
'"Dci
rl
en
ci
No
2.
N...
ci
No
2.
a::
Q'Z
00
r-,
D
ci
'"...
('oj...
ci
Mo
ci
('oj
Moo
....
g
o
v
........
........ 00oo
'".....
o
00-
eno
eno
2.
00-
M
ci
.....
o
2.
...
o
2.
00-
o
ci...
o
~
eno
2.
;::;-
o
ci...
o
~
N
o
r-,
o
N...
<D
o
ci
~o
N
o
2.
'".....
....
g
ov
en...
ci
o.....
.....
oo
No
ci
c
"''0
Q)
:E
~
'"~
Q...
I,...
~
'"~
1ft
I...
~
'"~
Q...
I,...
e
'"~
1ft
I...
00...
M
N
,...
Ma
~...
oa
Noa
...
o
9
....
8
c:i
v
...
oa
c
11)
'0
C1J
::E
Vi'
VIa
N
2.
...
o
2.
No
~
;:::;-
VIa
Mo
2.
M
Na
2.
N
Na...
o
~
N... <Doa
VI... <Doa
<Doa
....
8
c:i
v
N
M
<D
'"
<D.....a
Moa
,..._
oa
c
11)
'0
C1J
::E
~N
8
N~
III.co
1::o
Mo
2.
M
Na
2.
No
2.
00.....
00
00
N
N
...
00
00a
<D
M
'"a
M
Na
00oa Mo
2.
r-,
oa
....
8
c:i
v
M
Na
iD
'"a
,..._
o
2.
M.....a
No
2.
VIoa
00-oa
No
2.
c
11)
'0
C1J
::E
00.....
00
00
M.....
~..,
8
N~
III.cog
'"oa
VIoa
Moa
....
g
c:i
v
N
'"a
N.....a
<Doa
c
'"'0
C1J
::E
N
Na
g
2.
'"o2.
Vi'a
'"o
2.
m
Na
.....o
2.
<Doa...
o
2.
00
o...
N
.....
r-,
'",..._
>-
'"~
N.....a
M
oa
....
s
c:iv
00.....a
,..._
oa
o
c
'"'0
C1J
::E
N
Na
s
2.
'"q
o
N
o
2.
00-oa
....
o
~
00-
VIa
N
Na
N
o
2.
Noa
N....
'",..._
o,..._
.....
00-
Na
Mo
2.
<:toa M
o
2.
Moa
00-
oa
....o
2.
.....
8
c:iv
,..._
oa
o
~
E
~
OJ...
Co
.t:!.c
u
VI
e
"'~
()...
I,...
'"'"oo
00
1.0o
r::-ooo
, q-
'"'"2.
~
"'~
ttl
I...
00....
~
"'~
()...
I.....
'"....
N ~'"o 1.0....0
00o....
M
N
q-...o
00oo
00oo
.....o
2.
....
:§!
()
V
M
'"o
1.0
M
2.
M
No
~
'"o
00....
o
m-~o
r-o
2.
ccQz
'"....
N
M
1.0
'"
'"'"
M
<Yl
~N
:5
N...
OJ.co~o
M
00
Mo
'"....o
r-,....o
Moo
....
No
....
g
c:i
v
q-
Mo
r-
No
r-oo
r-oo
;:0-
mo
m
'"o
00o
2.
;:;-
mo
~
'"o m
2.
N
'"o
r::-
'"o
'"o
2.
'"...o
N
o
2.
e;:;-
rio
No
2.
00....
.......
00
q-
r-
oo
'"00
N
N
'"'"'"o
q-o
m...o
Moo
....
g
c:i
v
....
No
...o
Moo
c
'":a
QJ
~
r::-o
N
q-o
1.0o
2.
~
'"o
....
o
2.
m-mo m
2.
m
1.0o
1.0o
2.
N
No
'"o2.
~
rio
No
2.
00...
....
'"
00
00
'"00
m
ri
~8
N...
OJ.co~o
m
q-...o
'"mo
'"No
....... ...o
r-oo
00
'"o
r-
No
.......o
...o
c
ro
'i3
QJ
~
m
Mo
No
2.
00
N
2.
~
'"o
r::-
rio
mo
2.
cc
Q z
00
'"...
....r-
Nr-
>to
~
.......
C>
c:i
N
o
ci
a
ci
'"....ci
....
8
c:iv
.....
o
ci
'"....o
00....o
;n
oo
2.
r::-oo
No
2.
~
No
1.0o
2.
e;:;-
No
No
2.
m-
o~
N....
2.
N....
o
"
.",
1.0oo
v...
ci
N
No
r-,
q
o
ill....o
1.0o
2.
Noo
;:;-
o
....
o
2.
....
8
c:i
v
No
'"oo
moo
...
oo
I!!
"'~
o....
I....
I!!
"'~
'"I....
I!!
"'~
o....
I....
I!!
"'GI>
<D
I.,
I!!
"'GI>
'"I....
00....
Ol....
N
00.....
c:i
N.,
c:i
'i)
\J)
c:i
00
N
£
.....
\J)
c:i
m-
Ol
c:i
Ol
N
£
r-,
M
...;
;:n
'"...;
.....
8
Q
\J)
M
c:i
00
'"c:i
N
S
r:::....
c:i
00
N
£
Olo....
00
\J)
c:i
M
N
LJ')
00
c:i
c
"''0
QJ
~
N.....
LJ').....
N
8
N..
GI
.rJo
1:>o
LJ')
o
cYl
c:i
N
'"c:i
.,
\J)
c:i
M.....
...;
.",
8
Q
N
M
lD
'"
00.,
c:i
'",.._c:i
M
cYl
.....
...;
c
"''6
QJ
~
r:::
00
c:i
'"N£
m-o...;
00
00
...;
00
£
N
lD
c:i
r-
N
£
;:::;-....
...;
'"cYl
£
No
N
,.._
N
£
00....
.........
N
\J)
cYl
c:i
00
00 ..........
£
m
r-,
c:i
;:n
N
...;
Ol
N
£
\J)
ex>
c:i
\J)
m
c:i
;:::;-.....
N,
.....
N
£
,.._.,
c:i
N
'"c:i
,.._
N
£
00
00
,.._
'"c:i
No...;
00
N
£
N
N
Ol
cYl
...; Olo...;
c
"''0
QJ
~
.........
0'1r-,
o
c:i
0'1an
c:i
N
r-,
c:i
....
'"LJ')o
c:i
N
an
N...
c:i
00
00
.....
lD
c:i
(Y)..... '"'"c:i
c
"''6
QJ
~
(Y)
c:i
ex>.....
£
00
N...;
m-o...;
N
N
£
co
o.....
co
m
£
(Y)
'"...;
co
M
£
Cl:Qz
\"0'1
o
c:i
,....
N
c:i
;:n
'"c:i
N
£
co
an
c:i
'"c:i
;:::;-....
...;
N
,....
'"c:i
00
lD
c:i
cc.,
£
'"r-,-e-
c:i
....
r-,
lD
m
c:i
.....,....
00
00
c:i
\J)
N
£
0'1,.... \J)c:i
N
'"c:i
00
N
£
,.._
lD
c:i
c
"''0
QJ
~
Cl:
Q z
>
"'~
0'1
~
N..
<II
.rJ
o
1:>o
0'1
'"c:i
m-o
...;
N
N
£
00
CO
c:i
~
N...;
N
an
ID
c:i
N...
d
o,....
,....
'"d
00
0'1
d
'"N
£
...
ID
d
0'1....
d
c;;-....
d
0'1....
2.
c
"''6
Cl)
~
Cl:
Q
;;;
Eoz
....
N
....
cl
'"N ....o
1
No
cl
No
cl
8
'",
'"N
cl
....o
cl
g
cl
...
C
.,;
....
'"cl
N
'" '"cl
g
cl
c:..
iJ
"::;
en
'"
....
N
N
'"
en
cl
N
cc
cl
cc
'"cl
'b
'8.
00-
":
o
'"o2.
r-,
'"cl
'"o
2.
N
'"
'",
o
'"
....
'"
....
o
cl
...~o
...o
9
en
N
cl
...o
cl
....~o
;:::
'"cl...o
2.
5
cl
...o
~
ffi...
cl
'"o2.
;:::
00
cl
N
o
1
'"o
cl
'"'"
.
~o
'""!
o
....
o
cl
'",
'"'"
::;
o
8
cl
;:::
o
cl
en ~
o N
o
2.
00
'"cl
g
o
c:
.!!!
"0
"::;
....
'"
00
N
......
t...o
9
'",
mo
9
':1
Q
.,;
s
.,;
q
o
No
1
...o
9
....
o
1
men
ci
...
N
cl
...o
1
...
o
cl
mo
1
N
cl
so
ono
cl
;;;
N
cl
8
o
.,;
Cl
1
en
m Cl.,;
N
o
9
'",
'"N
'"N
...
o
9
e..~...
I
~..
",..o
;;
E
oz
....
....
N
ill
ci
mo
d
.."
m
d
8
d
.~
N
m
;n-
o
d
'"..
c:i
....o
9
....
o
d
"N
;;;-
co....
'"Cl
9.
....
N
ci
'" "'"d
.."
o
N
N
'"
.~
"N '"Nc:i
'"m ~"od
....o
S
N
o
S
cc
N
d
....o
d
.",
'"'"
mo
d
.~
"d
N
m
'"'"
is
d
0::
.!!!
""::;
....
o
1
....
o
d
....o
1
;0-
cc
d
'"oS
;;;-
c:i
....o
c:i
....
N
d
No
1
.~
o
....o
d
N
N
N
o
9
'"o
9
;n-
o
c:i
.",
m
m '"'"o
....
d
N
Cl
9
Cl
....
o
d
....
en
d
'"'"
.,.,
m
N
o
d
N>
Cls:
.,.,
o
1
....
'"d
....
o
~
.~
o
....
Cl
9
.",
cc
m isd
"m
....o
9
.."
'""1o
."
N
"m
N
o
d
'"o
9
N
cc
N
c:i
....
o
9
....
N
d
9.
o
r-,....
....
o
9
.."
N
Cl
o
o
'"
is
9
.",
..
N
d
;0-
N>
ci
N
o
S
....
N>
;;;-
N
d
N
o
1
0-
'"o
1
.5
e..~
'"I..
..
E
(;
z
...
N
'."
'"...
'"'"
~o
......
o
d
N
'"
No
c;j
No
c;j
<XI
<XI....
~
'" c;jq
o ...
o
8.
N
cc....
r-o
8.
;;;-
r-
c;j
'"o8.
N
o
o
N...
c;j
~
N
c;j
r-
o
8.
...
o
1
,._
N
Cl)
en
.~
C
c:i
'"o
c;j
'."
o
N
N
'"
...
o
9
.",
o
c;j
...
<t
c;j
-N
o
c;j
No
...
o
~
'b
'8.
Ul
o
c;j
No
1
Nen
'"en
.~
o
:;;
c;j
,._
"'
...
c;j
N
o
c;j
.~
...o
ci
<XI
N
c;j
~
"'c;j
Nq
:!.
N
<XI
rl
...
o
8.
N
o
c;j
"z
,._
o
c;j
N
N o
...
o
c;j
en
m
00
m
c;j
......
c
o
co
q
o
'"m
Nq
o
q
o ...
o
8.
N
N
ci
rl
o
1
,._
m
N
N
'"
......
'111
rl,._
c;j
'"o
9
rl
c;j
en
N
c;j
~o
...
o
c;j
N...
8.
;;;-
N
c;j
e.
~
c;j
N
o
1
;:;
o
9...o
1
;;:;
o
c;j
N
'"....
.....
m
'"N
'"o
c;j
N
N
ci
N
o
o
o
N
o
1
'."
,._
<t
'"o
c;j
'111
r-oo
o
iii
Eoz
e..
II
>-
o
....
N '"ci ....
E.
U'1
N
........
ci
;;;-
o
ci
....
o
E.
U'1
N
m
ci '"N
E.
N
m
U'1....
'"....
ci
....
N
ci
.....
o
S
~
ci
N....
ci
....
o
ci '"o
E.
....
q
.....
N
U'1
o
ci
........
ci
Nq
2-
U'1
o
ci
00o
ci
N
o
S
'b
U'1
0.
........
ci
s
ci
<D....
ci
.",
o
'"
r-,
U'1
'"'" '"oci
N
ci
N
'"ci
....
S
N
m
m
N
ci
;;;-
'"ci
U'1
'"
mo
ci
N....
ci
2-
".!!!
"0
~
1:o
1::o
....
ci
N
N
;;;-
'"ci
N
o
E.
~
ci
'i>q
o
No
S
's
o
ci
'"'"
....
N
ci
~
U'1
ci
.....
o
S
U'1
o
ci
'" U'1o
S
....
N
ci
'"'"ci
U'1
'"
'"....
ci '"o
S
".!!!
"0
"::< NZ
.~
ci
s
ci No
S
....
q
9
;:;-
o
9
....o
~
U'1~
o
eo
o
ci
....o
ci
o
'"o
ci ....
o
S
.,
N
....
ci
....
o
ci
o ....
o
1
N
N
r-,
o
....
o
S
U'1
o
ci N
o
S
.."
r-,
".
"-q
om
No
o
....
'"
8
o
'"N
~
~
o...
I,..
,..
~..
~
o...
;;;
Eoz
N
'"o
N~o
'"o
ci
o
.~
N....o
'"'"
'"oo
"oo
m
No
....o
o
N
m
d
N
q
2
M
N
o
....o
1.
...
o
1
0;-
'"...;
u;-
ci
N
o
8.
0;-
'"o
....o
o
...o
9
...
'"ci
...
o
1.
N
~
~o
tio
'"....o
N
ci
m
ocs
'",
'"m
ci
N
'" ""
....
ci
moo
'",...
o
ci
'"mci
...
ci
2
u;-
'"ci
m
o
8.
......
ci
2
;:;-
ci
No
8.
M
OJ
ci
.~
ci
....
2!o
'"Nci
t-
'"
......
o
en
m
t-o
ci
.~
§
ci
m
o
8.
N
o
8.
t-
m
ci
N
t-o
t-
o
8.
~
'"ci
....o
2
"r-,
00o
ci
~
o
'"N '"q
mo
ci
N...
o
co
oo
........
d
'"m
0;-
m
ci
N
o
8.
u;-
q
N
o
2
....
q
2
...o
8.
~
mo...o
8.
...
o
...q
2
...o
9
....
8
ci
"o
ci
t-
'"
8
o
8
ci
...
d
m
....
o
9
c..
'C..::;
u;-
No
m
o
8.
;:;-
o
9
....
o
'i
...o
8.
N
o
2
0;-
'"o
"o
8.
0;-
No
No
2
...
o
'i
~
N
]
o
tio
No
I
g
Nq
2
m
o
ci Nq
8.
'",
m~
ci
u;-
m
o
~
o
'::l
o
ci
~
o
'"N go
1z
~
~
'"I
'It
8
c:i
r-
'"ci
'"ci
LI\
'"ci
'"'"ci
'"'"
~o
c:i
LI\
....
":o
;;;
N...;
N
'"
....
8.
;:;..
c:i
........
8.
r-
N
........o
c:i
N
N
ci
r-,
o
c:i '"o
8.
o
N '"'"ci
'"'"
...... ~o
....
c:i
N
N
ci
'"'"ci
'"'"
....
ci
~
c:i
1::,
'"a.
....
'"c:i
N
o
1
....
'"c:i
rl
N
c:i
....
q
£
NZ
.~
ci
00
o
ci
....
ci
.",
o
'" '"
LI\
ci
'"oc:i
.~
'"'"
No
8.
N
o
9.
..
ci
00
'"ci
;;;
'"ci
.~
en....
o
"oo
N
'"
co
'"ci
'"LI\
r-;
N
ci
....
'"ci
LI\
'"
'"'"ci
LI\
'"
'"....
ci
c~
'6
"~
........
....
rl
9.
;;;
ci
N
o
9.
.~
ci
N
c:i
'"oci
g
ci
00
'"
00
'"
.~
N
N
'"o
ci
0\
N
00o
ci
....
o
8.
....
ci
....o
8.
;;;-
o
c:i
....
ci
....o
9.
0;-
N
c:i
'"o
9.
;;;
ci
'"o
8.
....
o
8.
;;;-
N
c:i
No
8.
....
8.
N....
c:i
;0
o
ci
.",
r-,..
0\
'"
r-,
o
ci
o
'"
N
o
c
.",
'"N N"!
....
'"
'"N '"oc:i
~
N
1:
Q
tlo
~
~
<:>....
I....
....
e
la.....
<:>....
;;;
E
Q
Z
'"....
....
'"c:i
........
c:i
N~
o
....
00
ci
N
'"c:i
00
o....
N
"'c:i
N
'"£
00
'"ci
00....
£
....
N
m
'"
'"'"c:i
'"00
ci
.",
'"<:>c:i
o
N
N
cc
'"....
c:i
........
c:i
'"'"o
c:i
....
N
!i
........
....
t--:
c:i
'"N
!i
N
"
N
'"
NZ
'"'"c:i
........
ci
....
'"....
'"'"c:i
;:;-
00
c:i
e-,
'"
m
'"
e-,
'"c:i
ino....
m
N
!i
;:;-
00....
'"....
....
":
o
....
'"c:i
'"'"c:i
'"'"....
....
c:i
'"co
ci
'"....c:i
.."
'"'"
Neo
ci
<t
ci
ci
00
'"c:i
NZ
........
....
'"
.....
'"c:i
N
N '"'"ci
'"'"ci
'"c:i
....
'"c:i
co
'"ci
........
c:i
m
N
!i
N
N
""'N£
<D
m
c:i
'"N£
;;;
o....
....
'"c:i
'"N
2.
'"'"
....
'"
'"N
NZ
'"00
c:i
'"....
00
c:i
00
N
!i
N....
ci
M
'"c:i
N
<t
ci
....
.,;
Table 33A Effect of different faeton on IgG responses to AMA1(HB3) in the May 1001 cross seetional
bleed.
AMA1IHBJ) May 2002
'195"Ot P-value'
Unlvaflate'
Ace (years) 0.13 (0.09-0.16) <0.001
Parasltemll 0.69 (0.48-0.89) <0.001
A1pha-thel HET -0.06 (-0.24-0.13) 0.533
A1pha-thel HOM -0.26 (-0.5-0.01) 0.038
SIcIde trait -0.23 (-0.46-0.01) 0.064
PrIor parasitemia 0.32 (0.23-0.41) <0.001
PrIor episode 0.36 (0.2-0.51) <0.001
Multivariate Iprw!ous plrlslUmla)'
All samples
Aae (yell'S) 0.09 (0.06-0.13) <0.001
Plrlsltemla 0.42 (0.22-0.62) <0.001
A1ph.thel HET -0.04 (-0.21-0.12) 0.606
A1pha-thel HOM -0.15 (-0.37-0.06) 0.155
Slcldetrllt -0.19 (-0.4-0.02) 0.074
PrIor parlsltemll 0.22 (0.13-0.3) <0.001
PllmIte ntptIve'
Ace (years) 0.08 (0.04-0.11) <0.001
Alphl-thal HET -0.02 (-0.18-0.14) 0.799
A1ph.thel HOM -0.15 (-0.35-0.06) 0.159
Slcldetrllt -O.U (-0.33-0.09) 0.269
PrIor parllSltemla 0.3 (0.2-0.39) <0.001
PllmIte pGIItIve'
Acelyelrs) 0.14 (-0.01-0.29) 0.073
Alph.thel HET -0.32 (-0.9-0.25) 0.263
Alph.thll HOM -0.36 (-1.33-0.61) 0.457
Slcldetrllt -0.39 (-1.02-0.25) 0.226
Prior paraslteml. o (-0.27-0.26) 0.982
Multlvart.t. Iprw!ou.lpIsod.)'
All samples
Ace (years) 0.1 (0.07-0.14) <0.001
Parlsltemll 0.46 (0.25-0.66) <0.001
AlphHhal HET -0.07 (-0.24-0.1) 0.43
Alph.thll HOM -0.16 (-0.38-0.06) 0.146
Sickle trllt -0.19 (-0.4-0.03) 0.086
Prior episode 0.23 (0.09-0.38) 0.002
PllmIte neptIve'
Aae (yelrs) 0.1 (0.06-0.13) <0.001
Alph.thll HET -0.03 (-0.21-0.14) 0.689
Alph.thll HOM -0.15 (-0.37-0.06) 0.162
Sickle trait -0.15 (-0.37-0.07) 0.175
PrIor episode 0.29 (0.13-0.45) 0.001
Plraslte positive'
Ale (yelrs) 0.14 (-0.01-0.3) 0.063
Alphl-thal HET -0.3 (-0.86-0.27) 0.294
Alpha-thai HOM -0.31 (-1.31-0.68) 0.53
Sickle trllt -0.36 (-1.01-0.29) 0.272
Prior episode 0.08 (-0.33-0.49) 0.711
298
298
297
299
304
304
289
239
so
289
239
so
t12W
I Ant.en teoted .tlndlcltod ero.... ctlonol bleed.
• Line" Ion ~ coefliclenU w~h 95%eonfldenco Int.N.I.
• '-val for Indlcltod factor (p-y.I.... ~ O.OSlndic.tod In bold).
• Number of .. mples Includ.d In the model.
, Univariate line" Ion.
6Multiv.n.bIe IIne.r re ion with Inclusion of either recorded episodes of parasltemll or mal.ri.ln the 6 months prior to AmpU ....
7 Stratified multlv.rlable Une" ... ,. .. Ion, para.~. nII.tlv. sample. only.
• St,..tlfled multlvara.ble IIne.r ,...,..ssion, pal'llslt. positive IIImpiel only.
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Table 338 Effect of different factors on IgG responses to AMAl(HB3) in the October 2002 cross sectional
bleed.
AMA1(HB3) ca 2002
IS (95%CI)' P-Yllu,'
Univariate'
Age (years) 0.07 (0.04-0.1) <0.001
Parasitemia 0.39 (0.12-0.66) 0.004
Alpha-thai HET -0.01 (-0.16-0.15) 0.93
Alpha-thai HOM -0.23 (-0.43-0.03) 0.026
Sickle trait -0.2 (-0.41-0.02) 0.069
Prior parasitemia 0.23 (0.09-0.36) 0.001
Prior episode 0.26 (0.09-0.43) 0.003
Multivariate (previous pe"sltemla)'
All samples
Age (years) 0.11 (0.08-0.14) <0.001
Parasitemia 0.26 (0.01-0.51) 0.042
Alpha-thai HET -0.03 (-0.18-0.12) 0.7
Alpha-thai HOM -0.17 (-0.37-0.02) 0.077
Sickle trait -0.15 (-0.36-0.05) 0.149
Prior parasitemia 0.19 (0.07-0.31) 0.002
P."slte ne.atlv.
7
Age (years) 0.11 (0.08-0.14) <0.001
Alpha-thai HET 0(-0.15-0.16) 0.983
Alpha-thai HOM -0.12 (-0.32-0.07) 0.201
Sickle trait -0.13 (-0.34-0.08) 0.214
Prior parasitemia 0.22 (0.09-0.34) 0.001
Pa"slt, positive'
Age (years) 0.09 (-0.19-0.37) 0.486
Alpha-thai HET -0.2 (·1.4-0.99) 0.721
Alpha-thai HOM -0.97 (·2.42-0.49) 0.175
Sickle trait -0.59 (-1.89-0.72) 0.348
Prior parasitemia -0.15 (-0.93-0.63) 0.684
Multivariate (previous episodes)'
A1ls.mples
Age (years) 0.11 (0.07-0.14) <0.001
Parasitemia 0.28 (0.03-0.53) 0.03
Alpha-thai HET -0.04 (-0.19-0.11) 0.622
Alpha-thai HOM -0.18 (-0.37-0.01) 0.069
Sickle trait -0.17 (-0.38-0.04) 0.114
Prior episode 0.21 (0.05-0.37) 0.009
Parasite ne .. tlva7
Age (years) 0.11 (0.08-0.14) <0.001
Alpha-thai HET -0.01 (-0.17-0.14) 0.853
Alpha-thai HOM -0.13 (-0.33-0.06) 0.175
Sickle trait -0.15 (-0.35-0.06) 0.17
Prior episode 0.24 (0.08-0.4) 0.003
P."slt, poSItIv,'
Age (vears) 0.1 (-0.16-0.37) 0.406
Alpha-thai HET -0.28 (-1.38-0.83) 0.599
Alpha-thai HOM -0.97 (-2.43-0.49) 0.173
Sickle trait -0.55 (-1.83-0.73) 0.368
Prior episode -0.14 (-0.97-0.68) 0.714
291
291
284
292
254
254
251
232
19
251
232
19
ti2l!l
1Ant •• n to.tod at Indlaltod eros. sectional biNd.
2 llnt.f r•• ression P coefficients with 95% confldenc. Intlrvlls
• P",aluo for Indicated factor (p-valuos S 0.05 Indlcatod In bold).
• Number of somple.lncludod In tho modol.
5 Unlvlriate llnelr relression .
• Multlvarlablo llnoar ro,,"sslon with Inclusion of o~hor recordod oplsodo. of paraslt.mil or mailrlaln tho 6 months prior to sompll"..
1Strlltlfi.d multlvlrllbl.lln •• r rl.",,,'on, plraslte nelatlvl simples only.
• Stratified multtvlrl.ble Ilnl.f rqr.sslon, parasite positivI AmpllS only.
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Table 33C Effect or different racton on IgG responses to AMAl(HBJ) in the May 2003 cross sectional
bleed.
AMA1(HB3) M-v z003
11(95"0)2 P-vII!ue'
Untv.rlate·
Ap(years) 0.11 (0.07-0.14) <0.001
Plraslteml. 0.56 (0.32-0.79) <0.001
Alpha-thal HET 0.04 (-0.15-0.23) 0.694
Alphl-thel HOM -0.15 (-0.4-0.09) 0.22
Sickle trait -0.29 (-0.54-0.04) 0.021
PrIor parasitemia 0.07 (0-0.14) 0.047
PrIor episode 0.12 (0.02-0.21) 0.015
MuItlverl8te (previous pe_ltemla)'
AlIA"""
Ale (years) 0.1 (0.06-0.14) <0.001
Parasitemia 0.44 (0.19-0.69) 0.001
Alph.-thal HET 0.03 (-0.17-0.22) 0.784
Alphl-thal HOM -0.06 (-0.31-0.18) 0.612
SIckle trait -0.27 (-0.53-0.01) 0.043
Prior parasitemia 0.05 (-0.02-0.11) 0.158
PlrnIte neptIve'
Ap(years) 0.08 (0.04-0.12) <0.001
Alpha-thaI HET 0.09 (-0.11-0.3) 0.367
Alpha-thaI HOM -0.05 (-0.3-0.2) 0.697
SIckle trait -0.17 (-0.44-0.09) 0.205
Prior parasitemia 0.07 (0.01-0.14) 0.031
PlrnIte positive·
Ap(years) 0.12 (-0.01-0.25) 0.072
Alpha-thaI HET -0.22 (-0.83-0.4) 0.474
Alpha-thai HOM 0.5 (-0.63-1.64) 0.373
SIckle trait -1.05 (-2.14-0.04) 0.059
Prior perasltemla -0.12 (-0.37-0.13) 0.323
Multlwrlate (prevlou.lplsod .. )·
All Ampl ..
Ale (years) 0.09 (0.05-0.13) <0.001
Parasitemia 0.46 (0.21-0.71) <0.001
Alpha-thaI HET 0.03 (-0.17-0.22) 0.769
Alph.-thal HOM -0.07 (-0.31-0.18) 0.597
SIckle trait -0.26 (-0.52·0) 0.047
Prior episode 0.09 (0-0.18) 0.052
Plraslll neptIve'
Ale (years) 0.08 (0.04-0.12) <0.001
Alpha-thai HET 0.09 (-0.11-0.3) 0.369
Alpha-thaI HOM -0.05 (·0.3-0.19) 0.671
Sickle trait -0.18 (-0.44-0.09) 0.19
Prior episode 0.11 (0.02-0.2) 0.015
P._1lI positive·
Ale (years) 0.13 (0-0.25) 0.055
Alpha·thal HET -0.25 (-0.85-0.36) 0.409
Alpha-thai HOM 0.69 (-0.5-1.88) 0.246
Sickle trait -1.21 (-2.31--0.12) 0.031
Prior episode -0.3 (-0.75-0.16) 0.193
~
285
285
279
283
253
253
247
213
34
247
213
34
1Antil.ntested It i"dated crOSI sectlon.r ble.d.
, Llne.r ....... Ion ~ coefficients with 95% confldoncolntorv.l.
J P",oIUl for Indlcoted fletor (p",oluo. S 0.05 Indlcotod In bold).
• Number of .. mple. Includod In tho modol.
, Unlvorllto IIno.r Ion.
'Mutttvirilble linear ,. "ion with Inclusion of either record.d episode, of plrasltemla or mlrarla in tha 6 months prior to AmpUl'll.
7 Strotlflod multlv.rllble llneor ....... Ion, poro.lto ne.otlvo .. mple. only.
• Stratified multlvlrtable linear re.re"io", parasite positivi samples only.
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Table 33D Effect of different factors on IgG responses to AMAl(HB3) in the October 2003 cross sectional
bleed.
AMA1(HB3) Oct 2003
II(95" Cl)" '-Vllue' N'
Univariate'
Age (years) 0.12 (0.09-0.15) <0.001
Parasitemia 1.09 (0.89-1.3) <0.001
Alpha-thai HET -0.09 (-0.28-0.1) 0.339
Alpha-thai HOM -0.28 (-0.53--0.04) 0.023
Sickle trait -0.24 (-0.49-0.01) 0.059
Prior parasitemia 0.25 (0.15-0.34) <0.001
Prior episode 0.25 (0.1-0.39) 0.001
Multlvlrllte (previous paresltemll)'
All Amples
Age (years) 0.11 (0.08-0.14) <0.001
Parasitemia 0.89 (0.69-1.1) <0.001
Alpha-thai HET -0.1 (-0.27-0.06) 0.2
Alpha-thai HOM -0.11 (-0.32-0.09) 0.281
Sickle trait -0.28 (-0.49--0.08) 0.007
Prior parasitemia 0.18 (0.1-0.26) <0.001
Plreslte ReSltlve'
Age (years) 0.1 (0.07-0.13) <0.001
Alpha-thai HET -0.07 (-0.23-0.1) 0.412
Alpha-thai HOM -0.05 (-0.25-0.15) 0.618
Sickle trait -0.15 (-0.36-0.05) 0.145
Prior parasitemia 0.21 (0.12-0.29) <0.001
Plrlslte positive·
Age (years) 0.19 (0.04-0.34) 0.015
Alpha-thai HET -0.24 (-0.8-0.32) 0.387
Alpha-thai HOM -0.3 (-1.43-0.83) 0.589
Sickle trait -0.99 (-1.71--0.27) 0.009
Prior parasitemia 0.13 (-0.18-0.44) 0.398
Multivariate (previous episodes)'
All Hmples
Age (years) 0.11 (0.08-0.14) <0.001
Parasitemia 0.95 (0.75-1.16) <0.001
Alpha-thai HET -0.1 (-0.26-0.06) 0.23
Alpha-thai HOM -0.08 (-0.29-0.13) 0.44
Sickle trait -0.28 (-0.49--0.07) 0.01
Prior episode 0.2 (0.09-0.32) 0.001
P.reslte nesatlve'
Age (years) 0.1 (0.07-0.14) <0.001
Alpha-thai HET -0.08 (-0.25-0.09) 0.341
Alpha-thai HOM -0.04 (-0.25-0.16) 0.677
Sickle trait -0.13 (-0.34-0.09) 0.236
Prior episode 0.21 (0.1-0.33) <0.001
Pareslte positive'
Age (years) 0.18 (0.04-0.33) 0.013
Alpha-thai HET -0.2 (-0.74-0.33) 0.444
Alpha-thai HOM -0.13 (-1.19-0.94) 0.811
Sickle trait -1.05 (-1.75 .. 0.35) 0.005
Prior episode 0.25 (-0.19-0.69) 0.255
M2l!!
294
293
285
284
261
261
248
212
36
248
212
36
1Antl.,n tested It IndlCllted cross s.ctlonll ble.d.
2 lint.r ,...re5510n p coefficients with 95% confidence Intervals
, P-Vilul for Indlcliid foetor (p-Vlluos S0.05 Indlcilid Inbold).
• Numbor of ",mplls Includld in lhe modll.
5Unlvlrllt. linelr rqression.
6Muttlvarlabl. lin,.r .... re5510" with Inclusion of either recorded episodes of p.ruitemla or mal.rliin the 6 months prior to SIImplin •.
7 Siroliflodmu~iv.rllbll lino., rolrosslon, p.,1S111no.III.1 ",mplls only.
• Stratified muttivlrlabl.lin •• r re.,.sslon, plta,itt positive Hmples onty.
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Table 33E Effect of different fadon on fgG responses to AMAl(HB3) in the May 2004 cross sectional
bleed.
AMA1(HIJI MIIy ZOO4
Unlvartlltl°
A&e(yeln)
Plrultemla
Alpha-thli HET
Alpha-th., HOM
SIcIde tnIIt
PrIor paresltemlll
0.1 (0.07~.12)
0.84 (0.55-1.14)
~.05 (~.22~.13)
~.31 (~.54-0.09)
~.22 (~.4~.01)
0.23 (0.06-0.41)
PrIor episode
MuIttvIIrIIIte (pnvlaul PllmItemII)'
AllllmpIei
A&e(yeen) 0.1 (0.06-0.13)
Paruiteml.
Alph.thal HET
Alpha-thll HOM
Slddetrllt
PrIor parasiteml.
Pamlte neptIve'
A&e(yeln)
Alpha-thll HET
AIph.-th., HOM
Sickle trlit
PrIor plreslteml.
Pamlte positive'
Ap(yean)
Alpha-thai HET
0.52 (0.22~.83)
~.03 (~.19-0.14)
~.19 (~.~.01)
~.21 (~.42~)
0.16(~.33)
0.08 (0.05-0.11)
~.03 (~.19-0.14)
~.19 (~.39-0.02)
~.2 H).41~.02)
0.26 (0.07~.4s)
0.27 (0.~.49)
~.57 (-1.~.4)
Alpha-thll HOM -1.33 (-2.96-0.29)
Sickle trait ~.56 (-1.9~.84)
PrIor parulteml. 0.02 (~.62~.66)
Multlva .... (prwIoul episodes)'
AllllmpIes
Ap(yean)
Pnsltemia
Alpha-th., HET
Alpha-thli HOM
Sicklet,,1t
Prior episode
Pamlte neptlve'
Aae (yelrs)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Parallte positive'
Ap(years)
Alph.thll HET
Alphl-thai HOM
Sickle trait
Prior episode
0.1 (0.07~.13)
0.57 (0.27~.88)
~.04 (-0.21-0.12)
~.2(~.41~)
-0.21 (~.42-0)
0.09 (0.06-0.12)
~.04 (~.21-0.13)
~.19 (-0.~.02)
~.19 (-0.41-0.03)
0.26 (0.1-0.42)
~.58 (-1.44-0.28)
-1.35(-2.~.1)
~.58 (-1.6~.49)
<0.001
<0.001
0.6
0.006
0.056
0.008
<0.001
0.001
0.728
0.064
0.051
0.051
<0.001
0.765
0.D78
0.069
0.006
0.026
0.218
0.095
0.391
0.943
<0.001
<0.001
0.594
0.054
0.053
<0.001
0.652
0.079
0.088
0.005
0.163
0.064
0.255
279
280
261
266
254
239
224
15
239
224
15
fjZtJ
I Ant •• n t.sted ot Indbted cross section.1 bleed.
a LlnII.r....... "Ion ~ coefflclenu with 95%confidence Intervol.
, P-vllue for Indbted fletor (p-vllue. S0.05 Indlclted In bold).
• Number of Simple. Included In the model.
, Unlvlrlltell".lr ....... "Ion.
'Multtv.ri.b .. llne.r ,...re.. km with Inclusion of either recorded episodes of parasitemia or MIIlari. in the 6 months PIiOr to "",pUr'll.
7 Strotlfledmultlvlrllble llnelr "ion. poro.1te nII,"tlve Simple. only.
• Strotlfledmultlvlrllble llnelr sslon. poro.lt. positivi SImple. only.
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Table 33F Effect of different factors on IgG responses to AMAl(HB3) in the October 2004 cross sectional
bleed.
AMA1(HB3) Oct 2004
P (95"CI)2 P-valu.' N'
Unlvarl.t.'
Ase (years) 0.07 (0.05-0.09) <0.001 273
Parasitemia 0.69 (0.37-1.01) <0.001 273
Alpha-thai HET -0.05 (-0.2-0.1) 0.543 268
Alpha-thai HOM -0.17 (-0.36-0.02) 0.079
Sickle trait -0.1 (-0.29-0.09) 0.3 270
Prior parasitemia 0.26 (-0.1-0.62) 0.161 235
Prior episode
Multivariate (previous p....slt.ml.)·
All samples
Age (years) 0.09 (0.06-0.12) <0.001 216
Parasitemia 0.72 (0.34-1.1) <0.001
Alpha-thai HET -0.06 (-0.21-0.09) 0.436
Alpha-thai HOM -0.17 (-0.36-0.02) 0.076
Sickle trait -0.13 (-0.32-0.06) 0.17
Prior parasitemia 0.27 (-0.06-0.61) 0.104
P.l'llsltl neeatlve'
Age (years) 0.09 (0.06-0.12) <0.001 209
Alpha-thai HET -0.07 (-0.22·0.09) 0.39
Alpha-thai HOM -0.18 (-0.37-0.01) 0.068
Sickle trait -0.1 (-0.29·0.1) 0.334
Prior parasitemia 0.28 (-0.05-0.61) 0.099
Pel'llsltt posltlv."
Age (years) 0.1 (-0.58-0.78) 0.587 7
Alpha-thai HET -0.3 (-4.52·3.91) 0.785
Alpha-thai HOM 0.39 (-5.03-5.81) 0.785
Sickle trait -0.93 (-4.93-3.06) 0.421
Prior parasitemia
Multlvarlat. (previous .plsodes)"
All samples
Age (years) 0.09 (0.06-0.12) <0.001 216
Parasitemia 0.72 (0.34-1.1) <0.001
Alpha-thai HET -0.05 (-0.2-0.1) 0.523
Alpha-thai HOM -0.15 (-0.34-0.04) 0.114
Sickle trait -0.13 (·0.32·0.06) 0.169
Prior episode
P.r .. lt. RI.atlve'
Age (years) 0.09 (0.06-0.12) <0.001 209
Alpha·thal HET -0.06 (-0.21·0.1) 0.475
Alpha-thai HOM -0.16 (-0.35·0.03) 0.104
Sickle trait -0.1 (-0.29-0.1) 0.332
Prior episode
Pal'llsltt positive"
Ase (years) 0.1 (-0.58-0.78) 0.587 7
Alpha-thai HET -0.3 (-4.52-3.91) 0.785
Alpha-thai HOM 0.39 (·5.03-5.81) 0.785
Sickle trait -0.93 (-4.93-3.06) 0.421
Prior episode
~
I Antleon tlltod at Indicated cross .. ctlonal blood.
2 lIne.r .... ,.."10" P coefficients with 95% confldenc. Intervlls
• P...,alue for Indicated foctor (p-values 5 0.05 Indlcatod In bold).
4 Number of samp~s Included In the model.
!I Unlvlrilte linelr r•• resskm.
• Multlvlrloblo IInoar re,rossion with Inclusion of olther rocordod oplsodos of parasitomla or malaria In tho 6 months prior to Slmpll"l.
1St,..ttfled muttlvlrilble linelr r8l,.sslon, parllslt. M,ltive Simples only.
• Stratified multivarioblelinOir ro,rossion. parasite positive Slmplos only.
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Table 34A Eft_t or different raeton on IgG responses to AMAl(3D7) in tbe May 2002 cross sectlona.
bleed.
AMA1(JD7) May 2002
,(95"Cl)' ,..,.Iue"
UIMrIRe"
Ale (years) 0.11 (0.08-0.15) <0.001
Paresltemll 0.61 (0.42..(l.8) <0.001
Alphl-tIIIl HET ..(l.04 (..(l.21..(l.13) 0.636
AIph.thaI HOM ..(l.24 (..(l.46-0.02) 0••
SIckle tnlit ..(l.21 (..(l.43..(l.01) 0.055
Prior parasitemia 0.29 (0.21..(l.37) <0.001
PrIor episode 0.33 (0.19-0.47) <0.001
MuItIw,.. (previous peraaItemII).
All ........
Ale (years) 0.08 (O.OS..(l.ll) <0.001
Parasitemia 0.37 (0.19..(l.5S) <0.001
Alpha-thai HET ..(l.03 (..(l.18..().13) 0.733
Alpha-thll HOM ..(l.14 (..(l.34-0.0S) 0.148
Skldetralt ..(l.18 (..(l.37..(l.01) 0.065
PrIor perasitemla 0.2 (0.1l..(l.28) <0.001
Ptmlte MptIft'
Ale (years) 0.07 (0.04-0.1) <0.001
Alpha-tIIIl HET 0.01 (..(l.14-0.1S) 0.937
Alpha-thai HOM ..(l.11 (..(l.29-0.07) 0.242
Sickle trllt ..(l.12 (-0.31-0.07) 0.199
PrIor perasltemla 0.27 (0.la-o.35) <0.001
Plmlte positive'
Ale (years) 0.12 (..(l.Ol-O.26) 0.124
Alpha-thai HET ..(l.33 (-0.89..().24) 0.249
Alpha-thai HOM ..(l.S7 (-1.S2..(l.38) 0.236
Sickle trllt ..(l.32 (..(l.9S..(l.3) 0.302
Prior parasitemia ..(l.01 (..(l.2a-o.2S) 0.914
MuItlvarlRe (prevIou.eplsocles)·
AIIumples
Aae (years) 0.09 (0.06-0.13) <0.001
Parasltemll 0.41 (0.22..(l.S9) <0.001
Alpha-thll HET ..(l.OS(..(l.2..(l.11) 0.547
Alpha-thel HOM -o.is (..(l.3S-0.0S) 0.141
SIckle trait ..(l.18 (..(l.37..(l.02) 0.078
Prior episode 0.22 (0.Oa-o.3S) 0.002
Parasite MptIft'
Aae (yelrs) 0.09 (0.06-0.12) <0.001
Alpha-thll HET ..(l.01 (..(l.16-0.1S) 0.937
Alphl-thal HOM ..(l.11 (-0.31..().08) 0.238
Sickle trait -o.is (-0.35-0.04) 0.129
PrIor episode 0.27 (0.12..(l.41) <0.001
Pamlte positive'
Aae (years) 0.12 (..(l.03..(l.27) 0.111
AlphHhl1 HET -o.a (..(l.86-0.25) 0.275
Alphl-thll HOM ..(l.54 (-1.52-0.44) 0.277
Sickle trait ..(l.31 (..(l.95-O.33) 0.337
Prior episode 0.04 (..(l.36-0.45) 0.829
fl2IU
N'
298
298
297
299
304
304
289
239
so
289
239
so
1Ant,..n leltod ot Indlcatod croulOCtlonal bleed.
, Llnoo, rolro"ion P coefficients with 95% confldonce IntoN.ls
• P.".I .. fo, Indicated fKto, (p-v.I ... S O.OSlndlcated In bold).
• Numbe, of Slmpleslncludod In tho modol.
• Unlvortole 11_, rolrolllon.
I Mutttvln.bIe Ilne.r re,reuion with Inclusion of .ither recorded episodes of parllllt.mla or malaria in the 6 months pr60r to Nmp11nc.
7 Strotlfled muitlv.rtoble lino ..... ,•• slon, poro.lto hOIotlvo Slmpl •• only.
a Strllttfied multtvlri.bie 1i,...lr re.fenion, parasite positive SIImpl., only.
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Table 34B Effect of different factors OD IgG responses to AMAl(3D7) in the October 2002 cross sectional
bleed.
AMA1(3D7) Oct 200l
P (95%CI)' P-value'
Univariate'
Age (years) 0.07 (0.05-0.1) <0.001
Parasitemia 0.34 (0.08'().S9) 0.01
Alpha-thai HET 0.01 (.().14-0.16) 0.862
Alpha-thai HOM '().2 ('().39-'().01) 0.039
Sickle trait '().21 (-0.41--0.01) 0.039
Prior parasitemia 0.2 (0.08-0.33) O.OOl
Prior episode 0.24 (0.08'().4) 0.004
Multivariate (previous p8r .. ltemla)'
All Hmples
Age (years) 0.1 (0.07-0.13) <0_001
Parasitemia 0.19 ('().OS'().43) 0.118
Alpha-thai HET -0.01 (-0.16-0.13) 0.848
Alpha-thai HOM -o.is (-0.33-0.03) 0.109
Sickle trait -0.17 (-0.37-0.02) 0.084
Prior parasitemia 0.17 (0.06-0.29) 0.004
Parasite n.. atlve7
Age (years) 0.1 (0.07-0.13) <0.001
Alpha-thai HET 0.02 ('().12-0.17) 0.768
Alpha-thai HOM -0.1 (-0.28'().08) 0.279
Sickle trait '().16 (-0.35-0.04) 0.124
Prior parasitemia 0.19 (0.08'().31) 0.001
Parasite positive'
Age (years) 0.17 ('().08-0.42) 0.16
Alpha-thai HET .().48 (-1.54-0.57) 0.34
Alpha-thai HOM -1.07 (-2.36-0.21) 0.095
Sickle trait .().57 (-1.71-0.58) 0.307
Prior parasitemia '().04 (-0.72-0.65) 0.91
Multivariate (previous episodes)'
All samples
Age (years) 0.1 (0.07-0.13) <0.001
Parasitemia 0.21 (-0.03'().45) 0.089
Alpha-thai HET -0.02 (-0.17-0.12) 0.77
Alpha-thai HOM '().15 (-0.34-0.03) 0.098
Sickle trait -0.19 (-0.3S-0.01) 0.063
Prior episode 0.19 (0.04-0.34) 0.014
Parasite ne,atlve7
Age (years) 0.1 (0.07-0.13) <0.001
Alpha-thai HET 0.01 ('().14'().15) 0.922
Alpha-thai HOM -o.n (-0.29-0.08) 0.246
Sickle trait '().17 (-0.37-0.03) 0.096
Prior episode 0.21 (0.06-0.36) 0.007
Parasite positive'
Age (years) 0.17 (.a.06-0.41) 0.129
Alpha-thai HET -0.5 (-1.47'().47) 0.284
Alpha-thai HOM -1.07 (-2.36-0.21) 0.095
Sickle trait -o,56 (-1.68-0.57) 0.306
Prior episode -0.03 (-0.76-0.7) 0.933
291
291
284
292
254
254
251
232
19
251
232
19
tJ2l!!
I Antl.en tested It Indlc.ted cross seetlonll bleed.
2 lIn •• r relresslon P coefficients with 95%confidence Intervals
• P-Vllue for Indlc.ted foetor ("...,llues S 0.05 Indlc.ted In boldl .
.. Number of Simples Included in the model.
5 Univariate IIn•• r rear.ssion.
6 Muitivlrilbl. Iln•• r ,...r.ssion with Inclusion of tither recorded episodes of parasitemia or mll.rl. in the 6 months prior to samplina.
1Stratlfl.d multlvarl.bl.Unel' ,...ress~n, parasite n•• atlv. Hmplt. onty.
eStratified multlvarllbl.llnt.r ,...re55Ion, plrastte positive amples only.
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Table 34C Iffeet of different faeton on IgG responses to AMAl(3D7) in the May 2003 eross sectional
bleed.
AMAJ,(J07) ~y 2003
11(."0)' P-value'
UrIIverlllte'
Acelvurs) 0.110.07-0.13) cO.ool
Plrultem .. 0.55 (0.33-0.78) cO.OOl
Alpha-tilil HET 0.041-0.14-0.22) 0.682
AlpM-tiIII HOM -0.14(-0.38-0.09) 0.23
Sickle tr8It -0.27(-0.51-0.03) 0.029
PrIor pamltem" 0.0610-0.13) 0.069
PrIor episode 0.11(0.02-0.2) 0.016
MultlvlrIIIte (pnv!ouspereslmnll)'
Allllmptes
AselyeltS) 0.1 (0.06-D.13) <0.001
Paresltem" 0.44 (0.2-0.67) <0.001
Alpha-thai HET 0.03 (-0.16-0.21) 0.789
Alpha-thll HOM -0.05 (-O.29-D.18) 0.666
Slclde trait -0.27 (-0.52-0.02) 0.032
PrIor paresltemla 0.04(-0.02-0.1) 0.222
Paralte neptIve'
Ase(years) 0.08(0.04-0.12) cO.OOl
Alpha-thll HET 0.08 (-0.11-0.28) 0.398
Alphl-thll HOM -0.05 (-0.28-0.19) 0.702
Sickle trllt -0.18(-0.43-0.07) 0.158
Prior parasitemia 0.07(0-0.13) 0.04
"reslta poIItlve'
Ap(yelrs) 0.15 (0.02-0.28) 0.021
Alpha-thai HET -0.15 (-0.74-0.45) 0.616
Alpha-thll HOM 0.531-0.57-1.63) 0.33
Sickle trait -0.91 (-1.96-0.15) 0.089
PrIor parasitemia -0.14 (-0.38-0.1) 0.236
Multlvlrlllte Ipnv!ouseplsodes)'
All samples
Ale (yelrs) 0.09 (0.06-0.13) cO.OOl
Parasitemia 0.46 (0.22-0.7) <0.001
Alpha-thai HET 0.03 (-0.16-0.21) 0.774
Alpha-thai HOM -0.05 (-0.29-D.18) 0.654
Slclde trait -0.26 (-0.51-0.02) 0.038
PrIor episode 0.08 (0-0.17) 0.056
Pare.1ta neptIve'
Ale lyelrs) 0.08 (0.04-0.12) <0.001
Alpha-thai HET 0.08 (-0.11-0.27) 0.399
Alpha-thai HOM -0.05 (-0.28-0.18) 0.68
Sickle trait -0.18 (-0.43·0.07) 0.149
PrIor episode 0.1 (0.02-0.19) 0.015
Piralte positive'
Ale (years) 0.16 (0.03-0.28) 0.016
Alpha-thai HET -0.18 (-0.77-0.41) 0.53
Alpha-thai HOM 0.68 (-0.48-1.84) 0.24
Sickle trait -1.07 (-2.14-0) 0.051
Prior episode -0.28 (-0.72-0.17) 0.212
285
285
279
283
253
253
247
213
34
247
213
34
Nml
IAnt".n t.st.d .t Indlcatod cross Sletlon.1 bl.. d.
, Unoar ","lSlon P cOiffic"nU with 95%confld.nce Int.rv_ls
, P..yll... for Indiclted foetor (p-v_lues S0.05 Indie_tld Inbold).
• Numbor of Slmploslnclud.d In tho mod.l.
, Unlvlrilt. llnoar ","lSlon.
6 Multlvanlbl. llnelr ,... ... uion with Inclusion of either recorded eplsod., of p.... stt.mlli or m.tllrl. in the 6 months prior to SIImpll ....
7Strotlfild multlvlrilbl.llno" ... " •• Ion. poro.lt. n... tlv. Simp'" only.
• Stratified multlvlrlable line.r """,sllon, parl,it. positive simples only.
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Table 34D Effect of different factors on IgG responses to AMAl(3D7) in the October 2003 cross sectional
bleed.
II (95"CI)'
AMAl(3D7) OCt 2003
,..".Iue' N'
<0.001 294
<0.001 293
0.377 285
0.023
0.092 284
<0.001 261
0.002 261
Unlvl1l1ate'
Age (years)
Parasitemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
0.11 (0.08-0.14)
1.04 (0.84-1.24)
-0.08 (-0.26-0.1)
-0.27 (-0.5--0.04)
-0.21 (-0.45-0.03)
0.23 (0.13-0.32)
Prior episode 0.22 (0.08-0.36)
Multivariate (previous parasitemia)'
Allsamples
Age (years) 0.11 (0.08-0.14)
Parasitemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
Parasite negative'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
Parasite positive'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
Multivariate (previous episodes)'
Allsamples
Age (years)
Parasitemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Parasite ne,atlve'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Parasite positive'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
0.86 (0.67-1.06)
-0.1 (-0.25-0.06)
-0.1 (-0.29-0.1)
-0.25 (-0.44--0.05)
0.17 (0.09-0.24)
0.09 (0.07-0.12)
-0.07 (-0.23-0.08)
-0.04 (-0.23-0.15)
-0.12 (-0.31-0.08)
0.18 (0.1-0.26)
0.24 (0.1-0.39)
-0.22 (-0.77-0.33)
-0.32 (-1.42-0.78)
-0.95 (-1.66--0.25)
0.22 (-0.08-0.52)
0.11 (0.08-0.14)
0.92 (0.72-1.12)
-0.09 (-0.25-0.06)
-0.07 (-0.27-0.13)
-0.24 (-0.44--0.04)
0.18 (0.07-0.3)
0.1 (0.07-0.12)
-0.09 (-0.24-0.07)
-0.03 (-0.23-0.16)
-0.09 (-0.3-0.11)
0.18 (0.07-0.3)
0.23 (0.08-0.37)
-0.14 (-0.68-0.39)
-0.04 (-1.1-1.02)
·1.06 (-1.75--0.36)
0.3 (-0.13-0.74)
<0.001
<0.001
0.209
0.33
0.015
<0.001
248
<0.001
0.339
212
0.673
0.247
<0.001
0.002 36
0.424
0.56
0.01
0.147
<0.001 248
<0.001
0.235
0.488
0.019
0.002
<0.001 212
0.28
0.723
0.359
0.001
0.003 36
0.584
0.943
0.004
0.162
M2lI!
1Ant •• " tested It indicated croll sectional bl•• d.
, Llnl.r rllresslon ~ coefflcllnts with 95%confldlncl IntoN.ls
• P..".luI for Indlcatod foetor (p.."aluls S0.05 Indlc.tld Inbold).
• Number of samples Includld Inthl model.
sUnlv.rllt. IInll' relf.sslon.
6 Multlvarlable linear r.,~sslon with Inclusion of either recorded episode, of p.,..,lt.mla or malaria in the 6 months prior to samplinl.
7 Strotlflodmu~lv.rlabll IInlar relresslon, PlroS~1 "I.tlvl samples only.
a Stratified multlvlnable linear "'.""160". ~,..stt. positive simples only.
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Table 34E Effecto( different (aeton on fgG responses to AMAI(3D7) in the May 2004 cross sectional
bleed.
AMA1(3D7, M.y 20M
II 195" Cl,. ,..".Iue" N'
Unlverlete'
Ale (ye.rs) 0.09 (0.06-0.11) <0.001 279
ParlSltemia 0.64 (0.36-0.92) <0.001 280
Alpha-tIIIl HET 0(-0.16-0.16) 0.984 261
Alpha-tilli HOM -0.24 (-0.45-0.04) 0.01
Sldele trllt -0.22 (-0.43-0) 0.045 266
PrIor Plraltemll 0.23 (0.07-0.39) 0.004 254
PrIor episode
Multlwlrllte (previous Plmltemll,'
All ........
Ace (ye.rs' 0.09 (0.06-0.11, <0.001 239
P.reslteml. 0.33(0.04-0.62, O.OlS
Alphl-thal HET 0.01(-0.14-0.16) 0.892
AlphI-thil HOM -0.14 (-0.34-0.05) 0.143
Slddetralt -0.21 (-0.41-0.01) 0.04
PrIor Plralteml. 0.19 (0.04-0.34) 0.015
Pal'llltl neptlve7
Aae(years) 0.08 (0.05-0.11) <0.001 224
Alpha-thai HET 0.02 (-0.14-0.17) 0.84
Alphl-thal HOM -0.13 (-0.32-0.07) 0.192
Slelde trait -0.2 (-0.4-0) 0.054
PrIor paraslteml. 0.24 (0.06-0.41) 0.008
Pal'llltl positive'
Ace (yelrs) 0.25 (0.01-0.49) 0.04 15
Alpha-thai HET -0.4 (-1.42-0.62) 0.398
Alpha-thai HOM -1.2 (-2.9-0.51) 0.147
Sickle trllt -0.34 (-1.81-1.13) 0.616
PrIor parlSlteml. 0.23 (-0.45-0.9) 0.465
MuItlVlrllte (previous .p!IodlS,'
Ail ........
Ale (yelrs) 0.09 (0.06-0.12) <0.001 239
Parasitemia 0.39 (0.1-0.67) 0.008
Alpha-thll HET -0.01 (-0.16-0.15) 0.924
Alpha-thai HOM -0.16 (-0.35-0.04) 0.119
Sickle trllt -0.21 (-0.41-0.01) 0.044
Prior episode
Parasttl neptlve7
Ace (years) 0.08 (0.05-0.11) <0.001 224
Alpha-thai HET 0(-0.15-0.16) 0.962
Alpha-thai HOM -0.13 (-0.33-0.07) 0.192
Sickle trait ·0.19 (-0.39-0.01) 0.068
Prior episode
Pamttl positIVI'
Ale (years) 0.2 (0.02-0.38) 0.03 15
Alpha-thai HET -0.52 (-1.45·0.42) 0.246
Alpha-thai HOM ·1.37 (-2.94-0.21) 0.082
Sickle trait -0.62 (-1.79-0.55) 0.265
Prior episode
f:lm!l
I Ant.en lestlel It Incllcatlelcross sectional blelel.
, Llnolr .... resslon ~ coefficients with 95%confldencelntervlls
• P","lue for Indlcetlel foctor (p-vllues ~0.05 Indicated in bold).
• Number of simples Included Inthe model.
5 Univ.riIt. Ifne.r re.ression.
: MuitlVlrtable 1I.,..r rqreulon with Incluston of either recorded episodes of p.rasltemill or mlliri. in the 6 months prior to samplinc.
Stretlfled multlvlrloblellnelr re,,,"lon, poreslte nel.tlve Simples onlv·
• Stmffled multlYlriable linear re.resstDn, parasite positive amp .. s onty.
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Table 34F Effect of different factors on IgG responses to AMAI(3D7) in the October 2004 cross sectional
bleed.
AMA1(3D7) Oct 2004
II (95%CI)' P-value' N'
UnlVllrlate'
Age (years) 0.06 (0.04-0.08) <0.001 273
Parasitemia 0.48 (0.19-0.77) 0.001 273
Alpha-thai HET -0.01 (-0.14-0.13) 0.925 268
Alpha-thai HOM -0.13 (-0.3-0.04) 0.133
Sickle trait -0.12 (-0.29-0.05) 0.168 270
Prior parasitemia 0.22 (-0.1-0.54) 0.18 235
Prior episode
Multivariate (previous parasitemia)'
Allnmples
Age (years) 0.08 (0.05-0.1) <0.001 216
Parasitemia 0.49 (0.15-0.84) 0.005
Alpha-thai HET -0.Ql (-0.15-0.12) 0.844
Alpha-thai HOM -0.13 (-0.3-0.04) 0.141
Sickle trait -0.15 (-0.32-0.02) 0.088
Prior parasitemia 0.22 (-0.08-0.52) 0.144
Parasite neptlve'
Age (years) 0.08 (0.05-0.1) <0.001 209
Alpha-thai HET -0.03 (-0.17-0.1) 0.637
Alpha-thai HOM -0.14 (-0.31-0.03) 0.104
Sickle trait -0.12 (-0.29-0.06) 0.18
Prior parasitemia 0.23 (-0.07-0.52) 0.131
Parasite positive'
Age (years) 0.04 (-0.66-0.73) 0.848 7
Alpha-thai HET 0.43 (-3.91-4.78) 0.709
Alpha-thai HOM 0.17 (-5.42-5.76) 0.909
Sickle trait -0.59 (-4.71-3.53) 0.601
Prior parasitemia
Multivariate (previous episodes)'
Allnmples
Age (years) 0.08 (0.05-0.1) <0.001 216
Parasitemia 0.49 (0.14-0.83) 0.006
Alpha-thai HET 0(-0.14-0.13) 0.943
Alpha-thai HOM -0.11 (-0.28-0.06) 0.194
Sickle trait -0.15 (-0.32-0.02) 0.088
Prior episode
Parasite Relative'
Age (years) 0.08 (0.05-0.1) <0.001 209
Alpha-thai HET -0.02 (-0.16-0.11) 0.735
Alpha-thai HOM -0.13 (-0.3-0.05) 0.149
Sickle trait -0.12 (-0.29-0.06) 0.18
Prior episode
Parasite poSitive'
Age (years) 0.04 (-0.66-0.73) 0.848 7
Alpha-thai HET 0.43 (-3.91-4.78) 0.709
Alpha-thai HOM 0.17 (-5.42-5.76) 0.909
Sickle trait -0.59 (-4.71-3.53) 0.601
Prior episode
~
1Ant.en tested It Indicated cross sectionll bleed.
2 Llnl.f l'alfesslon ~ coefficients with 95% confidence Intervals
• P-Vlluefor Indiclted factor (p-vllues S0.05 Indlclted Inbold).
4 Number of samples Included in the model.
5UnNlrilt. linear .... r.,slon .
• Mu~ivlrtlble linear re.re .. lon with Inclusionof e~her .. corded episodes of porosltemll or mlllril In the 6 months prior 10 Slmpli"l.
'strotlfied multivlrtable linear ion. porosite ","tive SImples only.
aStl1lttfl.d multlvlrllbl. IIn•• r r sston, PIIrlsitt POSlttvl'lmp'-s only.
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Table 3SA Effect or different raeton on laG responses to MSP2(3D7) in the May 2002 cross sectional
bleed.
MSP2(3D7) ~y 2002
,(95"0)' l'-vlllue"
UnlvlrIIte·
Ap(yeers) 0.12 (0.08-0.15) <0.001
Parasitemia 0.78 (0.59-0.98) <0.001
A1phe-thelHET 0.01 HI.17-O.19) 0.941
Alpha-thai HOM -0.25 (-0.48-0.01) 0.044
Sk:kIetralt -0.1 (-0.34-0.13) 0.393
PrIor penlsltemla 0.28 (0.19-0.36) <0.001
PrIor episode 0.33 (0.18-0.48) <0.001
Multlvlrla. (prwvIoul Pllralltemle)'
Allsemp!es
Ap(years) 0.08 (0.04-0.11) <0.001
ParlSltemla 0.57 (0.37-0.76) <0.001
Alpha-th.1 HET 0.03 (-0.13-0.19) 0.704
A1pha-thll HOM -0.13 (-0.34-0.08) 0.217
Sickletrait -0.09 (-0.29-0.12) 0.396
Prior p.resltemll 0.18 (0.09-0.26) <0.001
Pa...... neptlve'
Ap (years) 0.06 (0.03-0.09) <0.001
Alpha-thai HET 0.01 (-0.14.0.16) 0.904
Alpha-thai HOM -0.12 (-0.31-0.07) 0.213
SIckletrait -0.07 (-0.26-0.13) 0.507
Prtor paresltemla 0.26 (0.17-0.35) <0.001
Pa...... positive'
Ale (years) 0.12 (-0.04-0.29) 0.141
Alphe-thel HET -0.05 (-0.68-0.57) 0.863
Alpha-thai HOM -0.55 (·1.6-0.5) 0.294
Sickletrelt -0.1 (-0.79-0.59) 0.767
Prior parasitemia -0.03 (-0.32-0.26) 0.855
MultlvlrIaW (previous episodes)'
A1lsemples
All (years) 0.09 (0.05-0.12) <0.001
ParlSltemla 0.59 (0.4.0.79) <0.001
Alpha-thai HET 0.01 (-0.15-0.18) 0.864
Alpha-thel HOM -0.14 (-0.35-0.08) 0.208
Sickletrait -0.08 (-0.29-0.13) 0.439
Prior episode 0.21 (0.07-0.35) 0.004
, ....... neptJve'
Ase(ye.rs) 0.08 (0.05-0.11) <0.001
Alpha-thai HET 0(-0.17-0.16) 0.96
Alpha-thai HOM -0.13 (-0.33-0.08) 0.219
Sickletrait -0.1 (-0.31-0.11) 0.338
Prtor episode 0.21 (0.06-0.36) 0.005
Parasite positive·
Ase (years) 0.14 (-0.02-0.31) 0.082
Alpha-thai HET 0.05 (-0.56-0.65) 0.879
Alpha-thai HOM -0.39 (·1.46-0.67) 0.462
Sickletrait -0.01 (-0.71-0.68) 0.97
Prior episode 0.25 (-0.19-0.69) 0.261
298
298
297
299
304
304
289
239
50
289
239
50
~
1AntiCe"tested.t Indlcotld cross sectlonol bleld.
2 Llnelr re .... ssJon P coefficients with 95% confidence Intervlls
• P.. llue for Indlcotod foetor (p-v.lues S0.05 Indlcltld In bold).
• Numar of SImples Included In tile model.
• Unlvlrllte llnolr Ion.
: Mu~lvlrllble llnoor Ion w~h Inclusionof eniler recorded episodes of poresitemll or mllarilin the 6 months prior to Slmplln•.
Stretlfied multlvlrilble llnolr Ion. pores~e ne,"tlve simples only.
• Stretlfied mu~lvlrllble IIne.r sslon. p,resne pos~lve IImples only.
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Table 3SB Effect of different factors on IgG responses to MSP2(3D7) in the October 2002 cross sectional
bleed.
MSP2(3D7) Oct 2002
II (95% Cl)' P-value'
Unlvlr"te'
Age (years) 0.05 (0.03-0.07) <0.001
Parasitemia 0.52 (0.35-0.7) <0.001
Alpha-thai HET .(l.02 (-0.13-0.09) 0.691
Alpha-thai HOM -0.14 (-0.28-0) 0.045
Sickle trait .(l.OS (-0.19-0.1) 0.512
Prior parasitemia 0.05 (.(l.04-0.1S) 0.28
Prior episode 0.02 (-0.1.(l.14) 0.748
Multivariate (previous ~,.sltemla)·
All SImples
Age (years) 0.05 (0.03-0.08) <0.001
Parasitemia 0.49 (0.3-0.67) <0.001
Alpha-thai HET .(l.04 (-0.15-0.07) 0.528
Alpha-thai HOM .(l.11 (·0.25-0.03) 0.134
Sickle trait .(l.07 (-0.22-0.08) 0.361
Prior parasitemia 0.02 (-0.07.(l.11) 0.639
Pa,.slte n.. atlve'
Age (years) 0.05 (0.03.(l.07) <0.001
Alpha-thai HET .(l.03 (-0.13-0.07) 0.542
Alpha-thai HOM ·0.08 (-0.2·0.05) 0.222
Sickle trait .(l.11 (-0.24-0.02) 0.094
Prior parasitemia 0.02 (.(l.06-0.1) 0.587
Peraslte positive'
Age (years) 0.26 (.(l.04.(l.56) 0.084
Alpha-thai HET .(l.6S (-1.94-0.63) 0.292
Alpha-thai HOM -1.12 (-2.68-0.45) 0.149
Sickle trait 0.36 (-1.04-1.77) 0.586
Prior parasitemia 0.24 (.(l.6-1.08) 0.553
Multivariate (previous episodes)'
All SImples
Age (years) 0.05 (0.03-0.08) <0.001
Parasitemia 0.49 (0.31-0.67) <0.001
Alpha-thai HET .(l.04 (.(l.lS·0.07) 0.49
Alpha-thai HOM -0.11 (-0.25-0.03) 0.118
Sickle trait -0.07 (-0.22-0.07) 0.326
Prior episode .(l.01 (-0.13-0.1) 0.797
p.,.slte nesatlve'
Age (years) 0.05 (0.03.(l.07) <0.001
Alpha-thai HET .(l.04 (-0.13-0.06) 0.456
Alpha-thai HOM .(l.OS (-0.21-0.04) 0.175
Sickle trait -0.12 (-0.25·0.01) 0.071
Prior episode -0.06 (-0.16-0.04) 0.233
Pe,.slte positive'
Age (years) 0.27 (0.01.(l.S4) 0.043
Alpha-thai HET .(l.S9 (-1.69-0.51) 0.267
Alpha-thai HOM -1.09 (-2.55-0.37) 0.131
Sickle trait 0.36 (-0.92-1.64) 0.553
Prior episode 0.6 (.(l.22-1.43) 0.138
291
291
284
292
254
254
251
232
19
251
232
19
NotlS
1Antl,ln tlsttd It indlcattd cross sectional bl•• d.
2Llnt.r rl,,..'51o" p coefficients with 95% confidence Int.rvals
• P.y.luo for Indicated foetor (p ... luo. s 0.05 indlc.tod in bold) .
• Number of .. mple. Includod in tho modoi.
s Univariate IInl.f relression.
e MuttlvlI'llbl.lln •• r r",..'510" with Inclusion of .,ther recorded episodes of pIl'Isitlml. or mll.rla in thl 6 months prior to umpllnl,
7Stf'lltlfl.d muttlvlrl.bla Ilnl.r r•• rlsslon, parllslt. nea.tlv. SIImples only.
I Stratif~d mutttviriabl. IInl.r rll,..ssion, parult. positive samples only.
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Table 3SC Erred of dltrerent facton on IgG responses to MSPl(3D7) In the May 2003 cross sectional
bleed.
MSP2(JD7) _y 2003
11(95"01' ,...,....."
UnlvlrIIte'
Ale (yearsl 0.06 (0.~.091 <0.001
Plraltemll 0.65 (0.49-0.811 <0.001
AIph .. thll HET ~.11 (~.2~.021 0.105
Alphl-thil HOM ~.18(~.~1 0.049
SIckle trIIt ~.07 (~.2~.121 0.462
PrIor plrlSltemll 0.03 (~.02-O.081 0.266
PrIor episode 0.05 (~.02~.12) 0.147
MuIlIVIIrIItII (previous !lllrultem""
AllllmpIes
Act (ve'" 0.05 (0.0~.081 <0.001
Plraltemll 0.53 (0.3~.71 <0.001
Alph .. thal HET ~.08 (~.21~.061 0.259
Alphl-thll HOM ~.08 (~.2~.09) 0.376
Slddetralt ~.1 (~.2H.08) 0.284
PrIor perultemll 0.01 (~.0~.051 0.653
......... neptJve'
Ap(velrs) 0.04 (0.02-0.06) 0.001
AIph.. thll HET ~.05 (~.1~.07) 0.437
Alphl-thll HOM ~.06 (~.H.08) 0.398
Slcldetralt o (~.15~.15) 0.996
PrIor plrasltemll 0.05 (0.01~.08) 0.016
...mIte positive'
Ace (yelrsl 0.11 (~.01~.23) 0.077
Alph .. thli HET ~.08 (-0.67·0.5) 0.779
Alph .. thll HOM 0.31 (~.77-1.39) 0.558
SIckle trait ~.6 (·1.~.43) 0.241
PrIor perasltemll ~.23 (~.47-O) 0.052
Multlvlrlltll (previous episodes)'
Mllmples
A,e (velrs) 0.05 (0.03~.08) <0.001
Parlsltemla 0.54 (0.37-0.11) <0.001
Alph .. thal HET ~.08 (-0.21~.06) 0.261
Alph .. thal HOM ~.08 (~.2~.09) 0.375
Sleldetralt ~.09 (~.27~.09) 0.326
PrIor episode 0.04 (~.02~.1) 0.215
Parulte neptlve7
Ace (years) 0.04 (0.01-0.06) 0.002
Alph .. thll HET -0.05 (-0.16-0.07) 0.431
Alpha-thai HOM -0.06 (-0.2-0.08) 0.375
Sickle trait 0(-0.15-0.15) 0.976
PrIor episode 0.07 (0.02-0.12) 0.006
Parasite positive'
Ace (vears) 0.12 (Q.().251 0.054
Alpha-thai HET -0.14 (-0.72·0.44) 0.626
Alph .. thal HOM 0.53 (-0.61-1.681 0.349
SIckle trait -0.86 (-1.91-0.2) 0.107
285
285
279
283
253
253
247
213
34
247
213
34
Prior episode -0.43 (-0.87-0.01) 0.054
l!Iml
I Antil.n t.stod It Indlcotod crOll oectlonol bleod.
2 U.,..r ,...,.ulon , coefficients with 95" confidence Intervlls
• I'-v.I ... IDr IndlcolO<! factor (p-v.I .... ~ 0.05 Indlc.tod In bold) .
• Number of somp!ellnclud.d In the model.
s Unlv.r1ot. M ion.
• Multlvlrlable II ion w~h Inclu.lon of .~her recordod .plsod •• of po ... ~.mlo or m.lorllln the 6 month. prior to .. mpll ...
, St .. tlftod mu~lv.rlable 1I r ion, po ... ~..... tlv mples only.
• Stratlftod mu~lvorlabl.II r Ion. po .. s~. pos~IY mples only.
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Table 3SD Effect of different factors on IgG responses to MSP2(3D7) in the October 2003 cross sectional
bleed.
MSP2(iD7) Oct 2003
II (95" Cl)' P-vllu.' N"
UnlVllrilte'
Ale (years) 0.06 (0.04-0.09) <0.001 294
Parasitemia 0.63 (0.48-0.79) <0.001 293
Alpha-thai HET -0.03 (-0.17-0.1) 0.621 285
Alpha-thai HOM -0.13 (-0.3-0.05) 0.148
Sickle trait -0.1 (-0.28-0.08) 0.279 284
Prior parasitemia 0.12 (0.05-0.19) 0.001 261
Prior episode 0.05 (-0.05-0.16) 0.323 261
Multlvarillte (previous pilrasltemll)'
All samples
Ale (years) 0.05 (0.03-0.08) <0.001 248
Parasitemia 0.5 (0.34-0.67) <0.001
Alpha-thai HET -0.04 (-0.17-0.09) 0.567
Alpha-thai HOM -0.04 (-0.21-0.12) 0.616
Sickle trait -0.1 (-0.26-0.07) 0.256
Prior parasitemia 0.08 (0.02-0.15) 0.013
P.raslte nqltlve'
Ale (years) 0.04 (0.02-0.06) <0.001 212
Alpha-thai HET 0(-0.12-0.12) 0.993
Alpha-thai HOM o (-0.15-0.15) 0.991
Sickle trait 0.03 (-0.13-0.18) 0.726
Prior parasitemia 0.13 (0.07-0.19) <0.001
P.raslte positive'
Age (years) 0.13 (-0.01-0.27) 0.066 36
Alpha-thai HET -0.09 (-0.61-0.43) 0.726
Alpha-thai HOM 0.31 (-0.74-1.35) 0.554
Sickle trait -0.9 (-1.57--0.24) 0.01
Prior parasitemia -0.12 (-0.41-0.16) 0.377
Multivarillte (previous episodes)'
All samples
Age (years) 0.05 (0.03-0.08) <0.001 248
Parasitemia 0.53 (0.37-0.7) <0.001
Alpha-thai HET -0.04 (-0.17-0.09) 0.548
Alpha-thai HOM -0.04 (-0.21-0.13) 0.649
Sickle trait -0.1 (-0.27-0.07) 0.235
Prior episode 0.04 (-0.06-0.13) 0.453
Parasite M.atlve'
Age (years) 0.04 (0.02-0.07) <0.001 212
Alpha-thai HET -0.01 (-0.14-0.11) 0.824
Alpha-thai HOM -0.01 (-0.16-0.15) 0.91
Sickle trait 0.03 (-0.13-0.2) 0.686
Prior episode 0.08 (-0.01-0.17) 0.099
P.raslte positive'
Age (years) 0.14 (0.01-0.28) o.on 36
Alpha-thai HET -0.14 (-0.64-0.37) 0.583
Alpha-thai HOM 0.15 (-0.85-1.16) 0.756
Sickle trait -0.84 (·1.5--0.18) 0.014
Prior episode -0.1 (-0.52-0.31) 0.61
J:j21U
1Anti,." testld It IndiCllttdcross sectional bl•• d.
2 Linear ,...re55Ion ~ cOlfflcients with 95% confldenc. Int.rvlls
• P",aluo for indicated foctor (p-valuos 5 0.05 indlcatod in bold).
4 Number of SIImples included In thl modll.
s Unlvariltt linelr rell"ession.
6Multlvlrilbl. IInl.' ,...resslon with inclusionof .ith.r recorded episode. of parlsltemil or mlillria in the 6 months prior to sampll"..
7Stratified multlvlrllbl.lin •• r ",,..5510", plrlslt. n••• tlv.umples only.
• Stratlflod mu~iY"i.ble lino" rearosslon, parasito pos~iYoSImples only.
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Table 35E Effect of dlffennt faeton OD laG resPODses to MSPl(JD7) iD the May 2004 cross sectIo.al
bleed.
MSP2(3D7) Mev 2004
IICIWO)' ,..,...... rt
UnMrIIte'
Ace Cyell'S) 0.0610.04-0.08) cO.OOl 279
Plrlsltemla 0.7110.49-0.93) cO.OOl 280
Alphe-thel HET -0.091-0.22-0.05) 0.202 261
Alphl-thll HOM -0.21-0.37-0.03) 0.02
Slcldetnllt -0.111-0.28-0.07) 0.247 266
Prtor perultemla 0.11 (-0.02-0.24) 0.105 254
PrIor episode
MuItMrletll CprevIous plmItemIe)"
AII .. mpIe
Ale (years) O.OS(0.03-0.08) cO.OOI 239
PlrlSltemla 0.51 (0.27-0.75) cO.OOl
Alpha-thli HET -0.061-0.18-0.07) 0.371
Alph.thli HOM -0.12 (-0.28-0.04) 0.144
Slcldetrelt -0.08 (-0.24-0.08) 0.321
Prior parasitemia 0.06 (-0.07-0.18) 0.385
PIIIIIte .......,.'
All (years) 0.0410.02-0.07) <0.001 224
Alpha-thai HET -0.07 (-0.18-0.05) 0.251
AI~thIIHOM -0.11 (-0.26-0.03) 0.114
Slddetrllt -0.061-0.21-0.08) 0.386
PrIor peresltemla 0.1610.03-0.29) 0.015
PlrIIltI positive"
Aae (veers) 0(-0.38-0.39) 0.979 15
Alpha-thai HET -0.38 (-2.03-1.28) 0.618
Alpha-thll HOM -1.24 (-4-1.52) 0.337
Slcldetrelt -1 (-3.38-1.38) 0.367
PrIor peresltemla -0.49 (·1.59-0.6) 0.333
Multlvlrt.te CPrevlous eplsod .. )"
AlI .. mpIes
Alelyears) 0.0510.03-0.08) cO.OOI 239
PlrlSltemla 0.53 (0.29-0.76) cO.OOI
Alpha-thai HET -0.061-0.19-0.06) 0.326
Alph.thal HOM -0.121-0·28-0.04) 0.133
Sickle trait -0.081·0.24·0.08) 0.323
PrIor episode
PlrultllllletIve'
Ace lyears) 0.0510.03-0.07) cO.001 224
Alpha-thai HET -0.071-0.19-0.04) 0.202
Alpha-thai HOM -0.12 (-0.26-0.03) 0.114
Sickle trait -0.06 (-0.21-0.09) 0.433
PrIor episode
Plresltl positive'
Ace (years) 0.11 (-0.18-0.41) 0.407 15
Alpha-thai HET -0.13 (·1.67-1.41) 0.855
Alpha-thai HOM -0.87 (·3.47-1.73) 0.474
Sickle trait -0.39 (·2.32-1.55) 0.665
Prior episode
II21II
I Antilen talted .t Indicltod cro.1 .. <tlonal blHd.
a Une.r Ion ~ cOilliclentl wRh 95% confidence InteIV.II
, P..,.I for Indicltld foetor (p-y.I .... $ O.OSlndlc.tod In bold) .
• Number at IImplellncluded In the model.
5 Univariate linear ,...ression.
• Multlvlrleble llne.r ....... Ion wRh Inclullon of either record.d episode. of poro.~.mla or m.lorl. In the 6 month. prior to 11m II
7Stl'llttfled muitivarlllbl.llnear ,...,.."10", pal'llslt. n••• tlv. Amples onty. p ne·
I Strotlfled multlY.rleble llne.r ....... Ion. porollt. poIRIY•• Imple. only.
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Table 3SF Effect of different factors on IgG responses to MSP2(3D7) in the October 2004 cross sectional
bleed.
MSP2(3D7) Oct 2004
PI9S" Cl)' P-v.lue' N'
Univariate'
Age (years) 0.05 (0.03-0.07) <0.001 273
Parasitemia 1.08 (0.86-1.31) <0.001 273
Alpha-thai HET -0.07 (-0.18-0.05) 0.246 268
Alpha-thai HOM -0.14 (-0.29-0) 0.058
Sickle trait 0.02 (-0.12-0.17) 0.752 270
Prior parasitemia 0(-0.28-0.28) 0.986 235
Prior episode
Multlvarllte (previous peralltemil)'
All Simples
Age (years) 0.06 (0.04-0.08) <0.001 216
Parasitemia 1.25 (0.98-1.52) <0.001
Alpha-thai HET -0.04 (-0.14-0.07) 0.489
Alpha-thai HOM -0.11 (-0.24-0.02) 0.105
Sickle trait -0.12 (-0.25-0.02) 0.087
Prior parasitemia 0.04 (-0.2-0.27) 0.761
Plrlslte negative'
Age (years) 0.05 (0.04-0.07) <0.001 209
Alpha-thai HET -0.06 (-0.16-0.04) 0.207
Alpha-thai HOM -0.12 (-0.24-0.01) 0.063
Sickle trait -0.01 (-0.14-0.11) 0.855
Prior parasitemia 0.04 (-0.17-0.26) 0.709
Plraslte positive'
Age (years) 0.07 (-0.03-0.17) 0.088 7
Alpha-thai HET -0.04 (-0.64-0.56) 0.S07
Alpha-thai HOM 0.7 (-0.07-1.47) 0.06
Sickle trait -1.81 (-2.38--1.24) 0.005
Prior parasitemia
Multivarilte (previous episodes)'
All Simples
Age (years) 0.06 (0.04-0.08) <0.001 216
Parasitemia 1.25 (0.98-1.51) <0.001
Alpha-thai HET -0.04 (-0.14-0.07) 0.S03
Alpha-thai HOM -0.11 (-0.24-0.02) 0.11
Sickle trait -0.12 (-0.25-0.02) 0.086
Prior episode
P.raslte neg.tlve'
Age (years) 0.05 (0.04-0.07) <0.001 209
Alpha-thai HET -0.06 (-0.16-0.04) 0.216
Alpha-thai HOM -0.12 (-0.24-0.01) 0.067
Sickle trait -0.01 (-0.14-0.11) 0.854
Prior episode
Parasite positive'
Age (years) 0.07 (-0.03-0.17) 0.088 7
Alpha-thai HET -0.04 (-0.64-0.56) 0.S07
Alpha-thai HOM 0.7 (-0.07-1.47) 0.06
Sickle trait -1.81 (-2.38--1.24) 0.005
Prior episode
!I2W
I Antl.en t,sted It Indielted cross .. etlonll bleed.
I Lln•• r rearession ~ coefficients with 95% confidence Intervals
I P-v,lue fo, Indieltod foeto, (p-Vlluos 5 0.05 Indlclted Inbold).
• Numbe, of slmpleslncludod Intho modol.
5 Univariate Ii"..r ,..ress~n.
• MultlvlrllblelinOl' ,o,rosslon with Inclusionof olthor roco,dod oplsodes of po'lIltemll 0' moll,ll Intho 6 months p,lo, to IImplin •.
1 Stl'lltifi.d multlvarillbl. linear re,,.. .. Io". pa,..site n••• tlv. samples only.
• Strotlfledmultlvlrllblellnol' ,".rosslon, poroslte posltlvo SImples only.
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Table 36A Effect of differeDt faeton ODJiG resPODsesto MSPl(FC27) in the May 2002 cross seetioDat
bleed.
MSPZ(FC27) May 2002
11115"0)' P-va .... '
UIMrlate'
Ace (years) 0.07 (0.04-0.1) <0.001
Pll'Ultemill 0.51 (0.33-0.69) <0.001
Alphl-thll HET 0.07 (-0.09-0.24) 0.397
Alpha-thel HOM -0.02 (-0.23-0.2) 0.882
SIckle trIlt -0.15 (-0.36-0.06) 0.149
PrIor l*Ultem'- 0.25 (0.17-0.33) <0.001
PrIor episode 0.22 (0.08-0.35) 0.002
Mullivarlate (pnvlaul parultemla)'
AI.mpIeI
Ace (yelrs) 0.04 (0-0.07) 0.026
Parasitemia 0.39 (0.2-0.57) <0.001
Alphl-thll HET 0.1 (-0.06-0.25) 0.215
Alph.thll HOM 0.07 (-0.13-0.27) 0.478
Slcldetrllt -0.14 (-0.34-0.05) 0.156
PrIor parlsltemla 0.17 (0.09-0.26) <0.001
1II.... 1IIPtIft'
Ace (yelrs) 0.03 (0-0.06) 0.078
Alph.thll HET 0.06 (-0.09-0.22) 0.431
Alpha-thaI HOM 0.02 (-0.18-0.21) 0.873
Sickle trait -0.12 (-0.32-0.09) 0.259
PrIor parllitemla 0.2 (0.11-0.29) <0.001
III.... positive'
Aae (yelrs) 0.06 (-0.08-0.2) 0.409
Alpha-thaI HET 0.19 (-0.36-0.74) 0.486
Alpha-thai HOM 0.43 (-0.49-1.35) 0.348
Slcldetrllt -0.23 (-0.84-0.37) 0.441
PrIor p.rllitemla 0.13 (-0.12-0.38) 0.302
Multivariate (pnvlaul episodes)'
AHllmp!es
Aae (years) 0.05 (0.02-0.08) 0.004
Parasitemia 0.44 (0.25-0.63) <0.001
Alph.thal HET 0.07 (-0.09-0.23) 0.383
Alph.thel HOM 0.06 (-0.14-0.27) 0.553
SIckle trait -0.15 (-0.35-0.05) 0.138
Prior episode 0.11 (-0.02-0.25) 0.102
III.... neptlve'
Aae (years) 0.04 (0.01-0.08) 0.007
Alph.thal HET 0.05 (-0.11-0.21) 0.52
Alpha-thai HOM 0.01 (-0.19-0.21) 0.91
Slddetralt -0.14 (-0.35-0.07) 0.182
Prior episode 0.18 (0.03-0.33) 0.017
Plraslte positive'
Aae (years) 0.04 (-0.1-0.19) 0.544
Alpha-thai HET 0.09 (-0.45-0.64) 0.725
AlphHhal HOM 0.38 (-O.51H.33) 0.433
Sickle trait -0.23 (·0.86-0.4) 0.461
Prior episode -0.02 (-0.42-0.37) 0.909
298
298
297
299
304
304
289
239
50
289
239
50
H!zIu
1AntiCenwiled .t Indicated cr_seetloMI bleed.
2l1ne•r rwuion , coefficients with 95" confidence intervals
• ' .... 1 for Indicated foetor (p-yllues SO.OSlndlclted Inbold).
• Number of SImples Included In the model.
• Unlvlrllte lI_r ",.",,,Ion .
• Multlvlrllble line.. """,,,ion w~h Inclusionof e~her nscorded episodes of Plros~emll or mlllrilin the 6 months prior to Slmpll,..
7 Strotlfied multlv.rllble Ii_r """,,,ion, Plroslte ne,"tlv. SImples only.
• Strotlfledmultlvlrllble line.. "'I",,'on, Plrosltl positivI Slmpl.. only.
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Table 368 Effect of different factors on fgG responses to MSP2(FC27) in the October 2002 cross sectional
bleed.
MSP2(Fe27) Oct z002
II (95% Cl)' P-vllue' pt
Unlvllrlne'
Age (years) 0.06 (0.04-0.09) <0.001
Parasitemia 0.84 (0.65-1.03) <0.001
Alpha-thai HET 0.03 (-0.1-0.15) 0.655
Alpha-thai HOM -0.17 (-0.32--0.01) 0.04
Sickle trait -0.09 (-0.26-0.0S) 0.296
Prior parasitemia 0.17 (0.06-0.2S) 0.002
Prior episode 0.22 (0.08-0.36) 0.002
Multlverlete (previous peresltemle)'
All samples
Age (years) 0.06 (0.03-0.08) <0.001
Parasitemia 0.7(0.5-0.9) <0.001
Alpha-thai HET 0.02 (-0.1-0.14) 0.724
Alpha-thai HOM -0.11 (-0.27-0.04) 0.138
Sickle trait -0.08 (-0.24-0.09) 0.353
Prior parasitemia 0.13 (0.04-0.23) 0.007
Plresite nealtlve'
Age (years) 0.05 (0.03-0.07) <0.001
Alpha-thai HET 0.03 (-0.OS-O.14) 0.577
Alpha-thai HOM -0.07 (-0.21-0.07) 0.304
Sickle trait -0.05 (-0.2-0.1) 0.494
Prior parasitemia 0.14 (0.05-0.23) 0.002
Plraslte positive'
Age (years) 0.27 (-0.01-0.55) 0.059
Alpha-thai HET -0.61 (-1.8-0.59) 0.293
Alpha-thai HOM -1.46 (-2.92-0) 0.05
Sickle trait -0.65 (-1.95-0.66) 0.303
Prior parasitemia 0.15 (-0.63-0.93) 0.684
Multlvarllte (previous episodes)'
All samples
Age (years) 0.05 (0.03-0.08) <0.001
Parasitemia 0.72 (0.52-0.91) <0.001
Alpha-thai HET 0.02 (-0.1-0.14) 0.767
Alpha-thai HOM -0.11 (-0.27-0.04) 0.136
Sickle trait -0.08 (-0.25-0.0S) 0.307
Prior episode 0.18 (0.06-0.3) 0.004
Paresltl ne,atlve'
Age (years) 0.05 (0.03-0.07) <0.001
Alpha-thai HET 0.02 (-0.09-0.13) 0.67
Alpha-thai HOM -0.07 (-0.21-0.06) 0.293
Sickle trait -0.06 (-0.21-0.09) 0.446
Prior episode 0.21 (0.09-0.32) <0.001
Plreslle positive'
Age (years) 0.25 (-0.01-0.52) 0.061
Alpha-thai HET -0.52 (-1.63-0.59) 0.328
Alpha-thai HOM -1.46 (-2.93-0.01) 0.051
Sickle trait -0.69 (-1.9S-0.59) 0.265
Prior episode 0.06 (-O.77-O.S9) 0.884
M2l!!
1Antl,on tostod It Indlcltod cross Sletlonll blood.
2 Llnolr re,resslon P coefficlonts w~h 95% confldonco IntoNII,
• P.y.luo for Indlcotod foetor (p.ylluos 5 0.05 Indlc.tod In bold) .
• Number of Simples Included In tho model.
291
291
284
292
254
254
2S1
232
19
251
232
19
5Univariate linear ,...rellion.
6Multlvlrilblellnelr r•• rllslon with inclusion of eith.r r.corded episodes of ~l'Islt.mll or mIIt.rll In the 6 months prior to sampli"l.
7St,...tifled muttivlrlablelinelr r.lr,sslen. PI, .. It.M.ativ. umples onty.
• Slrltillod multlvlrllbleUno .. relresslon, porlslte posltillo Simples only.
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Table 36C Effed of different faeton on IIG responses to MSPl(FC27) in the May 2003 cross sectional
bleed.
MSPZ(FCZ7) Mev 2003
.eIWO)' Pow ... •
Unlvarllte'
Aaelyelrs) 0.07 (0.0~.1) <0.001
p_ltemhl 0.71 (0.54-0.87) <0.001
AIph.tIIll HET -0.07 (-0.21-0.07) 0.354
~tIIIIHOM -0.22 (-0.4-0.04) 0.016
Slddenlt -0.18 (-0.37-0.01) 0.064
Prior PIIl'ISlteml8 0.04 (-0.01-0.09) 0.119
PrIor episode 0.03 (-0.04-0.1) 0.429
MultMrIIte (prwIaus 1III'8IItem1ll)'
All .. ...,...
Ap(yelrs) 0.06 (0.04-0.09) <0.001
PlI'ISltemll 0.62 (0.4~.8) <0.001
Alph.thll HET -0.06 (-0.19-0.07) 0.372
AlphI-tIIll HOM -0.13 (-0.3-0.04) 0.138
Sldele trllt -0.16 (-0.34-0.02) 0.088
PrIor Pllrlsltemll 0.02 (-0.03-0.06) 0.485
PlraIta nepttw'
Ap(years) 0.04 (0.02-0.07) cO.OOl
AIph.tIIll HET -0.04 (-D.15-O.08) 0.561
AIphHhl1 HOM -0.11 (-0.26-0.03) 0.126
Slddenlt -0.09 (-0.24-0.07) 0.267
PrIor PIIrasltemll 0.02 (-0.02-0.06) 0.333
PlraIta positive'
Acelyelrs) 0.16 (0.03-0.3) 0.016
AlphI-thll HET -0.1 (-0.72-0.53) 0.753
Alpha-thai HOM -0.18 (-1.33-0.97) 0.752
Siddenlt -0.51-1.6-0.6) 0.359
PrIor PllrlSltemla 0.03 (-0.22-0.29) 0.786
MultMrIIte (prwlous episodes)'
All SImples
Ale (yelrs) 0.06 (0.04-0.09) cO.OOl
Plrlsltemla 0.63 (0.46-0.8) <0.001
Alpha-thai HET -0.06 (-0.19-0.07) 0.376
Alph.thal HOM -0.13 (-0.3-0.04) 0.134
Sickle trllt -0.16 (-0.34-0.02) 0.083
Prior episode 0.02 (-O.O~.08) 0.617
PlraIta neptIve'
Ale (yelrs) 0.04 (0.02-0.07) <0.001
Alpha-thai HET -0.04 (-0.15-0.08) 0.56
Alpha-thai HOM -0.11 (-0.26-0.03) 0.123
Sickle trait -0.09 (-0.24-0.07) 0.266
PrIor episode 0.03 (-0.02-0.08) 0.215
Plreslte positive'
Ap(years) 0.17 (0.04-0.3) 0.013
Alpha-thai HET -0.08 (-0.69-0.53) 0.789
Alpha-thai HOM 0.04 (·1.17·1.24) 0.952
Sickle trait -0.58 (-1.69-0.53) 0.29
Prior episode -0.19 (-0.64-0.27) 0.416
285
285
279
283
253
253
247
213
34
247
213
34
llml
1Antlpn tested It Indicated cross sectlonll bleed.
, Une ....... sslon ~ .... fftclents wtth 95" .o_nc:elntervol.
, P","IUI for Indicated foctor (P-YIIUi. S 0.05 Indicated In bold) .
• Number of Ample. Included In the model.
• Univlrilte IIn.. r Ion.
• Multivlrilbie line "Ion with Inclusion of either recordod oplsodes of parasltemll or mllarll In the 6 months prior to Ampll"..
7 Stratified multivlrilble llnelr "Ion. paraslto neeltlve Amples only.
• Stratified multlvlrlable llnelr "ion. paraslto posltlvo Simples only.
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Table 36D Effect of different factors on IgG responses to MSP2(FC27) in the October 2003 cross sectional
bleed.
MSP2(FC27) Oct 2003
UnlVllrlete5
Age (years) 0.08 (0.05-0.1) <0.001
Parasitemia 0.79 (0.63-0.95) <0.001
Alpha-thai HET -0.04 (-0.18-0.11) 0.61
Alpha-thai HOM -0.23 (-0.42--0.04) 0.015
Sickle trait -0.14 (-0.34-0.05) 0.147
Prior parasitemia 0.13 (0.05-0.21) 0.001
Prior episode 0.14 (0.03-0.26) 0.015
MuitlVllrlete (previous palllsitemle"
All Simples
Age (years) 0.06 (0.04-0.09) <0.001
Parasitemia 0.68 (0.51-0.86) <0.001
Alpha-thai HET -0.07 (-0.2-0.07) 0.323
Alpha-thai HOM -0.15 (-0.33-0.02) O.OSl
Sickle trait -0.17 (-0.34-0.01) 0.063
Prior parasitemia 0.08 (0.02-0.15) 0.017
PIllIllte nllltive 7
Age (years) 0.04 (0.02-0.07) <0.001
Alpha-thai HET 0.02 (-0.1-0.14) 0.731
Alpha-thai HOM -0.06 (-0.21-0.09) 0.434
Sickle trait -0.12 (-0.28-0.03) 0.126
Prior parasitemia 0.18 (0.12-0.24) <0.001
PIllIslte positive·
Age (years) 0.15 (0.01-0.29) 0.04
Alpha-thai HET -0.23 (-0.76-0.3) 0.388
Alpha-thai HOM -0.07 (-1.14-0.99) 0.891
Sickle trait -0.63 (-1.31-0.05) 0.067
Prior parasitemia -0.27 (·0.56-0.02' 0.065
MultlVllrlate (previous episodes)'
All Simples
Age (years) 0.06 (0.04-0.09) <0.001
Parasitemia 0.71(0.54-0.88) <0.001
Alpha-thai HET -0.07 (-0.2-0.07) 0.349
Alpha-thai HOM -0.14 (-0.31-0.04) 0.122
Sickle trait -0.16 (-0.34-0.01) 0.073
Prior episode 0.11 (0.01-0.21) 0.031
Plrlslte negltlve7
Age (years) 0.05 (0.02-0.07) <0.001
Alpha-thai HET 0.01 (-0.12-0.14) 0.875
Alpha-thai HOM -0.05 (-0.21-0.1) 0.501
Sickle trait -0.1 (-0.26-0.06) 0.227
Prior episode 0.18 (0.1-0.27) <0.001
P.llIllte positive·
Age (years) 0.18 (0.04-0.32) 0.015
Alpha-thai HET -0.33 (·0.86-0.2) 0.215
Alpha-thai HOM -0.4 (-1.46-0.65) 0.442
Sickle trait -0.51 (-1.2-0.19) 0.147
Prior episode -0.24 (-0.67-0.19) 0.264
294
293
285
284
261
261
248
212
36
248
212
36
~
1Ant.en tosted at indicated cross sectional biNd.
2linear r•• resslon P coefficients with 95% confldenc. Intervlls
• P.. alue for Indlcotod foetor (p.yaluos S0.05 Indicated In bold).
,. Number of Simples included In thl model.
SUntvlr.tl linelr re.re5510n .
• Mutttvirilble IInlar re.resslon wjth Inclusion of .Ith.r recorded episodes of parlSttlmil or mal.ria Inthe 6 months prior to sampli,..
1Stratified muIUvlrlabl.llnl.r rl.rlssion, plrllSlt. nlllttv. simples only.
• Strotlflod muklvariablellnear ro,resslon. poruke posklve .. mples only.
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Table 36E Effect or different raeton on fgG responses to MSP2(FC27) in tbe May 2004 cross sectional
bleed.
MSP2(FC27) May 2004
11(15"0,' P.value· N"
Unlvlrllte"
Ap(yearsl 0.05 (0.03-0.071 <0.001 279
Parasltemll 0.71 (0.5-0.91) <0.001 280
Alpha-thal HET ~.07 (~.2-O.061 0.274 261
Alpha-thal HOM ~.21 (~.37-O.041 0.012
SIcIde trlit ~.13 (~.~.031 0.117 266
PrIor peralternl. 0.23 (0.11-0.35) <0.001 254
PrIor episode
Multlvlrllte (previous PllrlSltem""
AII .. mpIts
Ap(vearsl 0.05 (0.02-0.071 <0.001 239
P.raItemi. 0.51 (0.28-0.73) <0.001
Alpha-thal HET ~.04 (~.l6.().OS) 0.485
Alpha-thill HOM -o.iz (~.27~.O3) 0.112
SIckle trill ~.ll (~.27~.03) 0.ll8
PrIor Pllrultemlll 0.16 (0.~.28) 0.01
,.,....neptIve'
Ap(years) 0.04 (0.02-0.06) <0.001 224
Alphe-thal HET -O.OS(~.19.().04) 0.191
AIph .. thal HOM -0.13 (~.27~.01) 0.063
Sickletrill -O.OS(~.22~.07' 0.29
PrIor Pllrultemla 0.14 (0.01-0.26) 0.032
,.,.... positive'
Ap(years) 0.2 (-0.12-0.53) 0.189 15
Alpha-thai HET 0.27 (-1.12-1.66) 0.668
Alpha-thai HOM ~.4(-2.72-1.92) 0.706
51c1detrllt -O.Q7(-2.07-1.93) 0.939
Prior parasitemia 0.55 (-0.37-1.46) 0.211
Multlvlrtete (previous episodes)'
AII .. mpIas
All (years) 0.05 (0.03-0.07) <0.001 239
Parasitemia 0.55 (0.33-0.78) <0.001
Alpha-thai HET ~.06 (-0.~.06) 0.349
Alpha-thai HOM ~.13 (-0.28-0.02) 0.092
Sickletrait -o.iz (-0.28-0.04) 0.135
Prior episode
PI...... neptIve'
Ale (years) 0.05 (0.02-0.07) <0.001 224
Alpha-thai HET -O.OS(~.2-O.03) 0.155
Alpha-thai HOM -0.13 (~.27~.01) 0.063
Sickletrait ~.07 (-0.22-0.07) 0.325
Prior episode
PI...... positive'
Ale (years) 0.08 (-0.17-0.34) 0.494 15
Alph.. thal HET 0(-1.34-1.34) 0.999
Alpha-thai HOM -0.81 (-3.07-1.46) 0.447
SIckletrait ~.7S (-2.43~.94) 0.348
Prior episode
I!I2IIl
IAnt"n t.sted .tlndlcllld cro., stCIlon.1 bleed.
, L1 'Ion ~ cOllllcl.nts with 95%confld.nc. IntoIV.I.
• ,.",.IUI for Indlc.lld fletor (P-VIIUi.S 0.05 Indlc.t.d Inbold).
• Number of umpil.lnclud.d Inthe mod.1.
'Unlv.riII. 1I r uIon.
• Multlv.rtlbilll , uion with Inclu.lon of .ither ord.d .plsod., of porl,it.mil 0' mol.,I. Inthe6 months prIo, to Slmpll"..
1Strltlfild multlv.rtlble II , 100.POrl.lto tlv. umple. only.
• Strltlfled multlv.rtlble II , Ion. POrl.lto po,ltlv. SImple, only.
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Table 36F Effect of different factors on JgG responses to MSP2(FC27) in the October 2004 cross sectional
bleed.
MSP2(FC27) Oct 2004
II(95"Cl)' P.... lu.· N'
UnlvarlateS
Age (years) 0.04 (0.03-0.06)
Parasitemia 0.55 (0.33-0.77)
Alpha-thai HET -0.02 (-0.11-0.08)
Alpha-thai HOM -0.1 (-0.23-0.02)
Sickle trait -0.06 (-0.19-0.07)
Prior parasitemia 0.05 (-0.21-0.3)
Prior episode
Multl... rllte (previous .,.raslt.mla)'
Allsamples
Age (years)
Parasitemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
P.r.slte ne.atlve'
Aae (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
P,raslt. positive'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior parasitemia
Multl... rlat. (previOUSepisodes)'
Allsamples
Age (years)
Parasitemia
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
Paraslt. nel'tlve'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
P.raslte posltlv.'
Age (years)
Alpha-thai HET
Alpha-thai HOM
Sickle trait
Prior episode
<0.001 273
<0.001 273
0.762 268
0.11
0.345 270
0.725 235
0.05 (0.03-0.07) <0.001
0.64 (0.36-0.92) <0.001
-0.02 (-0.13-0.09) 0.732
-0.11 (-0.25-0.03) 0.127
-0.11 (-0.25-0.03) 0.112
0.07 (-0.18-0.31) 0.596
0.05 (0.03-0.07) <0.001
-0.06 (-0.17-0.05) 0.289
-0.13 (-0.27-0.01) 0.065
-0.08 (-0.22-0.06) 0.279
0.07 (-0.16-0.31) 0.54
0.04 (-0.18-0.26) 0.528
1.33 (-0.05-2.72) 0.053
0.07 (-1.71-1.84) 0.883
0(-1.31-1.31) 0.995
216
209
7
0.05 (0.03-0.07) <0.001
0.64 (0.36-0.91) <0.001
-0.02 (-0.13-0.09) 0.766
-0.1 (-0.24-0.03) 0.141
-0.11 (-0.25-0.03) 0.111
0.05 (0.03-0.07) <0.001
-0.06 (-0.17-0.05) 0.312
-0.12 (-0.26-0.01) 0.074
-0.08 (-0.22-0.06) 0.277
0.04 (-0.18-0.26) 0.528
1.33 (-0.05-2.72) 0.053
0.07 (-1.71-1.84) 0.883
0(-1.31-1.31) 0.995
216
209
7
!!l2l!!
1Antl,"n tlstld It Indlcltld cross sictlonil bl•• d.
2 llne.r re.rlssion e coefficients with 95% confidence IntlNlls
• P.. IIUI for Indicltld flctor (p-VIIUlS S 0.05 Indlc.tld In bold) .
• Number of simplos Includld In tho modll.
SUntvlriate linelr ,..,rlulon.
6Multjylr~bl. lin•• r ,...ression with inclusion of either recorded episodes of p.rlsttlmll or militia In the 6 months prior to umplint.
1Stratified multlvlrilbl.Unl.t rl.tlssion, parasite nllative simples only.
• Strlltlfied multlvlrilble Ilnl.r rl.'lssion, plrlsit. posltiv. Simples only.
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Table 37 Correlations between IgG responses to AMAI(HB3) at each cross sectional bleed.
May 2002'
May 2002'
October 2002' 0.71· (308)
May 2003' 0.5i (263)
October 2003' 0.57· (249)
May 2004' 0.56· (231)
October 2004' 0.5i (226)
October 2002'
0.48· (294)
0.51· (259)
0.52· (242)
0.48· (236)
IgG responses to AMAl (HB3)
May 2003' October 2003' May 2004' October 2004'
0.5S· (293)
0.52· (259)
0.56· (255)
0.72· (278)
0.74· (274) 0.74· (277)
Notes
Spearman rank correlation coefficients for laG responses.
Number of samples in each comparison Indicated In brackets.
1 Cross sectional bleed,
P-value <0.001
Table 38 Correlations between IgG responses to AMAI(3D7) at each cross sectional bleed.
IgG responses to AMAl (307)
May 2002'
May 2002'
October 2002' 0.72· (308)
May2003' 0.6· (263)
October 2003' 0.62· (249)
May 2004' 0.63· (231)
October 2004' 0.6· (226)
October 2002'
0.54· (294)
0.51· (259)
0.56· (242)
O.4S· (236)
May 2003' October 2003' May 2004' October 2004'
0.56· (293)
0.56· (259)
0.55· (255)
0.72· (278)
0.7· (274) 0.73· (277)
Notes
Spearman rank correlation coefficients for IIG responses.
Number of samples in each comparison indicated in brackets.
1 Cross sectional bleed.
P-v.lue <0.001
Table 39 Correlations between JgG responses to MSP2(FC27) at each cross sectional bleed.
IgG responses to MSP2 (Fe27)
May 2002'
May 2002'
October 2002' 0.68· (308)
May 2003' 0.47· (263)
October 2003' 0.5· (249)
May 2004' 0.54· (231)
October 2004' 0.52· (226)
October 2002'
0.62· (294)
0.54· (259)
0.56· (242)
0.62· (236)
May 2003' October 2003' May 2004' October 2004'
0.56· (293)
0.58· (259)
0.52· (255)
0.6i (27S)
0.6· (274) 0.73· (277)
~
Spearman rank correlation coefficients for leG responses.
Number of samples in each comparison indicated in brackets.
1 Cross sectional bleed.
P·value <0.001
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APPENDIX2
The following appendix includes all results not included in Chapter 4 but mentioned in the text.
Tables 1-3: The rate of decay of antibody responses to AMA 1 and MSP2 between May 2004 and
October 2004.
Figures 1-4: Longitudinal antibody responses to AMA 1 and MSP2.
Tables 4-5: Antibody responses in aparasitemic and parasitemic individuals to AMA 1 and MSP2
in October 2002 categorised by their incidence of concurrent parasitemia at sampling throughout
the study.
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Table I Differences in the rate of anti-AMAI (H83) IgG decay between May and October 2004
Antl-AMA1(HB3) IgG
PI9S" Cl)' P-value' NI
Sample time' -0.2 (-0.26, -0.14) <0.001 91
Age 0-2 years -0.46 (-0.76, -0.17) 0.002 10
Age 3-5 years -0.2 1-0.31, -0.09) <0.001 27
Age 6-9 years -0.16 (-0.22, -0.1) <0.001 54
Compared to 0-2 year aids
... Age 3-5 years 0.28 (-0.18, 0.74) 0.233 91
... Age 6-9 years 0.54 (0.11, 0.97) 0.014
HbAA (Normal) -0.23 (-0.29, -0.16) <0.001 77
HbAS (Sickle trait) -0.04 (-0.24, 0.16) 0.685 11
Compared to HbAA chlldr.n
..... HbAS -0.26 (-0.67, 0.16) 0.221 88
Alpha-thalassemia NORM' -0.23 (-0.31, -0.15) <0.001 32
Alpha-thalassemia HET' -0.23 (-0.33, -0.12) <0.001 42
Alpha-thalassemia HOM' -0.04 (-0.19, 0.11) 0.584 12
Compared to normal children
.... Alpha-thalassemia HET -0.09 (-0.38, 0.21) 0.578 86
.... Alpha-thalassemia HOM -0.34 (-0.78,0.09) 0.119
Notes
Univariate leneralized estlmatlne equation (GEE) wIth stationary correlation structure.
'GEE re.f8sslon coefficients Indlcatine reduction/Increase in the rate of antibody decay between May and October 2004.
6P-values:s 0.05 Indicated In bold type.
tNumber of samples Included In the model.
'Chan,e In I,G response between Mav and October 2004.
lAlpha-thallssemia Ilnotypes: NORM = normal, HET = heterozygous, HOM = homozygous.
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Table 2 Differences in the rate of anti-AMAI (307) IgG decay between May and October 2004
Anti-AMA1(3D7) IgG
P(95%CI)' P-value6 N'
Sample time' -0.19 (-0.25, -0.13) <0.001 81
Age 0-2 years -0.36 (-0.64, -0.08) 0.011 10
Age 3-5 years -0.22 (-0.32. -0.12) <0.001 21
Age 6-9 years -0.15 (-0.21, -0.09) <0.001 50
Compared to 0-2 year olds
... Age 3-5 years 0.3 (-0.16, 0.76) 0.203 81
... Age 6-9 years 0.53 (0.11, 0.94) 0.013
HbAA (Normal) -0.21 (-0.27, -0.14) <0.001 70
HbAS (Sickle trait) -0.07 (-0.23, 0.09) 0.412 9
Compared to HbAA children
..... HbAS -0.29 (-0.72, 0.15) 0.197 79
Alpha-thalassemia NORM' -0.17 (-0.25, -0.1) <0.001 31
Alpha-thalassemia HET' -0.23 (-0.34, -0.12) <0.001 37
Alpha-thalassemia HOM' -0.08 (-0.15, -0.02) 0.013 9
Compared to normal children
.... Alpha-thalassemia HET 0.1 (-0.2, 0.4) 0.521 77
.... Alpha-thalassemia HOM . -0.15 (-0.62, 0.31) 0.520
Notes
Univariate generalized estimating equation (GEE)with stationary correlation structure.
'GEE regression coefficients indicating reduction/increase in the rate of antibody decay between May and October 2004.
liP-values S 0.05 indicated in bold type.
tNumber of samples included in the model.
'Change in IgG response between May and October 2004.
2Alpha-thalassemla genotypes: NORM = normal, HET = heterozygous, HOM = homozygous,
369
Table 3 Differences in the rate of anti-MSP2(FC27) IgG decay between May and October 2004
Antl-MSP2(FC27)lgG
P(9S%CI)' P-value4 N'
Sample time' -0.36 (-0.49, -0.23) <0.001 24
Age 0-2 years -0.85 (-1.41, -0.29) 0.003 3
Age 3-5 years -0.29 (-0.42, -0.15) <0.001 6
Age 6-9 years -0.29 (-0.4, -0.18) <0.001 15
Compared to 0-2 year aids
... Age 3-5 years 0.15 (-0.77, 1.06) 0.755 24
... Age 6-9 yea rs 0.62 (-0.2, 1.44) 0.138
HbAA (Normal) -0.35 (-0.48, -0.21) <0.001 22
HbAS (Sickle trait) -0.52 (-0.57, -0.47) <0.001 2
Compared to HbAA children
..... HbAS -0.55 (-1.55, 0.46) 0.286 24
Alpha-thalassemia NORM' -0.46 (-0.7, -0.21) <0.001 10
Alpha-thalassemia HET' -0.26 (-0.39, -0.13) <0.001 10
Alpha-thalassemia HOM' -0.25 (-0.45, -0.06) 0.010 3
Compered to normal children
.... Alpha-thalassemia HET 0.11 (-0.47, 0.7) 0.707 23
.... Alpha-thalassemia HOM -0.72 (-1.58, 0.14) 0.099
Notes
Univariate aeneralized estimatlnl equation (GEE) with stationary correlation structure.
'GEE rearesslon coefficients indicatinl reduction/Increase in the rate of antibody decay between May and October 2004.
·p",.lue.S 0.05 indicated in boid type.
(Number of samples Included in tne model.
lChanae In leG response between May and October 2004.
'Alpha-thalassemia I_notypes: NORM:: normal, HET = heterozygous, HOM = homozygous.
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AAMA1(W2mef)
c
AMA1(307)~
N
D
MSP2(3D7)
B
AMA1(HB3)
E
MSP2(FC27)
Figure I Longitudinal antibody (lgG) responses to merozoite antigens for children present at all six sample
times. Each line represents an individual. (A) AMA 1(W2met), (B) AMA I(HB3), (C) AMA I(3D7), (D)
MSP2(3D7), (E) MSP2(FC27).
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AAMA 1(HB3) 0-2 years in May 2002
c
AMA1(HB3) 6-7 years in May 2002
'"N
oo
Pr.sent In & conaecutive bI"6&. n-38
B
'"N
AMA1(HB3) 3-5 years in May 2002
PreMntln6c:on,eeutivebleedl,n:a81
Figure 2 Longitudinal antibody (lgG) responses to AMA 1(HB3) for children present at all sample times.
Each line represents an individual. Plots grouped by age of the child at the start of the study. (A) 0 - 2 years,
(8) 3 - 5years, (C) 6 - 7 years.
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AAMA 1(3D7) 0-2 years in May 2002
'"N
Present In 6 consecutive bleed., n"'54
c
AMA1{3D7) 6-7 years in May 2002
Pre58ntln6con&~utlvebtaed •. n"38
B
AMA 1(307) 3-5 years in May 2002
'"N
Prelentln6con.ecutivebleedl, ""'81
Figure 3 Longitudinal antibody (IgG) responses to AMAI(3D7) in children present at all ample times.
Each line represents an individual. Plots grouped by age of the child at the start of the study. (A) 0 - 2 years,
(B) 3 - 5years, (C) 6 - 7 years.
\
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AMSP2(FC27) 0-2 years in May 2002
PrlMnt In 6 coMeeutive bI•• de, n"64
c
MSP2(FC27) 6-7 years in May 2002
Pre.. rrtlneco~.cutiv.bI.ed •. n·38
B
MSP2(3D7) 3-5 years in May 2002
Present In 6 CO"$Ocuti'le bleeds, nz81
Figure 4 Longitudinal antibody ([gO) responses to MSP2(FC27) in children present at all sample times.
Each line represents an individual. Plots grouped by age of the child at the start of the study. (A) 0 - 2 years,
(B) 3 - 5years, (C) 6 - 7 years.
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APPENDIX3
The following appendix includes all results not included in Chapter 6 but mentioned in the text.
Tables 1-5: Correlations between antibody responses to AMAl(3D7) and A4 schizont extract at
each cross sectional bleed.
Tables 6-8: Antibody responses to AMAl(3D7) by age group and parasite status at each cross
sectional bleed.
Tables 9-12: Antibody responses to AMAI(3D7) by reactivity to A4 schizont extract at each cross
sectional bleed.
Tables 13-16: Antibody responses to AMAl(3D7) in the presence and absence of
haemoglobinopathies.
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Table 1 Correlations between antibody responses to AMAl(3D7) and schizont extract during the
October 2002 cross sectional bleed.
October 2002 Antibody responses
Schizont extract TotallgG' IgGl' IgG3' IgM'
TotallgG 0.7
IgGl 0.64 0.91
'IG] 0.42 0.56 0.64
IgM 0.13· 0.28 0.39 0.55
Notes
Spearman rank correlation coefficients for IgG responses.
All samples tested.
t Antibody response to AMA1(3D7) .
• P-value <0.001
'" P-value <0.05
Table 2 Correlations between antibody responses to AMAI(3D7) and schizont extract during the May
2003 cross sectional bleed.
May 2003 Antibody responses
Schizont extract TotallgG' IgGl' IgG3' IgM'
TotallgG 0.42
IgGl 0.57 0.67
'IG3 0.45 0.49 0.69
IgM 0.14· 0.31 0.36 0.55
Notes
Spearman rank correlation coefficients for JgG responses.
All samples tested.
, Antibody response to AMA1(307).
P-value <0.001
A P-value <0.05
Table 3 Correlations between antibody responses to AMAl(3D7) and schizont extract during the
October 2003 cross sectional bleed.
October 2003 Antibody responses
Schlzontextract TotallgG' IgGl' IgG3' IgM'
TotallgG 0.73'
IIGl
IIG3
11M
0.66'
0.50'
0.91'
0.62'
0.23'
Notes
Spearman rank correlation coefficients for IgG responses.
All samples tested.
t Antibody response to AMA1(307) .
• P-value <0.001
II P-value <0.05
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Table 4 Correlations between antibody responses to AMAI(3D7) and schizont extract during the May
2004 cross sectional bleed.
May 2004 Antibody responses
Schizont extract TotallgG' IgG1' IgG3' IgM'
TotallgG -0.176
IgG1 -0.166 0.88
IgG3 -0.08 0.58 0.70
IgM 0.01 0.32 0.47 0.58
Notes
Spearman rank correlation coefficients for IgG responses.
All samples tested.
I Antibody response to AMA1(307).
P-value <0.001
'" P-value <0.01
Table 5 Correlations between antibody responses to AMAI(3D7) and schizont extract during the
October 2004 cross sectional bleed.
October 2004 Antibody responses
Schizont extract TotallgG' IgG1' IgG3' IgM'
TotallgG 0.65
IgG1 0.61 0.88
IgG3 0.31 0.56 0.66
IgM 0.166 0.29 0.45 0.60
Notes
Spearman rank correlation coefficients for IgG responses.
All samples tested.
, Antibody response to AMA1(307).
P-value <0.001
A P-value <0.01
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Table 9 TotallgG responses to AMAl(3D7) by reactivity to A4 schizont extract.
Reactivity to schizont extract
TotallgG
P-value3low Medium High
May2002' N' 102 100 101
Median 0.00 0.07 0.61 <0.001'"
IQR (-0.02 - 0.03) (0.02 - 0.32) (0.16 - 1.76)
October 2002' N' 99 98 97
Median 0.00 0.05 0.38 <0.001'"
IQR (-0.02 - 0.04) (0-0.22) (0.15 - 1.34)
May200]' N' 97 98 95
Median 0.02 0.04 0.45 <0.001"
IQR (0- 0.09) (0-0.17) (0.07 - 1.68)
October 200]' N' 96 95 95
Median -0.01 0.08 0.96 <0.001'"
IQR (-0.02 - 0.03) (0-0.23) (0.18 - 1.97)
May2D04' N' 95 93 95
Median 0.06 0.05 0.02 0.016'
IQR (0- 0.74) (-0.01- 0.22) (-0.02 - 0.18)
October 2004' N' 101 101 100
Median -0.01 0.01 0.36 <0.001'"
IQR (-0.03 - 0.02) (-0.01- 0.07) (0.11- 0.95)
Notes
1Cross sectional bleed.
2 Number of samples tested by ELISA
3 P-values calculated using a Kruskal Wallis test (P-values S 0.05 indicated in bold type).
: Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with hi8h schizont reactivity (P-values not shown).
Significant difference (P:S: 0.05 Wilcoxon rank test) in median leG levels between children with low and children with medium schizont reactivity (P-values not shown).
t Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with medium and children with high schizont reactivity (P·values not Shown),
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Table 10 (gGI responses to AMAI(3D7) by reactivity to A4 schizont extract.
May2002'
October 2002'
May2003'
October 2003'
May2004'
October 2004'
Reactivity to schizont extract
IgGl
HighLow
N' 102
Median -0.01
IQR (·0.06 - 0.07)
N' 99
Median -0.05
IQR (-0.09 - 0.03)
N' 97
Median -0.04
IQR (-0.1- 0.05)
N' 96
Median 0.01
IQR (-0.04 - 0.1)
N' 95
Median 0.14
IQR (0.04 - 0.81)
N' 101
Median -0.03
IQR (-0.08 - 0.05)
Medium
100 101
0.06 0.56
(-0.01- 0.25) (0.14 - 1.5)
98 97
0.01 0.34
(-0.05 - 0.17) (0.11- 1.26)
98 95
-0.02 0.58
(-0.09 - 0.19) (0.14 - 1.76)
95 95
0.11 0.77
(0-0.28) (0.18 - 1.83)
93 95
0.10 0.07
(0.02 - 0.31) (0-0.26)
101 100
0.00 0.44
(-0.05 - 0.09) (0.08 - 1.09)
P-value3
<0.001'"
<0.001'"
<0.001"
<0.001'"
0.034'
<0.001'"
Notes
1Cross sectional bleed.
2 Number of samples tested by ELISA
3 s-vafues calculated using iii Kruskal Wallis test (P-values S 0.05 indicated in bold type).
t Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with high schizont reactivity (P-values not shown) .
• Significant difference (P:S; 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with medium schizont reactivity Is-values not shown).
, Significant difference (P S 0.05 Wilcoxon rank test) in median leG levels between children with medium and children with high schizont reactivity (P-values not shown).
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Table II IgG3 responses to AMAI(3D7) by reactivity to A4 schizont extract.
Reactivity to schizont extract
IgG3
P·value'
May2002'
October 2002'
May2003'
October 2003'
May2004'
October 2004'
Low Medium High
<0.001'"
<0.001'"
<0.001"
<0.001"
0.128'
<0.001"
N' 102 100 101
Median 0.01 0.01 0.07
IQR (-0.01·0.02) (0-0.03) (0.03 . 0.17)
N' 99 98 97
Median 0.01 0.02 0.04
IQR (0 ·0.02) (0.01- 0.04) (0.02·0.1)
N' 97 98 95
Median 0.00 0.00 0.04
IQR (-0.01- 0.02) (-0.01· 0.03) (0.01· 0.17)
N' 96 95 95
Median 0.01 0.Q2 0.08
IQR (0-0.03) (0.01·0.04) (0.02·0.18)
N' 95 93 95
Median 0.02 0.01 0.01
IQR (0 ·0.05) (D· 0.03) (0- 0.05)
N' 101 101 100
Median 0.00 0.00 0.03
IQR (·0.01· 0.02) (·0.01- 0.02) (0.01·0.06)
~
1Cross sectional bleed.
1 Number of samples tested by ELISA
3 P-values calculated using a Kruskal Wallis test (P-values S 0.05 indicated in bold type).
1 Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with high schizont reactivity lP-values not shown),
• Significant difference (P S; 0.05 Wilcoxon rank test) in median IgG levels between children with low and children with medium schizont reactivity (P-values not shown).
'Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children with medium and children with high schizont reactivity (P-values not shown).
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Table 12 IgM responses to AMA1(3D7) by reactivity to A4 schizont extract.
Reactivity to schizont extract
IgM
P-value'
MayZOOZ'
October ZOOZ'
May Z003'
October Z003'
MayZOO4'
October ZOO4'
Low Medium High
<0.001"
0.082'
<0.001"
0.051'
0.950
0.03Z"
N' 102 100 101
Median 0.03 0.03 0.06
IQR (0-0.06) (0.01 - 0.07) (0.02 - 0.09)
N' 99 98 97
Median 0.02 0.02 0.03
IQR (0- 0.05) (0.01- 0.05) (0.01- 0.09)
N' 97 98 95
Median 0.01 0.00 0.02
IQR (-0.01- 0.04) (-0.03 - 0.02) (-0.01 - 0.07)
N' 96 95 95
Median 0.02 0.02 0.03
IQR (0- 0.04) (0-0.05) (0.01 - 0.08)
N' 95 93 95
Median 0.02 0.03 0.03
IQR (0.01 - 0.07) (0.02 - 0.05) (0.02 - 0.06)
N' 101 101 100
Median 0.03 0.03 0.04
IQR (0.01- 0.05) (0.01- 0.05) (0.02 - 0.08)
Notes
1Cross sectional bleed.
2 Number of samples tested by ELISA
3 s-velues calculated usinl Cl Kruskal Wallis test (P-values s: 0.05 indicated in bold type).
• Significant difference (P S 0,05 Wilcoxon rank test) in median IgG levels between children with low and children with high schizont reactivity lP-values not shown) .
• Significant difference (P S0.05 Wilcoxon rank test) in median leG levels between children with low and children with medium schizont reactivity (P-values not shown),
1Silnificant difference (P S0.05 wnecxcn rank test) in median IgG levels between children with medium and children with high schizont reactivity {P-values not shown}.
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Table 13 TotallgG responses to AMAl(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
TotallgG
P-value'HbAA HBAS P-value' Norm HbAA HBAS
MayZOOZ' N' 258 41 93 152 52
Median 0.07 0.04 0.162 0.06 0.08 0.04 0.357
IQR (0-0.6) (0-0.15) (-0.01 - 0.59) (0.01- 0.51) (0.01- 0.21)
October ZOOZ' N' 258 34 92 138 54
Median 0.06 0.05 0.368 0.05 0.09 0.02 0.051"
IQR (0 -0.33) (0- 0.19) (0-0.31) (0-0.38) (-0.01- 0.14)
May2oo3' N' 246 37 90 137 52
Median 0.08 0.02 0.02 0.06 0.08 0.03 0.02'
IQR (0.01- 0.6) (-0.01- 0.24) (0- 0.5) (0.01- 0.65) (-0.01- 0.13)
October 2003' N' 246 38 97 136 52
Median 0.08 0.07 0.843 0.10 0.08 0.02 0.07
IQR (-0.01 - 0,46) (0.01- 0.19) (0 -0.74) (0 - 0,45) (-0.01- 0.13)
May2004' N' 231 35 88 124 49
Median 0.04 0.04 0.47 0.07 0.04 0.00 0.03i'
IQR (-0.01- 0.36) (-0.01- 0.14) (-0.01- 0.6) (-0.Q1- 0.36) (-0.01- 0.08)
October 2004' N' 232 38 92 126 50
Median 0.02 0.04 0.728 0.03 0.04 0.02 0.721
IQR (-0.01- 0.22) (-0.02 - 0.18) (-0.01- 0.27) (-0.02 - 0.24) (-0.01- 0.18)
Notes
1Cross sectional bleed.
, Number of samples tested by ELISA
3 P-values calculated using ill Wilcoxon rank test (P-values ~ 0.05 indicated in bold type).
4 s-vefues calculated using ill Kruskal Wallis test (P-values S 0.05 indicated in bold type).
: Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between normal children and children heterozygous for a-thalassemia (P-values not shown).
Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between normal children and children homozygous fora-thalassemia [s-values not shown).
t Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children heterozygous and homozygous for a-thalassemia (P-values not shown).
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Table 14 IgGI responses to AMA1(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
IgG1
P-value'HbAA HBAS Norm HbAA HBAS P-value'
May2002' N' 258 41 93 152 52
Median 0.08 0.08 0.54 0.05 0.09 0.05 0.343
IQR (-0.03 - 0.49) (-0.01- 0.19) (-0.03 - 0.62) (-0.01- 0.46) (-0.04 - 0.18)
October 2002' N' 258 34 92 138 54
Median 0.03 0.03 0.365 0.03 0.05 -0.01 0.132'
IQR (-0.05 - 0.3) (-0.06 - 0.18) (-0.04 - 0.33) (-0.05 - 0.33) (-0.07 - 0.15)
May2003' N' 246 37 90 137 52
Median 0.05 0.01 0.258 0.05 0.07 -0.01 0.094'
IQR (-0.07 - 0.58) (-0.08 - 0.17) (-0.06 - 0.46) (-0.06 - 0.63) (-0.11- 0.18)
October 2003' N' 246 38 97 136 52
Median 0.12 0.11 0.638 0.15 0.13 0.06 0.033
IQR (0 - 0.48) (0.01 - 0.28) (0.05 - 0.63) (0.01- 0.45) (-0.01- 0.19)
May2004' N' 231 35 88 124 49
Median 0.11 0.12 0.606 0.14 0.12 0.06 0.063
IQR (0.02 - 0.48) (0.03 - 0.22) (0.03 - 0.73) (0.02 - 0.5) (0.02 - 0.16)
October 2004' N' 258 41 92 126 50
Median 0.08 0.08 0.54 0.08 0.04 0.02 0.225
IQR (-0.03 - 0.49) (-0.01- 0.19) (-0.03 - 0.36) (-0.05 - 0.36) (-0.05 - 0.22)
Notes
1Cross sectional bleed.
zNumberof samplestested byELISA
3P-values calculated using a Wilcoxon rank test (P-values S 0,05 indicated in bold type) .
..P-values calculated using a Kruskal Wallis test (P-values S 0.05 indicated in bold type).
: Significant difference (P S 0.05 Wilcoxon rank test) in median IIG levels between normal children and children heterozygous for a-thalassemia (P-values not shown).
Significant difference (P S0.05 Wilcoxon rank test) in median IgG levels between normal children and children homozygous fora-thalassemia (P-values not shown).
r Significant difference (P S0,05 Wilcoxon rank test) in median IKG levels between children heterozygous and homozygous for a-thalassemia (P-values not shown).
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Table 15 IgG3 responses to AMAl(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
Ig63
HbAA HBAS P-value' Norm HbAA HBAS P-value'
May2002' N' 258 41 93 152 52
Median 0.02 0.02 0.912 0.02 0.02 0.01 0.745
IQR (0-0.07) (0-0.05) (0-0.07) (0-0.06) (0 - 0.05)
October 2002' N' 258 34 92 138 54
Median 0.02 0.02 0.925 0.02 0.02 0.02 0.474
IQR (0.01- 0.05) (0-0.03) (0.01- 0.04) (0.01- 0.05) (0-0.03)
May2003' N' 246 37 90 137 52
Median 0.01 0.01 0.255 0.01 0.01 0.01 0.363
IQR (0-0.04) (-0.01- 0.03) (0-0.04) (0-0.05) (-0.01- 0.03)
October 2003' N' 246 38 97 136 52
Median 0.Q2 0.03 0.758 0.03 0.02 0.02 0.191
IQR (0.01 - 0.07) (0.01 - 0.07) (0.01 - 0.08) (0.01- 0.06) (0.01- 0.05)
May2004' N' 231 35 88 124 49
Median 0.02 0.01 0.849 0.Q2 0.02 0.01 0.536
IQR (0-0.04) (0 -0.04) (0-0.05) (0-0.04) (0- 0.04)
October 2004' N' 232 38 92 126 50
Median 0.01 0.02 0.158 0.01 0.01 0.01 0.306
IQR (0 -0.03) (0-0.05) (0- 0.03) (0 -0.03) (0-0.03)
Notes
1 Cross sectional bleed.
, Number of samples tested by ELISA
3 P-values calculated using a Wilcoxon rank test (P-values S 0.05 indicated in bold type).
4 P-values calculated using a Kruskal Wallis test (P-values 5 0.05 indicated in bold type).
: Significant difference (P S 0.05 Wilcoxon rank test) in median JgGlevels between normal children and children heterozygous for a-thalassemia (P-values not shown).
Significant difference (P S 0.05 Wilcoxon rank test) in median JgGlevels between normal children and children homozygous fora-thalassemia (P-values not shown) .
• Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children heterozygous and homozygous for c-thalassemia (P-values not shown).
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Table 16 JgM responses to AMAl(3D7) in the presence or absence of hemoglobinopathies.
Sickle trait Alpha-Thalassemia
IgM
HbAA HBAS P-value3 Norm HbAA HBAS P-value4
May2002' N' 258 41 93 152 52
Median 0,03 0,05 0,147 0,03 0,04 0,04 0,672
IQR (0,01 - 0.07) (0.02 - 0,09) (0.01 - 0.07) (0.01· 0,07) (0.01 - 0.09)
October 2002' N' 258 34 92 138 54
Median 0,03 0.02 0,534 0,03 0,03 0,02 0,345
IQR (0,01- 0,06) (0- 0,05) (0,01- 0,06) (0-0.05) (0,01 - 0,05)
May2003' N' 246 37 90 137 52
Median 0,01 0.00 0,538 0.01 0.01 -0,01 0.005"
IQR (-0.02 - 0,05) (-0,02 - 0.04) (-0.02 - 0.05) (-0.01- 0.05) (-0.03 - 0.02)
October 2003' N' 246 38 97 136 52
Median 0,02 0,03 0,284 0,02 0,02 0,02 0,801
IQR (0-0,05) (0-0,07) (0-0.06) (0- 0,05) (0- 0,04)
May2004' N' 231 35 88 124 49
Median 0,03 0.04 0,356 0,03 0.03 0.02 0,508
IQR (0,01 - 0.06) (0,02 - 0,09) (0.02 - 0.06) (0.01- 0.07) (0.01 - 0.05)
October 2004' N' 232 38 92 126 50
Median 0,03 0.04 0.58 0,03 0,03 0.03 0,371
IQR (0,01- 0,06) (0,01 - 0,06) (0,02 - 0.07) (0,01 - 0,06) (0,02 - 0,06)
Notes
ICross sectional bleed.
2 Number of samples tested by ELISA
3 P-values calculated using a Wilcoxon rank test (P-values S 0.05 indicated in bold type).
4 P-values calculated using a Kruskal Wallis test lP-values S 0.05 indicated in bold type).
: Significant difference (P S 0.05 wttcoxon rank test) in median fgG levels between normal children and children heterozygous for a-thalassemia (P-values not shown).
Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between normal children and children homozygous for a-thalassemia (P-values not shown).
I Significant difference (P S 0.05 Wilcoxon rank test) in median IgG levels between children heterozygous and homozygous for a-thalassemia (P-values not shown).
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